activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
No data	866064	CHEMBL766071	Inhibition of chimeric PDGF receptor with CSF-1R cytoplasmic domain phosphorylation in CHO cells	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCC(C)CC1		CHEMBL330863		Inhibition	%		CHEMBL1844	Homo sapiens	Inhibition		
No data	866064	CHEMBL766071	Inhibition of chimeric PDGF receptor with CSF-1R cytoplasmic domain phosphorylation in CHO cells	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCC(C)CC1		CHEMBL330863		Inhibition	%		CHEMBL1844	Homo sapiens	Inhibition		
	872533	CHEMBL766070	Inhibition of chimeric PDGF receptor with CSF-1R cytoplasmic domain phosphorylation in CHO cells	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	=	IC50	nM	3430.0	CHEMBL1844	Homo sapiens	IC50	uM	3.43
No data	872565	CHEMBL766071	Inhibition of chimeric PDGF receptor with CSF-1R cytoplasmic domain phosphorylation in CHO cells	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(C#N)cc4)CC3)ncnc2cc1OCCCN1CCCCC1C		CHEMBL126699		Inhibition	%		CHEMBL1844	Homo sapiens	Inhibition		
No data	879719	CHEMBL766071	Inhibition of chimeric PDGF receptor with CSF-1R cytoplasmic domain phosphorylation in CHO cells	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(C#N)cc4)CC3)ncnc2cc1OCCCN1CCC(C)CC1		CHEMBL445636		Inhibition	%		CHEMBL1844	Homo sapiens	Inhibition		
	884646	CHEMBL766070	Inhibition of chimeric PDGF receptor with CSF-1R cytoplasmic domain phosphorylation in CHO cells	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	IC50	nM	960.0	CHEMBL1844	Homo sapiens	IC50	uM	0.96
	886059	CHEMBL766070	Inhibition of chimeric PDGF receptor with CSF-1R cytoplasmic domain phosphorylation in CHO cells	B	COCCOc1cc2ncnc(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)c2cc1OC		CHEMBL124035	=	IC50	nM	5460.0	CHEMBL1844	Homo sapiens	IC50	uM	5.46
	895435	CHEMBL766070	Inhibition of chimeric PDGF receptor with CSF-1R cytoplasmic domain phosphorylation in CHO cells	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCOCC1		CHEMBL125898	=	IC50	nM	1400.0	CHEMBL1844	Homo sapiens	IC50	uM	1.4
No data	896683	CHEMBL766071	Inhibition of chimeric PDGF receptor with CSF-1R cytoplasmic domain phosphorylation in CHO cells	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1C		CHEMBL107599		Inhibition	%		CHEMBL1844	Homo sapiens	Inhibition		
	897824	CHEMBL766070	Inhibition of chimeric PDGF receptor with CSF-1R cytoplasmic domain phosphorylation in CHO cells	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCN1CCCCC1		CHEMBL444064	=	IC50	nM	3430.0	CHEMBL1844	Homo sapiens	IC50	uM	3.43
	1066784	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	COc1ccc2ncnc(N(C)c3ccccc3)c2c1.Cl		CHEMBL542955	=	IC50	nM	20000.0	CHEMBL1844	Homo sapiens	IC50	uM	20.0
	1067940	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	COc1cc2ncnc(Nc3cc(OC)c(OC)c(OC)c3)c2cc1OC.Cl		CHEMBL543904	>	IC50	nM	100000.0	CHEMBL1844	Homo sapiens	IC50	uM	100.0
	1067942	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	COc1cc2ncnc(N(C)c3cccc(Cl)c3)c2cc1OC.Cl		CHEMBL553908	=	IC50	nM	1500.0	CHEMBL1844	Homo sapiens	IC50	uM	1.5
	1067944	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	Cc1cccc(N(C)c2ncnc3cc(C)c(C)cc23)c1.Cl		CHEMBL554566	=	IC50	nM	1600.0	CHEMBL1844	Homo sapiens	IC50	uM	1.6
	1071547	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	Cc1cccc(N(C)c2[nH]cnc3nncc2-3)c1		CHEMBL136011	=	IC50	nM	180.0	CHEMBL1844	Homo sapiens	IC50	uM	0.18
	1073910	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	COc1cc2ncnc(N(C)c3ccc(C)cc3)c2cc1OC.Cl		CHEMBL545538	=	IC50	nM	2000.0	CHEMBL1844	Homo sapiens	IC50	uM	2.0
	1080946	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	COc1cc2nc(Cl)nc(N(C)c3ccccc3)c2cc1OC		CHEMBL135417	>	IC50	nM	50000.0	CHEMBL1844	Homo sapiens	IC50	uM	50.0
	1083249	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	COc1cc2ncnc(N(C)c3cccc(C)c3)c2cc1OC.Cl		CHEMBL553523	=	IC50	nM	180.0	CHEMBL1844	Homo sapiens	IC50	uM	0.18
	1083251	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	CN(c1ccccc1)c1[nH]cnc2ncnc1-2		CHEMBL335052	=	IC50	nM	4000.0	CHEMBL1844	Homo sapiens	IC50	uM	4.0
	1084341	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	CN(c1ccccc1)c1ncnc2ccc(Cl)cc12		CHEMBL134439	=	IC50	nM	5000.0	CHEMBL1844	Homo sapiens	IC50	uM	5.0
	1086484	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	COc1cc2ncnc(N(C)c3ccc(Cl)cc3)c2cc1OC.Cl		CHEMBL543195	=	IC50	nM	2100.0	CHEMBL1844	Homo sapiens	IC50	uM	2.1
	1086486	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	COc1cc2c(N(C)c3ccccc3)ncnc2c(OC)c1OC.Cl		CHEMBL545302	>	IC50	nM	20000.0	CHEMBL1844	Homo sapiens	IC50	uM	20.0
	1087512	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	CN(c1ccccc1)c1[nH]cnc2nncc1-2.Cl		CHEMBL541334	=	IC50	nM	600.0	CHEMBL1844	Homo sapiens	IC50	uM	0.6
	1090888	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	COc1cc2ncnc(N(C)c3ccccc3)c2cc1OC.Cl		CHEMBL543669	=	IC50	nM	500.0	CHEMBL1844	Homo sapiens	IC50	uM	0.5
	1090890	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	COc1cc2ncnc(Nc3ccccc3)c2cc1OC.Cl		CHEMBL542484	>	IC50	nM	50000.0	CHEMBL1844	Homo sapiens	IC50	uM	50.0
	1092028	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	COc1nc(N(C)c2ccccc2)c2cc(OC)c(OC)cc2n1		CHEMBL135928	>	IC50	nM	50000.0	CHEMBL1844	Homo sapiens	IC50	uM	50.0
	1093087	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	COc1cc2ncnc(N(C)c3cccc(C(F)(F)F)c3)c2cc1OC.Cl		CHEMBL539807	=	IC50	nM	500.0	CHEMBL1844	Homo sapiens	IC50	uM	0.5
	1094316	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	CN(c1ccccc1)c1ncnc2ccccc12		CHEMBL324371	>	IC50	nM	20000.0	CHEMBL1844	Homo sapiens	IC50	uM	20.0
	1096478	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	CCN(c1ccccc1)c1ncnc2cc(OC)c(OC)cc12.Cl		CHEMBL554053	=	IC50	nM	4000.0	CHEMBL1844	Homo sapiens	IC50	uM	4.0
	1098821	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	COc1cc2ncnc(N3CCc4ccccc43)c2cc1OC.Cl		CHEMBL545776	=	IC50	nM	5000.0	CHEMBL1844	Homo sapiens	IC50	uM	5.0
	1102179	CHEMBL657534	Antagonism towards Colony stimulating factor 1 receptor (CSF-1R)	F	Cc1cc(C)c2ncnc(N(C)c3ccccc3)c2c1		CHEMBL133147	>	IC50	nM	20000.0	CHEMBL1844	Homo sapiens	IC50	uM	20.0
	1106340	CHEMBL657538	Inhibition of Colony stimulating factor 1 receptor (CSF-1R)	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc([N+](=O)[O-])cc4)CC3)c2cc1OC		CHEMBL99743	>	IC50	nM	30000.0	CHEMBL1844	Homo sapiens	IC50	uM l-1	30.0
Not Determined	1108585	CHEMBL657536	Inhibition of Colony stimulating factor 1 receptor (CSF-1R) (Not tested)	F	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(C(C)C)cc4)CC3)c2cc1OC		CHEMBL104067		IC50	nM		CHEMBL1844	Homo sapiens	IC50	uM l-1	
Not Determined	1112121	CHEMBL657540	Inhibition of Colony stimulating factor 1 receptor (CSF-1R) (Not tested)	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346		NT			CHEMBL1844	Homo sapiens	NT		
	1114586	CHEMBL657538	Inhibition of Colony stimulating factor 1 receptor (CSF-1R)	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Br)cc4)CC3)c2cc1OC		CHEMBL323336	>	IC50	nM	30000.0	CHEMBL1844	Homo sapiens	IC50	uM l-1	30.0
	1130110	CHEMBL657538	Inhibition of Colony stimulating factor 1 receptor (CSF-1R)	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(C#N)cc4)CC3)c2cc1OC		CHEMBL106966	>	IC50	nM	30000.0	CHEMBL1844	Homo sapiens	IC50	uM l-1	30.0
	1152814	CHEMBL657537	In vitro inhibition of Colony stimulating factor 1 receptor (CSF-1R) expressed in baculovirus	B	O=C(Nc1cccc(C(F)(F)F)c1)c1ccccc1NCc1ccncc1		CHEMBL153843	=	IC50	nM	380.0	CHEMBL1844	Homo sapiens	IC50	nM	380.0
	1175321	CHEMBL657537	In vitro inhibition of Colony stimulating factor 1 receptor (CSF-1R) expressed in baculovirus	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	=	IC50	nM	1600.0	CHEMBL1844	Homo sapiens	IC50	nM	1600.0
	1175346	CHEMBL657537	In vitro inhibition of Colony stimulating factor 1 receptor (CSF-1R) expressed in baculovirus	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	IC50	nM	84.0	CHEMBL1844	Homo sapiens	IC50	nM	84.0
	1180535	CHEMBL657537	In vitro inhibition of Colony stimulating factor 1 receptor (CSF-1R) expressed in baculovirus	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1.O=C(O)CCC(=O)O		CHEMBL75232	=	IC50	nM	1240.0	CHEMBL1844	Homo sapiens	IC50	nM	1240.0
	1183187	CHEMBL657537	In vitro inhibition of Colony stimulating factor 1 receptor (CSF-1R) expressed in baculovirus	B	O=C(Nc1cccc(-c2cncc3ccccc23)c1)c1ccccc1NCc1ccncc1		CHEMBL347537	=	IC50	nM	99.0	CHEMBL1844	Homo sapiens	IC50	nM	99.0
Not Determined	1235224	CHEMBL657535	Inhibition of Colony stimulating factor 1 receptor (CSF-1R) autophosphorylation (not tested)	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccsc4)CC3)c2cc1OC.Cl		CHEMBL553824		NT			CHEMBL1844	Homo sapiens	NT		
	1236586	CHEMBL884250	Inhibition of Colony stimulating factor 1 receptor (CSF-1R) autophosphorylation	B	COc1cc2ncnc(N3CCN(/C(S)=N\Cc4ccc5c(c4)OCO5)CC3)c2cc1OC		CHEMBL102301	>	IC50	nM	30000.0	CHEMBL1844	Homo sapiens	IC50	uM l-1	30.0
	1245747	CHEMBL884250	Inhibition of Colony stimulating factor 1 receptor (CSF-1R) autophosphorylation	B	COc1cc2ncnc(N3CCN(/C(S)=N\Cc4ccccc4)CC3)c2cc1OC		CHEMBL319894	>	IC50	nM	30000.0	CHEMBL1844	Homo sapiens	IC50	uM l-1	30.0
	1257898	CHEMBL657539	Inhibition of Colony stimulating factor 1 receptor at 30 uM	B	COc1cc2ncc(N[C@H]3CC[C@H](O)CC3)nc2cc1OC		CHEMBL104466	=	Inhibition	%	2.0	CHEMBL1844	Homo sapiens	Inhibition	%	2.0
	1401262	CHEMBL832900	Inhibition of c-fms tyrosine kinase	B	CC(C)(Nc1nc(NO)nc(Nc2ccc3ncsc3c2)n1)c1ccccc1		CHEMBL177298	=	IC50	nM	14000.0	CHEMBL1844	Homo sapiens	IC50	uM	14.0
	1401278	CHEMBL832900	Inhibition of c-fms tyrosine kinase	B	CC(C)(Nc1nc(O)nc(Nc2ccc3ncsc3c2)n1)c1ccccc1		CHEMBL175862	>	IC50	nM	12500.0	CHEMBL1844	Homo sapiens	IC50	uM	12.5
	1401294	CHEMBL832900	Inhibition of c-fms tyrosine kinase	B	CCN(Cc1ccccc1)c1nc(O)nc(Nc2ccc3ncsc3c2)n1		CHEMBL176078	=	IC50	nM	4300.0	CHEMBL1844	Homo sapiens	IC50	uM	4.3
	1401309	CHEMBL832900	Inhibition of c-fms tyrosine kinase	B	CC(C)N(Cc1ccccc1)c1nc(O)nc(Nc2ccc3ncsc3c2)n1		CHEMBL176019	>	IC50	nM	12500.0	CHEMBL1844	Homo sapiens	IC50	uM	12.5
	1516927	CHEMBL832164	Selectivity for colony stimulating factor 1 receptor by plate capture and filtration binding assay	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccn4)c3)o2)c1		CHEMBL194176	=	Selectivity	uM	0.14	CHEMBL1844	Homo sapiens	Selectivity	uM	0.14
	1517061	CHEMBL832164	Selectivity for colony stimulating factor 1 receptor by plate capture and filtration binding assay	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Selectivity	uM	0.38	CHEMBL1844	Homo sapiens	Selectivity	uM	0.38
	1517176	CHEMBL832164	Selectivity for colony stimulating factor 1 receptor by plate capture and filtration binding assay	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4Cl)c3)o2)c1		CHEMBL191993	=	Selectivity	uM	1.9	CHEMBL1844	Homo sapiens	Selectivity	uM	1.9
	1609152	CHEMBL884687	Inhibitory concentration against CSF1R with 4 uM Biotin-Ahx-AEEEYFFLFA-amide for 1 hr at ambient temperature	B	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)c1		CHEMBL196363	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	nM	3.0
	1609238	CHEMBL872200	Inhibitory activity against CSF1R	B	Cc1sc2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)cc1		CHEMBL381207	=	IC50	nM	57.0	CHEMBL1844	Homo sapiens	IC50	nM	57.0
	1723013	CHEMBL860201	Inhibition of CSF1R	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	>	Ki	nM	2500.0	CHEMBL1844	Homo sapiens	Ki	nM	2500.0
	1723116	CHEMBL860201	Inhibition of CSF1R	B	CCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL208637	>	Ki	nM	2500.0	CHEMBL1844	Homo sapiens	Ki	nM	2500.0
	1723309	CHEMBL860201	Inhibition of CSF1R	B	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	>	Ki	nM	2500.0	CHEMBL1844	Homo sapiens	Ki	nM	2500.0
	1723435	CHEMBL860201	Inhibition of CSF1R	B	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	>	Ki	nM	2500.0	CHEMBL1844	Homo sapiens	Ki	nM	2500.0
	1723436	CHEMBL860201	Inhibition of CSF1R	B	CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1		CHEMBL210032	>	Ki	nM	2500.0	CHEMBL1844	Homo sapiens	Ki	nM	2500.0
	1723440	CHEMBL860201	Inhibition of CSF1R	B	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	>	Ki	nM	2500.0	CHEMBL1844	Homo sapiens	Ki	nM	2500.0
	1744490	CHEMBL867303	Inhibition of CSF1R	B	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	>	Ki	nM	2500.0	CHEMBL1844	Homo sapiens	Ki	uM	2.5
	1815201	CHEMBL908510	Inhibition of c-fms	B	CNc1ncnc(-c2cccnc2Oc2ccc(F)c(C(=O)Nc3cc(C(F)(F)F)ccc3N(C)CCCN(C)C)c2)n1		CHEMBL373882	=	IC50	nM	25000.0	CHEMBL1844	Homo sapiens	IC50	nM	25000.0
	1826433	CHEMBL919911	Inhibition of CSF1R by HTRF assay	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	nM	3.0
	1849892	CHEMBL914197	Inhibition of CSF1R	B	CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOc5ccccc5)c4)n[nH]c2-3)CC1		CHEMBL390156	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	nM	8.0
	1849904	CHEMBL914197	Inhibition of CSF1R	B	COCCOCC#Cc1cc(-c2n[nH]c3c2Cc2ccc(Cn4cncn4)cc2-3)cs1		CHEMBL223971	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	nM	9.0
Not Determined	1916318	CHEMBL894169	Inhibition of recombinant CSF1R by radiometric assay	B	COc1cc(-c2ccc3c(c2)Nc2ccc(CC(=O)Nc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1N		CHEMBL395080		IC50			CHEMBL1844	Homo sapiens	IC50		
	1916370	CHEMBL894169	Inhibition of recombinant CSF1R by radiometric assay	B	COc1cc(-c2ccc3c(c2)Nc2ccc(C(C)(C)C(=O)Nc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1N		CHEMBL389745	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	1922393	CHEMBL895914	Inhibition of cFMS kinase	B	CNC(=O)c1cc(Oc2ccc3oc(Nc4ccc(Cl)c(OC[C@@H]5CCCN5C)c4)nc3c2)ccn1		CHEMBL231568	=	IC50	nM	80.0	CHEMBL1844	Homo sapiens	IC50	uM	0.08
	1964236	CHEMBL897073	Inhibition of cFms	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	<	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	pIC50		5.0
	1964245	CHEMBL897073	Inhibition of cFms	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	<	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	pIC50		5.0
	1986219	CHEMBL899839	Inhibition of cFMS	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	IC50	nM	550.0	CHEMBL1844	Homo sapiens	IC50	nM	550.0
	2021693	CHEMBL903569	Inhibition of human cFMS	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	IC50	nM	38.9	CHEMBL1844	Homo sapiens	Log IC50		-7.41
	2025142	CHEMBL886969	Inhibition of human Fms at 1 uM relative to control	B	CN(C)c1cc2cc(n1)CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CCC2		CHEMBL247067	=	Inhibition	%	101.0	CHEMBL1844	Homo sapiens	Inhibition	%	101.0
	2025318	CHEMBL886969	Inhibition of human Fms at 1 uM relative to control	B	CN(C)c1nc2ccc1CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CC2		CHEMBL1162963	=	Inhibition	%	94.0	CHEMBL1844	Homo sapiens	Inhibition	%	94.0
	2025319	CHEMBL886969	Inhibition of human Fms at 1 uM relative to control	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCc1ccc(c(N3CCCC3)n1)CCCn1cc2c2ccccc21		CHEMBL396327	=	Inhibition	%	106.0	CHEMBL1844	Homo sapiens	Inhibition	%	106.0
	2025320	CHEMBL886969	Inhibition of human Fms at 1 uM relative to control	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCc1cc(nc(N3CCCC3)c1)CCCn1cc2c2ccccc21		CHEMBL397771	=	Inhibition	%	99.0	CHEMBL1844	Homo sapiens	Inhibition	%	99.0
	2027324	CHEMBL906392	Inhibition of CSF1R by HTRF assay	B	COCC(=O)Nc1cccc2c1Cc1c-2n[nH]c1-c1csc(C#CCOc2ccccc2)c1		CHEMBL245769	=	IC50	nM	113.0	CHEMBL1844	Homo sapiens	IC50	uM	0.113
	2027332	CHEMBL906392	Inhibition of CSF1R by HTRF assay	B	CN1CCN(CC(=O)Nc2cccc3c2Cc2c-3n[nH]c2-c2csc(C#CCOc3ccccc3)c2)CC1		CHEMBL245377	=	IC50	nM	45.0	CHEMBL1844	Homo sapiens	IC50	uM	0.045
	2027333	CHEMBL906392	Inhibition of CSF1R by HTRF assay	B	CCOC(=O)CC(=O)Nc1cccc2c1Cc1c-2n[nH]c1-c1csc(C#CCOc2ccccc2)c1		CHEMBL395427	=	IC50	nM	2975.0	CHEMBL1844	Homo sapiens	IC50	uM	2.975
	2027334	CHEMBL906392	Inhibition of CSF1R by HTRF assay	B	COC(=O)C(=O)Nc1cccc2c1Cc1c-2n[nH]c1-c1csc(C#CCOc2ccccc2)c1		CHEMBL246166	=	IC50	nM	190.0	CHEMBL1844	Homo sapiens	IC50	uM	0.19
	2027335	CHEMBL906392	Inhibition of CSF1R by HTRF assay	B	COCCOCC(=O)Nc1cccc2c1Cc1c-2n[nH]c1-c1csc(C#CCOc2ccccc2)c1		CHEMBL245968	=	IC50	nM	1271.0	CHEMBL1844	Homo sapiens	IC50	uM	1.271
	2047693	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccncc3)ccc2c1Nc1ccccc1		CHEMBL249169	=	IC50	nM	16.0	CHEMBL1844	Homo sapiens	IC50	uM	0.016
	2047699	CHEMBL925269	Inhibition of cfms	B	COc1ccc(Nc2c(C(N)=O)cnc3cc(-c4ccc(S(C)(=O)=O)cc4)ccc23)cc1F		CHEMBL250775	=	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	uM	0.1
Not Determined	2047700	CHEMBL925269	Inhibition of cfms	B	COc1ccc(Nc2c(C(N)=O)cnc3cc(-c4ccc(S(C)(=O)=O)cc4)ccc23)cc1Cl		CHEMBL399703		IC50			CHEMBL1844	Homo sapiens	IC50		
	2047701	CHEMBL925269	Inhibition of cfms	B	CS(=O)(=O)c1ccc(-c2ccc3c(Nc4ccc(F)cc4)c(C(N)=O)cnc3c2)cc1		CHEMBL250774	=	IC50	nM	160.0	CHEMBL1844	Homo sapiens	IC50	uM	0.16
	2047702	CHEMBL925269	Inhibition of cfms	B	CS(=O)(=O)c1ccc(-c2ccc3c(Nc4ccc(F)c(F)c4)c(C(N)=O)cnc3c2)cc1		CHEMBL399702	=	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	uM	0.2
	2047703	CHEMBL925269	Inhibition of cfms	B	Cc1ccc(Nc2c(C(N)=O)cnc3cc(-c4ccc(S(C)(=O)=O)cc4)ccc23)cc1F		CHEMBL250572	=	IC50	nM	63.0	CHEMBL1844	Homo sapiens	IC50	uM	0.063
	2047704	CHEMBL925269	Inhibition of cfms	B	Cc1ccc(Nc2c(C(N)=O)cnc3cc(-c4ccc(S(C)(=O)=O)cc4)ccc23)cc1C		CHEMBL250571	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	uM	0.008
	2047705	CHEMBL925269	Inhibition of cfms	B	CS(=O)(=O)c1ccc(-c2ccc3c(Nc4ccccc4)c(C(N)=O)cnc3c2)cc1		CHEMBL250364	=	IC50	nM	16.0	CHEMBL1844	Homo sapiens	IC50	uM	0.016
	2047706	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccc(S(N)(=O)=O)cc3)ccc2c1Nc1ccccc1		CHEMBL398469	=	IC50	nM	80.0	CHEMBL1844	Homo sapiens	IC50	uM	0.08
	2047707	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccc(C(=O)N4CCOCC4)cc3)ccc2c1Nc1ccccc1		CHEMBL250362	=	IC50	nM	80.0	CHEMBL1844	Homo sapiens	IC50	uM	0.08
	2047708	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccc(C(=O)N4CCCCC4)cc3)ccc2c1Nc1ccccc1		CHEMBL250161	=	IC50	nM	16.0	CHEMBL1844	Homo sapiens	IC50	uM	0.016
	2047709	CHEMBL925269	Inhibition of cfms	B	CCS(=O)(=O)c1ccc(-c2ccc3c(Nc4ccccc4)c(C(N)=O)cnc3c2)cc1		CHEMBL250160	=	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	uM	0.2
	2047710	CHEMBL925269	Inhibition of cfms	B	CS(=O)(=O)Cc1ccc(-c2ccc3c(Nc4ccccc4)c(C(N)=O)cnc3c2)cc1		CHEMBL249960	=	IC50	nM	50.0	CHEMBL1844	Homo sapiens	IC50	uM	0.05
	2047711	CHEMBL925269	Inhibition of cfms	B	CS(=O)(=O)Cc1cccc(-c2ccc3c(Nc4ccccc4)c(C(N)=O)cnc3c2)c1		CHEMBL249139	=	IC50	nM	25.0	CHEMBL1844	Homo sapiens	IC50	uM	0.025
	2047712	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccc(C(=O)C4CCCC4)cc3)ccc2c1Nc1ccccc1		CHEMBL249138	=	IC50	nM	32.0	CHEMBL1844	Homo sapiens	IC50	uM	0.032
	2047713	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccc(C(=O)C4CC4)cc3)ccc2c1Nc1ccccc1		CHEMBL249137	=	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	uM	0.1
	2047714	CHEMBL925269	Inhibition of cfms	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(Nc4ccccc4)c(C(N)=O)cnc3c2)cc1		CHEMBL428228	=	IC50	nM	63.0	CHEMBL1844	Homo sapiens	IC50	uM	0.063
	2047715	CHEMBL925269	Inhibition of cfms	B	CC(=O)Nc1ccc(-c2ccc3c(Nc4ccccc4)c(C(N)=O)cnc3c2)cc1		CHEMBL443587	=	IC50	nM	80.0	CHEMBL1844	Homo sapiens	IC50	uM	0.08
	2047716	CHEMBL925269	Inhibition of cfms	B	CN(C)c1ccc(-c2ccc3c(Nc4ccccc4)c(C(N)=O)cnc3c2)cc1		CHEMBL248931	=	IC50	nM	40.0	CHEMBL1844	Homo sapiens	IC50	uM	0.04
	2047717	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccc(N)cc3)ccc2c1Nc1ccccc1		CHEMBL399647	=	IC50	nM	160.0	CHEMBL1844	Homo sapiens	IC50	uM	0.16
	2047718	CHEMBL925269	Inhibition of cfms	B	N#Cc1cccc(-c2ccc3c(Nc4ccccc4)c(C(N)=O)cnc3c2)c1		CHEMBL249371	=	IC50	nM	320.0	CHEMBL1844	Homo sapiens	IC50	uM	0.32
	2047719	CHEMBL925269	Inhibition of cfms	B	N#Cc1ccc(-c2ccc3c(Nc4ccccc4)c(C(N)=O)cnc3c2)cc1		CHEMBL249163	=	IC50	nM	50.0	CHEMBL1844	Homo sapiens	IC50	uM	0.05
	2047720	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccc(Br)cc3)ccc2c1Nc1ccccc1		CHEMBL399441	=	IC50	nM	16.0	CHEMBL1844	Homo sapiens	IC50	uM	0.016
	2047721	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccc(C(F)(F)F)cc3)ccc2c1Nc1ccccc1		CHEMBL401420	=	IC50	nM	130.0	CHEMBL1844	Homo sapiens	IC50	uM	0.13
	2047722	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccc(F)cc3)ccc2c1Nc1ccccc1		CHEMBL251367	=	IC50	nM	32.0	CHEMBL1844	Homo sapiens	IC50	uM	0.032
	2047723	CHEMBL925269	Inhibition of cfms	B	COc1ccc(-c2ccc3c(Nc4ccccc4)c(C(N)=O)cnc3c2)cc1		CHEMBL251174	=	IC50	nM	25.0	CHEMBL1844	Homo sapiens	IC50	uM	0.025
	2047724	CHEMBL925269	Inhibition of cfms	B	Cc1ccc(-c2ccc3c(Nc4ccccc4)c(C(N)=O)cnc3c2)cc1		CHEMBL251173	=	IC50	nM	50.0	CHEMBL1844	Homo sapiens	IC50	uM	0.05
	2047725	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccccc3)ccc2c1Nc1ccccc1		CHEMBL249752	=	IC50	nM	250.0	CHEMBL1844	Homo sapiens	IC50	uM	0.25
	2047726	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccncc3)ccc2c1Nc1cccc2[nH]ncc12		CHEMBL249751	=	IC50	nM	160.0	CHEMBL1844	Homo sapiens	IC50	uM	0.16
	2047727	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccncc3)ccc2c1Nc1n[nH]c2ccccc12		CHEMBL400289	=	IC50	nM	320.0	CHEMBL1844	Homo sapiens	IC50	uM	0.32
	2047728	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccncc3)ccc2c1Nc1ccon1		CHEMBL400288	=	IC50	nM	3200.0	CHEMBL1844	Homo sapiens	IC50	uM	3.2
	2047729	CHEMBL925269	Inhibition of cfms	B	CC(C)Oc1ccc(Nc2c(C(N)=O)cnc3cc(-c4ccncc4)ccc23)cc1F		CHEMBL249545	=	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	2047730	CHEMBL925269	Inhibition of cfms	B	CCOc1ccc(Nc2c(C(N)=O)cnc3cc(-c4ccncc4)ccc23)cc1F		CHEMBL249544	=	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	uM	0.1
	2047731	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccncc3)ccc2c1Nc1ccc(OC(F)(F)F)c(Cl)c1		CHEMBL399932	=	IC50	nM	32.0	CHEMBL1844	Homo sapiens	IC50	uM	0.032
	2047732	CHEMBL925269	Inhibition of cfms	B	COc1ccc(Nc2c(C(N)=O)cnc3cc(-c4ccncc4)ccc23)cc1Cl		CHEMBL248933	=	IC50	nM	32.0	CHEMBL1844	Homo sapiens	IC50	uM	0.032
	2047733	CHEMBL925269	Inhibition of cfms	B	COc1ccc(Nc2c(C(N)=O)cnc3cc(-c4ccncc4)ccc23)cc1F		CHEMBL248740	=	IC50	nM	40.0	CHEMBL1844	Homo sapiens	IC50	uM	0.04
	2047734	CHEMBL925269	Inhibition of cfms	B	Cc1cc(Nc2c(C(N)=O)cnc3cc(-c4ccncc4)ccc23)ccc1Cl		CHEMBL248930	=	IC50	nM	160.0	CHEMBL1844	Homo sapiens	IC50	uM	0.16
	2047735	CHEMBL925269	Inhibition of cfms	B	Cc1ccc(Nc2c(C(N)=O)cnc3cc(-c4ccncc4)ccc23)cc1Cl		CHEMBL399739	=	IC50	nM	40.0	CHEMBL1844	Homo sapiens	IC50	uM	0.04
	2047736	CHEMBL925269	Inhibition of cfms	B	Cc1cc(Nc2c(C(N)=O)cnc3cc(-c4ccncc4)ccc23)ccc1F		CHEMBL249781	=	IC50	nM	50.0	CHEMBL1844	Homo sapiens	IC50	uM	0.05
	2047737	CHEMBL925269	Inhibition of cfms	B	Cc1ccc(Nc2c(C(N)=O)cnc3cc(-c4ccncc4)ccc23)cc1F		CHEMBL399118	=	IC50	nM	80.0	CHEMBL1844	Homo sapiens	IC50	uM	0.08
	2047738	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccncc3)ccc2c1Nc1ccc(F)c(F)c1		CHEMBL249779	=	IC50	nM	32.0	CHEMBL1844	Homo sapiens	IC50	uM	0.032
	2047739	CHEMBL925269	Inhibition of cfms	B	Cc1ccc(Nc2c(C(N)=O)cnc3cc(-c4ccncc4)ccc23)cc1C		CHEMBL399117	=	IC50	nM	80.0	CHEMBL1844	Homo sapiens	IC50	uM	0.08
	2047740	CHEMBL925269	Inhibition of cfms	B	CC(C)Oc1ccc(Nc2c(C(N)=O)cnc3cc(-c4ccncc4)ccc23)cc1		CHEMBL249574	=	IC50	nM	630.0	CHEMBL1844	Homo sapiens	IC50	uM	0.63
	2047741	CHEMBL925269	Inhibition of cfms	B	CN(C)c1ccc(Nc2c(C(N)=O)cnc3cc(-c4ccncc4)ccc23)cc1		CHEMBL249573	=	IC50	nM	63.0	CHEMBL1844	Homo sapiens	IC50	uM	0.063
	2047742	CHEMBL925269	Inhibition of cfms	B	CSc1ccc(Nc2c(C(N)=O)cnc3cc(-c4ccncc4)ccc23)cc1		CHEMBL249377	=	IC50	nM	130.0	CHEMBL1844	Homo sapiens	IC50	uM	0.13
	2047743	CHEMBL925269	Inhibition of cfms	B	NC(=O)c1cnc2cc(-c3ccncc3)ccc2c1Nc1ccc(F)cc1		CHEMBL398920	=	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	uM	0.1
	2047744	CHEMBL925269	Inhibition of cfms	B	COc1ccc(Nc2c(C(N)=O)cnc3cc(-c4ccncc4)ccc23)cc1		CHEMBL249170	=	IC50	nM	63.0	CHEMBL1844	Homo sapiens	IC50	uM	0.063
	2050184	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCCCC1)c1ccc([N+](=O)[O-])o1		CHEMBL428056	=	IC50	nM	53.0	CHEMBL1844	Homo sapiens	IC50	uM	0.053
	2050185	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	CC1CCN(c2ccc(CO)cc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL400754	=	IC50	nM	24.0	CHEMBL1844	Homo sapiens	IC50	uM	0.024
	2050186	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	N#Cc1ccc(C(=O)Nc2cc(CNC(=N)N)ccc2N2CCCCC2)o1		CHEMBL400753	=	IC50	nM	34.0	CHEMBL1844	Homo sapiens	IC50	uM	0.034
	2050187	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	CS(=O)(=O)NCc1ccc(N2CCCCC2)c(NC(=O)c2ccc(C#N)o2)c1		CHEMBL250157	=	IC50	nM	37.0	CHEMBL1844	Homo sapiens	IC50	uM	0.037
	2050188	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	N#Cc1ccc(C(=O)Nc2cc(COCC(O)CO)ccc2N2CCCCC2)o1		CHEMBL398360	=	IC50	nM	19.0	CHEMBL1844	Homo sapiens	IC50	uM	0.019
	2050189	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	CN1CCN(Cc2ccc(N3CCCCC3)c(NC(=O)c3ccc(C#N)o3)c2)CC1		CHEMBL250156	=	IC50	nM	80.0	CHEMBL1844	Homo sapiens	IC50	uM	0.08
	2050190	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	N#Cc1ccc(C(=O)Nc2cc(N3CCCCC3)ccc2N2CCCCC2)o1		CHEMBL249957	=	IC50	nM	17.0	CHEMBL1844	Homo sapiens	IC50	uM	0.017
	2050191	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	N#Cc1ccc(N2CCCCC2)c(NC(=O)c2ccc(C#N)o2)c1		CHEMBL399543	=	IC50	nM	120.0	CHEMBL1844	Homo sapiens	IC50	uM	0.12
	2050192	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	N#Cc1ccc(C(=O)Nc2cc(C(=O)O)ccc2N2CCCCC2)o1		CHEMBL249956	>	IC50	nM	2000.0	CHEMBL1844	Homo sapiens	IC50	uM	2.0
	2050193	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	N#Cc1ccc(C(=O)Nc2cc(C=O)ccc2N2CCCCC2)o1		CHEMBL249955	=	IC50	nM	37.0	CHEMBL1844	Homo sapiens	IC50	uM	0.037
	2050194	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	N#Cc1ccc(C(=O)Nc2cc(CN)ccc2N2CCCCC2)o1		CHEMBL249749	=	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	uM	0.2
	2050195	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	N#Cc1ccc(C(=O)Nc2cc(CO)ccc2N2CCCCC2)o1		CHEMBL399542	=	IC50	nM	25.0	CHEMBL1844	Homo sapiens	IC50	uM	0.025
	2050196	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	COc1ccc(N2CCCCC2)c(NC(=O)c2ccc(C#N)o2)c1		CHEMBL249748	=	IC50	nM	90.0	CHEMBL1844	Homo sapiens	IC50	uM	0.09
	2050197	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	N#Cc1ccc(C(=O)Nc2cc(O)ccc2N2CCCCC2)o1		CHEMBL249747	=	IC50	nM	17.0	CHEMBL1844	Homo sapiens	IC50	uM	0.017
	2050198	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	N#Cc1c[nH]c(C(=O)Nc2ccccc2N2CCCCC2)c1		CHEMBL398933	=	IC50	nM	47.0	CHEMBL1844	Homo sapiens	IC50	uM	0.047
	2050199	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCCCC1)c1cc([N+](=O)[O-])c[nH]1		CHEMBL398734	=	IC50	nM	47.0	CHEMBL1844	Homo sapiens	IC50	uM	0.047
	2050200	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	N#Cc1ccc(C(=O)Nc2ccccc2N2CCCCC2)o1		CHEMBL249543	=	IC50	nM	36.0	CHEMBL1844	Homo sapiens	IC50	uM	0.036
	2050201	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCCCC1)c1ccc(C(F)(F)F)o1		CHEMBL249542	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2050202	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	NC(=O)c1ccc(C(=O)Nc2ccccc2N2CCCCC2)o1		CHEMBL400123	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2050203	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(O)c1ccc(C(=O)Nc2ccccc2N2CCCCC2)o1		CHEMBL249346	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2050204	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=Cc1ccc(C(=O)Nc2ccccc2N2CCCCC2)o1		CHEMBL399343	=	IC50	nM	1100.0	CHEMBL1844	Homo sapiens	IC50	uM	1.1
	2050205	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCCCC1)c1ccc(Cl)o1		CHEMBL251157	=	IC50	nM	1900.0	CHEMBL1844	Homo sapiens	IC50	uM	1.9
	2050206	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCCCC1)c1ccc(Br)o1		CHEMBL251156	=	IC50	nM	4400.0	CHEMBL1844	Homo sapiens	IC50	uM	4.4
	2050207	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCCCC1)c1ccc(-c2ccccc2)o1		CHEMBL250959	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2050208	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCCCC1)c1ccc(Nc2ccccc2)o1		CHEMBL250958	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2050209	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	Nc1ccc(C(=O)Nc2ccccc2N2CCCCC2)o1		CHEMBL400939	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2050210	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCCCC1)c1ccco1		CHEMBL250757	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2050211	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCC(CO)C1)c1ccc([N+](=O)[O-])o1		CHEMBL399130	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2050212	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCC(O)C1)c1ccc([N+](=O)[O-])o1		CHEMBL399541	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2050213	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCC(CCO)CC1)c1ccc([N+](=O)[O-])o1		CHEMBL251351	=	IC50	nM	43.0	CHEMBL1844	Homo sapiens	IC50	uM	0.043
	2050214	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCC(CO)CC1)c1ccc([N+](=O)[O-])o1		CHEMBL249330	=	IC50	nM	130.0	CHEMBL1844	Homo sapiens	IC50	uM	0.13
	2050215	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCC(O)CC1)c1ccc([N+](=O)[O-])o1		CHEMBL249124	=	IC50	nM	140.0	CHEMBL1844	Homo sapiens	IC50	uM	0.14
	2050216	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCN(c2ccccc2)CC1)c1ccc([N+](=O)[O-])o1		CHEMBL399957	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2050217	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	CN1CCN(c2ccccc2NC(=O)c2ccc([N+](=O)[O-])o2)CC1		CHEMBL251603	=	IC50	nM	390.0	CHEMBL1844	Homo sapiens	IC50	uM	0.39
	2050218	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	CC1CCN(c2ccccc2NC(=O)c2ccc([N+](=O)[O-])o2)CC1		CHEMBL251602	=	IC50	nM	78.0	CHEMBL1844	Homo sapiens	IC50	uM	0.078
	2050219	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	CC1CC(C)CN(c2ccccc2NC(=O)c2ccc([N+](=O)[O-])o2)C1		CHEMBL401198	=	IC50	nM	5300.0	CHEMBL1844	Homo sapiens	IC50	uM	5.3
	2050220	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	CC1CCCN(c2ccccc2NC(=O)c2ccc([N+](=O)[O-])o2)C1		CHEMBL439233	=	IC50	nM	380.0	CHEMBL1844	Homo sapiens	IC50	uM	0.38
	2050221	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	CC1CCCCN1c1ccccc1NC(=O)c1ccc([N+](=O)[O-])o1		CHEMBL250188	=	IC50	nM	720.0	CHEMBL1844	Homo sapiens	IC50	uM	0.72
	2050222	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1C=CC=CC=C1)c1ccc([N+](=O)[O-])o1		CHEMBL250187	=	IC50	nM	260.0	CHEMBL1844	Homo sapiens	IC50	uM	0.26
	2050223	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCCC1)c1ccc([N+](=O)[O-])o1		CHEMBL249987	=	IC50	nM	1900.0	CHEMBL1844	Homo sapiens	IC50	uM	1.9
	2050224	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCC1)c1ccc([N+](=O)[O-])o1		CHEMBL249162	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2050225	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1Nc1ccccc1)c1ccc([N+](=O)[O-])o1		CHEMBL248959	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2050226	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	CCCN(CCC)c1ccccc1NC(=O)c1ccc([N+](=O)[O-])o1		CHEMBL248958	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2050227	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	CCCN(CC)c1ccccc1NC(=O)c1ccc([N+](=O)[O-])o1		CHEMBL251586	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2050228	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCNCC1)c1ccc([N+](=O)[O-])o1		CHEMBL251575	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2050229	CHEMBL925553	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase	B	O=C(Nc1ccccc1N1CCOCC1)c1ccc([N+](=O)[O-])o1		CHEMBL251369	=	IC50	nM	1100.0	CHEMBL1844	Homo sapiens	IC50	uM	1.1
	2050230	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	O=C(Nc1ccccc1N1CCCCC1)c1ccc([N+](=O)[O-])o1		CHEMBL428056	=	IC50	nM	360.0	CHEMBL1844	Homo sapiens	IC50	uM	0.36
	2050231	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	CC1CCN(c2ccc(CO)cc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL400754	=	IC50	nM	250.0	CHEMBL1844	Homo sapiens	IC50	uM	0.25
	2050232	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	N#Cc1ccc(C(=O)Nc2cc(CNC(=N)N)ccc2N2CCCCC2)o1		CHEMBL400753	=	IC50	nM	2600.0	CHEMBL1844	Homo sapiens	IC50	uM	2.6
	2050233	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	CS(=O)(=O)NCc1ccc(N2CCCCC2)c(NC(=O)c2ccc(C#N)o2)c1		CHEMBL250157	=	IC50	nM	310.0	CHEMBL1844	Homo sapiens	IC50	uM	0.31
	2050234	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	N#Cc1ccc(C(=O)Nc2cc(COCC(O)CO)ccc2N2CCCCC2)o1		CHEMBL398360	=	IC50	nM	170.0	CHEMBL1844	Homo sapiens	IC50	uM	0.17
	2050235	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	CN1CCN(Cc2ccc(N3CCCCC3)c(NC(=O)c3ccc(C#N)o3)c2)CC1		CHEMBL250156	=	IC50	nM	1010.0	CHEMBL1844	Homo sapiens	IC50	uM	1.01
	2050236	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	N#Cc1ccc(C(=O)Nc2cc(N3CCCCC3)ccc2N2CCCCC2)o1		CHEMBL249957	=	IC50	nM	76.0	CHEMBL1844	Homo sapiens	IC50	uM	0.076
	2050237	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	N#Cc1ccc(N2CCCCC2)c(NC(=O)c2ccc(C#N)o2)c1		CHEMBL399543	=	IC50	nM	750.0	CHEMBL1844	Homo sapiens	IC50	uM	0.75
	2050238	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	N#Cc1ccc(C(=O)Nc2cc(C(=O)O)ccc2N2CCCCC2)o1		CHEMBL249956	>	IC50	nM	2000.0	CHEMBL1844	Homo sapiens	IC50	uM	2.0
	2050239	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	N#Cc1ccc(C(=O)Nc2cc(C=O)ccc2N2CCCCC2)o1		CHEMBL249955	=	IC50	nM	330.0	CHEMBL1844	Homo sapiens	IC50	uM	0.33
	2050240	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	N#Cc1ccc(C(=O)Nc2cc(CN)ccc2N2CCCCC2)o1		CHEMBL249749	=	IC50	nM	3100.0	CHEMBL1844	Homo sapiens	IC50	uM	3.1
	2050241	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	N#Cc1ccc(C(=O)Nc2cc(CO)ccc2N2CCCCC2)o1		CHEMBL399542	=	IC50	nM	190.0	CHEMBL1844	Homo sapiens	IC50	uM	0.19
	2050242	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	COc1ccc(N2CCCCC2)c(NC(=O)c2ccc(C#N)o2)c1		CHEMBL249748	=	IC50	nM	960.0	CHEMBL1844	Homo sapiens	IC50	uM	0.96
	2050243	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	N#Cc1ccc(C(=O)Nc2cc(O)ccc2N2CCCCC2)o1		CHEMBL249747	=	IC50	nM	2700.0	CHEMBL1844	Homo sapiens	IC50	uM	2.7
	2050244	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	N#Cc1c[nH]c(C(=O)Nc2ccccc2N2CCCCC2)c1		CHEMBL398933	=	IC50	nM	150.0	CHEMBL1844	Homo sapiens	IC50	uM	0.15
	2050245	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	O=C(Nc1ccccc1N1CCCCC1)c1cc([N+](=O)[O-])c[nH]1		CHEMBL398734	=	IC50	nM	180.0	CHEMBL1844	Homo sapiens	IC50	uM	0.18
	2050246	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	N#Cc1ccc(C(=O)Nc2ccccc2N2CCCCC2)o1		CHEMBL249543	=	IC50	nM	370.0	CHEMBL1844	Homo sapiens	IC50	uM	0.37
	2050247	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	O=C(Nc1ccccc1N1CCC(CCO)CC1)c1ccc([N+](=O)[O-])o1		CHEMBL251351	=	IC50	nM	230.0	CHEMBL1844	Homo sapiens	IC50	uM	0.23
	2050248	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	O=C(Nc1ccccc1N1CCC(CO)CC1)c1ccc([N+](=O)[O-])o1		CHEMBL249330	=	IC50	nM	1400.0	CHEMBL1844	Homo sapiens	IC50	uM	1.4
	2050249	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	O=C(Nc1ccccc1N1CCC(O)CC1)c1ccc([N+](=O)[O-])o1		CHEMBL249124	=	IC50	nM	370.0	CHEMBL1844	Homo sapiens	IC50	uM	0.37
	2050250	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	CN1CCN(c2ccccc2NC(=O)c2ccc([N+](=O)[O-])o2)CC1		CHEMBL251603	=	IC50	nM	1400.0	CHEMBL1844	Homo sapiens	IC50	uM	1.4
	2050251	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	CC1CCN(c2ccccc2NC(=O)c2ccc([N+](=O)[O-])o2)CC1		CHEMBL251602	=	IC50	nM	300.0	CHEMBL1844	Homo sapiens	IC50	uM	0.3
	2050252	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	CC1CCCN(c2ccccc2NC(=O)c2ccc([N+](=O)[O-])o2)C1		CHEMBL439233	=	IC50	nM	2200.0	CHEMBL1844	Homo sapiens	IC50	uM	2.2
	2050253	CHEMBL925554	Inhibition of ATP-induced autophosphorylation of cFMS tyrosine kinase in HEK 293 cells	B	O=C(Nc1ccccc1N1C=CC=CC=C1)c1ccc([N+](=O)[O-])o1		CHEMBL250187	=	IC50	nM	2000.0	CHEMBL1844	Homo sapiens	IC50	uM	2.0
	2079182	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	O=C(Nc1ccccc1N1CCCCC1)c1ccno1		CHEMBL253864	=	IC50	nM	400.0	CHEMBL1844	Homo sapiens	IC50	uM	0.4
	2079183	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CC1CCN(c2cc(N3CCN(C)CC3)cnc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL251842	=	IC50	nM	720.0	CHEMBL1844	Homo sapiens	IC50	uM	0.72
	2079184	CHEMBL927236	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system at 2 uM by fluorescence polarization	B	CC1CCN(c2cc(N3CCN(C)CC3)cnc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL251842	=	Inhibition	%	69.0	CHEMBL1844	Homo sapiens	Inhibition	%	69.0
	2079185	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CC1CCN(c2nc(N3CCN(C)CC3)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL252834	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	uM	0.01
	2079186	CHEMBL927236	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system at 2 uM by fluorescence polarization	B	CC1CCN(c2nc(N3CCN(C)CC3)cnc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL252833	=	Inhibition	%	8.0	CHEMBL1844	Homo sapiens	Inhibition	%	8.0
	2079187	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CN1CCN(c2ccc(NC(=O)c3ccc(C#N)o3)c(N3CCOCC3)c2)CC1		CHEMBL252832	=	IC50	nM	80.0	CHEMBL1844	Homo sapiens	IC50	uM	0.08
	2079188	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CN1CCN(c2ccc(NC(=O)c3ccc(C#N)o3)c(N3CCCCC3=O)c2)CC1		CHEMBL252634	>	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	uM	0.06
	2079189	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CN1CCN(c2ccc(NC(=O)c3ccc(C#N)o3)c(N3CCCC(F)C3)c2)CC1		CHEMBL252633	=	IC50	nM	6.3	CHEMBL1844	Homo sapiens	IC50	uM	0.0063
	2079190	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CC1CCN(c2cc(N3CCN(C)CC3)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL252436	=	IC50	nM	1.0	CHEMBL1844	Homo sapiens	IC50	uM	0.001
	2079191	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CN1CCN(c2ccc(NC(=O)c3cc(C#N)c[nH]3)c(N3CCCCC3)c2)CC1		CHEMBL399763	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	uM	0.0017
	2079192	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CN1CCN(c2ccc(NC(=O)c3ccc(C#N)o3)c(N3CCCCC3)c2)CC1		CHEMBL398509	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	uM	0.0008
	2079193	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	N#Cc1ccc(C(=O)Nc2ccc(F)cc2N2CCCCC2)o1		CHEMBL429837	=	IC50	nM	63.0	CHEMBL1844	Homo sapiens	IC50	uM	0.063
	2079194	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CCN(C)CCCc1ccc(NC(=O)c2ccc(C#N)o2)c(N2CCCCC2)c1		CHEMBL398508	=	IC50	nM	52.0	CHEMBL1844	Homo sapiens	IC50	uM	0.052
	2079195	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CCOc1ccc(NC(=O)c2ccc(C#N)o2)c(N2CCCCC2)c1		CHEMBL253884	=	IC50	nM	21.0	CHEMBL1844	Homo sapiens	IC50	uM	0.021
	2079196	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CN(c1ccc(NC(=O)c2ccc(C#N)o2)c(N2CCCCC2)c1)S(C)(=O)=O		CHEMBL400259	=	IC50	nM	25.0	CHEMBL1844	Homo sapiens	IC50	uM	0.025
	2079197	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CS(=O)(=O)Nc1ccc(NC(=O)c2ccc(C#N)o2)c(N2CCCCC2)c1		CHEMBL428945	=	IC50	nM	71.0	CHEMBL1844	Homo sapiens	IC50	uM	0.071
	2079198	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	N#Cc1ccc(C(=O)Nc2ccc(-n3ccnc3)cc2N2CCCCC2)o1		CHEMBL253027	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	uM	0.003
	2079199	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	Cc1cnn(-c2ccc(NC(=O)c3ccc(C#N)o3)c(N3CCCCC3)c2)c1		CHEMBL253026	=	IC50	nM	64.0	CHEMBL1844	Homo sapiens	IC50	uM	0.064
	2079200	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	N#Cc1ccc(C(=O)Nc2ccc(N3CCS(=O)(=O)CC3)cc2N2CCCCC2)o1		CHEMBL252822	=	IC50	nM	0.7	CHEMBL1844	Homo sapiens	IC50	uM	0.0007
	2079201	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CN1CCN(C(=O)N(C)c2ccc(NC(=O)c3ccc(C#N)o3)c(N3CCCCC3)c2)CC1		CHEMBL254498	=	IC50	nM	83.0	CHEMBL1844	Homo sapiens	IC50	uM	0.083
	2079202	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	N#Cc1ccc(C(=O)Nc2ccc(N3CCCCC3)cc2N2CCCCC2)o1		CHEMBL398238	=	IC50	nM	17.0	CHEMBL1844	Homo sapiens	IC50	uM	0.017
	2079203	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CC1CCN(c2cc(N3CCOCC3)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL254496	=	IC50	nM	11.0	CHEMBL1844	Homo sapiens	IC50	uM	0.011
	2079204	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CC1CCN(c2cc(N3CCN(CCO)CC3)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL398237	=	IC50	nM	0.6	CHEMBL1844	Homo sapiens	IC50	uM	0.0006
	2079205	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CC1CCN(c2cc(N3CCN(S(C)(=O)=O)CC3)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL254910	=	IC50	nM	0.9	CHEMBL1844	Homo sapiens	IC50	uM	0.0009
	2079206	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CC(=O)N1CCN(c2ccc(NC(=O)c3cc(C#N)c[nH]3)c(N3CCC(C)CC3)c2)CC1		CHEMBL254909	=	IC50	nM	0.7	CHEMBL1844	Homo sapiens	IC50	uM	0.0007
	2079207	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CC1CCN(c2cc(N3CCNCC3)ccc2NC(=O)c2cc(C#N)c[nH]2)CC1		CHEMBL254908	=	IC50	nM	1.0	CHEMBL1844	Homo sapiens	IC50	uM	0.001
	2079208	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CC1CCN(c2cc(N3CCN(C)CC3)ccc2NC(=O)c2cc(C#N)c[nH]2)CC1		CHEMBL254702	=	IC50	nM	0.78	CHEMBL1844	Homo sapiens	IC50	uM	0.00078
	2079209	CHEMBL927234	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system after 80 mins by fluorescence polarization	B	CC1CCN(c2ccc(CO)cc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL400754	=	IC50	nM	24.0	CHEMBL1844	Homo sapiens	IC50	uM	0.024
	2079210	CHEMBL927236	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system at 2 uM by fluorescence polarization	B	CC1CCN(c2nc(N3CCN(C)CC3)ncc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL251841	=	Inhibition	%	2.0	CHEMBL1844	Homo sapiens	Inhibition	%	2.0
	2079211	CHEMBL927236	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system at 2 uM by fluorescence polarization	B	CC1CCN(c2nc(N3CCN(C)CC3)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL252834	=	Inhibition	%	97.0	CHEMBL1844	Homo sapiens	Inhibition	%	97.0
	2079212	CHEMBL927236	Inhibition of human cytoplasmic FMS expressed in Sf9-baculovirus system at 2 uM by fluorescence polarization	B	CC1CCN(c2cc(N3CCN(C)CC3)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL252436	=	Inhibition	%	100.0	CHEMBL1844	Homo sapiens	Inhibition	%	100.0
	2081487	CHEMBL928672	Inhibition of CSF1R	B	O=C(Cn1cc(Nc2nncc3cc(OCCCN4CCC[C@@H]4CO)ccc23)cn1)Nc1cccc(F)c1F		CHEMBL253968	=	IC50	nM	36.0	CHEMBL1844	Homo sapiens	IC50	uM	0.036
	2088338	CHEMBL930128	Inhibition of CSF1R by HTRF assay	B	Cc1cccc(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL404367	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
	2088344	CHEMBL930128	Inhibition of CSF1R by HTRF assay	B	Nc1n[nH]c2nccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL255955	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	nM	3.0
	2109086	CHEMBL949294	Inhibition of CSF1R by HTRF assay	B	COc1ccc(-c2ccc(NC(=O)Nc3cc(C)ccc3F)cc2)c2c(N)noc12		CHEMBL270084	=	IC50	nM	27.0	CHEMBL1844	Homo sapiens	IC50	nM	27.0
	2109094	CHEMBL949294	Inhibition of CSF1R by HTRF assay	B	COc1ccc(-c2ccc(NC(=O)Nc3cccc(Cl)c3)cc2)c2c(N)noc12		CHEMBL269884	=	IC50	nM	40.0	CHEMBL1844	Homo sapiens	IC50	nM	40.0
	2109095	CHEMBL949294	Inhibition of CSF1R by HTRF assay	B	COc1ccc(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)c2c(N)noc12		CHEMBL430090	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	nM	30.0
	2114349	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	CCOC(=O)c1c(-c2ccccc2)c2cc(Cl)ccc2[nH]c1=O		CHEMBL257323	=	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	2114350	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	CCc1ccc(-c2c(-c3cnc(C)[nH]3)c(=O)[nH]c3ccc(C#N)cc23)cc1		CHEMBL273198	=	IC50	nM	2.5	CHEMBL1844	Homo sapiens	IC50	uM	0.0025
	2114351	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	CCc1ccc(-c2c(-c3cnc(C)[nH]3)c(=O)[nH]c3ccc(Cl)cc23)cc1		CHEMBL403661	=	IC50	nM	2.1	CHEMBL1844	Homo sapiens	IC50	uM	0.0021
	2114352	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cccc(-c2c(-c3cc(C)no3)c(=O)[nH]c3ccc(Cl)cc23)c1		CHEMBL403621	=	IC50	nM	240.0	CHEMBL1844	Homo sapiens	IC50	uM	0.24
	2114353	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cc(-c2c(-c3ccncc3)c3cc(Cl)ccc3[nH]c2=O)on1		CHEMBL270566	=	IC50	nM	2100.0	CHEMBL1844	Homo sapiens	IC50	uM	2.1
	2114354	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cc(-c2c(C3CCCCC3)c3cc(Cl)ccc3[nH]c2=O)on1		CHEMBL270783	=	IC50	nM	340.0	CHEMBL1844	Homo sapiens	IC50	uM	0.34
	2114355	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cc(-c2c(C3=CCCCCC3)c3cc(Cl)ccc3[nH]c2=O)on1		CHEMBL436651	=	IC50	nM	90.0	CHEMBL1844	Homo sapiens	IC50	uM	0.09
	2114356	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cc(-c2c(C3=CCCCC3)c3cc(Cl)ccc3[nH]c2=O)on1		CHEMBL270463	=	IC50	nM	220.0	CHEMBL1844	Homo sapiens	IC50	uM	0.22
	2114357	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	COc1ccc(-c2c(-c3cc(C)no3)c(=O)[nH]c3ccc(Cl)cc23)cc1		CHEMBL270464	=	IC50	nM	140.0	CHEMBL1844	Homo sapiens	IC50	uM	0.14
	2114358	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cc(-c2c(-c3ccc(O)cc3)c3cc(Cl)ccc3[nH]c2=O)on1		CHEMBL255634	=	IC50	nM	170.0	CHEMBL1844	Homo sapiens	IC50	uM	0.17
	2114359	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cc(-c2c(-c3ccc(C(C)C)cc3)c3cc(Cl)ccc3[nH]c2=O)on1		CHEMBL402429	=	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	uM	0.2
	2114360	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	CCc1ccc(-c2c(-c3cc(C)no3)c(=O)[nH]c3ccc(Cl)cc23)cc1		CHEMBL255213	=	IC50	nM	90.0	CHEMBL1844	Homo sapiens	IC50	uM	0.09
	2114361	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1ccc(-c2c(-c3cc(C)no3)c(=O)[nH]c3ccc(Cl)cc23)cc1		CHEMBL255215	=	IC50	nM	110.0	CHEMBL1844	Homo sapiens	IC50	uM	0.11
	2114362	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cc(-c2c(-c3ccccc3)c3ncccc3[nH]c2=O)on1		CHEMBL403243	>	IC50	nM	20000.0	CHEMBL1844	Homo sapiens	IC50	uM	20.0
	2114363	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cc(-c2c(-c3ccccc3)c3cc(Cl)ncc3[nH]c2=O)on1		CHEMBL271259	=	IC50	nM	720.0	CHEMBL1844	Homo sapiens	IC50	uM	0.72
	2114364	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cc(-c2c(-c3ccccc3)c3cc(Cl)cnc3[nH]c2=O)on1		CHEMBL401618	=	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	2114365	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cn1cnc(-c2c(-c3ccccc3)c3cc(C#N)ccc3[nH]c2=O)c1		CHEMBL273011	=	IC50	nM	550.0	CHEMBL1844	Homo sapiens	IC50	uM	0.55
	2114366	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	N#Cc1ccc2[nH]c(=O)c(-c3cnc[nH]3)c(-c3ccccc3)c2c1		CHEMBL401736	=	IC50	nM	280.0	CHEMBL1844	Homo sapiens	IC50	uM	0.28
	2114367	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	O=c1[nH]c2ccc(Cl)cc2c(-c2ccccc2)c1-c1cnc[nH]1		CHEMBL258088	=	IC50	nM	180.0	CHEMBL1844	Homo sapiens	IC50	uM	0.18
	2114368	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cc(-c2c(-c3ccccc3)c3cc(Cl)ccc3[nH]c2=O)[nH]n1		CHEMBL401738	=	IC50	nM	830.0	CHEMBL1844	Homo sapiens	IC50	uM	0.83
	2114369	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	O=c1[nH]c2ccc(Cl)cc2c(-c2ccccc2)c1-c1ccc[nH]1		CHEMBL257456	=	IC50	nM	360.0	CHEMBL1844	Homo sapiens	IC50	uM	0.36
	2114370	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Nc1cc(-c2c(-c3ccccc3)c3cc(Cl)ccc3[nH]c2=O)on1		CHEMBL403097	=	IC50	nM	320.0	CHEMBL1844	Homo sapiens	IC50	uM	0.32
	2114371	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	CC(C)c1cc(-c2c(-c3ccccc3)c3cc(Cl)ccc3[nH]c2=O)on1		CHEMBL271479	=	IC50	nM	300.0	CHEMBL1844	Homo sapiens	IC50	uM	0.3
	2114372	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cc(-c2c(-c3ccccc3)c3ccccc3[nH]c2=O)on1		CHEMBL402635	>	IC50	nM	5000.0	CHEMBL1844	Homo sapiens	IC50	uM	5.0
	2114373	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cc(-c2c(-c3ccccc3)c3cc(N)ccc3[nH]c2=O)on1		CHEMBL271523	>	IC50	nM	5000.0	CHEMBL1844	Homo sapiens	IC50	uM	5.0
	2114374	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cc(-c2c(-c3ccccc3)c3cc([N+](=O)[O-])ccc3[nH]c2=O)on1		CHEMBL256836	=	IC50	nM	340.0	CHEMBL1844	Homo sapiens	IC50	uM	0.34
	2114375	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cc(-c2c(-c3ccccc3)c3cc(F)ccc3[nH]c2=O)on1		CHEMBL401691	=	IC50	nM	250.0	CHEMBL1844	Homo sapiens	IC50	uM	0.25
	2114376	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cc(-c2c(-c3ccccc3)c3cc(C#N)ccc3[nH]c2=O)on1		CHEMBL272119	=	IC50	nM	90.0	CHEMBL1844	Homo sapiens	IC50	uM	0.09
	2114377	CHEMBL951197	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor by fluorescence polarization	B	Cc1cc(-c2c(-c3ccccc3)c3cc(Cl)ccc3[nH]c2=O)on1		CHEMBL257705	=	IC50	nM	140.0	CHEMBL1844	Homo sapiens	IC50	uM	0.14
	2114400	CHEMBL951196	Inhibition of human cytoplasmic macrophage colony-stimulating factor 1 receptor at 5 uM by fluorescence polarization	B	Cc1cc(-c2c(-c3ccccc3)c3cnccc3[nH]c2=O)on1		CHEMBL271049	=	Inhibition	%	8.0	CHEMBL1844	Homo sapiens	Inhibition	%	8.0
	2120499	CHEMBL951263	Inhibition of cFMS by HTRF assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cnc(Nc2ccc(N3CCN(C)CC3)cc2)nc1		CHEMBL272888	=	IC50	nM	40.0	CHEMBL1844	Homo sapiens	IC50	uM	0.04
Active	2120840	CHEMBL950236	Inhibition of c-fms	B	COc1cc2nccc(Oc3ccc4c(C(=O)NC5CC5)cccc4c3)c2cc1OC		CHEMBL272198		Activity			CHEMBL1844	Homo sapiens	Activity		
Active	2120847	CHEMBL950236	Inhibition of c-fms	B	COc1cc2nccc(Oc3ccc4c(C(N)=O)cccc4c3)c2cc1OC		CHEMBL271984		Activity			CHEMBL1844	Homo sapiens	Activity		
Active	2120848	CHEMBL950236	Inhibition of c-fms	B	COCCNC(=O)c1cccc2cc(Oc3ccnc4cc(OC)c(OC)cc34)ccc12		CHEMBL271188		Activity			CHEMBL1844	Homo sapiens	Activity		
	2121147	CHEMBL932999	Inhibition of c-FMS	B	COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccc(Cl)cc5)cccc4c3)c2cc1OC		CHEMBL429743	=	IC50	nM	20.0	CHEMBL1844	Homo sapiens	IC50	nM	20.0
	2122118	CHEMBL950217	Inhibition of CSF1R	B	CCOC(=O)c1nc2cnc(Nc3ccccc3)nc2n(-c2ccccc2)c1=O		CHEMBL258365	=	IC50	nM	180.0	CHEMBL1844	Homo sapiens	IC50	uM	0.18
	2122119	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CCOC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2c1=O		CHEMBL273194	=	IC50	nM	250.0	CHEMBL1844	Homo sapiens	IC50	uM	0.25
	2122120	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	NC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(NCCCn3ccnc3)ncc2c1=O		CHEMBL257318	=	IC50	nM	2300.0	CHEMBL1844	Homo sapiens	IC50	uM	2.3
	2122121	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CN1CCN(CCCNc2ncc3c(=O)c(C(N)=O)cn(-c4ccc5c(c4)CCC5)c3n2)CC1		CHEMBL272560	=	IC50	nM	1800.0	CHEMBL1844	Homo sapiens	IC50	uM	1.8
	2122122	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	NC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(NCCN3CCOCC3)ncc2c1=O		CHEMBL272773	=	IC50	nM	3300.0	CHEMBL1844	Homo sapiens	IC50	uM	3.3
	2122123	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	NC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(C[C@H]4COC(=O)N4)cc3)ncc2c1=O		CHEMBL273193	=	IC50	nM	12.0	CHEMBL1844	Homo sapiens	IC50	uM	0.012
	2122124	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	NC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3cccc(C(=O)N4CCCCC4)c3)ncc2c1=O		CHEMBL402852	=	IC50	nM	4.0	CHEMBL1844	Homo sapiens	IC50	uM	0.004
	2122125	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CN(C)CCc1ccc(Nc2ncc3c(=O)c(C(N)=O)cn(-c4ccc5c(c4)CCC5)c3n2)cc1		CHEMBL256459	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	uM	0.003
	2122126	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CN(C)Cc1ccc(Nc2ncc3c(=O)c(C(N)=O)cn(-c4ccc5c(c4)CCC5)c3n2)cc1		CHEMBL256405	=	IC50	nM	21.0	CHEMBL1844	Homo sapiens	IC50	uM	0.021
	2122127	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	NC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(CCN4CCOCC4)cc3)ncc2c1=O		CHEMBL404188	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	uM	0.008
	2122128	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	NC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(CN4CCOCC4)cc3)ncc2c1=O		CHEMBL256406	=	IC50	nM	22.0	CHEMBL1844	Homo sapiens	IC50	uM	0.022
	2122129	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CN1CCN(CCc2ccc(Nc3ncc4c(=O)c(C(N)=O)cn(-c5ccc6c(c5)CCC6)c4n3)cc2)CC1		CHEMBL403776	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	uM	0.008
	2122130	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CN1CCN(Cc2ccc(Nc3ncc4c(=O)c(C(N)=O)cn(-c5ccc6c(c5)CCC6)c4n3)cc2)CC1		CHEMBL256893	=	IC50	nM	14.0	CHEMBL1844	Homo sapiens	IC50	uM	0.014
	2122131	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	NC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(C4CCNCC4)cc3)ncc2c1=O		CHEMBL257528	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	uM	0.008
	2122132	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CN1CCN(c2ccc(Nc3ncc4c(=O)c(C(N)=O)cn(-c5ccc6c(c5)CCC6)c4n3)c(O)c2)CC1		CHEMBL404909	=	IC50	nM	93.0	CHEMBL1844	Homo sapiens	IC50	uM	0.093
	2122133	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CN1CCN(c2cccc(Nc3ncc4c(=O)c(C(N)=O)cn(-c5ccc6c(c5)CCC6)c4n3)c2)CC1		CHEMBL255584	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	uM	0.008
	2122134	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CC1CN(c2ccc(Nc3ncc4c(=O)c(C(N)=O)cn(-c5ccc6c(c5)CCC6)c4n3)cc2)CC(C)N1		CHEMBL255794	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	uM	0.007
	2122135	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	NC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(N4CCNCC4)cc3)ncc2c1=O		CHEMBL271461	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	uM	0.005
	2122136	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	NC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccccc3)ncc2c1=O		CHEMBL271460	=	IC50	nM	280.0	CHEMBL1844	Homo sapiens	IC50	uM	0.28
	2122137	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CNC(=O)c1cn(Cc2ccccc2)c2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2c1=O		CHEMBL257664	=	IC50	nM	420.0	CHEMBL1844	Homo sapiens	IC50	uM	0.42
	2122138	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CN1CCN(c2ccc(Nc3ncc4c(=O)c(C(N)=O)cn(-c5ccccc5)c4n3)cc2)CC1		CHEMBL257865	=	IC50	nM	730.0	CHEMBL1844	Homo sapiens	IC50	uM	0.73
	2122139	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CN1CCN(c2ccc(Nc3ncc4c(=O)c(C(N)=O)cn(C5CC6CCC5C6)c4n3)cc2)CC1		CHEMBL257665	=	IC50	nM	81.0	CHEMBL1844	Homo sapiens	IC50	uM	0.081
	2122140	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CN1CCN(c2ccc(Nc3ncc4c(=O)c(C(N)=O)cn(C5CCCC5)c4n3)cc2)CC1		CHEMBL272117	=	IC50	nM	56.0	CHEMBL1844	Homo sapiens	IC50	uM	0.056
	2122141	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CN1CCN(c2ccc(Nc3ncc4c(=O)c(C(N)=O)cn(C5CCCCC5)c4n3)cc2)CC1		CHEMBL272332	=	IC50	nM	35.0	CHEMBL1844	Homo sapiens	IC50	uM	0.035
	2122142	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CCNC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2c1=O		CHEMBL255181	=	IC50	nM	68.0	CHEMBL1844	Homo sapiens	IC50	uM	0.068
	2122143	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CNC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2c1=O		CHEMBL255182	=	IC50	nM	31.0	CHEMBL1844	Homo sapiens	IC50	uM	0.031
	2122144	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CN1CCN(c2ccc(Nc3cc4c(cn3)c(=O)c(C(N)=O)cn4-c3ccc4c(c3)CCC4)cc2)CC1		CHEMBL272738	=	IC50	nM	56.0	CHEMBL1844	Homo sapiens	IC50	uM	0.056
	2122145	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CN1CCN(c2ccc(Nc3ncc4c(=O)c(C(N)=O)cn(-c5ccc6c(c5)CCC6)c4n3)cc2)CC1		CHEMBL414001	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	uM	0.013
	2122146	CHEMBL950218	Inhibition of ATP-induced CSF1R autophosphorylation	B	CN1CCN(c2ccc(Nc3ncc4c(=O)c(C(=O)O)cn(-c5ccc6c(c5)CCC6)c4n3)cc2)CC1		CHEMBL257320	=	IC50	nM	1100.0	CHEMBL1844	Homo sapiens	IC50	uM	1.1
	2122197	CHEMBL950217	Inhibition of CSF1R	B	CN1CCN(Cc2ccc(Nc3ncc4c(=O)c(C(N)=O)cn(-c5ccc6c(c5)CCC6)c4n3)cc2)CC1		CHEMBL256893	=	IC50	nM	14.0	CHEMBL1844	Homo sapiens	IC50	uM	0.014
	2122198	CHEMBL950217	Inhibition of CSF1R	B	CN1CCN(c2ccc(Nc3ncc4c(=O)c(C(N)=O)cn(-c5ccc6c(c5)CCC6)c4n3)cc2)CC1		CHEMBL414001	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	uM	0.013
	2136926	CHEMBL939336	Inhibition of cFMS	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	nM	30.0
	2136972	CHEMBL939336	Inhibition of cFMS	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	IC50	nM	300.0	CHEMBL1844	Homo sapiens	IC50	nM	300.0
	2137069	CHEMBL921708	Inhibition of cFms	B	O=C1Nc2ccc(I)cc2/C1=C\c1cc(Br)c(O)c(Br)c1		CHEMBL264949	>=	Selectivity ratio		100.0	CHEMBL1844	Homo sapiens	Selectivity ratio		100.0
	2147270	CHEMBL921860	Activity of human FMS kinase at 1 uM	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Activity	%	95.0	CHEMBL1844	Homo sapiens	Activity	%	95.0
	2171992	CHEMBL933669	Inhibition of FMS	B	CC1CCN(c2cc(N3CCN(C)CC3)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL252436	=	IC50	nM	1.0	CHEMBL1844	Homo sapiens	IC50	uM	0.001
	2171993	CHEMBL933669	Inhibition of FMS	B	CC(=O)N1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCS(=O)(=O)CC3)c2)CC1		CHEMBL429855	=	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	uM	0.06
	2171994	CHEMBL933669	Inhibition of FMS	B	CC(=O)N1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CNCCC3)c2)CC1		CHEMBL258238	>	IC50	nM	150.0	CHEMBL1844	Homo sapiens	IC50	uM	0.15
	2171995	CHEMBL933669	Inhibition of FMS	B	CC(=O)N1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL256712	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	uM	0.002
	2171996	CHEMBL933669	Inhibition of FMS	B	N#Cc1cnc(C(=O)Nc2ccc(C3CCNCC3)cc2C2=CCS(=O)(=O)CC2)[nH]1		CHEMBL257153	=	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	uM	0.06
	2171997	CHEMBL933669	Inhibition of FMS	B	N#Cc1cnc(C(=O)Nc2ccc(C3CCNCC3)cc2C2=CCCC2)[nH]1		CHEMBL256950	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	uM	0.008
	2171998	CHEMBL933669	Inhibition of FMS	B	CC1CC=C(c2cc(C3CCNCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL402337	=	IC50	nM	0.4	CHEMBL1844	Homo sapiens	IC50	uM	0.0004
	2171999	CHEMBL933669	Inhibition of FMS	B	N#Cc1cnc(C(=O)Nc2ccc(C3CCNCC3)cc2C2=CCCCC2)[nH]1		CHEMBL257154	=	IC50	nM	1.0	CHEMBL1844	Homo sapiens	IC50	uM	0.001
	2172000	CHEMBL933669	Inhibition of FMS	B	CC(=O)N1CCC(c2ccc(NC(=O)c3ccc(C#N)o3)c(N3CCC(C)CC3)c2)CC1		CHEMBL257620	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	uM	0.0008
	2172001	CHEMBL933669	Inhibition of FMS	B	CC1CCN(c2cc(C3CCNCC3)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL438533	=	IC50	nM	0.3	CHEMBL1844	Homo sapiens	IC50	uM	0.0003
	2172002	CHEMBL933669	Inhibition of FMS	B	CC1CCN(c2cc(C3=CCNCC3)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL255443	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	uM	0.0008
	2172003	CHEMBL933669	Inhibition of FMS	B	CC1CCN(c2cc(C#CCN3CCOCC3)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL402908	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	uM	0.005
	2172004	CHEMBL933669	Inhibition of FMS	B	CC1CCN(c2cc(C#CCN(C)S(C)(=O)=O)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL430214	=	IC50	nM	16.0	CHEMBL1844	Homo sapiens	IC50	uM	0.016
	2172005	CHEMBL933669	Inhibition of FMS	B	CC1CCN(c2cc(C#CCN(C)C)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL255501	=	IC50	nM	15.0	CHEMBL1844	Homo sapiens	IC50	uM	0.015
	2172006	CHEMBL933669	Inhibition of FMS	B	CC1CCN(c2cc(/C=C/C(=O)O)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL261699	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	uM	0.002
	2172007	CHEMBL933669	Inhibition of FMS	B	CC1CCN(c2cc(/C=C/C(=O)OC(C)(C)C)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL411471	=	IC50	nM	38.0	CHEMBL1844	Homo sapiens	IC50	uM	0.038
	2172008	CHEMBL933669	Inhibition of FMS	B	CC1CCN(c2cc(-c3ccncc3)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL258709	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	uM	0.01
	2172009	CHEMBL933669	Inhibition of FMS	B	CC1=C(c2cc(N3CCN(C)CC3)ccc2NC(=O)c2ccc(C#N)o2)CCCC1		CHEMBL408431	=	IC50	nM	54.0	CHEMBL1844	Homo sapiens	IC50	uM	0.054
	2172010	CHEMBL933669	Inhibition of FMS	B	CN1CCN(c2ccc(NC(=O)c3ccc(C#N)o3)c(C3=CCCCC3)c2)CC1		CHEMBL265432	=	IC50	nM	18.0	CHEMBL1844	Homo sapiens	IC50	uM	0.018
	2172011	CHEMBL933669	Inhibition of FMS	B	CN1CCN(c2ccc(NC(=O)c3ccc(C#N)o3)c(C3=CCOCC3)c2)CC1		CHEMBL427775	=	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	uM	0.06
	2172012	CHEMBL933669	Inhibition of FMS	B	Cc1sccc1-c1cc(N2CCN(C)CC2)ccc1NC(=O)c1ccc(C#N)o1		CHEMBL265433	=	IC50	nM	940.0	CHEMBL1844	Homo sapiens	IC50	uM	0.94
	2172013	CHEMBL933669	Inhibition of FMS	B	Cc1ccsc1-c1cc(N2CCN(C)CC2)ccc1NC(=O)c1ccc(C#N)o1		CHEMBL258461	=	IC50	nM	470.0	CHEMBL1844	Homo sapiens	IC50	uM	0.47
	2172014	CHEMBL933669	Inhibition of FMS	B	CN1CCN(c2ccc(NC(=O)c3ccc(C#N)o3)c(-c3ccccc3F)c2)CC1		CHEMBL258680	=	IC50	nM	890.0	CHEMBL1844	Homo sapiens	IC50	uM	0.89
	2172015	CHEMBL933669	Inhibition of FMS	B	Cc1ccccc1-c1cc(N2CCN(C)CC2)ccc1NC(=O)c1ccc(C#N)o1		CHEMBL258474	=	IC50	nM	630.0	CHEMBL1844	Homo sapiens	IC50	uM	0.63
	2172016	CHEMBL933669	Inhibition of FMS	B	CC1CCN(c2cc(N3CCN(C)CC3)ccc2NC(=O)c2cc(C#N)c[nH]2)CC1		CHEMBL254702	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	uM	0.0008
	2206980	CHEMBL966753	Inhibition of Fms	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2238311	CHEMBL976278	Inhibition of Fms	B	Cc1cccc(C)c1/C=C/n1cnc2c(Nc3ccc(P(C)(C)=O)cc3)ncnc21		CHEMBL488840	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	nM	3.0
	2239294	CHEMBL980054	Inhibition of CSF1R	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1NC(=O)c1cccnc1		CHEMBL507803	=	IC50	nM	11.0	CHEMBL1844	Homo sapiens	IC50	uM	0.011
	2239296	CHEMBL980054	Inhibition of CSF1R	B	O=C(Nc1ccc(Cl)c(C(=O)Nc2cnc(C3CC3)s2)c1)c1cccc(C(F)(F)F)c1		CHEMBL472512	=	IC50	nM	140.0	CHEMBL1844	Homo sapiens	IC50	uM	0.14
	2239297	CHEMBL980054	Inhibition of CSF1R	B	Cc1cc(C)cc(C(=O)Nc2ccc(Cl)c(C(=O)Nc3cnc(C(C)C)s3)c2)c1		CHEMBL472343	=	IC50	nM	31.0	CHEMBL1844	Homo sapiens	IC50	uM	0.031
	2239298	CHEMBL980054	Inhibition of CSF1R	B	CC(C)c1ncc(NC(=O)c2cc(NC(=O)c3cccc(C(F)(F)F)c3)ccc2Cl)s1		CHEMBL472342	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	uM	0.013
	2239299	CHEMBL980054	Inhibition of CSF1R	B	Cc1ncc(NC(=O)c2cc(NC(=O)c3cc(F)cc(Cl)c3)ccc2Cl)s1		CHEMBL513588	=	IC50	nM	11.0	CHEMBL1844	Homo sapiens	IC50	uM	0.011
	2239300	CHEMBL980054	Inhibition of CSF1R	B	Cc1ncc(NC(=O)c2cc(NC(=O)c3cc(F)cc(C(F)(F)F)c3)ccc2Cl)s1		CHEMBL459675	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	uM	0.007
	2239301	CHEMBL980054	Inhibition of CSF1R	B	Cc1cc(C)cc(C(=O)Nc2ccc(Cl)c(C(=O)Nc3cnc(C)s3)c2)c1		CHEMBL462128	=	IC50	nM	6.0	CHEMBL1844	Homo sapiens	IC50	uM	0.006
	2239302	CHEMBL980054	Inhibition of CSF1R	B	Cc1cc(C)cc(C(=O)Nc2ccc(C)c(C(=O)Nc3cnc(C)s3)c2)c1		CHEMBL444671	=	IC50	nM	4.0	CHEMBL1844	Homo sapiens	IC50	uM	0.004
	2239303	CHEMBL980054	Inhibition of CSF1R	B	Cc1ncc(NC(=O)c2cc(NC(=O)c3cccc(Cl)c3)ccc2Cl)s1		CHEMBL462133	=	IC50	nM	4.0	CHEMBL1844	Homo sapiens	IC50	uM	0.004
	2239304	CHEMBL980054	Inhibition of CSF1R	B	Cc1ncc(NC(=O)c2cc(NC(=O)c3cccc(Cl)c3)ccc2C)s1		CHEMBL462130	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	uM	0.007
	2239305	CHEMBL980054	Inhibition of CSF1R	B	Cc1ncc(NC(=O)c2cc(NC(=O)c3cccc(C(F)(F)F)c3)ccc2Cl)s1		CHEMBL462132	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	uM	0.007
	2239306	CHEMBL980054	Inhibition of CSF1R	B	Cc1ncc(NC(=O)c2cc(NC(=O)c3cccc(C(F)(F)F)c3)ccc2C)s1		CHEMBL461574	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	uM	0.01
	2239307	CHEMBL980054	Inhibition of CSF1R	B	Cc1cc(C)cc(C(=O)Nc2ccc(Cl)c(C(=O)Nc3cncs3)c2)c1		CHEMBL461573	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	uM	0.003
	2239308	CHEMBL980054	Inhibition of CSF1R	B	O=C(Nc1ccc(Cl)c(C(=O)Nc2cncs2)c1)c1cccc(Cl)c1		CHEMBL461572	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	uM	0.005
	2239309	CHEMBL980054	Inhibition of CSF1R	B	O=C(Nc1ccc(Cl)c(C(=O)Nc2cncs2)c1)c1cccc(C(F)(F)F)c1		CHEMBL517437	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	uM	0.003
	2239310	CHEMBL980054	Inhibition of CSF1R	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(=O)Nc1ccccc1		CHEMBL461366	>	IC50	nM	50000.0	CHEMBL1844	Homo sapiens	IC50	uM	50.0
	2239311	CHEMBL980054	Inhibition of CSF1R	B	O=C(Nc1ccc(Cl)c(C(=O)Nc2cccnc2)c1)c1ccc(Cl)c(Cl)c1		CHEMBL461365	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	uM	0.003
	2239312	CHEMBL980054	Inhibition of CSF1R	B	O=C(Nc1ccc(Cl)c(C(=O)Nc2cccnc2)c1)c1cc(Cl)cc(Cl)c1		CHEMBL459674	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	uM	0.003
	2239313	CHEMBL980054	Inhibition of CSF1R	B	Cc1ccc(C(=O)Nc2ccc(Cl)c(C(=O)Nc3cccnc3)c2)cc1C		CHEMBL459471	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	uM	0.005
	2239314	CHEMBL980054	Inhibition of CSF1R	B	Cc1cc(C)cc(C(=O)Nc2ccc(Cl)c(C(=O)Nc3cccnc3)c2)c1		CHEMBL459470	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	uM	0.008
	2239315	CHEMBL980054	Inhibition of CSF1R	B	CN(C)c1cccc(C(=O)Nc2ccc(Cl)c(C(=O)Nc3cccnc3)c2)c1		CHEMBL516813	=	IC50	nM	16.0	CHEMBL1844	Homo sapiens	IC50	uM	0.016
	2239316	CHEMBL980054	Inhibition of CSF1R	B	COc1cccc(C(=O)Nc2ccc(Cl)c(C(=O)Nc3cccnc3)c2)c1		CHEMBL461952	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	uM	0.009
	2239317	CHEMBL980054	Inhibition of CSF1R	B	O=C(Nc1ccc(Cl)c(C(=O)Nc2cccnc2)c1)c1cccc(Br)c1		CHEMBL461951	=	IC50	nM	14.0	CHEMBL1844	Homo sapiens	IC50	uM	0.014
	2239318	CHEMBL980054	Inhibition of CSF1R	B	O=C(Nc1ccc(Cl)c(C(=O)Nc2cccnc2)c1)c1cccc(Cl)c1		CHEMBL461950	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	uM	0.01
	2239319	CHEMBL980054	Inhibition of CSF1R	B	O=C(Nc1ccc(Cl)c(C(=O)Nc2cccnc2)c1)c1cccc(F)c1		CHEMBL512385	=	IC50	nM	25.0	CHEMBL1844	Homo sapiens	IC50	uM	0.025
	2239320	CHEMBL980054	Inhibition of CSF1R	B	Cc1cccc(C(=O)Nc2ccc(Cl)c(C(=O)Nc3cccnc3)c2)c1		CHEMBL454876	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	uM	0.01
	2239321	CHEMBL980054	Inhibition of CSF1R	B	O=C(Nc1ccc(Cl)c(C(=O)Nc2cccnc2)c1)c1cccc(C(F)(F)F)c1		CHEMBL510386	=	IC50	nM	16.0	CHEMBL1844	Homo sapiens	IC50	uM	0.016
	2239322	CHEMBL980054	Inhibition of CSF1R	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cccnc1		CHEMBL469883	=	IC50	nM	6900.0	CHEMBL1844	Homo sapiens	IC50	uM	6.9
	2239323	CHEMBL980054	Inhibition of CSF1R	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1NC(=O)c1cccnc1		CHEMBL454105	=	IC50	nM	32.0	CHEMBL1844	Homo sapiens	IC50	uM	0.032
	2239324	CHEMBL980054	Inhibition of CSF1R	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(=O)Nc1cccnc1		CHEMBL454104	=	IC50	nM	37.0	CHEMBL1844	Homo sapiens	IC50	uM	0.037
	2239325	CHEMBL980054	Inhibition of CSF1R	B	Cc1ccc(NC(=O)c2cccc(N(C)S(C)(=O)=O)c2)cc1NC(=O)c1ccc2ncccc2c1		CHEMBL454616	=	IC50	nM	89.0	CHEMBL1844	Homo sapiens	IC50	nM	89.0
	2239371	CHEMBL980060	Inhibition of CSF1R assessed as residual enzyme activity at 1 uM	B	Cc1ncc(NC(=O)c2cc(NC(=O)c3cccc(C(F)(F)F)c3)ccc2Cl)s1		CHEMBL462132	=	Activity	%	1.0	CHEMBL1844	Homo sapiens	Activity	%	1.0
	2239427	CHEMBL980054	Inhibition of CSF1R	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O		CHEMBL1567	=	IC50	nM	12.0	CHEMBL1844	Homo sapiens	IC50	nM	12.0
	2240279	CHEMBL973568	Inhibition of Fms by radiometric assay	B	CS(=O)(=O)O.O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL518051	=	IC50	nM	15.0	CHEMBL1844	Homo sapiens	IC50	nM	15.0
	2250299	CHEMBL1009186	Inhibition of CSF1R	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	nM	3.0
	2251506	CHEMBL998565	Inhibition of cFMS	B	Cc1nnc(-c2ccc(-c3cc(NC(=O)c4ccc(CN5CCN(C)CC5)cc4)ccc3C)c(C)c2)o1		CHEMBL497350	=	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	uM	0.1
	2251515	CHEMBL998565	Inhibition of cFMS	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1-c1ccc2ccncc2c1		CHEMBL521887	=	IC50	nM	4.0	CHEMBL1844	Homo sapiens	IC50	uM	0.004
	2251524	CHEMBL998565	Inhibition of cFMS	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1-c1ccc2c(N)noc2c1		CHEMBL497353	=	IC50	nM	90.0	CHEMBL1844	Homo sapiens	IC50	uM	0.09
	2251533	CHEMBL998565	Inhibition of cFMS	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1-c1ccc(-c2csc(N)n2)cc1		CHEMBL496129	=	IC50	nM	90.0	CHEMBL1844	Homo sapiens	IC50	uM	0.09
	2256996	CHEMBL1001229	Inhibition of C-FMS	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	2261799	CHEMBL998565	Inhibition of cFMS	B	Cc1ccc(C(=O)Nc2cccc(N3CCOCC3)c2)cc1-c1ccc2c(C3CCNCC3)noc2c1		CHEMBL485285	>	IC50	nM	20000.0	CHEMBL1844	Homo sapiens	IC50	uM	20.0
	2261809	CHEMBL998565	Inhibition of cFMS	B	Cc1nnc(-c2ccc(-c3cc(C(=O)Nc4cccc(N5CCOCC5)c4)ccc3C)c(C)c2)o1		CHEMBL523559	=	IC50	nM	700.0	CHEMBL1844	Homo sapiens	IC50	uM	0.7
	2261819	CHEMBL998565	Inhibition of cFMS	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc2c(C3CCNCC3)noc2c1		CHEMBL485286	=	IC50	nM	7000.0	CHEMBL1844	Homo sapiens	IC50	uM	7.0
	2261831	CHEMBL998565	Inhibition of cFMS	B	Cc1nnc(-c2ccc(-c3cc(NC(=O)c4ccnc(N5CCCC5)c4)ccc3C)c(C)c2)o1		CHEMBL495729	>	IC50	nM	20000.0	CHEMBL1844	Homo sapiens	IC50	uM	20.0
	2261843	CHEMBL998565	Inhibition of cFMS	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2c(C3CCNCC3)noc2c1		CHEMBL497563	>	IC50	nM	20000.0	CHEMBL1844	Homo sapiens	IC50	uM	20.0
	2261855	CHEMBL998565	Inhibition of cFMS	B	Cc1nnc(-c2ccc(-c3cc(C(=O)NC4CC4)ccc3C)c(C)c2)o1		CHEMBL522579	>	IC50	nM	20000.0	CHEMBL1844	Homo sapiens	IC50	uM	20.0
	2261866	CHEMBL998565	Inhibition of cFMS	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2c(=O)n(CC3CC3)nnc2c1		CHEMBL521734	>	IC50	nM	20000.0	CHEMBL1844	Homo sapiens	IC50	uM	20.0
	2261877	CHEMBL998565	Inhibition of cFMS	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2ccncc2c1		CHEMBL526639	=	IC50	nM	600.0	CHEMBL1844	Homo sapiens	IC50	uM	0.6
	2261889	CHEMBL998565	Inhibition of cFMS	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL478649	>	IC50	nM	20000.0	CHEMBL1844	Homo sapiens	IC50	uM	20.0
	2361219	CHEMBL971578	Inhibition of cFMS kinase	B	COc1cc2c(Oc3ccc(-c4cnc(Cc5ccccc5)n(C)c4=O)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL505896	=	IC50	nM	37.0	CHEMBL1844	Homo sapiens	IC50	nM	37.0
Not Determined	2361220	CHEMBL971578	Inhibition of cFMS kinase	B	COc1cc2c(Oc3ccc(-c4cnc(Nc5ccc(F)cc5)n(C)c4=O)nc3)ccnc2cc1OCCCN1CCOCC1		CHEMBL447602		IC50			CHEMBL1844	Homo sapiens	IC50		
	2372057	CHEMBL990806	Inhibition of cFMS	B	O=C(Nc1cncnc1)c1c(Cl)ccc2c(Nc3cccc(C(F)(F)F)c3)noc12		CHEMBL491429	=	IC50	nM	71.0	CHEMBL1844	Homo sapiens	IC50	uM	0.071
	2394382	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CN1CCN(c2ccc(Nc3ncc4c(=O)c(C(N)=O)cn(-c5ccc6c(c5)CCC6)c4n3)cc2)CC1		CHEMBL414001	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	nM	13.0
	2394383	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CN1CCN(CCc2ccc(Nc3ncc4c(=O)c(C(N)=O)cn(-c5ccc6c(c5)CCC6)c4n3)cc2)CC1		CHEMBL403776	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	nM	0.8
	2394384	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CNC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(CCN4CCN(C)CC4)cc3)ncc2c1=O		CHEMBL511484	=	IC50	nM	1.2	CHEMBL1844	Homo sapiens	IC50	nM	1.2
	2394385	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CNC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(CCN4CCOCC4)cc3)ncc2c1=O		CHEMBL472403	=	IC50	nM	1.4	CHEMBL1844	Homo sapiens	IC50	nM	1.4
	2394386	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CCNC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(CCN4CCN(C)CC4)cc3)ncc2c1=O		CHEMBL507619	=	IC50	nM	3.2	CHEMBL1844	Homo sapiens	IC50	nM	3.2
	2394387	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CN1CCN(CCc2ccc(Nc3ncc4c(=O)c(C(=O)NCCO)cn(-c5ccc6c(c5)CCC6)c4n3)cc2)CC1		CHEMBL451918	=	IC50	nM	0.7	CHEMBL1844	Homo sapiens	IC50	nM	0.7
	2394388	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CONC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(CCN4CCN(C)CC4)cc3)ncc2c1=O		CHEMBL505830	=	IC50	nM	0.7	CHEMBL1844	Homo sapiens	IC50	nM	0.7
	2394389	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CCONC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(CCN4CCN(C)CC4)cc3)ncc2c1=O		CHEMBL451575	=	IC50	nM	0.5	CHEMBL1844	Homo sapiens	IC50	nM	0.5
	2394390	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CC(C)ONC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(CCN4CCN(C)CC4)cc3)ncc2c1=O		CHEMBL509044	=	IC50	nM	0.5	CHEMBL1844	Homo sapiens	IC50	nM	0.5
	2394391	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CONC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(NCc3ccccc3)ncc2c1=O		CHEMBL514153	=	IC50	nM	75.0	CHEMBL1844	Homo sapiens	IC50	nM	75.0
	2394392	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CCCCNc1ncc2c(=O)c(C(=O)NOC)cn(-c3ccc4c(c3)CCC4)c2n1		CHEMBL523802	=	IC50	nM	15.0	CHEMBL1844	Homo sapiens	IC50	nM	15.0
	2394393	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CONC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(OC)nc3)ncc2c1=O		CHEMBL491078	=	IC50	nM	5.2	CHEMBL1844	Homo sapiens	IC50	nM	5.2
	2394394	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CONC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(CCN4CCOCC4)cc3)ncc2c1=O		CHEMBL522834	=	IC50	nM	1.3	CHEMBL1844	Homo sapiens	IC50	nM	1.3
	2394395	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CONC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(CCN4CCC(F)(F)CC4)cc3)ncc2c1=O		CHEMBL455591	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	nM	1.7
	2394396	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CONC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(CCN4CCNC(=O)C4)cc3)ncc2c1=O		CHEMBL448117	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	nM	0.8
	2394397	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CONC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(CCN4CCN(C)C(=O)C4)cc3)ncc2c1=O		CHEMBL508935	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	nM	0.8
	2394398	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CONC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(CCS(=O)(=O)NC(C)=O)cc3)ncc2c1=O		CHEMBL444454	=	IC50	nM	2.4	CHEMBL1844	Homo sapiens	IC50	nM	2.4
	2394399	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CONC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(C4CCNCC4)cc3)ncc2c1=O		CHEMBL489298	=	IC50	nM	0.5	CHEMBL1844	Homo sapiens	IC50	nM	0.5
	2394400	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CONC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(C4CCN(CCO)CC4)cc3)ncc2c1=O		CHEMBL451931	=	IC50	nM	1.3	CHEMBL1844	Homo sapiens	IC50	nM	1.3
	2394401	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CONC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(C4CCN(CC(=O)O)CC4)cc3)ncc2c1=O		CHEMBL452965	=	IC50	nM	2.2	CHEMBL1844	Homo sapiens	IC50	nM	2.2
	2394402	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CONC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(C4CCN(C)CC4)cc3)ncc2c1=O		CHEMBL492809	=	IC50	nM	0.4	CHEMBL1844	Homo sapiens	IC50	nM	0.4
	2394403	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CONC(=O)c1cn(-c2ccc3c(c2)CCC3)c2nc(Nc3ccc(C4CCN(C)CC4(F)F)cc3)ncc2c1=O		CHEMBL445519	=	IC50	nM	0.7	CHEMBL1844	Homo sapiens	IC50	nM	0.7
	2394404	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CCN1CCCC(O)(c2cccc(Nc3ncc4c(=O)c(C(=O)NOC)cn(-c5ccc6c(c5)CCC6)c4n3)c2)C1		CHEMBL448339	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	nM	0.8
	2394405	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CCc1ccc(-n2cc(C(=O)NOC)c(=O)c3cnc(Nc4ccc(C5CCN(C)CC5)cc4)nc32)cc1		CHEMBL489684	=	IC50	nM	0.3	CHEMBL1844	Homo sapiens	IC50	nM	0.3
	2394406	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CCc1cccc(-n2cc(C(=O)NOC)c(=O)c3cnc(Nc4ccc(C5CCN(C)CC5)cc4)nc32)c1		CHEMBL489881	=	IC50	nM	0.4	CHEMBL1844	Homo sapiens	IC50	nM	0.4
	2394407	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CCN1CCCC(O)(c2cccc(Nc3ncc4c(=O)c(C(=O)NOC)cn(-c5cnc6c(c5)CCC6)c4n3)c2)C1		CHEMBL450914	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	nM	7.0
	2394408	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CONC(=O)c1cn(C2CCC(C)(C)CC2)c2nc(Nc3ccc(C4CCN(C)CC4)cc3)ncc2c1=O		CHEMBL521580	=	IC50	nM	0.4	CHEMBL1844	Homo sapiens	IC50	nM	0.4
	2394409	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CONC(=O)c1cn(C2CCCCC2)c2nc(Nc3ccc(C4CCN(C)CC4)cc3)ncc2c1=O		CHEMBL489883	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	nM	5.0
	2394595	CHEMBL961253	Inhibition of Fms by fluorescence polarization competition immunoassay	B	CONC(=O)c1cn(C2CCCCC2)c2nc(Nc3ccc(CCN4CCCC4)cc3)ncc2c1=O		CHEMBL490080	=	IC50	nM	4.1	CHEMBL1844	Homo sapiens	IC50	nM	4.1
	2395446	CHEMBL961273	Binding affinity to CSF1R at 10 uM by Ambit binding assay relative to control	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	=	Activity	%	0.0	CHEMBL1844	Homo sapiens	Activity	%	0.0
	2397095	CHEMBL946287	Inhibition of CSF1R kinase	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	=	IC50	nM	19.0	CHEMBL1844	Homo sapiens	IC50	nM	19.0
	2418047	CHEMBL1019609	Inhibition of CSF1R at 1 uM	B	C[C@H]1O[C@@H]2CC(=O)O[C@@H]2C2=C1C(=O)c1c(ccc([C@H]3C[C@@H](N(C)C)[C@H](O)[C@@H](C)O3)c1O)C2=O		CHEMBL2216825	=	Inhibition	%	6.0	CHEMBL1844	Homo sapiens	INH	%	6.0
	2449125	CHEMBL985578	Inhibition of CFMS	B	COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1		CHEMBL460472	=	IC50	nM	238.0	CHEMBL1844	Homo sapiens	IC50	nM	238.0
	2453572	CHEMBL948369	Inhibition of CSF1R by HTRF assay	B	Cc1cccc(NC(=O)Nc2ccc(-c3cnc4c(-c5cnn(C)c5)ccn4c3N)cc2)c1		CHEMBL453057	=	IC50	nM	4.0	CHEMBL1844	Homo sapiens	IC50	nM	4.0
	2470134	CHEMBL1033254	Inhibition of CSF1R at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL1844	Homo sapiens	INH	%	10.0
	2476628	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Activity	%	0.6	CHEMBL1844	Homo sapiens	Activity	%	0.6
	2476831	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	NC(=O)c1ccc(-c2cc(C(N)=O)c(N)c(-c3ccc(S(N)(=O)=O)cc3)c2)cc1		CHEMBL514582	=	Activity	%	14.3	CHEMBL1844	Homo sapiens	Activity	%	14.3
Not Evaluated	2478670	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	N#Cc1c(NC(=O)c2ccccc2)sc2c1CCCC2		CHEMBL233000		Activity			CHEMBL1844	Homo sapiens	Activity		
	2478873	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	O=C1Nc2ccccc2/C1=C/c1ccc[nH]1		CHEMBL86755	=	Activity	%	0.6	CHEMBL1844	Homo sapiens	Activity	%	0.6
	2479728	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	N#Cc1ccc(-c2cnc3[nH]cc(NC(=O)c4cccnc4)c3c2)cc1		CHEMBL516312	=	Activity	%	23.5	CHEMBL1844	Homo sapiens	Activity	%	23.5
Active	2480727	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2		CHEMBL514409		Activity			CHEMBL1844	Homo sapiens	Activity		
	2489573	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2c(Nc3cccc(Cl)c3Cl)c(C(N)=O)cnc2cc1NCCN(C)C		CHEMBL521262	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	uM	0.003
	2489574	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	CCOc1cc2ncc(C(N)=O)c(Nc3cccc(Cl)c3Cl)c2cc1NCCN(C)C		CHEMBL480814	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	uM	0.003
	2489575	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3cccc(Cl)c3Cl)c2cc1OC		CHEMBL519779	=	IC50	nM	6.0	CHEMBL1844	Homo sapiens	IC50	uM	0.006
	2489576	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	CCOc1cc2ncc(C(N)=O)c(Nc3cccc(Cl)c3Cl)c2cc1NCCN1CCCCC1		CHEMBL480815	=	IC50	nM	6.0	CHEMBL1844	Homo sapiens	IC50	uM	0.006
	2489577	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2c(Nc3ccc(F)c(Cl)c3)c(C(N)=O)cnc2cc1OCCCN1CCN(C)CC1		CHEMBL481231	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	uM	0.007
	2489578	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3cccc(Cl)c3Cl)c2cc1NCCN1CCCCC1		CHEMBL481595	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	uM	0.007
	2489579	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1NCCN(C)C		CHEMBL479445	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	uM	0.007
	2489580	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1NCCN1CCOCC1		CHEMBL479446	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	uM	0.007
	2489581	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccccc3F)c2cc1OC		CHEMBL442591	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	uM	0.009
	2489582	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(Cl)c(Cl)c3)c2cc1OC		CHEMBL480630	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	uM	0.009
	2489583	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(C)cc3F)c2cc1OC		CHEMBL516601	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	uM	0.01
	2489584	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2c(Nc3ccc(F)c(Cl)c3)c(C(N)=O)cnc2cc1OCCN(C)CCO		CHEMBL481230	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	uM	0.01
	2489585	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCN(C)CC1		CHEMBL481402	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	uM	0.01
	2489586	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2c(Nc3ccc(F)c(Cl)c3)c(C(N)=O)cnc2cc1OCCN(C)C		CHEMBL517069	=	IC50	nM	12.0	CHEMBL1844	Homo sapiens	IC50	uM	0.012
	2489587	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3cccc(Cl)c3F)c2cc1OC		CHEMBL520925	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	uM	0.013
	2489588	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3cc(C)ccc3F)c2cc1OC		CHEMBL521248	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	uM	0.013
	2489589	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CCCC1		CHEMBL480646	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	uM	0.013
	2489590	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3cc(F)ccc3F)c2cc1OC		CHEMBL480825	=	IC50	nM	15.0	CHEMBL1844	Homo sapiens	IC50	uM	0.015
	2489591	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2c(Nc3cccc(Cl)c3Cl)c(C(N)=O)cnc2cc1NCCN1CCCCC1		CHEMBL480813	=	IC50	nM	15.0	CHEMBL1844	Homo sapiens	IC50	uM	0.015
	2489592	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(F)c(Cl)c3)c2cc1OC		CHEMBL482000	=	IC50	nM	16.0	CHEMBL1844	Homo sapiens	IC50	uM	0.016
	2489593	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2c(Nc3ccc(F)c(Cl)c3)c(C(N)=O)cnc2cc1OCCNC1CC1		CHEMBL521255	=	IC50	nM	17.0	CHEMBL1844	Homo sapiens	IC50	uM	0.017
	2489594	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2c(Nc3ccc(F)c(Cl)c3)c(C(N)=O)cnc2cc1OCCN1CCCC1		CHEMBL521422	=	IC50	nM	17.0	CHEMBL1844	Homo sapiens	IC50	uM	0.017
	2489595	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL517544	=	IC50	nM	18.0	CHEMBL1844	Homo sapiens	IC50	uM	0.018
	2489596	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(Cl)cc3F)c2cc1OC		CHEMBL479845	=	IC50	nM	18.0	CHEMBL1844	Homo sapiens	IC50	uM	0.018
	2489597	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COCCN(C)CCOc1cc2ncc(C(N)=O)c(Nc3ccc(F)c(Cl)c3)c2cc1OC		CHEMBL481222	=	IC50	nM	18.0	CHEMBL1844	Homo sapiens	IC50	uM	0.018
	2489598	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccccc3Cl)c2cc1OC		CHEMBL450208	=	IC50	nM	22.0	CHEMBL1844	Homo sapiens	IC50	uM	0.022
	2489599	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3cc(Cl)cc(Cl)c3)c2cc1OC		CHEMBL479267	=	IC50	nM	22.0	CHEMBL1844	Homo sapiens	IC50	uM	0.022
	2489600	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1NCCN1CCCCC1		CHEMBL518760	=	IC50	nM	22.0	CHEMBL1844	Homo sapiens	IC50	uM	0.022
	2489601	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2c(Nc3ccc(F)cc3F)c(C(N)=O)cnc2cc1NCCN(C)C		CHEMBL479447	=	IC50	nM	23.0	CHEMBL1844	Homo sapiens	IC50	uM	0.023
	2489602	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1OC		CHEMBL479847	=	IC50	nM	25.0	CHEMBL1844	Homo sapiens	IC50	uM	0.025
	2489603	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3cccc(F)c3F)c2cc1OC		CHEMBL482192	=	IC50	nM	26.0	CHEMBL1844	Homo sapiens	IC50	uM	0.026
	2489604	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(F)c(F)c3)c2cc1OC		CHEMBL479846	=	IC50	nM	28.0	CHEMBL1844	Homo sapiens	IC50	uM	0.028
	2489605	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3cccc(Cl)c3C)c2cc1OC		CHEMBL481407	=	IC50	nM	29.0	CHEMBL1844	Homo sapiens	IC50	uM	0.029
	2489606	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(F)cc3)c2cc1OC		CHEMBL520742	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	uM	0.03
	2489607	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(Cl)cc3)c2cc1OC		CHEMBL517530	=	IC50	nM	31.0	CHEMBL1844	Homo sapiens	IC50	uM	0.031
	2489608	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3cccc(C)c3C)c2cc1OC		CHEMBL481406	=	IC50	nM	31.0	CHEMBL1844	Homo sapiens	IC50	uM	0.031
	2489609	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3cccc(F)c3)c2cc1OC		CHEMBL480058	=	IC50	nM	33.0	CHEMBL1844	Homo sapiens	IC50	uM	0.033
	2489610	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccccc3Br)c2cc1OC		CHEMBL480056	=	IC50	nM	36.0	CHEMBL1844	Homo sapiens	IC50	uM	0.036
	2489611	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3cccc(C)c3)c2cc1OC		CHEMBL480417	=	IC50	nM	38.0	CHEMBL1844	Homo sapiens	IC50	uM	0.038
	2489612	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1ccc(Nc2c(C(N)=O)cnc3cc(OC)c(OC)cc23)cc1		CHEMBL479636	=	IC50	nM	46.0	CHEMBL1844	Homo sapiens	IC50	uM	0.046
	2489613	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccccc3C)c2cc1OC		CHEMBL480057	=	IC50	nM	52.0	CHEMBL1844	Homo sapiens	IC50	uM	0.052
	2489614	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(Cl)cc3Cl)c2cc1OC		CHEMBL355505	=	IC50	nM	52.0	CHEMBL1844	Homo sapiens	IC50	uM	0.052
	2489615	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2c(Nc3ccc(F)c(Cl)c3)c(C(N)=O)cnc2cc1OCCN1CCC(O)CC1		CHEMBL480455	=	IC50	nM	80.0	CHEMBL1844	Homo sapiens	IC50	uM	0.08
	2489616	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(N(C)C)cc3)c2cc1OC		CHEMBL503866	=	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	uM	0.1
	2489617	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3cc(F)cc(F)c3)c2cc1OC		CHEMBL480826	=	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	uM	0.1
	2489618	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(F)cc3Cl)c2cc1OC		CHEMBL481995	=	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	uM	0.2
	2489619	CHEMBL991297	Inhibition of His-tagged CSF1R catalytic domain expressed in baculovirus by HTRF assay	B	COc1cc2ncc(C(N)=O)c(Nc3cccc(Cl)c3Cl)c2cc1NCCN(C)C		CHEMBL452664	<	IC50	nM	1.0	CHEMBL1844	Homo sapiens	IC50	uM	0.001
	2489758	CHEMBL1035623	Inhibition of CSF1R at 1 uM	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1OC		CHEMBL479847	=	Inhibition	%	97.0	CHEMBL1844	Homo sapiens	INH	%	97.0
	2490061	CHEMBL1025517	Inhibition of CSF1R	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(Cl)c(Cl)c3)c2cc1N1CCN(C)CC1		CHEMBL481423	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	uM	0.002
	2490062	CHEMBL1025517	Inhibition of CSF1R	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(Cl)cc3Cl)c2cc1N1CCN(C)CC1		CHEMBL481223	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	uM	0.003
	2490063	CHEMBL1025517	Inhibition of CSF1R	B	CN1CCN(c2cc3c(Nc4cccc(Cl)c4Cl)c(C(N)=O)cnc3cc2F)CC1		CHEMBL481401	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	uM	0.003
	2490064	CHEMBL1025517	Inhibition of CSF1R	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1N1CCN(C)CC1		CHEMBL480445	=	IC50	nM	6.0	CHEMBL1844	Homo sapiens	IC50	uM	0.006
	2490065	CHEMBL1025517	Inhibition of CSF1R	B	CN1CCN(c2ccc3ncc(C(N)=O)c(Nc4cccc(Cl)c4Cl)c3c2)CC1		CHEMBL480457	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	uM	0.008
	2490066	CHEMBL1025517	Inhibition of CSF1R	B	COc1cc2c(Nc3ccc(F)cc3F)c(C(N)=O)cnc2cc1N1CCN(C)CC1		CHEMBL480618	=	IC50	nM	11.0	CHEMBL1844	Homo sapiens	IC50	uM	0.011
	2490067	CHEMBL1025517	Inhibition of CSF1R	B	COc1cc2c(Nc3cccc(Cl)c3Cl)c(C(N)=O)cnc2cc1N1CCN(C)CC1		CHEMBL480617	=	IC50	nM	23.0	CHEMBL1844	Homo sapiens	IC50	uM	0.023
	2490068	CHEMBL1025517	Inhibition of CSF1R	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3)c(C(N)=O)cnc2cc1N1CCN(C)CC1		CHEMBL519924	=	IC50	nM	24.0	CHEMBL1844	Homo sapiens	IC50	uM	0.024
	2490069	CHEMBL1025517	Inhibition of CSF1R	B	COc1cc2ncc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1OC		CHEMBL479847	=	IC50	nM	25.0	CHEMBL1844	Homo sapiens	IC50	uM	0.025
	2490070	CHEMBL1025517	Inhibition of CSF1R	B	CN1CCN(c2cc3c(Nc4ccc(F)cc4F)c(C(N)=O)cnc3cc2F)CC1		CHEMBL481596	=	IC50	nM	54.0	CHEMBL1844	Homo sapiens	IC50	uM	0.054
	2490071	CHEMBL1025517	Inhibition of CSF1R	B	CN1CCN(c2ccc3ncc(C(N)=O)c(Nc4ccc(Cl)c(Cl)c4)c3c2)CC1		CHEMBL480456	=	IC50	nM	59.0	CHEMBL1844	Homo sapiens	IC50	uM	0.059
	2490073	CHEMBL1025517	Inhibition of CSF1R	B	CN1CCN(c2ccc3ncc(C(N)=O)c(Nc4ccc(F)cc4F)c3c2)CC1		CHEMBL481400	=	IC50	nM	110.0	CHEMBL1844	Homo sapiens	IC50	uM	0.11
	2490074	CHEMBL1025517	Inhibition of CSF1R	B	CN1CCN(c2ccc3ncc(C(N)=O)c(Nc4ccc(Cl)cc4Cl)c3c2)CC1		CHEMBL521407	=	IC50	nM	129.0	CHEMBL1844	Homo sapiens	IC50	uM	0.129
	2490359	CHEMBL1025517	Inhibition of CSF1R	B	CCOc1cc2ncc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1N1CCN(C)CC1		CHEMBL481806	=	IC50	nM	6.0	CHEMBL1844	Homo sapiens	IC50	uM	0.006
	2490360	CHEMBL1025528	Inhibition of CSF1R at 1 uM	B	CCOc1cc2ncc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1N1CCN(C)CC1		CHEMBL481806	=	Inhibition	%	96.0	CHEMBL1844	Homo sapiens	INH	%	96.0
	2490364	CHEMBL1025517	Inhibition of CSF1R	B	CCOc1cc2ncc(C(N)=O)c(Nc3cccc(Cl)c3Cl)c2cc1N1CCN(C)CC1		CHEMBL481008	<	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	uM	0.003
	2490387	CHEMBL1025517	Inhibition of CSF1R	B	COc1cc2ncc(C(N)=O)c(Nc3cccc(Cl)c3Cl)c2cc1N1CCN(C)CC1		CHEMBL480250	<	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	uM	0.003
	2505609	CHEMBL941568	Inhibition of cFMS	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	IC50	nM	620.0	CHEMBL1844	Homo sapiens	IC50	nM	620.0
	2507002	CHEMBL947772	Inhibition of CSF1R	B	Nc1ncc(NC(=O)c2cc(NC(=O)c3cccc(C(F)(F)F)c3)ccc2Cl)cc1Cl		CHEMBL475817	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	uM	0.005
	2512016	CHEMBL970579	Inhibition of FMS at 1 uM	B	CC(=O)N1CCN(C(=O)Cc2ccc(Nc3ncc(F)c(Nc4ccc(C(=O)Nc5ccccc5Cl)cc4)n3)cc2)CC1		CHEMBL508307	=	Inhibition	%	79.0	CHEMBL1844	Homo sapiens	INH	%	79.0
	2561555	CHEMBL981081	Inhibition of human c-fms	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	=	IC50	nM	146.0	CHEMBL1844	Homo sapiens	IC50	nM	146.0
	2564861	CHEMBL971735	Inhibition of CSF1R	B	COc1cc2ncnc(N(C)c3ccccc3)c2cc1OC		CHEMBL456375	=	IC50	nM	500.0	CHEMBL1844	Homo sapiens	IC50	nM	500.0
	2567245	CHEMBL974577	Inhibition of human Fms kinase assessed as residual enzyme activity at 0.1 uM	B	CCN1C(=O)C(C)(C)c2cc3[nH]c4c(c3cc21)CCCc1c(C)n[nH]c1-4		CHEMBL223147	=	Activity	%	2.0	CHEMBL1844	Homo sapiens	Activity	%	2.0
Not Evaluated	2577349	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	CC(=O)c1c(-c2ccncc2)[nH]c(-c2ccncc2)c1C		CHEMBL526901		Activity			CHEMBL1844	Homo sapiens	Activity		
	2577552	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	NC(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1		CHEMBL511337	=	Activity	%	11.4	CHEMBL1844	Homo sapiens	Activity	%	11.4
	2593554	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Activity	%	7.9	CHEMBL1844	Homo sapiens	Activity	%	7.9
	2593757	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(C(N)=O)c2)n1		CHEMBL249097	=	Activity	%	1.1	CHEMBL1844	Homo sapiens	Activity	%	1.1
	2594023	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCNCC1		CHEMBL450519	=	Activity	%	0.6	CHEMBL1844	Homo sapiens	Activity	%	0.6
Not Evaluated	2594966	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL478649		Activity			CHEMBL1844	Homo sapiens	Activity		
Not Evaluated	2595169	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	Cc1ccc(NC(=O)c2cccc(N3CCCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL1964275		Activity			CHEMBL1844	Homo sapiens	Activity		
	2595235	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(C)(C)C)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL515466	=	Activity	%	0.4	CHEMBL1844	Homo sapiens	Activity	%	0.4
	2596366	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	CN(C)c1ccc(-c2cc3ncccc3c(NCCCCN)n2)cc1		CHEMBL282342	=	Activity	%	0.9	CHEMBL1844	Homo sapiens	Activity	%	0.9
Not Evaluated	2597635	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1		CHEMBL408019		Activity			CHEMBL1844	Homo sapiens	Activity		
Not Evaluated	2597838	CHEMBL1035892	Binding affinity to human FMS at 10 uM relative to control	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454		Activity			CHEMBL1844	Homo sapiens	Activity		
	2603034	CHEMBL1023850	Inhibition of FMS	B	C[C@H](Nc1cncc(Cl)n1)c1cccc(NC(=O)c2cccnc2)c1		CHEMBL458348	=	IC50	nM	857.0	CHEMBL1844	Homo sapiens	IC50	nM	857.0
	2603035	CHEMBL1023850	Inhibition of FMS	B	C[C@H](Nc1cncc(Cl)n1)c1cccc(N)c1		CHEMBL456410	>	IC50	nM	5000.0	CHEMBL1844	Homo sapiens	IC50	nM	5000.0
	2603036	CHEMBL1023850	Inhibition of FMS	B	C[C@H](Nc1cncc(Cl)n1)c1cccc(N(C)C(=O)c2cccnc2)c1		CHEMBL456411	>	IC50	nM	5000.0	CHEMBL1844	Homo sapiens	IC50	nM	5000.0
	2603037	CHEMBL1023850	Inhibition of FMS	B	C[C@H](Nc1cncc(Cl)n1)c1cccc(NCc2cccnc2)c1		CHEMBL456000	>	IC50	nM	5000.0	CHEMBL1844	Homo sapiens	IC50	nM	5000.0
	2603038	CHEMBL1023850	Inhibition of FMS	B	C[C@H](Nc1cncc(Cl)n1)c1cccc(NS(=O)(=O)c2cccnc2)c1		CHEMBL456007	>	IC50	nM	5000.0	CHEMBL1844	Homo sapiens	IC50	nM	5000.0
	2603039	CHEMBL1023850	Inhibition of FMS	B	Cc1ccc(C(=O)Nc2cccc([C@H](C)Nc3cncc(Cl)n3)c2)cn1		CHEMBL510215	=	IC50	nM	40.0	CHEMBL1844	Homo sapiens	IC50	nM	40.0
	2603040	CHEMBL1023850	Inhibition of FMS	B	Cc1cc(C(=O)Nc2cccc([C@H](C)Nc3cncc(Cl)n3)c2)ccn1		CHEMBL456008	=	IC50	nM	15.0	CHEMBL1844	Homo sapiens	IC50	nM	15.0
	2603041	CHEMBL1023850	Inhibition of FMS	B	Cc1cncc(C(=O)Nc2cccc([C@H](C)Nc3cncc(Cl)n3)c2)c1		CHEMBL472860	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	nM	5.0
	2603042	CHEMBL1023850	Inhibition of FMS	B	C[C@H](Nc1cncc(Cl)n1)c1cccc(NC(=O)c2cncc(Br)c2)c1		CHEMBL515867	=	IC50	nM	4.0	CHEMBL1844	Homo sapiens	IC50	nM	4.0
	2603043	CHEMBL1023850	Inhibition of FMS	B	C[C@H](Nc1cncc(Cl)n1)c1cccc(NC(=O)c2ccccc2)c1		CHEMBL499667	=	IC50	nM	40.0	CHEMBL1844	Homo sapiens	IC50	nM	40.0
	2603044	CHEMBL1023850	Inhibition of FMS	B	C[C@H](Nc1cncc(Cl)n1)c1cccc(NC(=O)c2cccc(C(F)(F)F)c2)c1		CHEMBL473061	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	2603045	CHEMBL1023850	Inhibition of FMS	B	C[C@H](Nc1cncc(Cl)n1)c1cccc(NC(=O)c2ccc(F)c(Cl)c2)c1		CHEMBL474489	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	nM	9.0
	2603046	CHEMBL1023850	Inhibition of FMS	B	Cc1ccc(C(=O)Nc2cccc([C@H](C)Nc3cncc(Cl)n3)c2)cc1		CHEMBL472864	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	nM	9.0
	2603047	CHEMBL1023850	Inhibition of FMS	B	Cc1cccc(C(=O)Nc2cccc([C@H](C)Nc3cncc(Cl)n3)c2)c1		CHEMBL504075	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
	2603048	CHEMBL1023850	Inhibition of FMS	B	Cc1ccc(F)c(C(=O)Nc2cccc([C@H](C)Nc3cncc(Cl)n3)c2)c1		CHEMBL474695	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
	2603049	CHEMBL1023850	Inhibition of FMS	B	C[C@H](Nc1cncc(Cl)n1)c1cccc(NC(=O)c2cncs2)c1		CHEMBL514491	=	IC50	nM	2000.0	CHEMBL1844	Homo sapiens	IC50	nM	2000.0
	2603050	CHEMBL1023850	Inhibition of FMS	B	C[C@H](Nc1cncc(Cl)n1)c1cccc(NC(=O)C2CCCN(C)C2)c1		CHEMBL474895	=	IC50	nM	5000.0	CHEMBL1844	Homo sapiens	IC50	nM	5000.0
	2603051	CHEMBL1023850	Inhibition of FMS	B	Cc1cncc(C(=O)Nc2cccc([C@H](C)Nc3cncc(Br)c3)c2)c1		CHEMBL514619	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	nM	5.0
	2603052	CHEMBL1023850	Inhibition of FMS	B	Cc1cncc(C(=O)Nc2cccc([C@H](C)Nc3cccc(Br)n3)c2)c1		CHEMBL473283	>	IC50	nM	5000.0	CHEMBL1844	Homo sapiens	IC50	nM	5000.0
	2603053	CHEMBL1023850	Inhibition of FMS	B	COc1cc(-c2cncc(NC(C)c3cccc(NC(=O)c4cccnc4)c3)n2)ccc1O		CHEMBL473487	=	IC50	nM	22.0	CHEMBL1844	Homo sapiens	IC50	nM	22.0
	2603054	CHEMBL1023850	Inhibition of FMS	B	COc1cc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cccnc4)c3)n2)ccc1O		CHEMBL516200	=	IC50	nM	11.0	CHEMBL1844	Homo sapiens	IC50	nM	11.0
	2603055	CHEMBL1023850	Inhibition of FMS	B	COc1cc(-c2cncc(N[C@H](C)c3cccc(NC(=O)c4cccnc4)c3)n2)ccc1O		CHEMBL474100	=	IC50	nM	416.0	CHEMBL1844	Homo sapiens	IC50	nM	416.0
	2603082	CHEMBL1023850	Inhibition of FMS	B	Cc1cccc(C(=O)Nc2cccc([C@H](C)Nc3cncc(Cl)n3)c2)c1		CHEMBL504075	=	Kd	nM	1.9	CHEMBL1844	Homo sapiens	Kd	nM	1.9
	2719526	CHEMBL1059976	Inhibition of Tel fused Fms expressed in mouse BA/F3 cells	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(NC(=O)c4cncc(-c5cccs5)c4)c3)cc2C(F)(F)F)CC1		CHEMBL556140	<	EC50	nM	500.0	CHEMBL1844	Homo sapiens	EC50	nM	500.0
Active	2719534	CHEMBL1059984	Inhibition of CSF1R at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(NC(=O)c4cncc(-c5cccs5)c4)c3)cc2C(F)(F)F)CC1		CHEMBL556140		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
	2721615	CHEMBL1057443	Inhibition of Fms at 1 uM	B	C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F		CHEMBL551079	<	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	2892454	CHEMBL1051265	Selectivity for CSF1R as proportion of 290 kinases in screen with similar potency; non-selective = 1 highly selective = 0	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Selectivity		0.0	CHEMBL1844	Homo sapiens	Selectivity		0.0
	2892455	CHEMBL1062790	Selectivity for EGFR as proportion of 290 kinases in screen with similar potency; non-selective = 1 highly selective = 0	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	=	Selectivity		0.0	CHEMBL1844	Homo sapiens	Selectivity		0.0
	2892456	CHEMBL1062790	Selectivity for EGFR as proportion of 290 kinases in screen with similar potency; non-selective = 1 highly selective = 0	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	=	Selectivity		0.0	CHEMBL1844	Homo sapiens	Selectivity		0.0
	2892457	CHEMBL1062790	Selectivity for EGFR as proportion of 290 kinases in screen with similar potency; non-selective = 1 highly selective = 0	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	=	Selectivity		0.0035	CHEMBL1844	Homo sapiens	Selectivity		0.0035
	2892458	CHEMBL1062790	Selectivity for EGFR as proportion of 290 kinases in screen with similar potency; non-selective = 1 highly selective = 0	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	=	Selectivity		0.0	CHEMBL1844	Homo sapiens	Selectivity		0.0
	2892459	CHEMBL1062790	Selectivity for EGFR as proportion of 290 kinases in screen with similar potency; non-selective = 1 highly selective = 0	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	=	Selectivity		0.0	CHEMBL1844	Homo sapiens	Selectivity		0.0
	2902370	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	=	Kd	nM	3.4	CHEMBL1844	Homo sapiens	Kd	nM	3.4
	2902371	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	=	Kd	nM	5.6	CHEMBL1844	Homo sapiens	Kd	nM	5.6
	2902372	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	=	Kd	nM	5.8	CHEMBL1844	Homo sapiens	Kd	nM	5.8
	2902373	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	=	Kd	nM	1400.0	CHEMBL1844	Homo sapiens	Kd	nM	1400.0
	2902374	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	Kd	nM	8100.0	CHEMBL1844	Homo sapiens	Kd	nM	8100.0
	2902375	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	uM	10.0
	2902376	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	60.0	CHEMBL1844	Homo sapiens	Kd	nM	60.0
	2902377	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	=	Kd	nM	250.0	CHEMBL1844	Homo sapiens	Kd	nM	250.0
	2902378	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	uM	10.0
	2902379	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	uM	10.0
	2902380	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	uM	10.0
	2902381	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Kd	nM	0.58	CHEMBL1844	Homo sapiens	Kd	nM	0.58
	2902382	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	=	Kd	nM	4300.0	CHEMBL1844	Homo sapiens	Kd	nM	4300.0
	2902383	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	uM	10.0
	2902384	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	2800.0	CHEMBL1844	Homo sapiens	Kd	nM	2800.0
	2902385	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	uM	10.0
	2902386	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Kd	nM	1.6	CHEMBL1844	Homo sapiens	Kd	nM	1.6
	2902387	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	=	Kd	nM	7.9	CHEMBL1844	Homo sapiens	Kd	nM	7.9
	2902388	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Kd	nM	19.0	CHEMBL1844	Homo sapiens	Kd	nM	19.0
	2902389	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Kd	nM	4200.0	CHEMBL1844	Homo sapiens	Kd	nM	4200.0
	2902390	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	uM	10.0
	2902391	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	uM	10.0
	2902392	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	=	Kd	nM	4.9	CHEMBL1844	Homo sapiens	Kd	nM	4.9
	2902393	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	uM	10.0
	2902394	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	uM	10.0
	2902395	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	330.0	CHEMBL1844	Homo sapiens	Kd	nM	330.0
	2902396	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	=	Kd	nM	18.0	CHEMBL1844	Homo sapiens	Kd	nM	18.0
	2902397	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	uM	10.0
	2902398	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	uM	10.0
	2902399	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	uM	10.0
	2902400	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	uM	10.0
	2902401	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	=	Kd	nM	28.0	CHEMBL1844	Homo sapiens	Kd	nM	28.0
	2902402	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	12.0	CHEMBL1844	Homo sapiens	Kd	nM	12.0
	2902403	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	3.6	CHEMBL1844	Homo sapiens	Kd	nM	3.6
	2902404	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	2.0	CHEMBL1844	Homo sapiens	Kd	nM	2.0
	2902405	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	1800.0	CHEMBL1844	Homo sapiens	Kd	nM	1800.0
	2902406	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	=	Kd	nM	2600.0	CHEMBL1844	Homo sapiens	Kd	nM	2600.0
	2902407	CHEMBL1063702	Binding constant for CSF1R kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	=	Kd	nM	1200.0	CHEMBL1844	Homo sapiens	Kd	nM	1200.0
	2921394	CHEMBL1052898	Inhibition of CSF1R assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	0.25	CHEMBL1844	Homo sapiens	Activity	%	0.25
	2930032	CHEMBL1057696	Binding affinity to CSF1R	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	=	Kd	nM	12.0	CHEMBL1844	Homo sapiens	Kd	nM	12.0
	2938501	CHEMBL1041364	Inhibition of FMS at 1 uM	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	=	Inhibition	%	6.0	CHEMBL1844	Homo sapiens	INH	%	6.0
	3052574	CHEMBL1037115	Residual activity of CSF1R at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	105.0	CHEMBL1844	Homo sapiens	Residual activity	%	105.0
	3053883	CHEMBL1044283	Residual activity of CSF1R at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	55.0	CHEMBL1844	Homo sapiens	Residual activity	%	55.0
	3054135	CHEMBL1040239	Residual activity of CSF1R at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	93.0	CHEMBL1844	Homo sapiens	Residual activity	%	93.0
	3055422	CHEMBL1037115	Residual activity of CSF1R at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	118.0	CHEMBL1844	Homo sapiens	Residual activity	%	118.0
	3055674	CHEMBL1044283	Residual activity of CSF1R at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	127.0	CHEMBL1844	Homo sapiens	Residual activity	%	127.0
	3056979	CHEMBL1040239	Residual activity of CSF1R at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	120.0	CHEMBL1844	Homo sapiens	Residual activity	%	120.0
	3058299	CHEMBL1037115	Residual activity of CSF1R at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	112.0	CHEMBL1844	Homo sapiens	Residual activity	%	112.0
	3058551	CHEMBL1044283	Residual activity of CSF1R at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	131.0	CHEMBL1844	Homo sapiens	Residual activity	%	131.0
	3062454	CHEMBL1048647	Binding affinity to human CSF1R at 200 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CSSC[C@@H](C(=O)NCC(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL595545	=	Activity	%	44.0	CHEMBL1844	Homo sapiens	Activity	%	44.0
	3063589	CHEMBL1039786	Binding affinity to human CSF1R at 500 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(N)=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL595546	=	Activity	%	22.0	CHEMBL1844	Homo sapiens	Activity	%	22.0
	3063679	CHEMBL1038890	Binding affinity to human CSF1R at 50 nM by cell-based competition binding assay relative to control in presence of DTT	B	CO[C@@H]1[C@H](N(C)C(=O)CCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)NCCC(=O)N[C@H]2CNC(=O)C[C@@H](C(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](C(C)C)NC2=O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL609010	=	Activity	%	83.0	CHEMBL1844	Homo sapiens	Activity	%	83.0
	3065859	CHEMBL1069291	Inhibition of CSF1R at 10 uM	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Inhibition	%	0.0	CHEMBL1844	Homo sapiens	INH	%	0.0
	3066925	CHEMBL1069291	Inhibition of CSF1R at 10 uM	B	O=C1Nc2ccccc2/C1=C1\C(=O)N(CCCc2ccccc2)c2ccccc21		CHEMBL607196	=	Inhibition	%	11.0	CHEMBL1844	Homo sapiens	INH	%	11.0
	3072897	CHEMBL1040239	Residual activity of CSF1R at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	88.0	CHEMBL1844	Homo sapiens	Residual activity	%	88.0
	3084424	CHEMBL1073287	Inhibition of CSF1R	B	NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL590109	=	IC50	nM	9200.0	CHEMBL1844	Homo sapiens	IC50	uM	9.2
	3116378	CHEMBL1067459	Inhibition of human FMS expressed in growth factor dependent mouse FDC-P1 cells assessed as inhibition of FMS-mediated cell proliferation in presence human CSF1 after 48 hrs by resazurin dye reduction assay	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	IC50	nM	31.0	CHEMBL1844	Homo sapiens	IC50	nM	31.0
	3116379	CHEMBL1067459	Inhibition of human FMS expressed in growth factor dependent mouse FDC-P1 cells assessed as inhibition of FMS-mediated cell proliferation in presence human CSF1 after 48 hrs by resazurin dye reduction assay	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	IC50	nM	7.4	CHEMBL1844	Homo sapiens	IC50	nM	7.4
	3116380	CHEMBL1067459	Inhibition of human FMS expressed in growth factor dependent mouse FDC-P1 cells assessed as inhibition of FMS-mediated cell proliferation in presence human CSF1 after 48 hrs by resazurin dye reduction assay	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	IC50	nM	1274.0	CHEMBL1844	Homo sapiens	IC50	nM	1274.0
	3116381	CHEMBL1067459	Inhibition of human FMS expressed in growth factor dependent mouse FDC-P1 cells assessed as inhibition of FMS-mediated cell proliferation in presence human CSF1 after 48 hrs by resazurin dye reduction assay	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	IC50	nM	142.0	CHEMBL1844	Homo sapiens	IC50	nM	142.0
	3116382	CHEMBL1067459	Inhibition of human FMS expressed in growth factor dependent mouse FDC-P1 cells assessed as inhibition of FMS-mediated cell proliferation in presence human CSF1 after 48 hrs by resazurin dye reduction assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	IC50	nM	155.0	CHEMBL1844	Homo sapiens	IC50	nM	155.0
	3116389	CHEMBL1067462	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 25 nM relative to control by Western blot	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Activity	%	9.0	CHEMBL1844	Homo sapiens	Activity	%	9.0
	3116390	CHEMBL1067463	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 2.5 nM relative to control by Western blot	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Activity	%	72.0	CHEMBL1844	Homo sapiens	Activity	%	72.0
	3116391	CHEMBL1067464	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 0.25 nM relative to control by Western blot	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Activity	%	121.0	CHEMBL1844	Homo sapiens	Activity	%	121.0
	3116392	CHEMBL1068694	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 14 uM relative to control by Western blot	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Activity	%	2.0	CHEMBL1844	Homo sapiens	Activity	%	2.0
	3116393	CHEMBL1068695	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 1.4 uM relative to control by Western blot	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Activity	%	52.0	CHEMBL1844	Homo sapiens	Activity	%	52.0
	3116394	CHEMBL1068696	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 0.14 uM relative to control by Western blot	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Activity	%	92.0	CHEMBL1844	Homo sapiens	Activity	%	92.0
Dose-dependent effect	3116395	CHEMBL1068700	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells relative to control by Western blot	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
Dose-dependent effect	3116396	CHEMBL1068700	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells relative to control by Western blot	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
Dose-dependent effect	3116397	CHEMBL1068700	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells relative to control by Western blot	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
Dose-dependent effect	3116398	CHEMBL1068700	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells relative to control by Western blot	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
Dose-dependent effect	3116399	CHEMBL1068700	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells relative to control by Western blot	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
	3116400	CHEMBL1068701	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 10 uM relative to control by Western blot	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Activity	%	106.0	CHEMBL1844	Homo sapiens	Activity	%	106.0
	3116401	CHEMBL1068702	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 3.3 uM relative to control by Western blot	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Activity	%	97.0	CHEMBL1844	Homo sapiens	Activity	%	97.0
	3116402	CHEMBL1068703	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 1.1 uM relative to control by Western blot	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Activity	%	104.0	CHEMBL1844	Homo sapiens	Activity	%	104.0
	3116403	CHEMBL1068704	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 0.33 uM relative to control by Western blot	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Activity	%	109.0	CHEMBL1844	Homo sapiens	Activity	%	109.0
	3116404	CHEMBL1068705	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 0.11 uM relative to control by Western blot	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Activity	%	104.0	CHEMBL1844	Homo sapiens	Activity	%	104.0
	3116405	CHEMBL1067459	Inhibition of human FMS expressed in growth factor dependent mouse FDC-P1 cells assessed as inhibition of FMS-mediated cell proliferation in presence human CSF1 after 48 hrs by resazurin dye reduction assay	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	logIC50		1.49	CHEMBL1844	Homo sapiens	logIC50		1.49
	3116406	CHEMBL1067459	Inhibition of human FMS expressed in growth factor dependent mouse FDC-P1 cells assessed as inhibition of FMS-mediated cell proliferation in presence human CSF1 after 48 hrs by resazurin dye reduction assay	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	logIC50		0.87	CHEMBL1844	Homo sapiens	logIC50		0.87
	3116407	CHEMBL1067459	Inhibition of human FMS expressed in growth factor dependent mouse FDC-P1 cells assessed as inhibition of FMS-mediated cell proliferation in presence human CSF1 after 48 hrs by resazurin dye reduction assay	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	logIC50		3.1	CHEMBL1844	Homo sapiens	logIC50		3.1
	3116408	CHEMBL1067459	Inhibition of human FMS expressed in growth factor dependent mouse FDC-P1 cells assessed as inhibition of FMS-mediated cell proliferation in presence human CSF1 after 48 hrs by resazurin dye reduction assay	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	logIC50		2.15	CHEMBL1844	Homo sapiens	logIC50		2.15
	3116409	CHEMBL1067459	Inhibition of human FMS expressed in growth factor dependent mouse FDC-P1 cells assessed as inhibition of FMS-mediated cell proliferation in presence human CSF1 after 48 hrs by resazurin dye reduction assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	logIC50		2.18	CHEMBL1844	Homo sapiens	logIC50		2.18
	3116413	CHEMBL1068697	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 500 nM relative to control by Western blot	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Activity	%	3.0	CHEMBL1844	Homo sapiens	Activity	%	3.0
	3116414	CHEMBL1068698	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 50 nM relative to control by Western blot	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Activity	%	21.0	CHEMBL1844	Homo sapiens	Activity	%	21.0
	3116415	CHEMBL1068699	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 5 nM relative to control by Western blot	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Activity	%	110.0	CHEMBL1844	Homo sapiens	Activity	%	110.0
	3116416	CHEMBL1068706	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 1000 nM relative to control by Western blot	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Activity	%	15.0	CHEMBL1844	Homo sapiens	Activity	%	15.0
	3116417	CHEMBL1069359	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 61 nM relative to control by Western blot	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Activity	%	62.0	CHEMBL1844	Homo sapiens	Activity	%	62.0
	3116418	CHEMBL1069360	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 1 nM relative to control by Western blot	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Activity	%	85.0	CHEMBL1844	Homo sapiens	Activity	%	85.0
	3116419	CHEMBL1068697	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 500 nM relative to control by Western blot	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Activity	%	2.0	CHEMBL1844	Homo sapiens	Activity	%	2.0
	3116420	CHEMBL1069361	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 31 nM relative to control by Western blot	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Activity	%	37.0	CHEMBL1844	Homo sapiens	Activity	%	37.0
	3116421	CHEMBL1069360	Inhibition of CSF1-stimulated human FMS autophosphorylation expressed in growth factor dependent mouse FDC-P1 cells assessed as phosphorylated receptor level at 1 nM relative to control by Western blot	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Activity	%	90.0	CHEMBL1844	Homo sapiens	Activity	%	90.0
	3186250	CHEMBL1110566	Inhibition of CSF1R	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	IC50	nM	35.0	CHEMBL1844	Homo sapiens	IC50	nM	35.0
	3186261	CHEMBL1110566	Inhibition of CSF1R	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	=	IC50	nM	58.0	CHEMBL1844	Homo sapiens	IC50	nM	58.0
	3192007	CHEMBL1104216	Inhibition of human CSF1R autophosphorylation expressed in HEK293 cells after 1 hr by ELISA	B	Nc1ncc(-c2ccc(C(=O)N3CCC[C@H]3CN3CCCC3)cc2)nc1NCc1c(Cl)cccc1Cl		CHEMBL1088598	=	IC50	nM	40.0	CHEMBL1844	Homo sapiens	IC50	nM	40.0
	3192008	CHEMBL1104216	Inhibition of human CSF1R autophosphorylation expressed in HEK293 cells after 1 hr by ELISA	B	Nc1ncc(-c2ccc(C(=O)N3CCC[C@H]3CN3CCCC3)cc2)nc1OCc1c(Cl)cccc1Cl		CHEMBL1088599	=	IC50	nM	57.0	CHEMBL1844	Homo sapiens	IC50	nM	57.0
	3192009	CHEMBL1104216	Inhibition of human CSF1R autophosphorylation expressed in HEK293 cells after 1 hr by ELISA	B	Cn1cc(-c2cnc(N)c(NCc3c(Cl)cccc3Cl)n2)cn1		CHEMBL1088040	=	IC50	nM	345.0	CHEMBL1844	Homo sapiens	IC50	nM	345.0
	3192010	CHEMBL1104216	Inhibition of human CSF1R autophosphorylation expressed in HEK293 cells after 1 hr by ELISA	B	Cn1cc(-c2cnc(N)c(OCc3c(Cl)cccc3Cl)n2)cn1		CHEMBL1076735	=	IC50	nM	1700.0	CHEMBL1844	Homo sapiens	IC50	nM	1700.0
	3192011	CHEMBL1104216	Inhibition of human CSF1R autophosphorylation expressed in HEK293 cells after 1 hr by ELISA	B	Cn1cc(-c2cnc(N)c(OCc3ccccc3Cl)n2)cn1		CHEMBL1088175	=	IC50	nM	1990.0	CHEMBL1844	Homo sapiens	IC50	nM	1990.0
	3192012	CHEMBL1104216	Inhibition of human CSF1R autophosphorylation expressed in HEK293 cells after 1 hr by ELISA	B	COc1ccc(COc2ccc(COc3nc(-c4cnn(C)c4)cnc3N)cc2OC)cc1		CHEMBL1087661	=	IC50	nM	56.0	CHEMBL1844	Homo sapiens	IC50	nM	56.0
	3192013	CHEMBL1104216	Inhibition of human CSF1R autophosphorylation expressed in HEK293 cells after 1 hr by ELISA	B	COc1ccc(COc2cnc(COc3nc(-c4cnn(C)c4)cnc3N)cc2OC)cc1		CHEMBL1087662	=	IC50	nM	143.0	CHEMBL1844	Homo sapiens	IC50	nM	143.0
	3192014	CHEMBL1104216	Inhibition of human CSF1R autophosphorylation expressed in HEK293 cells after 1 hr by ELISA	B	COc1ccc(COc2ncc(COc3nc(-c4cnn(C)c4)cnc3N)cc2OC)cc1		CHEMBL1087279	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	nM	30.0
	3192015	CHEMBL1104216	Inhibition of human CSF1R autophosphorylation expressed in HEK293 cells after 1 hr by ELISA	B	COc1ccc(COc2ncc(Oc3nc(-c4cnn(C)c4)cnc3N)cc2OC)cc1		CHEMBL1087280	=	IC50	nM	12.0	CHEMBL1844	Homo sapiens	IC50	nM	12.0
	3213820	CHEMBL1108407	Inhibition of FMS at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	103.0	CHEMBL1844	Homo sapiens	INH	%	103.0
	3224784	CHEMBL1102778	Inhibition of CSF1R at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	3225034	CHEMBL1102778	Inhibition of CSF1R at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	3226152	CHEMBL1112288	Binding affinity to CSF1R	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(NC(=O)c3ncccc3O)cc2)no1		CHEMBL1079545	=	Kd	nM	4.4	CHEMBL1844	Homo sapiens	Kd	nM	4.4
	3226153	CHEMBL1112288	Binding affinity to CSF1R	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(NC(=O)c3cc4ccccc4cn3)cc2)no1		CHEMBL1081509	=	Kd	nM	8.5	CHEMBL1844	Homo sapiens	Kd	nM	8.5
	3226154	CHEMBL1112288	Binding affinity to CSF1R	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(NC(=O)c3cn4c(n3)sc3ccccc34)cc2)no1		CHEMBL575925	=	Kd	nM	10.0	CHEMBL1844	Homo sapiens	Kd	nM	10.0
	3229264	CHEMBL1108484	Inhibition of c-Fms	B	COc1cc2c(cc1Cl)C(c1ccc(Cl)c(Cl)c1)=NCC2		CHEMBL1087421	<	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	pIC50		5.0
	3229277	CHEMBL1108484	Inhibition of c-Fms	B	COc1cc2c(cc1Cl)C(c1cccc(Cl)c1)=NCC2		CHEMBL1088633	<	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	pIC50		5.0
	3240800	CHEMBL1109663	Inhibition of CSF1R	B	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1		CHEMBL1090360	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	3307957	CHEMBL1119360	Inhibition of human FMS	B	Cc1cn(-c2cc(NC(=O)Nc3ccc(-c4nc5[nH]ncc5[nH]4)c(C)c3)cc(C(F)(F)F)c2)cn1		CHEMBL1084036	=	Inhibition	%	42.0	CHEMBL1844	Homo sapiens	INH	%	42.0
	3327240	CHEMBL1168285	Inhibition of FMS at 10 uM by HotSpot assay	B	CC(=O)Nc1cccc(-c2ccc(-c3ccnc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)cn2)c1.Cl		CHEMBL1164847	<	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	3331877	CHEMBL1168836	Inhibition of CSF1R at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	3333292	CHEMBL1168836	Inhibition of CSF1R at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	=	Inhibition	%	88.0	CHEMBL1844	Homo sapiens	INH	%	88.0
	3334697	CHEMBL1168836	Inhibition of CSF1R at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	=	Inhibition	%	88.0	CHEMBL1844	Homo sapiens	INH	%	88.0
	3336117	CHEMBL1168836	Inhibition of CSF1R at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	=	Inhibition	%	96.0	CHEMBL1844	Homo sapiens	INH	%	96.0
	3337484	CHEMBL1168836	Inhibition of CSF1R at 1 uM	B	O=C(O)c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1		CHEMBL1163510	<	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	3337732	CHEMBL1168836	Inhibition of CSF1R at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1		CHEMBL1163518	<	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	3339064	CHEMBL1168836	Inhibition of CSF1R at 1 uM	B	COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1		CHEMBL1163567	=	Inhibition	%	74.2	CHEMBL1844	Homo sapiens	INH	%	74.2
	3340366	CHEMBL1168836	Inhibition of CSF1R at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1		CHEMBL1163559	=	Inhibition	%	96.6	CHEMBL1844	Homo sapiens	INH	%	96.6
	3340645	CHEMBL1168836	Inhibition of CSF1R at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	=	Inhibition	%	99.0	CHEMBL1844	Homo sapiens	INH	%	99.0
	3342061	CHEMBL1168836	Inhibition of CSF1R at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	=	Inhibition	%	93.0	CHEMBL1844	Homo sapiens	INH	%	93.0
	3355505	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(-c3cc[n+]([O-])cc3)cc2C2=CCCCC2)n1		CHEMBL1172345	=	IC50	nM	1.5	CHEMBL1844	Homo sapiens	IC50	nM	1.5
	3355506	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(-c3ccncc3)cc2C2=CCCCC2)n1		CHEMBL1172346	=	IC50	nM	4.5	CHEMBL1844	Homo sapiens	IC50	nM	4.5
	3355507	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(-c3ccc[n+]([O-])c3)cc2C2=CCCCC2)n1		CHEMBL1172347	=	IC50	nM	1.4	CHEMBL1844	Homo sapiens	IC50	nM	1.4
	3355508	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(-c3cccnc3)cc2C2=CCCCC2)n1		CHEMBL1172528	=	IC50	nM	2.3	CHEMBL1844	Homo sapiens	IC50	nM	2.3
	3355509	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(-c3cccc[n+]3[O-])cc2C2=CCCCC2)n1		CHEMBL1172116	=	IC50	nM	7.1	CHEMBL1844	Homo sapiens	IC50	nM	7.1
	3355510	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(-c3ccccn3)cc2C2=CCCCC2)n1		CHEMBL1172117	=	IC50	nM	11.0	CHEMBL1844	Homo sapiens	IC50	nM	11.0
	3355511	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(-c3ccc(N)nc3)cc2C2=CCCCC2)n1		CHEMBL1172313	=	IC50	nM	4.5	CHEMBL1844	Homo sapiens	IC50	nM	4.5
	3355512	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	COc1ccc(-c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCC(C)(C)CC3)c2)cn1		CHEMBL1172314	=	IC50	nM	41.0	CHEMBL1844	Homo sapiens	IC50	nM	41.0
	3355513	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	CN(C)S(=O)(=O)c1ccc(-c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)cc1		CHEMBL1172529	=	IC50	nM	20.0	CHEMBL1844	Homo sapiens	IC50	nM	20.0
	3355514	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(-c3ccc(N)cc3)cc2C2=CCCCC2)n1		CHEMBL1172530	=	IC50	nM	23.0	CHEMBL1844	Homo sapiens	IC50	nM	23.0
	3355515	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(-c3ccccc3)cc2C2=CCCCC2)n1		CHEMBL1171776	>	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	nM	60.0
	3355516	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CC(=O)NC(=O)C3)cc2C2=CCCCC2)n1		CHEMBL1171777	=	IC50	nM	1.0	CHEMBL1844	Homo sapiens	IC50	nM	1.0
	3355517	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	CC1(C)CC=C(c2cc(C3CC(=O)NC(=O)C3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL1171385	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	nM	0.8
	3355518	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	CN1C(=O)CC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1=O		CHEMBL1170784	=	IC50	nM	0.5	CHEMBL1844	Homo sapiens	IC50	nM	0.5
	3355519	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CNC(=O)NC3)cc2C2=CCCCC2)n1		CHEMBL1170785	=	IC50	nM	2.3	CHEMBL1844	Homo sapiens	IC50	nM	2.3
	3355520	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	CN1CC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CN(C)C1=O		CHEMBL1170786	=	IC50	nM	0.5	CHEMBL1844	Homo sapiens	IC50	nM	0.5
	3355521	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	CN1CC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCC(C)(C)CC3)c2)CN(C)C1=O		CHEMBL1171604	=	IC50	nM	0.3	CHEMBL1844	Homo sapiens	IC50	nM	0.3
	3355522	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	CN1CC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCCC3)c2)CN(C)C1=O		CHEMBL1171605	=	IC50	nM	0.9	CHEMBL1844	Homo sapiens	IC50	nM	0.9
	3355523	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CNS(=O)(=O)NC3)cc2C2=CCCCC2)n1		CHEMBL1171606	=	IC50	nM	2.9	CHEMBL1844	Homo sapiens	IC50	nM	2.9
	3355524	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	CN1CC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CN(C)S1(=O)=O		CHEMBL1171607	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	nM	1.7
	3355525	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	CC1(C)CC=C(c2cc(C3CNC(=NC#N)NC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL1170997	=	IC50	nM	2.5	CHEMBL1844	Homo sapiens	IC50	nM	2.5
	3355526	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	CN1CC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCC(C)(C)CC3)c2)CN(C)C1=NC#N		CHEMBL3349454	=	IC50	nM	0.4	CHEMBL1844	Homo sapiens	IC50	nM	0.4
	3355527	CHEMBL1174608	Inhibition of human FMS by fluorescence polarization	B	CN1CC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCC(C)(C)CC3)c2)CN(C)C1=NS(C)(=O)=O		CHEMBL1169980	=	IC50	nM	1.9	CHEMBL1844	Homo sapiens	IC50	nM	1.9
	3358509	CHEMBL1174181	Inhibition of CSF1R at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	0.0	CHEMBL1844	Homo sapiens	INH	%	0.0
	3358951	CHEMBL1174181	Inhibition of CSF1R at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	0.0	CHEMBL1844	Homo sapiens	INH	%	0.0
	3407692	CHEMBL1219740	Inhibition of CSF1R at 1 uM by radiometric method	B	CCOC(=O)CCc1c(/C=C2\C(=O)Nc3ccc(NS(=O)(=O)c4ccccc4)cc32)[nH]c2c1C(=O)CCC2		CHEMBL1215218	=	Inhibition	%	34.0	CHEMBL1844	Homo sapiens	INH	%	34.0
	3407693	CHEMBL1219740	Inhibition of CSF1R at 1 uM by radiometric method	B	CN(C)CCCc1c(/C=C2\C(=O)Nc3ccc(NS(=O)(=O)c4ccccc4)cc32)[nH]c2c1C(=O)CCC2		CHEMBL1215346	=	Inhibition	%	56.0	CHEMBL1844	Homo sapiens	INH	%	56.0
	3407744	CHEMBL1219786	Inhibition of CSF1R by radiometric method	B	CCOC(=O)CCc1c(/C=C2\C(=O)Nc3ccc(NS(=O)(=O)c4ccccc4)cc32)[nH]c2c1C(=O)CCC2		CHEMBL1215218	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	3407745	CHEMBL1219786	Inhibition of CSF1R by radiometric method	B	CN(C)CCCc1c(/C=C2\C(=O)Nc3ccc(NS(=O)(=O)c4ccccc4)cc32)[nH]c2c1C(=O)CCC2		CHEMBL1215346	<	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	3439113	CHEMBL1247960	Inhibition of c-Fms by HTRF assay	B	CNc1nccc(-c2cccnc2Oc2ccc(NC(=O)c3cccc(C(F)(F)F)c3)cc2C)n1		CHEMBL1242977	=	IC50	nM	1580.0	CHEMBL1844	Homo sapiens	IC50	nM	1580.0
	3443363	CHEMBL1244396	Inhibition of CSF1R at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21		CHEMBL1241578	=	Inhibition	%	53.0	CHEMBL1844	Homo sapiens	INH	%	53.0
	3443580	CHEMBL1244396	Inhibition of CSF1R at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Inhibition	%	84.0	CHEMBL1844	Homo sapiens	INH	%	84.0
	3444735	CHEMBL1244396	Inhibition of CSF1R at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882	=	Inhibition	%	37.0	CHEMBL1844	Homo sapiens	INH	%	37.0
	3444975	CHEMBL1244774	Binding affinity to CSF1R	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	=	Kd	nM	12.0	CHEMBL1844	Homo sapiens	Kd	nM	12.0
	3445071	CHEMBL1244774	Binding affinity to CSF1R	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	110.0	CHEMBL1844	Homo sapiens	Kd	nM	110.0
	3445359	CHEMBL1244396	Inhibition of CSF1R at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC		CHEMBL1233881	=	Inhibition	%	48.0	CHEMBL1844	Homo sapiens	INH	%	48.0
	3445576	CHEMBL1244396	Inhibition of CSF1R at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Inhibition	%	4.0	CHEMBL1844	Homo sapiens	INH	%	4.0
	3445788	CHEMBL1244396	Inhibition of CSF1R at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL1230790	=	Inhibition	%	67.0	CHEMBL1844	Homo sapiens	INH	%	67.0
	3445978	CHEMBL1244396	Inhibition of CSF1R at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21		CHEMBL1234815	=	Inhibition	%	44.0	CHEMBL1844	Homo sapiens	INH	%	44.0
	3448838	CHEMBL1244774	Binding affinity to CSF1R	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	=	Kd	nM	4.9	CHEMBL1844	Homo sapiens	Kd	nM	4.9
	3448899	CHEMBL1244774	Binding affinity to CSF1R	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	330.0	CHEMBL1844	Homo sapiens	Kd	nM	330.0
	3449136	CHEMBL1244774	Binding affinity to CSF1R	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	2.0	CHEMBL1844	Homo sapiens	Kd	nM	2.0
	3449137	CHEMBL1244774	Binding affinity to CSF1R	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	=	Kd	nM	28.0	CHEMBL1844	Homo sapiens	Kd	nM	28.0
	3450950	CHEMBL1244774	Binding affinity to CSF1R	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	=	Kd	nM	560.0	CHEMBL1844	Homo sapiens	Kd	nM	560.0
	3463196	CHEMBL1252284	Inhibition of CSF1R at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Inhibition	%	5.0	CHEMBL1844	Homo sapiens	INH	%	5.0
	3463415	CHEMBL1252284	Inhibition of CSF1R at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	COc1ccccc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL1254209	=	Inhibition	%	26.0	CHEMBL1844	Homo sapiens	INH	%	26.0
	3463959	CHEMBL1252284	Inhibition of CSF1R at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Inhibition	%	44.0	CHEMBL1844	Homo sapiens	INH	%	44.0
	3471363	CHEMBL1251497	Inhibition of autophosphorylation of CSF1R expressed in HEK293 cells by ELISA	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	IC50	nM	291.0	CHEMBL1844	Homo sapiens	IC50	nM	291.0
	3471377	CHEMBL1251497	Inhibition of autophosphorylation of CSF1R expressed in HEK293 cells by ELISA	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	=	IC50	nM	677.0	CHEMBL1844	Homo sapiens	IC50	nM	677.0
	3526135	CHEMBL1274461	Binding affinity to CSF1R	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	=	Kd	nM	1.6	CHEMBL1844	Homo sapiens	Kd	nM	1.6
	3603104	CHEMBL1291201	Inhibition of CSF1R at 10 uM	B	O=C(Cc1cccc2cnccc12)Nc1scnc1-c1cscn1		CHEMBL1288160	=	Inihibition	%	33.0	CHEMBL1844	Homo sapiens	Inihibition	%	33.0
	5120100	CHEMBL1648797	Inhibition of CSF1R at 10 uM after 60 mins by TR-FRET assay	B	O=c1n(Cc2ccccn2)nc(-c2ccnc(NC3CCOCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644615	=	Inhibition	%	4.0	CHEMBL1844	Homo sapiens	INH	%	4.0
	5120132	CHEMBL1648797	Inhibition of CSF1R at 10 uM after 60 mins by TR-FRET assay	B	O=c1n(C2CCOCC2)nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644639	=	Inhibition	%	7.0	CHEMBL1844	Homo sapiens	INH	%	7.0
	5120235	CHEMBL1648797	Inhibition of CSF1R at 10 uM after 60 mins by TR-FRET assay	B	O=c1[nH]nc(-c2ccnc(NC3CCCOC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644619	=	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	5120248	CHEMBL1648797	Inhibition of CSF1R at 10 uM after 60 mins by TR-FRET assay	B	O=c1[nH]nc(-c2ccnc(NC3CCOCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644620	=	Inhibition	%	74.0	CHEMBL1844	Homo sapiens	INH	%	74.0
	5120295	CHEMBL1645973	Inhibition of human Fms at 10 uM after 60 mins by TR-FRET assay	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	96.0	CHEMBL1844	Homo sapiens	INH	%	96.0
	5139760	CHEMBL1648797	Inhibition of CSF1R at 10 uM after 60 mins by TR-FRET assay	B	O=c1[nH]nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644618	=	Inhibition	%	-1.0	CHEMBL1844	Homo sapiens	INH	%	-1.0
	5139842	CHEMBL1648797	Inhibition of CSF1R at 10 uM after 60 mins by TR-FRET assay	B	O=c1n(Cc2ccncc2)nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644642	=	Inhibition	%	1.0	CHEMBL1844	Homo sapiens	INH	%	1.0
	5223281	CHEMBL1679277	Binding affinity to c-FMS at 10 uM by immobilized ligand displacement assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2		CHEMBL1672987	>	Inhibition	%	90.0	CHEMBL1844	Homo sapiens	INH	%	90.0
	5243711	CHEMBL1685674	Inhibition of Fms at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCN(Cc6ccccc6)CC5)cc34)[nH]c2c1		CHEMBL1684543	=	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	5243819	CHEMBL1685923	Inhibition of Fms at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCN(Cc6ccccc6)CC5)cc34)[nH]c2c1		CHEMBL1684543	=	Inhibition	%	20.0	CHEMBL1844	Homo sapiens	INH	%	20.0
	5243932	CHEMBL1685674	Inhibition of Fms at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCNC5)cc34)[nH]c2c1		CHEMBL1684654	=	Inhibition	%	57.0	CHEMBL1844	Homo sapiens	INH	%	57.0
	5244040	CHEMBL1685923	Inhibition of Fms at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCNC5)cc34)[nH]c2c1		CHEMBL1684654	=	Inhibition	%	10.0	CHEMBL1844	Homo sapiens	INH	%	10.0
	5244913	CHEMBL1685674	Inhibition of Fms at 0.1 uM	B	O=C(Cc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1)c1ccccc1		CHEMBL1684662	=	Inhibition	%	70.0	CHEMBL1844	Homo sapiens	INH	%	70.0
	5245021	CHEMBL1685923	Inhibition of Fms at 1 uM	B	O=C(Cc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1)c1ccccc1		CHEMBL1684662	=	Inhibition	%	21.0	CHEMBL1844	Homo sapiens	INH	%	21.0
	5245172	CHEMBL1685674	Inhibition of Fms at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NS(=O)(=O)c5ncn(C)c5C)cc34)[nH]c2c1		CHEMBL1684525	=	Inhibition	%	99.0	CHEMBL1844	Homo sapiens	INH	%	99.0
	5246002	CHEMBL1685923	Inhibition of Fms at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NS(=O)(=O)c5ncn(C)c5C)cc34)[nH]c2c1		CHEMBL1684525	=	Inhibition	%	58.0	CHEMBL1844	Homo sapiens	INH	%	58.0
	5248387	CHEMBL1686634	Inhibition of CSF1R	B	CCNC(=O)Nc1ccc(Oc2ncnc(N)c2/C=N/OC)cc1Cl		CHEMBL1681932	=	IC50	nM	622.0	CHEMBL1844	Homo sapiens	IC50	nM	622.0
	5249427	CHEMBL1686778	Inhibition of CSF1R at 10 uM	B	O=C(Cc1cccc2cnccc12)Nc1scc(Cl)c1-c1ncn[nH]1		CHEMBL1682017	=	Inhibition	%	5.0	CHEMBL1844	Homo sapiens	INH	%	5.0
	5250027	CHEMBL1685563	Inhibition of CSF1R at 0.1 uM	B	CCOc1cc2nnc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1N1CCN(C)CC1		CHEMBL1683030	=	Inhibition	%	100.0	CHEMBL1844	Homo sapiens	INH	%	100.0
	5250028	CHEMBL1685562	Inhibition of CSF1R at 1 uM	B	CCOc1cc2nnc(C(N)=O)c(Nc3ccc(F)cc3F)c2cc1N1CCN(C)CC1		CHEMBL1683030	=	Inhibition	%	95.0	CHEMBL1844	Homo sapiens	INH	%	95.0
	6161903	CHEMBL1764211	Inhibition of c-FMS	B	NC(=O)c1cc(-c2ccccc2)cc2c(C3CCCNC3)c[nH]c12		CHEMBL1761510	=	IC50	nM	1584.89	CHEMBL1844	Homo sapiens	pIC50		5.8
	6167353	CHEMBL1768568	Binding affinity to CSF1R at 1 uM relative to control	B	Nc1ccc(-c2ccc3ncc4ccc(=O)n(-c5cccc(C(F)(F)F)c5)c4c3c2)cn1		CHEMBL1765602	=	Activity	%	2.4	CHEMBL1844	Homo sapiens	Activity	%	2.4
	6167558	CHEMBL1769031	Binding affinity to human CSF1R assessed as residual binding at 1 uM by site dependent competitive binding assay	B	Cc1ccc(NC(=O)c2ccc(CNC(=O)CCl)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL1765717	=	Activity	%	5.0	CHEMBL1844	Homo sapiens	Activity	%	5.0
	6167574	CHEMBL1769048	Binding affinity to human CSF1R assessed as residual binding at 10 uM by site dependent competitive binding assay	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Activity	%	0.0	CHEMBL1844	Homo sapiens	Activity	%	0.0
	6167596	CHEMBL1769239	Binding affinity to human CSF1R cysteine residue assessed as residual binding at 1 uM by site dependent competitive binding assay	B	Cc1ccc(NC(=O)c2ccc(CNC(=O)CCl)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL1765717	=	Activity	%	5.0	CHEMBL1844	Homo sapiens	Activity	%	5.0
	6167620	CHEMBL1768480	Binding affinity to human CSF1R cysteine residue assessed as residual binding at 10 uM by site dependent competitive binding assay	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Activity	%	0.0	CHEMBL1844	Homo sapiens	Activity	%	0.0
Active	6204071	CHEMBL1781332	Inhibition of CSFR1	B	CNC(=O)c1cc(Oc2ccc3sc(Nc4cccc(C(C)(C)C)c4)nc3c2)ccn1		CHEMBL1778403		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
Active	6204072	CHEMBL1781332	Inhibition of CSFR1	B	CNC(=O)c1cc(Oc2ccc3oc(Nc4cccc(C(C)C)c4)nc3c2)ccn1		CHEMBL1778392		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
	6218825	CHEMBL1786916	Binding affinity to human CSF1R at 10 uM incubated for 1 hr by kinase binding assay relative to untreated control	B	c1ccc(Cc2cnc(N3CCN(c4ncnc5ccccc45)CC3)nc2)cc1		CHEMBL1782075	=	Activity	%	31.0	CHEMBL1844	Homo sapiens	Activity	%	31.0
Not Determined	6218851	CHEMBL1787155	Binding affinity to human CSF1R incubated for 1 hr by kinase binding assay	B	c1ccc(Cc2cnc(N3CCN(c4ncnc5ccccc45)CC3)nc2)cc1		CHEMBL1782075		Kd			CHEMBL1844	Homo sapiens	Kd		
	6219029	CHEMBL1786916	Binding affinity to human CSF1R at 10 uM incubated for 1 hr by kinase binding assay relative to untreated control	B	CCc1cnc(N2CCN(C(=O)c3ccc(CNc4ncnc5ccccc45)cc3)CC2)nc1		CHEMBL1783929	>	Activity	%	50.0	CHEMBL1844	Homo sapiens	Activity	%	50.0
	6220378	CHEMBL1786916	Binding affinity to human CSF1R at 10 uM incubated for 1 hr by kinase binding assay relative to untreated control	B	O=C(c1cccc(Nc2ncnc3ccccc23)c1)N1CCN(c2ncc(Cc3ccccc3)cn2)CC1		CHEMBL1783930	>	Activity	%	50.0	CHEMBL1844	Homo sapiens	Activity	%	50.0
	6221243	CHEMBL1786868	Inhibition of CSF1R at 10 uM	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	46.0	CHEMBL1844	Homo sapiens	INH	%	46.0
	6230425	CHEMBL1786948	Inhibition of CSF1R	B	O=C(c1cccs1)N1N=C(c2cccnc2)CC1c1ccccc1O		CHEMBL1782188	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	6230426	CHEMBL1786948	Inhibition of CSF1R	B	O=C(c1ccc[nH]1)N1N=C(c2cccnc2)CC1c1ccccc1O		CHEMBL1782187	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	6230427	CHEMBL1786948	Inhibition of CSF1R	B	CCOc1cccc2cc(C(=O)N3N=C(c4cccnc4)CC3c3ccccc3O)oc12		CHEMBL1782186	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	6230428	CHEMBL1786948	Inhibition of CSF1R	B	O=C(c1ccc(Br)o1)N1N=C(c2cccnc2)CC1c1ccccc1O		CHEMBL1782185	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	6230429	CHEMBL1786948	Inhibition of CSF1R	B	O=C(c1cccc(-n2cccn2)c1)N1N=C(c2cccnc2)CC1c1ccccc1O		CHEMBL1782182	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	6231466	CHEMBL1786948	Inhibition of CSF1R	B	O=C(c1ccco1)N1N=C(c2cccnc2)CC1c1ccccc1O		CHEMBL1779593	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	6264917	CHEMBL1799800	Inhibition of CSF1R at 1 uM	B	COCCN1CCc2cc(Nc3ncc(Cl)c(N[C@@H]4CCCC[C@H]4NS(C)(=O)=O)n3)c(OC)cc2CC1		CHEMBL1796254	<	Inhibition	%	65.0	CHEMBL1844	Homo sapiens	INH	%	65.0
	6265641	CHEMBL1799800	Inhibition of CSF1R at 1 uM	B	COCCN1CCc2cc(Nc3ncc(Cl)c(N[C@@H]4CCCC[C@H]4N(C)S(C)(=O)=O)n3)c(OC)cc2CC1		CHEMBL1796257	=	Inhibition	%	98.0	CHEMBL1844	Homo sapiens	INH	%	98.0
	6286556	CHEMBL1810341	Inhibition of CSF1R at 0.1 uM	B	Cc1nc(Nc2cc(-c3cccc(NS(=O)(=O)c4ccccc4)c3)n[nH]2)cc(N2CCN(C)CC2)n1		CHEMBL1807483	=	Inhibition	%	16.0	CHEMBL1844	Homo sapiens	INH	%	16.0
	6341032	CHEMBL1827762	Activity of CSF1R kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	100.0	CHEMBL1844	Homo sapiens	Activity	%	100.0
	6353456	CHEMBL1825702	Inhibition of CSF1R at 10 uM	B	O=C(Cn1c(=O)ccc2cc(C(F)(F)F)ccc21)Nc1scc(Br)c1-c1ncn[nH]1		CHEMBL1822146	=	Inhibition	%	-2.0	CHEMBL1844	Homo sapiens	INH	%	-2.0
	7567393	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	=	Kd	nM	13.0	CHEMBL1844	Homo sapiens	Kd	nM	13.0
	7567852	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7567881	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	=	Kd	nM	670.0	CHEMBL1844	Homo sapiens	Kd	nM	670.0
	7568349	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	=	Kd	nM	0.67	CHEMBL1844	Homo sapiens	Kd	nM	0.67
	7568781	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	3.6	CHEMBL1844	Homo sapiens	Kd	nM	3.6
	7569366	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7569856	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Kd	nM	11.0	CHEMBL1844	Homo sapiens	Kd	nM	11.0
	7570319	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	=	Kd	nM	700.0	CHEMBL1844	Homo sapiens	Kd	nM	700.0
	7570746	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	2.5	CHEMBL1844	Homo sapiens	Kd	nM	2.5
	7571357	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	=	Kd	nM	210.0	CHEMBL1844	Homo sapiens	Kd	nM	210.0
	7571833	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7572296	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7572712	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Kd	nM	48.0	CHEMBL1844	Homo sapiens	Kd	nM	48.0
	7572881	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7573338	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Kd	nM	0.58	CHEMBL1844	Homo sapiens	Kd	nM	0.58
	7573814	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	=	Kd	nM	3.2	CHEMBL1844	Homo sapiens	Kd	nM	3.2
	7574283	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	330.0	CHEMBL1844	Homo sapiens	Kd	nM	330.0
	7574691	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7574859	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	48.0	CHEMBL1844	Homo sapiens	Kd	nM	48.0
	7575320	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7575791	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	=	Kd	nM	0.83	CHEMBL1844	Homo sapiens	Kd	nM	0.83
	7576256	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	=	Kd	nM	2700.0	CHEMBL1844	Homo sapiens	Kd	nM	2700.0
	7576664	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	620.0	CHEMBL1844	Homo sapiens	Kd	nM	620.0
	7576833	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7577292	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	=	Kd	nM	1.8	CHEMBL1844	Homo sapiens	Kd	nM	1.8
	7577770	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	120.0	CHEMBL1844	Homo sapiens	Kd	nM	120.0
	7578841	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7579215	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	Kd	nM	8100.0	CHEMBL1844	Homo sapiens	Kd	nM	8100.0
	7579665	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	2800.0	CHEMBL1844	Homo sapiens	Kd	nM	2800.0
	7580139	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7580166	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Kd	nM	3300.0	CHEMBL1844	Homo sapiens	Kd	nM	3300.0
	7580569	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	=	Kd	nM	1200.0	CHEMBL1844	Homo sapiens	Kd	nM	1200.0
	7581199	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	=	Kd	nM	7.6	CHEMBL1844	Homo sapiens	Kd	nM	7.6
	7581584	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7582029	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7582522	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	=	Kd	nM	45.0	CHEMBL1844	Homo sapiens	Kd	nM	45.0
	7582922	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	1800.0	CHEMBL1844	Homo sapiens	Kd	nM	1800.0
	7583545	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	=	Kd	nM	3.4	CHEMBL1844	Homo sapiens	Kd	nM	3.4
	7583942	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7584416	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7584878	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	31.0	CHEMBL1844	Homo sapiens	Kd	nM	31.0
	7585282	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	=	Kd	nM	2600.0	CHEMBL1844	Homo sapiens	Kd	nM	2600.0
	7585875	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	=	Kd	nM	10.0	CHEMBL1844	Homo sapiens	Kd	nM	10.0
	7586287	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7586758	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7587212	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7587813	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	=	Kd	nM	1900.0	CHEMBL1844	Homo sapiens	Kd	nM	1900.0
	7588266	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7588737	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7589188	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7589359	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	=	Kd	nM	21.0	CHEMBL1844	Homo sapiens	Kd	nM	21.0
	7589783	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	110.0	CHEMBL1844	Homo sapiens	Kd	nM	110.0
	7590250	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7590724	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	=	Kd	nM	4.9	CHEMBL1844	Homo sapiens	Kd	nM	4.9
	7591175	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7591332	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	=	Kd	nM	5.6	CHEMBL1844	Homo sapiens	Kd	nM	5.6
	7591754	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	60.0	CHEMBL1844	Homo sapiens	Kd	nM	60.0
	7592226	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7592699	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7593152	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	Kd	nM	380.0	CHEMBL1844	Homo sapiens	Kd	nM	380.0
	7593299	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	=	Kd	nM	5.8	CHEMBL1844	Homo sapiens	Kd	nM	5.8
	7593734	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	=	Kd	nM	250.0	CHEMBL1844	Homo sapiens	Kd	nM	250.0
	7594206	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7594679	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	=	Kd	nM	45.0	CHEMBL1844	Homo sapiens	Kd	nM	45.0
	7595267	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7595711	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7596185	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Kd	nM	2.2	CHEMBL1844	Homo sapiens	Kd	nM	2.2
	7596661	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	=	Kd	nM	28.0	CHEMBL1844	Homo sapiens	Kd	nM	28.0
	7597239	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	=	Kd	nM	1400.0	CHEMBL1844	Homo sapiens	Kd	nM	1400.0
	7597692	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	7598193	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	=	Kd	nM	7.9	CHEMBL1844	Homo sapiens	Kd	nM	7.9
	7598635	CHEMBL1908692	Binding constant for CSF1R kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	12.0	CHEMBL1844	Homo sapiens	Kd	nM	12.0
	7922653	CHEMBL1918995	Inhibition of human recombinant CSF1R at 0.5 uM by radiometric filter-binding assay	B	Clc1ccccc1Nc1nc2c(-c3nnc[nH]3)cccc2c2cnccc12		CHEMBL1915438	=	Inhibition	%	83.0	CHEMBL1844	Homo sapiens	INH	%	83.0
	7943736	CHEMBL1921579	Inhibition of FMS	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	3.13	CHEMBL1844	Homo sapiens	IC50	nM	3.13
	7943776	CHEMBL1921544	Inhibition of FMS at 10 uM	B	O=C1CC(c2cccc(NC(=O)c3ccc(Cl)c(C(F)(F)F)c3)c2)=Nc2cnn(Cc3ccccc3)c2N1		CHEMBL1917776	=	Inhibition	%	0.5	CHEMBL1844	Homo sapiens	INH	%	0.5
	7959781	CHEMBL1932865	Inhibition of FMS	B	CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O		CHEMBL1929238	>	IC50	nM	30000.0	CHEMBL1844	Homo sapiens	IC50	uM	30.0
	7959782	CHEMBL1932865	Inhibition of FMS	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	IC50	nM	30000.0	CHEMBL1844	Homo sapiens	IC50	uM	30.0
	8005106	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cc2ncnc(Nc3cnn(CC(=O)Nc4cccc(F)c4)c3)c2cc1OC		CHEMBL1940103	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	8005107	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cccc(NC(=O)Cn2cc(Nc3ncnc4cc(OC)c(OC)cc34)cn2)c1		CHEMBL1940104	>	IC50	nM	900.0	CHEMBL1844	Homo sapiens	IC50	uM	0.9
	8005108	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cc2ncnc(Nc3cnn(CC(=O)Nc4ccc(N(C)C)cc4)c3)c2cc1OC		CHEMBL1940105	=	IC50	nM	600.0	CHEMBL1844	Homo sapiens	IC50	uM	0.6
	8005109	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cc2ncnc(Nc3cnn(CC(=O)Nc4ccc(N(C)C)cn4)c3)c2cc1OC		CHEMBL1940106	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	8005110	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cc2ncnc(Oc3cnn(CC(=O)Nc4ccc(N(C)C)cn4)c3)c2cc1OC		CHEMBL1940107	=	IC50	nM	20.0	CHEMBL1844	Homo sapiens	IC50	uM	0.02
	8005111	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cccc(NC(=O)Cn2cc(Oc3ncnc4cc(OC)c(OC)cc34)cn2)c1		CHEMBL1940108	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	uM	0.01
	8005112	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COCCOc1cc2ncnc(Oc3cnn(CC(=O)Nc4cccc(OC)c4)c3)c2cc1OC		CHEMBL1940109	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	uM	0.008
	8005113	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COCCOc1cc2c(Oc3cnn(CC(=O)Nc4cccc(OC)c4)c3)ncnc2cc1OC		CHEMBL1940110	=	IC50	nM	90.0	CHEMBL1844	Homo sapiens	IC50	uM	0.09
	8005114	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cccc(NC(=O)Cn2cc(Oc3ncnc4cc(OC)c(OCCN5CCCCC5)cc34)cn2)c1		CHEMBL1940111	=	IC50	nM	400.0	CHEMBL1844	Homo sapiens	IC50	uM	0.4
	8005115	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cccc(NC(=O)Cn2cc(Oc3ncnc4cc(OCCN5CCCC5)c(OC)cc34)cn2)c1		CHEMBL1940112	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	uM	0.03
	8005116	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cccc(NC(=O)Cn2cc(Oc3ncnc4cc(OC)cc(OC)c34)cn2)c1		CHEMBL1940113	=	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	uM	0.1
	8005117	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cccc(NC(=O)Cn2cc(Oc3ccnc4cc(OC)c(C#N)cc34)cn2)c1		CHEMBL1940114	=	IC50	nM	50.0	CHEMBL1844	Homo sapiens	IC50	uM	0.05
	8005118	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cccc(NC(=O)Cn2cc(Oc3ccnc4cc(OC)c(OC)cc34)cn2)c1		CHEMBL1940115	=	IC50	nM	40.0	CHEMBL1844	Homo sapiens	IC50	uM	0.04
	8005119	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	CCn1cc(NC(=O)Cn2cc(Oc3ncnc4cc(OC)c(OC)cc34)cn2)cn1		CHEMBL1940116	=	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	uM	0.2
	8005120	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	CCn1cc(NC(=O)Cc2cc(Oc3ccnc4cc(OC)c(OC)cc34)n[nH]2)cn1		CHEMBL1940117	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	8005121	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cc2ncnc(Oc3ccc(CC(=O)Nc4ccc(N(C)C)cn4)cc3)c2cc1OC		CHEMBL1940118	=	IC50	nM	600.0	CHEMBL1844	Homo sapiens	IC50	uM	0.6
	8005122	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cccc(NC(=O)Cc2ccc(Oc3ncnc4cc(OC)c(OC)cc34)cc2)c1		CHEMBL1940259	=	IC50	nM	300.0	CHEMBL1844	Homo sapiens	IC50	uM	0.3
	8005123	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cccc(NC(=O)Cc2ccc(Nc3ncnc4cc(OC)c(OC)cc34)cc2)c1		CHEMBL1940260	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	8005124	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cccc(NC(=O)Cc2cccc(Oc3ncnc4cc(OC)c(OC)cc34)c2)c1		CHEMBL1940261	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	8005125	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cccc(NC(=O)NCc2ccc(Oc3ncnc4cc(OC)c(OC)cc34)cc2)c1		CHEMBL1940262	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	8005126	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cccc(S(=O)(=O)NCc2ccc(Oc3ncnc4cc(OC)c(OC)cc34)cc2)c1		CHEMBL1940263	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	8005127	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cccc(C(=O)NCc2ccc(Oc3ncnc4cc(OC)c(OC)cc34)cc2)c1		CHEMBL1940264	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	8005128	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cccc(CNC(=O)c2ccc(Oc3ncnc4cc(OC)c(OC)cc34)cc2)c1		CHEMBL1940265	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	8005129	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cccc(CC(=O)Nc2ccc(Oc3ncnc4cc(OC)c(OC)cc34)cc2)c1		CHEMBL1940266	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	uM	0.03
	8005130	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cccc(COc2ccc(Oc3ncnc4cc(OC)c(OC)cc34)cc2)c1		CHEMBL1940267	=	IC50	nM	300.0	CHEMBL1844	Homo sapiens	IC50	uM	0.3
	8005131	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	CCc1cc(NC(=O)Cc2ccc(Oc3ncnc4cc(OC)c(OC)cc34)cc2)n[nH]1		CHEMBL1940268	>	IC50	nM	600.0	CHEMBL1844	Homo sapiens	IC50	uM	0.6
	8005132	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	CCn1ccc(NC(=O)Cc2ccc(Oc3ncnc4cc(OC)c(OC)cc34)cc2)n1		CHEMBL1940269	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	8005133	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cc2ncnc(Oc3ccc(CC(=O)Nc4cn[nH]c4)cc3)c2cc1OC		CHEMBL1940270	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	8005134	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cc2ncnc(Oc3ccc(CC(=O)Nc4cnn(C)c4)cc3)c2cc1OC		CHEMBL1940271	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	8005135	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	CCn1cc(NC(=O)Cc2ccc(Oc3ncnc4cc(OC)c(OC)cc34)cc2)cn1		CHEMBL1940272	>	IC50	nM	800.0	CHEMBL1844	Homo sapiens	IC50	uM	0.8
	8005136	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	CCn1cc(NC(=O)Cc2ccc(Oc3ccnc4cc(OC)c(OC)cc34)cc2)cn1		CHEMBL1940273	=	IC50	nM	40.0	CHEMBL1844	Homo sapiens	IC50	uM	0.04
	8005137	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cc2ncnc(Oc3ccc(CC(=O)Nc4cnn(C(C)C)c4)cc3)c2cc1OC		CHEMBL1940274	=	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	uM	0.1
	8005138	CHEMBL1942931	Inhibition of CSF1R phosphorylation by cell based assay	B	COc1cc2ncnc(Nc3ccc(CC(=O)Nc4cnn(C(C)C)c4)cc3)c2cc1OC		CHEMBL1940275	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	8018774	CHEMBL1948828	Inhibition of Fms assessed as activity remaining at 10 uM	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CC1CCOCC1		CHEMBL1945953	=	Activity	%	37.0	CHEMBL1844	Homo sapiens	Activity	%	37.0
	8018775	CHEMBL1948828	Inhibition of Fms assessed as activity remaining at 10 uM	B	CC(C)(O)c1ccc(-c2cnc3[nH]c(=O)n(CC4CCCCC4)c3n2)cc1		CHEMBL1945950	=	Activity	%	26.0	CHEMBL1844	Homo sapiens	Activity	%	26.0
	8018776	CHEMBL1948828	Inhibition of Fms assessed as activity remaining at 10 uM	B	O=c1[nH]c2ncc(-c3ccc4[nH]cnc4c3)nc2n1CC1CCCCC1		CHEMBL1946262	=	Activity	%	23.0	CHEMBL1844	Homo sapiens	Activity	%	23.0
	8033747	CHEMBL1953552	Inhibition of CSFR1	B	CNC(=O)c1cc(Oc2ccc3nc(Nc4cccc(C(C)(C)C)c4)ncc3c2)ccn1		CHEMBL1950886	<	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	8033748	CHEMBL1953552	Inhibition of CSFR1	B	CNC(=O)c1cc(Oc2ccc3nc(Nc4cccc(C(C)(C)C)c4)cnc3c2)ccn1		CHEMBL1950983	<	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	8033749	CHEMBL1953552	Inhibition of CSFR1	B	CNC(=O)c1cc(Oc2ccc3nc(Nc4cccc(C(C)(C)C)c4)ccc3c2)ccn1		CHEMBL1950984	<	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	8045844	CHEMBL1959323	Inhibition of recombinant human GST-tagged CFMS kinase catalytic domain using biotin-EAIYAPFAKKK-NH2 as substrate after 40 mins by NXT scintillation counting	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	uM	0.03
	8061564	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	58.7	CHEMBL1844	Homo sapiens	Inhibition	%	58.7
	8061671	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	-1.19	CHEMBL1844	Homo sapiens	Inhibition	%	-1.19
	8061895	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	4.11	CHEMBL1844	Homo sapiens	Inhibition	%	4.11
	8062086	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	6.48	CHEMBL1844	Homo sapiens	Inhibition	%	6.48
	8062426	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	-0.13	CHEMBL1844	Homo sapiens	Inhibition	%	-0.13
	8062588	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	0.92	CHEMBL1844	Homo sapiens	Inhibition	%	0.92
	8062910	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	0.0	CHEMBL1844	Homo sapiens	Inhibition	%	0.0
	8063042	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	0.23	CHEMBL1844	Homo sapiens	Inhibition	%	0.23
	8063266	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	5.68	CHEMBL1844	Homo sapiens	Inhibition	%	5.68
	8063433	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	-1.71	CHEMBL1844	Homo sapiens	Inhibition	%	-1.71
	8063765	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	1.36	CHEMBL1844	Homo sapiens	Inhibition	%	1.36
	8063947	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	30.86	CHEMBL1844	Homo sapiens	Inhibition	%	30.86
	8064286	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	4.58	CHEMBL1844	Homo sapiens	Inhibition	%	4.58
	8064496	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-1.87	CHEMBL1844	Homo sapiens	Inhibition	%	-1.87
	8064858	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	21.86	CHEMBL1844	Homo sapiens	Inhibition	%	21.86
	8065024	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	5.03	CHEMBL1844	Homo sapiens	Inhibition	%	5.03
	8065364	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	2.49	CHEMBL1844	Homo sapiens	Inhibition	%	2.49
	8065539	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	1.23	CHEMBL1844	Homo sapiens	Inhibition	%	1.23
	8065878	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	-0.02	CHEMBL1844	Homo sapiens	Inhibition	%	-0.02
	8066088	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	2.32	CHEMBL1844	Homo sapiens	Inhibition	%	2.32
	8066448	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	77.15	CHEMBL1844	Homo sapiens	Inhibition	%	77.15
	8066614	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	1.02	CHEMBL1844	Homo sapiens	Inhibition	%	1.02
	8066838	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	1.62	CHEMBL1844	Homo sapiens	Inhibition	%	1.62
	8066962	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	19.89	CHEMBL1844	Homo sapiens	Inhibition	%	19.89
	8067137	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	7.02	CHEMBL1844	Homo sapiens	Inhibition	%	7.02
	8067361	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	-1.07	CHEMBL1844	Homo sapiens	Inhibition	%	-1.07
	8067482	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	0.23	CHEMBL1844	Homo sapiens	Inhibition	%	0.23
	8067692	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	-0.59	CHEMBL1844	Homo sapiens	Inhibition	%	-0.59
	8067916	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	1.95	CHEMBL1844	Homo sapiens	Inhibition	%	1.95
	8068051	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	68.19	CHEMBL1844	Homo sapiens	Inhibition	%	68.19
	8068439	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	3.05	CHEMBL1844	Homo sapiens	Inhibition	%	3.05
	8068564	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	43.23	CHEMBL1844	Homo sapiens	Inhibition	%	43.23
	8068962	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	2.06	CHEMBL1844	Homo sapiens	Inhibition	%	2.06
	8069087	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	-0.59	CHEMBL1844	Homo sapiens	Inhibition	%	-0.59
	8069311	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	7.67	CHEMBL1844	Homo sapiens	Inhibition	%	7.67
	8069382	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	94.17	CHEMBL1844	Homo sapiens	Inhibition	%	94.17
	8069606	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	65.02	CHEMBL1844	Homo sapiens	Inhibition	%	65.02
	8069767	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	14.58	CHEMBL1844	Homo sapiens	Inhibition	%	14.58
	8069893	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	0.56	CHEMBL1844	Homo sapiens	Inhibition	%	0.56
	8070117	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	-0.85	CHEMBL1844	Homo sapiens	Inhibition	%	-0.85
	8070289	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	-0.21	CHEMBL1844	Homo sapiens	Inhibition	%	-0.21
	8070638	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	0.03	CHEMBL1844	Homo sapiens	Inhibition	%	0.03
	8070936	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	92.15	CHEMBL1844	Homo sapiens	Inhibition	%	92.15
	8071093	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	-2.64	CHEMBL1844	Homo sapiens	Inhibition	%	-2.64
	8071443	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	2.38	CHEMBL1844	Homo sapiens	Inhibition	%	2.38
	8071616	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	-0.69	CHEMBL1844	Homo sapiens	Inhibition	%	-0.69
	8071965	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	3.63	CHEMBL1844	Homo sapiens	Inhibition	%	3.63
	8072279	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	4.37	CHEMBL1844	Homo sapiens	Inhibition	%	4.37
	8072436	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	8.32	CHEMBL1844	Homo sapiens	Inhibition	%	8.32
	8072660	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	11.43	CHEMBL1844	Homo sapiens	Inhibition	%	11.43
	8072785	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	2.47	CHEMBL1844	Homo sapiens	Inhibition	%	2.47
	8072952	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	0.44	CHEMBL1844	Homo sapiens	Inhibition	%	0.44
	8073176	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	1.78	CHEMBL1844	Homo sapiens	Inhibition	%	1.78
	8073301	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	2.52	CHEMBL1844	Homo sapiens	Inhibition	%	2.52
	8073644	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	2.64	CHEMBL1844	Homo sapiens	Inhibition	%	2.64
	8073877	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	27.75	CHEMBL1844	Homo sapiens	Inhibition	%	27.75
	8074253	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	21.82	CHEMBL1844	Homo sapiens	Inhibition	%	21.82
	8074383	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	4.5	CHEMBL1844	Homo sapiens	Inhibition	%	4.5
	8074764	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	0.18	CHEMBL1844	Homo sapiens	Inhibition	%	0.18
	8074891	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	39.14	CHEMBL1844	Homo sapiens	Inhibition	%	39.14
	8075115	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	1.9	CHEMBL1844	Homo sapiens	Inhibition	%	1.9
	8075226	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	16.71	CHEMBL1844	Homo sapiens	Inhibition	%	16.71
	8075463	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	-0.03	CHEMBL1844	Homo sapiens	Inhibition	%	-0.03
	8075828	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	-0.3	CHEMBL1844	Homo sapiens	Inhibition	%	-0.3
	8075970	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	3.31	CHEMBL1844	Homo sapiens	Inhibition	%	3.31
	8076194	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-0.05	CHEMBL1844	Homo sapiens	Inhibition	%	-0.05
	8076342	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	1.47	CHEMBL1844	Homo sapiens	Inhibition	%	1.47
	8076700	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	3.33	CHEMBL1844	Homo sapiens	Inhibition	%	3.33
	8076802	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.18	CHEMBL1844	Homo sapiens	Inhibition	%	0.18
	8077049	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	2.57	CHEMBL1844	Homo sapiens	Inhibition	%	2.57
	8077273	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	0.67	CHEMBL1844	Homo sapiens	Inhibition	%	0.67
	8077401	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	10.72	CHEMBL1844	Homo sapiens	Inhibition	%	10.72
	8077776	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	5.84	CHEMBL1844	Homo sapiens	Inhibition	%	5.84
	8077919	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	-0.81	CHEMBL1844	Homo sapiens	Inhibition	%	-0.81
	8078282	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	0.43	CHEMBL1844	Homo sapiens	Inhibition	%	0.43
	8078384	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	1.37	CHEMBL1844	Homo sapiens	Inhibition	%	1.37
	8078608	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	2.19	CHEMBL1844	Homo sapiens	Inhibition	%	2.19
	8078858	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	1.9	CHEMBL1844	Homo sapiens	Inhibition	%	1.9
	8078974	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	-0.4	CHEMBL1844	Homo sapiens	Inhibition	%	-0.4
	8079356	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	0.22	CHEMBL1844	Homo sapiens	Inhibition	%	0.22
	8079498	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	4.7	CHEMBL1844	Homo sapiens	Inhibition	%	4.7
	8079722	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	0.26	CHEMBL1844	Homo sapiens	Inhibition	%	0.26
	8079861	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	23.58	CHEMBL1844	Homo sapiens	Inhibition	%	23.58
	8080190	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	0.63	CHEMBL1844	Homo sapiens	Inhibition	%	0.63
	8080442	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	7.27	CHEMBL1844	Homo sapiens	Inhibition	%	7.27
	8080557	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	0.77	CHEMBL1844	Homo sapiens	Inhibition	%	0.77
	8080781	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	3.05	CHEMBL1844	Homo sapiens	Inhibition	%	3.05
	8080945	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	9.24	CHEMBL1844	Homo sapiens	Inhibition	%	9.24
	8081304	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	3.3	CHEMBL1844	Homo sapiens	Inhibition	%	3.3
	8081448	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	34.31	CHEMBL1844	Homo sapiens	Inhibition	%	34.31
	8081775	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	5.89	CHEMBL1844	Homo sapiens	Inhibition	%	5.89
	8082027	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	45.79	CHEMBL1844	Homo sapiens	Inhibition	%	45.79
	8082364	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	3.66	CHEMBL1844	Homo sapiens	Inhibition	%	3.66
	8082537	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-0.4	CHEMBL1844	Homo sapiens	Inhibition	%	-0.4
	8082884	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	-2.9	CHEMBL1844	Homo sapiens	Inhibition	%	-2.9
	8083040	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	81.47	CHEMBL1844	Homo sapiens	Inhibition	%	81.47
	8083264	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	2.86	CHEMBL1844	Homo sapiens	Inhibition	%	2.86
	8083363	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	46.82	CHEMBL1844	Homo sapiens	Inhibition	%	46.82
	8083617	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	27.43	CHEMBL1844	Homo sapiens	Inhibition	%	27.43
	8083951	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	2.19	CHEMBL1844	Homo sapiens	Inhibition	%	2.19
	8084136	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.46	CHEMBL1844	Homo sapiens	Inhibition	%	0.46
	8084360	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	34.78	CHEMBL1844	Homo sapiens	Inhibition	%	34.78
	8084478	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	4.65	CHEMBL1844	Homo sapiens	Inhibition	%	4.65
	8084863	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	6.33	CHEMBL1844	Homo sapiens	Inhibition	%	6.33
	8084961	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	-0.21	CHEMBL1844	Homo sapiens	Inhibition	%	-0.21
	8085185	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	1.8	CHEMBL1844	Homo sapiens	Inhibition	%	1.8
	8085217	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	76.31	CHEMBL1844	Homo sapiens	Inhibition	%	76.31
	8085441	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	14.53	CHEMBL1844	Homo sapiens	Inhibition	%	14.53
	8085549	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	6.29	CHEMBL1844	Homo sapiens	Inhibition	%	6.29
	8085962	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	79.32	CHEMBL1844	Homo sapiens	Inhibition	%	79.32
	8086077	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	1.36	CHEMBL1844	Homo sapiens	Inhibition	%	1.36
	8086301	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	3.34	CHEMBL1844	Homo sapiens	Inhibition	%	3.34
	8086463	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	-1.7	CHEMBL1844	Homo sapiens	Inhibition	%	-1.7
	8086786	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	0.3	CHEMBL1844	Homo sapiens	Inhibition	%	0.3
	8086997	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	7.17	CHEMBL1844	Homo sapiens	Inhibition	%	7.17
	8087155	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	22.9	CHEMBL1844	Homo sapiens	Inhibition	%	22.9
	8087379	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	-2.39	CHEMBL1844	Homo sapiens	Inhibition	%	-2.39
	8087493	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	32.24	CHEMBL1844	Homo sapiens	Inhibition	%	32.24
	8087855	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	27.92	CHEMBL1844	Homo sapiens	Inhibition	%	27.92
	8087997	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	4.42	CHEMBL1844	Homo sapiens	Inhibition	%	4.42
	8088221	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	5.74	CHEMBL1844	Homo sapiens	Inhibition	%	5.74
	8088369	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	1.42	CHEMBL1844	Homo sapiens	Inhibition	%	1.42
	8088497	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	3.41	CHEMBL1844	Homo sapiens	Inhibition	%	3.41
	8088721	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	1.84	CHEMBL1844	Homo sapiens	Inhibition	%	1.84
	8088814	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	0.61	CHEMBL1844	Homo sapiens	Inhibition	%	0.61
	8089038	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	2.71	CHEMBL1844	Homo sapiens	Inhibition	%	2.71
	8089166	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	-0.53	CHEMBL1844	Homo sapiens	Inhibition	%	-0.53
	8089314	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	7.16	CHEMBL1844	Homo sapiens	Inhibition	%	7.16
	8089538	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	41.75	CHEMBL1844	Homo sapiens	Inhibition	%	41.75
	8089658	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	1.26	CHEMBL1844	Homo sapiens	Inhibition	%	1.26
	8090062	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	7.32	CHEMBL1844	Homo sapiens	Inhibition	%	7.32
	8090227	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	-0.95	CHEMBL1844	Homo sapiens	Inhibition	%	-0.95
	8090618	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	1.73	CHEMBL1844	Homo sapiens	Inhibition	%	1.73
	8090757	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	14.07	CHEMBL1844	Homo sapiens	Inhibition	%	14.07
	8090962	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	19.35	CHEMBL1844	Homo sapiens	Inhibition	%	19.35
	8091186	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	1.81	CHEMBL1844	Homo sapiens	Inhibition	%	1.81
	8091323	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	41.1	CHEMBL1844	Homo sapiens	Inhibition	%	41.1
	8091702	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	2.95	CHEMBL1844	Homo sapiens	Inhibition	%	2.95
	8091818	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	12.01	CHEMBL1844	Homo sapiens	Inhibition	%	12.01
	8092042	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	53.51	CHEMBL1844	Homo sapiens	Inhibition	%	53.51
	8092179	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	-0.76	CHEMBL1844	Homo sapiens	Inhibition	%	-0.76
	8092554	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	7.21	CHEMBL1844	Homo sapiens	Inhibition	%	7.21
	8092702	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	9.05	CHEMBL1844	Homo sapiens	Inhibition	%	9.05
	8093055	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	9.87	CHEMBL1844	Homo sapiens	Inhibition	%	9.87
	8093367	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	1.88	CHEMBL1844	Homo sapiens	Inhibition	%	1.88
	8093507	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	3.9	CHEMBL1844	Homo sapiens	Inhibition	%	3.9
	8093870	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	86.81	CHEMBL1844	Homo sapiens	Inhibition	%	86.81
	8093990	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	9.53	CHEMBL1844	Homo sapiens	Inhibition	%	9.53
	8094214	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	40.26	CHEMBL1844	Homo sapiens	Inhibition	%	40.26
	8094394	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	-0.94	CHEMBL1844	Homo sapiens	Inhibition	%	-0.94
	8094569	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	5.37	CHEMBL1844	Homo sapiens	Inhibition	%	5.37
	8094949	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	10.89	CHEMBL1844	Homo sapiens	Inhibition	%	10.89
	8095089	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	42.62	CHEMBL1844	Homo sapiens	Inhibition	%	42.62
	8095313	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	86.12	CHEMBL1844	Homo sapiens	Inhibition	%	86.12
	8095516	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	6.19	CHEMBL1844	Homo sapiens	Inhibition	%	6.19
	8095657	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	27.38	CHEMBL1844	Homo sapiens	Inhibition	%	27.38
	8095881	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	63.09	CHEMBL1844	Homo sapiens	Inhibition	%	63.09
	8096029	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	-1.86	CHEMBL1844	Homo sapiens	Inhibition	%	-1.86
	8096370	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	-0.43	CHEMBL1844	Homo sapiens	Inhibition	%	-0.43
	8096509	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	3.02	CHEMBL1844	Homo sapiens	Inhibition	%	3.02
	8096889	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	7.82	CHEMBL1844	Homo sapiens	Inhibition	%	7.82
	8097036	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	0.1	CHEMBL1844	Homo sapiens	Inhibition	%	0.1
	8097260	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	11.17	CHEMBL1844	Homo sapiens	Inhibition	%	11.17
	8097347	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	14.42	CHEMBL1844	Homo sapiens	Inhibition	%	14.42
	8097567	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	6.34	CHEMBL1844	Homo sapiens	Inhibition	%	6.34
	8097717	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	-0.21	CHEMBL1844	Homo sapiens	Inhibition	%	-0.21
	8097941	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	-0.91	CHEMBL1844	Homo sapiens	Inhibition	%	-0.91
	8098074	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	3.75	CHEMBL1844	Homo sapiens	Inhibition	%	3.75
	8098418	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-8.31	CHEMBL1844	Homo sapiens	Inhibition	%	-8.31
	8098598	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	2.32	CHEMBL1844	Homo sapiens	Inhibition	%	2.32
	8098783	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	11.68	CHEMBL1844	Homo sapiens	Inhibition	%	11.68
	8099007	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	48.14	CHEMBL1844	Homo sapiens	Inhibition	%	48.14
	8099151	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	0.22	CHEMBL1844	Homo sapiens	Inhibition	%	0.22
	8099517	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	0.38	CHEMBL1844	Homo sapiens	Inhibition	%	0.38
	8099711	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	-2.75	CHEMBL1844	Homo sapiens	Inhibition	%	-2.75
	8100082	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	4.53	CHEMBL1844	Homo sapiens	Inhibition	%	4.53
	8100228	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	3.16	CHEMBL1844	Homo sapiens	Inhibition	%	3.16
	8100568	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	10.25	CHEMBL1844	Homo sapiens	Inhibition	%	10.25
	8100708	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	-0.34	CHEMBL1844	Homo sapiens	Inhibition	%	-0.34
	8100932	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	0.13	CHEMBL1844	Homo sapiens	Inhibition	%	0.13
	8101092	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	2.6	CHEMBL1844	Homo sapiens	Inhibition	%	2.6
	8101458	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	20.13	CHEMBL1844	Homo sapiens	Inhibition	%	20.13
	8101643	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	3.05	CHEMBL1844	Homo sapiens	Inhibition	%	3.05
	8101896	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	21.58	CHEMBL1844	Homo sapiens	Inhibition	%	21.58
	8102275	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	3.46	CHEMBL1844	Homo sapiens	Inhibition	%	3.46
	8102406	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	8.4	CHEMBL1844	Homo sapiens	Inhibition	%	8.4
	8102750	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-1.4	CHEMBL1844	Homo sapiens	Inhibition	%	-1.4
	8102928	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	-2.64	CHEMBL1844	Homo sapiens	Inhibition	%	-2.64
	8103152	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	0.74	CHEMBL1844	Homo sapiens	Inhibition	%	0.74
	8103348	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	3.84	CHEMBL1844	Homo sapiens	Inhibition	%	3.84
	8103486	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	7.42	CHEMBL1844	Homo sapiens	Inhibition	%	7.42
	8103860	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	10.78	CHEMBL1844	Homo sapiens	Inhibition	%	10.78
	8104045	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	4.65	CHEMBL1844	Homo sapiens	Inhibition	%	4.65
	8104417	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	12.89	CHEMBL1844	Homo sapiens	Inhibition	%	12.89
	8104563	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	4.76	CHEMBL1844	Homo sapiens	Inhibition	%	4.76
	8104787	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	27.81	CHEMBL1844	Homo sapiens	Inhibition	%	27.81
	8104901	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	0.11	CHEMBL1844	Homo sapiens	Inhibition	%	0.11
	8105265	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	-2.07	CHEMBL1844	Homo sapiens	Inhibition	%	-2.07
	8105431	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	5.33	CHEMBL1844	Homo sapiens	Inhibition	%	5.33
	8105793	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	57.64	CHEMBL1844	Homo sapiens	Inhibition	%	57.64
	8106073	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	0.82	CHEMBL1844	Homo sapiens	Inhibition	%	0.82
	8106238	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	68.6	CHEMBL1844	Homo sapiens	Inhibition	%	68.6
	8106618	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	34.09	CHEMBL1844	Homo sapiens	Inhibition	%	34.09
	8106747	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	42.39	CHEMBL1844	Homo sapiens	Inhibition	%	42.39
	8106971	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	84.81	CHEMBL1844	Homo sapiens	Inhibition	%	84.81
	8107092	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	-7.9	CHEMBL1844	Homo sapiens	Inhibition	%	-7.9
	8107488	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	-0.7	CHEMBL1844	Homo sapiens	Inhibition	%	-0.7
	8107689	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	5.51	CHEMBL1844	Homo sapiens	Inhibition	%	5.51
	8107824	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	22.06	CHEMBL1844	Homo sapiens	Inhibition	%	22.06
	8108048	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	62.55	CHEMBL1844	Homo sapiens	Inhibition	%	62.55
	8108206	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	-2.22	CHEMBL1844	Homo sapiens	Inhibition	%	-2.22
	8108381	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	16.47	CHEMBL1844	Homo sapiens	Inhibition	%	16.47
	8108605	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	45.21	CHEMBL1844	Homo sapiens	Inhibition	%	45.21
	8108752	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	4.53	CHEMBL1844	Homo sapiens	Inhibition	%	4.53
	8109118	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	-1.86	CHEMBL1844	Homo sapiens	Inhibition	%	-1.86
	8109232	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	9.12	CHEMBL1844	Homo sapiens	Inhibition	%	9.12
	8109586	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	0.01	CHEMBL1844	Homo sapiens	Inhibition	%	0.01
	8109757	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	3.34	CHEMBL1844	Homo sapiens	Inhibition	%	3.34
	8109981	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	16.33	CHEMBL1844	Homo sapiens	Inhibition	%	16.33
	8110113	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	14.52	CHEMBL1844	Homo sapiens	Inhibition	%	14.52
	8110392	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	4.6	CHEMBL1844	Homo sapiens	Inhibition	%	4.6
	8110558	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	2.1	CHEMBL1844	Homo sapiens	Inhibition	%	2.1
	8110782	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	2.47	CHEMBL1844	Homo sapiens	Inhibition	%	2.47
	8110940	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	-1.23	CHEMBL1844	Homo sapiens	Inhibition	%	-1.23
	8111287	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	44.83	CHEMBL1844	Homo sapiens	Inhibition	%	44.83
	8111414	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	0.27	CHEMBL1844	Homo sapiens	Inhibition	%	0.27
	8111638	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	-2.54	CHEMBL1844	Homo sapiens	Inhibition	%	-2.54
	8111804	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	3.85	CHEMBL1844	Homo sapiens	Inhibition	%	3.85
	8112009	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	9.54	CHEMBL1844	Homo sapiens	Inhibition	%	9.54
	8112370	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-1.96	CHEMBL1844	Homo sapiens	Inhibition	%	-1.96
	8112538	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	7.07	CHEMBL1844	Homo sapiens	Inhibition	%	7.07
	8112934	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	-0.38	CHEMBL1844	Homo sapiens	Inhibition	%	-0.38
	8113086	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	17.92	CHEMBL1844	Homo sapiens	Inhibition	%	17.92
	8113446	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	7.49	CHEMBL1844	Homo sapiens	Inhibition	%	7.49
	8113570	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	-3.93	CHEMBL1844	Homo sapiens	Inhibition	%	-3.93
	8113794	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	3.13	CHEMBL1844	Homo sapiens	Inhibition	%	3.13
	8113910	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-3.35	CHEMBL1844	Homo sapiens	Inhibition	%	-3.35
	8114310	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	3.92	CHEMBL1844	Homo sapiens	Inhibition	%	3.92
	8114442	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	56.29	CHEMBL1844	Homo sapiens	Inhibition	%	56.29
	8114718	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	-0.58	CHEMBL1844	Homo sapiens	Inhibition	%	-0.58
	8115108	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	91.21	CHEMBL1844	Homo sapiens	Inhibition	%	91.21
	8115273	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	0.9	CHEMBL1844	Homo sapiens	Inhibition	%	0.9
	8115617	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	54.63	CHEMBL1844	Homo sapiens	Inhibition	%	54.63
	8115974	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	1.4	CHEMBL1844	Homo sapiens	Inhibition	%	1.4
	8116133	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	-6.57	CHEMBL1844	Homo sapiens	Inhibition	%	-6.57
	8116336	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	25.66	CHEMBL1844	Homo sapiens	Inhibition	%	25.66
	8116560	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	1.2	CHEMBL1844	Homo sapiens	Inhibition	%	1.2
	8116694	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	5.8	CHEMBL1844	Homo sapiens	Inhibition	%	5.8
	8116866	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	6.9	CHEMBL1844	Homo sapiens	Inhibition	%	6.9
	8117090	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	43.73	CHEMBL1844	Homo sapiens	Inhibition	%	43.73
	8117261	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	6.09	CHEMBL1844	Homo sapiens	Inhibition	%	6.09
	8117419	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	-0.38	CHEMBL1844	Homo sapiens	Inhibition	%	-0.38
	8117643	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	3.67	CHEMBL1844	Homo sapiens	Inhibition	%	3.67
	8117773	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	-2.83	CHEMBL1844	Homo sapiens	Inhibition	%	-2.83
	8118135	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	1.11	CHEMBL1844	Homo sapiens	Inhibition	%	1.11
	8118251	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-0.19	CHEMBL1844	Homo sapiens	Inhibition	%	-0.19
	8118475	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	5.24	CHEMBL1844	Homo sapiens	Inhibition	%	5.24
	8118647	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	9.05	CHEMBL1844	Homo sapiens	Inhibition	%	9.05
	8118783	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	0.84	CHEMBL1844	Homo sapiens	Inhibition	%	0.84
	8119007	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	8.62	CHEMBL1844	Homo sapiens	Inhibition	%	8.62
	8119054	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	5.17	CHEMBL1844	Homo sapiens	Inhibition	%	5.17
	8119278	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	3.71	CHEMBL1844	Homo sapiens	Inhibition	%	3.71
	8119437	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	96.1	CHEMBL1844	Homo sapiens	Inhibition	%	96.1
	8119604	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	0.5	CHEMBL1844	Homo sapiens	Inhibition	%	0.5
	8119828	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	-0.39	CHEMBL1844	Homo sapiens	Inhibition	%	-0.39
	8119947	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	1.81	CHEMBL1844	Homo sapiens	Inhibition	%	1.81
	8120310	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	-1.16	CHEMBL1844	Homo sapiens	Inhibition	%	-1.16
	8120470	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	3.69	CHEMBL1844	Homo sapiens	Inhibition	%	3.69
	8120895	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	2.92	CHEMBL1844	Homo sapiens	Inhibition	%	2.92
	8121023	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	5.18	CHEMBL1844	Homo sapiens	Inhibition	%	5.18
	8121419	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	-3.48	CHEMBL1844	Homo sapiens	Inhibition	%	-3.48
	8121586	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	39.9	CHEMBL1844	Homo sapiens	Inhibition	%	39.9
	8121973	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	-0.73	CHEMBL1844	Homo sapiens	Inhibition	%	-0.73
	8122094	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	10.02	CHEMBL1844	Homo sapiens	Inhibition	%	10.02
	8122456	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	7.56	CHEMBL1844	Homo sapiens	Inhibition	%	7.56
	8122800	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	4.74	CHEMBL1844	Homo sapiens	Inhibition	%	4.74
	8122967	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	4.37	CHEMBL1844	Homo sapiens	Inhibition	%	4.37
	8123333	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	6.67	CHEMBL1844	Homo sapiens	Inhibition	%	6.67
	8123611	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	26.62	CHEMBL1844	Homo sapiens	Inhibition	%	26.62
	8123761	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	7.04	CHEMBL1844	Homo sapiens	Inhibition	%	7.04
	8124152	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	4.43	CHEMBL1844	Homo sapiens	Inhibition	%	4.43
	8124271	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	3.54	CHEMBL1844	Homo sapiens	Inhibition	%	3.54
	8124495	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	50.35	CHEMBL1844	Homo sapiens	Inhibition	%	50.35
	8124634	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	14.59	CHEMBL1844	Homo sapiens	Inhibition	%	14.59
	8124799	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-6.02	CHEMBL1844	Homo sapiens	Inhibition	%	-6.02
	8125023	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	4.04	CHEMBL1844	Homo sapiens	Inhibition	%	4.04
	8125224	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	1.36	CHEMBL1844	Homo sapiens	Inhibition	%	1.36
	8125354	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	34.59	CHEMBL1844	Homo sapiens	Inhibition	%	34.59
	8125578	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	-1.71	CHEMBL1844	Homo sapiens	Inhibition	%	-1.71
	8125746	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	3.66	CHEMBL1844	Homo sapiens	Inhibition	%	3.66
	8125910	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	46.22	CHEMBL1844	Homo sapiens	Inhibition	%	46.22
	8126134	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-1.42	CHEMBL1844	Homo sapiens	Inhibition	%	-1.42
	8126298	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	7.89	CHEMBL1844	Homo sapiens	Inhibition	%	7.89
	8126413	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	83.51	CHEMBL1844	Homo sapiens	Inhibition	%	83.51
	8126637	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	81.2	CHEMBL1844	Homo sapiens	Inhibition	%	81.2
	8126773	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	29.52	CHEMBL1844	Homo sapiens	Inhibition	%	29.52
	8127119	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	2.27	CHEMBL1844	Homo sapiens	Inhibition	%	2.27
	8127286	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	10.54	CHEMBL1844	Homo sapiens	Inhibition	%	10.54
	8127510	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	33.67	CHEMBL1844	Homo sapiens	Inhibition	%	33.67
	8127652	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	29.05	CHEMBL1844	Homo sapiens	Inhibition	%	29.05
	8127940	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	1.83	CHEMBL1844	Homo sapiens	Inhibition	%	1.83
	8128092	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	26.76	CHEMBL1844	Homo sapiens	Inhibition	%	26.76
	8128316	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	1.52	CHEMBL1844	Homo sapiens	Inhibition	%	1.52
	8128483	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	24.9	CHEMBL1844	Homo sapiens	Inhibition	%	24.9
	8128826	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	90.86	CHEMBL1844	Homo sapiens	Inhibition	%	90.86
	8128963	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	0.1	CHEMBL1844	Homo sapiens	Inhibition	%	0.1
	8129358	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-3.24	CHEMBL1844	Homo sapiens	Inhibition	%	-3.24
	8129547	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	6.16	CHEMBL1844	Homo sapiens	Inhibition	%	6.16
	8129910	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	5.46	CHEMBL1844	Homo sapiens	Inhibition	%	5.46
	8130071	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	-4.71	CHEMBL1844	Homo sapiens	Inhibition	%	-4.71
	8130467	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	7.94	CHEMBL1844	Homo sapiens	Inhibition	%	7.94
	8130627	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	29.64	CHEMBL1844	Homo sapiens	Inhibition	%	29.64
	8130967	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	-1.87	CHEMBL1844	Homo sapiens	Inhibition	%	-1.87
	8131106	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	58.61	CHEMBL1844	Homo sapiens	Inhibition	%	58.61
	8131330	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	-0.34	CHEMBL1844	Homo sapiens	Inhibition	%	-0.34
	8131450	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	3.02	CHEMBL1844	Homo sapiens	Inhibition	%	3.02
	8131841	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	66.66	CHEMBL1844	Homo sapiens	Inhibition	%	66.66
	8131982	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	98.11	CHEMBL1844	Homo sapiens	Inhibition	%	98.11
	8132268	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	22.32	CHEMBL1844	Homo sapiens	Inhibition	%	22.32
	8132639	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	5.32	CHEMBL1844	Homo sapiens	Inhibition	%	5.32
	8132807	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	3.45	CHEMBL1844	Homo sapiens	Inhibition	%	3.45
	8133152	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	1.45	CHEMBL1844	Homo sapiens	Inhibition	%	1.45
	8133290	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	27.01	CHEMBL1844	Homo sapiens	Inhibition	%	27.01
	8133514	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	-1.12	CHEMBL1844	Homo sapiens	Inhibition	%	-1.12
	8133686	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-0.1	CHEMBL1844	Homo sapiens	Inhibition	%	-0.1
	8133866	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	87.69	CHEMBL1844	Homo sapiens	Inhibition	%	87.69
	8134238	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	2.06	CHEMBL1844	Homo sapiens	Inhibition	%	2.06
	8134398	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	3.68	CHEMBL1844	Homo sapiens	Inhibition	%	3.68
	8134622	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	-2.68	CHEMBL1844	Homo sapiens	Inhibition	%	-2.68
	8134806	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	7.03	CHEMBL1844	Homo sapiens	Inhibition	%	7.03
	8134966	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	68.87	CHEMBL1844	Homo sapiens	Inhibition	%	68.87
	8135305	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	3.3	CHEMBL1844	Homo sapiens	Inhibition	%	3.3
	8135670	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	7.51	CHEMBL1844	Homo sapiens	Inhibition	%	7.51
	8135791	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	4.05	CHEMBL1844	Homo sapiens	Inhibition	%	4.05
	8136183	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	1.79	CHEMBL1844	Homo sapiens	Inhibition	%	1.79
	8136327	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	77.99	CHEMBL1844	Homo sapiens	Inhibition	%	77.99
	8136551	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	2.5	CHEMBL1844	Homo sapiens	Inhibition	%	2.5
	8136617	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	-0.28	CHEMBL1844	Homo sapiens	Inhibition	%	-0.28
	8136976	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	-0.52	CHEMBL1844	Homo sapiens	Inhibition	%	-0.52
	8137139	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	4.05	CHEMBL1844	Homo sapiens	Inhibition	%	4.05
	8137363	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	3.81	CHEMBL1844	Homo sapiens	Inhibition	%	3.81
	8137483	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	10.49	CHEMBL1844	Homo sapiens	Inhibition	%	10.49
	8137855	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	5.72	CHEMBL1844	Homo sapiens	Inhibition	%	5.72
	8138021	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-4.22	CHEMBL1844	Homo sapiens	Inhibition	%	-4.22
	8138200	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	81.21	CHEMBL1844	Homo sapiens	Inhibition	%	81.21
	8138424	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	0.88	CHEMBL1844	Homo sapiens	Inhibition	%	0.88
	8138572	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	17.89	CHEMBL1844	Homo sapiens	Inhibition	%	17.89
	8138954	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	2.71	CHEMBL1844	Homo sapiens	Inhibition	%	2.71
	8139139	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	41.66	CHEMBL1844	Homo sapiens	Inhibition	%	41.66
	8139298	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	1.45	CHEMBL1844	Homo sapiens	Inhibition	%	1.45
	8139522	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	12.32	CHEMBL1844	Homo sapiens	Inhibition	%	12.32
	8139636	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	-3.68	CHEMBL1844	Homo sapiens	Inhibition	%	-3.68
	8140001	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	1.84	CHEMBL1844	Homo sapiens	Inhibition	%	1.84
	8140124	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	8.52	CHEMBL1844	Homo sapiens	Inhibition	%	8.52
	8140348	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	7.73	CHEMBL1844	Homo sapiens	Inhibition	%	7.73
	8140507	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	6.37	CHEMBL1844	Homo sapiens	Inhibition	%	6.37
	8140874	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	12.11	CHEMBL1844	Homo sapiens	Inhibition	%	12.11
	8140952	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	4.04	CHEMBL1844	Homo sapiens	Inhibition	%	4.04
	8141176	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	1.41	CHEMBL1844	Homo sapiens	Inhibition	%	1.41
	8141306	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	1.97	CHEMBL1844	Homo sapiens	Inhibition	%	1.97
	8141690	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	17.55	CHEMBL1844	Homo sapiens	Inhibition	%	17.55
	8141809	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	12.0	CHEMBL1844	Homo sapiens	Inhibition	%	12.0
	8142194	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	19.6	CHEMBL1844	Homo sapiens	Inhibition	%	19.6
	8142362	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-1.66	CHEMBL1844	Homo sapiens	Inhibition	%	-1.66
	8142762	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	8.87	CHEMBL1844	Homo sapiens	Inhibition	%	8.87
	8142911	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-3.16	CHEMBL1844	Homo sapiens	Inhibition	%	-3.16
	8143290	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	0.06	CHEMBL1844	Homo sapiens	Inhibition	%	0.06
	8143477	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	4.92	CHEMBL1844	Homo sapiens	Inhibition	%	4.92
	8143860	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	1.77	CHEMBL1844	Homo sapiens	Inhibition	%	1.77
	8143974	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	1.56	CHEMBL1844	Homo sapiens	Inhibition	%	1.56
	8144198	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	-1.9	CHEMBL1844	Homo sapiens	Inhibition	%	-1.9
	8144337	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	5.71	CHEMBL1844	Homo sapiens	Inhibition	%	5.71
	8144691	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	4.11	CHEMBL1844	Homo sapiens	Inhibition	%	4.11
	8144844	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	0.47	CHEMBL1844	Homo sapiens	Inhibition	%	0.47
	8145205	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	2.22	CHEMBL1844	Homo sapiens	Inhibition	%	2.22
	8145518	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	2.14	CHEMBL1844	Homo sapiens	Inhibition	%	2.14
	8145642	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	-1.01	CHEMBL1844	Homo sapiens	Inhibition	%	-1.01
	8145866	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	2.62	CHEMBL1844	Homo sapiens	Inhibition	%	2.62
	8146027	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	92.06	CHEMBL1844	Homo sapiens	Inhibition	%	92.06
	8146147	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	44.44	CHEMBL1844	Homo sapiens	Inhibition	%	44.44
	8146371	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	0.81	CHEMBL1844	Homo sapiens	Inhibition	%	0.81
	8146531	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	66.75	CHEMBL1844	Homo sapiens	Inhibition	%	66.75
	8146698	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	-4.84	CHEMBL1844	Homo sapiens	Inhibition	%	-4.84
	8146922	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	8.46	CHEMBL1844	Homo sapiens	Inhibition	%	8.46
	8147091	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	0.14	CHEMBL1844	Homo sapiens	Inhibition	%	0.14
	8147233	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	0.94	CHEMBL1844	Homo sapiens	Inhibition	%	0.94
	8147457	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	-2.73	CHEMBL1844	Homo sapiens	Inhibition	%	-2.73
	8147610	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	3.9	CHEMBL1844	Homo sapiens	Inhibition	%	3.9
	8147797	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	5.58	CHEMBL1844	Homo sapiens	Inhibition	%	5.58
	8148021	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	2.87	CHEMBL1844	Homo sapiens	Inhibition	%	2.87
	8148179	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	23.14	CHEMBL1844	Homo sapiens	Inhibition	%	23.14
	8148517	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	6.06	CHEMBL1844	Homo sapiens	Inhibition	%	6.06
	8148656	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	-0.24	CHEMBL1844	Homo sapiens	Inhibition	%	-0.24
	8149018	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	5.61	CHEMBL1844	Homo sapiens	Inhibition	%	5.61
	8149177	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	1.28	CHEMBL1844	Homo sapiens	Inhibition	%	1.28
	8149401	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	1.14	CHEMBL1844	Homo sapiens	Inhibition	%	1.14
	8149535	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	8.85	CHEMBL1844	Homo sapiens	Inhibition	%	8.85
	8149857	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	4.08	CHEMBL1844	Homo sapiens	Inhibition	%	4.08
	8150206	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	15.41	CHEMBL1844	Homo sapiens	Inhibition	%	15.41
	8150366	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	96.15	CHEMBL1844	Homo sapiens	Inhibition	%	96.15
	8150710	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	3.42	CHEMBL1844	Homo sapiens	Inhibition	%	3.42
	8150875	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	55.0	CHEMBL1844	Homo sapiens	Inhibition	%	55.0
	8151262	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-5.43	CHEMBL1844	Homo sapiens	Inhibition	%	-5.43
	8151439	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	5.04	CHEMBL1844	Homo sapiens	Inhibition	%	5.04
	8151801	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	16.41	CHEMBL1844	Homo sapiens	Inhibition	%	16.41
	8151955	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	2.47	CHEMBL1844	Homo sapiens	Inhibition	%	2.47
	8152367	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	16.53	CHEMBL1844	Homo sapiens	Inhibition	%	16.53
	8152525	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	3.76	CHEMBL1844	Homo sapiens	Inhibition	%	3.76
	8152863	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	5.72	CHEMBL1844	Homo sapiens	Inhibition	%	5.72
	8153002	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	2.13	CHEMBL1844	Homo sapiens	Inhibition	%	2.13
	8153226	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	3.64	CHEMBL1844	Homo sapiens	Inhibition	%	3.64
	8153363	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	6.15	CHEMBL1844	Homo sapiens	Inhibition	%	6.15
	8153744	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	5.44	CHEMBL1844	Homo sapiens	Inhibition	%	5.44
	8153877	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	-0.11	CHEMBL1844	Homo sapiens	Inhibition	%	-0.11
	8154198	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	28.33	CHEMBL1844	Homo sapiens	Inhibition	%	28.33
	8154548	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	72.84	CHEMBL1844	Homo sapiens	Inhibition	%	72.84
	8154707	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	1.48	CHEMBL1844	Homo sapiens	Inhibition	%	1.48
	8155051	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	0.64	CHEMBL1844	Homo sapiens	Inhibition	%	0.64
	8155227	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	82.83	CHEMBL1844	Homo sapiens	Inhibition	%	82.83
	8155451	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-4.62	CHEMBL1844	Homo sapiens	Inhibition	%	-4.62
	8155612	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	4.56	CHEMBL1844	Homo sapiens	Inhibition	%	4.56
	8155790	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	2.72	CHEMBL1844	Homo sapiens	Inhibition	%	2.72
	8156014	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	4.83	CHEMBL1844	Homo sapiens	Inhibition	%	4.83
	8156152	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	-2.9	CHEMBL1844	Homo sapiens	Inhibition	%	-2.9
	8156364	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	5.18	CHEMBL1844	Homo sapiens	Inhibition	%	5.18
	8156738	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	34.74	CHEMBL1844	Homo sapiens	Inhibition	%	34.74
	8156881	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	6.69	CHEMBL1844	Homo sapiens	Inhibition	%	6.69
	8157105	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	32.48	CHEMBL1844	Homo sapiens	Inhibition	%	32.48
	8157225	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	1.56	CHEMBL1844	Homo sapiens	Inhibition	%	1.56
	8157590	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	32.92	CHEMBL1844	Homo sapiens	Inhibition	%	32.92
	8157720	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	48.12	CHEMBL1844	Homo sapiens	Inhibition	%	48.12
	8157944	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	0.47	CHEMBL1844	Homo sapiens	Inhibition	%	0.47
	8158105	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	95.81	CHEMBL1844	Homo sapiens	Inhibition	%	95.81
	8158355	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	-1.08	CHEMBL1844	Homo sapiens	Inhibition	%	-1.08
	8158513	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	1.57	CHEMBL1844	Homo sapiens	Inhibition	%	1.57
	8158737	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	2.74	CHEMBL1844	Homo sapiens	Inhibition	%	2.74
	8158906	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	-1.77	CHEMBL1844	Homo sapiens	Inhibition	%	-1.77
	8159265	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	1.07	CHEMBL1844	Homo sapiens	Inhibition	%	1.07
	8159385	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	1.8	CHEMBL1844	Homo sapiens	Inhibition	%	1.8
	8159740	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	15.44	CHEMBL1844	Homo sapiens	Inhibition	%	15.44
	8159881	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	4.57	CHEMBL1844	Homo sapiens	Inhibition	%	4.57
	8160105	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	1.74	CHEMBL1844	Homo sapiens	Inhibition	%	1.74
	8160242	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	5.19	CHEMBL1844	Homo sapiens	Inhibition	%	5.19
	8160616	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	2.19	CHEMBL1844	Homo sapiens	Inhibition	%	2.19
	8160686	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	20.64	CHEMBL1844	Homo sapiens	Inhibition	%	20.64
	8160910	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	66.92	CHEMBL1844	Homo sapiens	Inhibition	%	66.92
	8161060	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	79.65	CHEMBL1844	Homo sapiens	Inhibition	%	79.65
	8161427	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	44.52	CHEMBL1844	Homo sapiens	Inhibition	%	44.52
	8161552	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	2.04	CHEMBL1844	Homo sapiens	Inhibition	%	2.04
	8161914	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	79.83	CHEMBL1844	Homo sapiens	Inhibition	%	79.83
	8162268	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	4.75	CHEMBL1844	Homo sapiens	Inhibition	%	4.75
	8162428	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	3.57	CHEMBL1844	Homo sapiens	Inhibition	%	3.57
	8162681	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	1.27	CHEMBL1844	Homo sapiens	Inhibition	%	1.27
	8163053	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	47.5	CHEMBL1844	Homo sapiens	Inhibition	%	47.5
	8163222	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	2.78	CHEMBL1844	Homo sapiens	Inhibition	%	2.78
	8163580	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	1.72	CHEMBL1844	Homo sapiens	Inhibition	%	1.72
	8163703	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	1.54	CHEMBL1844	Homo sapiens	Inhibition	%	1.54
	8163927	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	1.37	CHEMBL1844	Homo sapiens	Inhibition	%	1.37
	8164061	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	34.59	CHEMBL1844	Homo sapiens	Inhibition	%	34.59
	8164425	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	1.31	CHEMBL1844	Homo sapiens	Inhibition	%	1.31
	8164580	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	2.67	CHEMBL1844	Homo sapiens	Inhibition	%	2.67
	8164948	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	14.68	CHEMBL1844	Homo sapiens	Inhibition	%	14.68
	8165242	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	7.05	CHEMBL1844	Homo sapiens	Inhibition	%	7.05
	8165383	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	96.98	CHEMBL1844	Homo sapiens	Inhibition	%	96.98
	8165750	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	85.65	CHEMBL1844	Homo sapiens	Inhibition	%	85.65
	8165876	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	-1.08	CHEMBL1844	Homo sapiens	Inhibition	%	-1.08
	8166100	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	2.71	CHEMBL1844	Homo sapiens	Inhibition	%	2.71
	8166238	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	3.25	CHEMBL1844	Homo sapiens	Inhibition	%	3.25
	8166592	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	1.63	CHEMBL1844	Homo sapiens	Inhibition	%	1.63
	8166917	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	94.06	CHEMBL1844	Homo sapiens	Inhibition	%	94.06
	8167005	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	3.01	CHEMBL1844	Homo sapiens	Inhibition	%	3.01
	8167229	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	1.4	CHEMBL1844	Homo sapiens	Inhibition	%	1.4
	8167370	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	85.49	CHEMBL1844	Homo sapiens	Inhibition	%	85.49
	8167534	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	0.85	CHEMBL1844	Homo sapiens	Inhibition	%	0.85
	8167758	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	1.31	CHEMBL1844	Homo sapiens	Inhibition	%	1.31
	8167891	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	1.29	CHEMBL1844	Homo sapiens	Inhibition	%	1.29
	8168239	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	1.12	CHEMBL1844	Homo sapiens	Inhibition	%	1.12
	8168380	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	78.58	CHEMBL1844	Homo sapiens	Inhibition	%	78.58
	8168604	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	5.2	CHEMBL1844	Homo sapiens	Inhibition	%	5.2
	8168740	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	0.54	CHEMBL1844	Homo sapiens	Inhibition	%	0.54
	8168904	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	34.36	CHEMBL1844	Homo sapiens	Inhibition	%	34.36
	8169128	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	79.4	CHEMBL1844	Homo sapiens	Inhibition	%	79.4
	8169270	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	1.7	CHEMBL1844	Homo sapiens	Inhibition	%	1.7
	8169574	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	3.9	CHEMBL1844	Homo sapiens	Inhibition	%	3.9
	8169708	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	4.22	CHEMBL1844	Homo sapiens	Inhibition	%	4.22
	8169932	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	5.16	CHEMBL1844	Homo sapiens	Inhibition	%	5.16
	8170077	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	51.19	CHEMBL1844	Homo sapiens	Inhibition	%	51.19
	8170426	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	2.22	CHEMBL1844	Homo sapiens	Inhibition	%	2.22
	8170566	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	16.57	CHEMBL1844	Homo sapiens	Inhibition	%	16.57
	8170790	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	1.63	CHEMBL1844	Homo sapiens	Inhibition	%	1.63
	8170925	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	5.02	CHEMBL1844	Homo sapiens	Inhibition	%	5.02
	8171122	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	17.32	CHEMBL1844	Homo sapiens	Inhibition	%	17.32
	8171346	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	79.26	CHEMBL1844	Homo sapiens	Inhibition	%	79.26
	8171563	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	2.86	CHEMBL1844	Homo sapiens	Inhibition	%	2.86
	8171704	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	81.66	CHEMBL1844	Homo sapiens	Inhibition	%	81.66
	8172081	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	-0.57	CHEMBL1844	Homo sapiens	Inhibition	%	-0.57
	8172213	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	0.35	CHEMBL1844	Homo sapiens	Inhibition	%	0.35
	8172565	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	0.9	CHEMBL1844	Homo sapiens	Inhibition	%	0.9
	8172931	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	8.64	CHEMBL1844	Homo sapiens	Inhibition	%	8.64
	8173067	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-0.02	CHEMBL1844	Homo sapiens	Inhibition	%	-0.02
	8173456	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	6.17	CHEMBL1844	Homo sapiens	Inhibition	%	6.17
	8173597	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	3.16	CHEMBL1844	Homo sapiens	Inhibition	%	3.16
	8173908	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%		CHEMBL1844	Homo sapiens	Inhibition	%	
	8174264	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	6.96	CHEMBL1844	Homo sapiens	Inhibition	%	6.96
	8174412	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	95.34	CHEMBL1844	Homo sapiens	Inhibition	%	95.34
	8174636	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	1.67	CHEMBL1844	Homo sapiens	Inhibition	%	1.67
	8174758	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	7.87	CHEMBL1844	Homo sapiens	Inhibition	%	7.87
	8175125	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	1.19	CHEMBL1844	Homo sapiens	Inhibition	%	1.19
	8175261	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	23.01	CHEMBL1844	Homo sapiens	Inhibition	%	23.01
	8175517	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	6.47	CHEMBL1844	Homo sapiens	Inhibition	%	6.47
	8175904	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	75.51	CHEMBL1844	Homo sapiens	Inhibition	%	75.51
	8176057	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	94.26	CHEMBL1844	Homo sapiens	Inhibition	%	94.26
	8176281	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	12.49	CHEMBL1844	Homo sapiens	Inhibition	%	12.49
	8176430	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	3.43	CHEMBL1844	Homo sapiens	Inhibition	%	3.43
	8176562	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	11.94	CHEMBL1844	Homo sapiens	Inhibition	%	11.94
	8176786	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	48.22	CHEMBL1844	Homo sapiens	Inhibition	%	48.22
	8176916	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	2.61	CHEMBL1844	Homo sapiens	Inhibition	%	2.61
	8177282	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	8.02	CHEMBL1844	Homo sapiens	Inhibition	%	8.02
	8177420	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	2.28	CHEMBL1844	Homo sapiens	Inhibition	%	2.28
	8177644	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	12.93	CHEMBL1844	Homo sapiens	Inhibition	%	12.93
	8177808	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	30.18	CHEMBL1844	Homo sapiens	Inhibition	%	30.18
	8177948	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	4.24	CHEMBL1844	Homo sapiens	Inhibition	%	4.24
	8178172	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	7.78	CHEMBL1844	Homo sapiens	Inhibition	%	7.78
	8178260	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	15.45	CHEMBL1844	Homo sapiens	Inhibition	%	15.45
	8178484	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	10.5	CHEMBL1844	Homo sapiens	Inhibition	%	10.5
	8178611	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	37.71	CHEMBL1844	Homo sapiens	Inhibition	%	37.71
	8178984	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	5.35	CHEMBL1844	Homo sapiens	Inhibition	%	5.35
	8179107	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	3.01	CHEMBL1844	Homo sapiens	Inhibition	%	3.01
	8179475	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	3.12	CHEMBL1844	Homo sapiens	Inhibition	%	3.12
	8179612	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	72.12	CHEMBL1844	Homo sapiens	Inhibition	%	72.12
	8179836	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	0.78	CHEMBL1844	Homo sapiens	Inhibition	%	0.78
	8179869	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	34.52	CHEMBL1844	Homo sapiens	Inhibition	%	34.52
	8180093	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	0.38	CHEMBL1844	Homo sapiens	Inhibition	%	0.38
	8180247	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	93.94	CHEMBL1844	Homo sapiens	Inhibition	%	93.94
	8180627	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	49.56	CHEMBL1844	Homo sapiens	Inhibition	%	49.56
	8180775	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	4.82	CHEMBL1844	Homo sapiens	Inhibition	%	4.82
	8181132	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	5.71	CHEMBL1844	Homo sapiens	Inhibition	%	5.71
	8181263	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	11.84	CHEMBL1844	Homo sapiens	Inhibition	%	11.84
	8181487	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	12.12	CHEMBL1844	Homo sapiens	Inhibition	%	12.12
	8181627	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	36.13	CHEMBL1844	Homo sapiens	Inhibition	%	36.13
	8181990	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	50.88	CHEMBL1844	Homo sapiens	Inhibition	%	50.88
	8182153	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	3.44	CHEMBL1844	Homo sapiens	Inhibition	%	3.44
	8182517	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	2.64	CHEMBL1844	Homo sapiens	Inhibition	%	2.64
	8182833	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	3.36	CHEMBL1844	Homo sapiens	Inhibition	%	3.36
	8182955	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	6.04	CHEMBL1844	Homo sapiens	Inhibition	%	6.04
	8183328	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	26.38	CHEMBL1844	Homo sapiens	Inhibition	%	26.38
	8183457	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	2.53	CHEMBL1844	Homo sapiens	Inhibition	%	2.53
	8183681	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	0.29	CHEMBL1844	Homo sapiens	Inhibition	%	0.29
	8183823	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	8.74	CHEMBL1844	Homo sapiens	Inhibition	%	8.74
	8184183	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	1.0	CHEMBL1844	Homo sapiens	Inhibition	%	1.0
	8184449	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	3.05	CHEMBL1844	Homo sapiens	Inhibition	%	3.05
	8184596	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	0.63	CHEMBL1844	Homo sapiens	Inhibition	%	0.63
	8184977	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	14.39	CHEMBL1844	Homo sapiens	Inhibition	%	14.39
	8185126	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	18.81	CHEMBL1844	Homo sapiens	Inhibition	%	18.81
	8185350	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	1.13	CHEMBL1844	Homo sapiens	Inhibition	%	1.13
	8185481	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	15.76	CHEMBL1844	Homo sapiens	Inhibition	%	15.76
	8185836	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	50.62	CHEMBL1844	Homo sapiens	Inhibition	%	50.62
	8185975	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	4.54	CHEMBL1844	Homo sapiens	Inhibition	%	4.54
	8186340	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	5.19	CHEMBL1844	Homo sapiens	Inhibition	%	5.19
	8186504	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	7.59	CHEMBL1844	Homo sapiens	Inhibition	%	7.59
	8186728	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	2.49	CHEMBL1844	Homo sapiens	Inhibition	%	2.49
	8186867	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	6.66	CHEMBL1844	Homo sapiens	Inhibition	%	6.66
	8187189	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	5.27	CHEMBL1844	Homo sapiens	Inhibition	%	5.27
	8187313	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	5.69	CHEMBL1844	Homo sapiens	Inhibition	%	5.69
	8187537	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	7.22	CHEMBL1844	Homo sapiens	Inhibition	%	7.22
	8187685	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	71.92	CHEMBL1844	Homo sapiens	Inhibition	%	71.92
	8188038	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	10.3	CHEMBL1844	Homo sapiens	Inhibition	%	10.3
	8188181	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	3.24	CHEMBL1844	Homo sapiens	Inhibition	%	3.24
	8188540	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	6.39	CHEMBL1844	Homo sapiens	Inhibition	%	6.39
	8188814	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	7.74	CHEMBL1844	Homo sapiens	Inhibition	%	7.74
	8188962	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	8.96	CHEMBL1844	Homo sapiens	Inhibition	%	8.96
	8189186	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	8.23	CHEMBL1844	Homo sapiens	Inhibition	%	8.23
	8189342	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	59.14	CHEMBL1844	Homo sapiens	Inhibition	%	59.14
	8189715	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	0.82	CHEMBL1844	Homo sapiens	Inhibition	%	0.82
	8189847	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	4.11	CHEMBL1844	Homo sapiens	Inhibition	%	4.11
	8190203	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	3.88	CHEMBL1844	Homo sapiens	Inhibition	%	3.88
	8190343	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	5.1	CHEMBL1844	Homo sapiens	Inhibition	%	5.1
	8190567	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	22.84	CHEMBL1844	Homo sapiens	Inhibition	%	22.84
	8190704	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	14.85	CHEMBL1844	Homo sapiens	Inhibition	%	14.85
	8191092	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	4.23	CHEMBL1844	Homo sapiens	Inhibition	%	4.23
	8191230	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	14.78	CHEMBL1844	Homo sapiens	Inhibition	%	14.78
	8191550	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	31.34	CHEMBL1844	Homo sapiens	Inhibition	%	31.34
	8191896	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	33.28	CHEMBL1844	Homo sapiens	Inhibition	%	33.28
	8192045	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	-1.63	CHEMBL1844	Homo sapiens	Inhibition	%	-1.63
	8192398	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	1.47	CHEMBL1844	Homo sapiens	Inhibition	%	1.47
	8192542	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	31.8	CHEMBL1844	Homo sapiens	Inhibition	%	31.8
	8192766	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	-0.27	CHEMBL1844	Homo sapiens	Inhibition	%	-0.27
	8192902	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	22.46	CHEMBL1844	Homo sapiens	Inhibition	%	22.46
	8193174	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	35.79	CHEMBL1844	Homo sapiens	Inhibition	%	35.79
	8193543	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	42.33	CHEMBL1844	Homo sapiens	Inhibition	%	42.33
	8193700	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	5.41	CHEMBL1844	Homo sapiens	Inhibition	%	5.41
	8194073	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-0.51	CHEMBL1844	Homo sapiens	Inhibition	%	-0.51
	8194204	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	2.93	CHEMBL1844	Homo sapiens	Inhibition	%	2.93
	8194428	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	4.29	CHEMBL1844	Homo sapiens	Inhibition	%	4.29
	8194559	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	7.16	CHEMBL1844	Homo sapiens	Inhibition	%	7.16
	8194926	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	64.83	CHEMBL1844	Homo sapiens	Inhibition	%	64.83
	8195059	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	3.25	CHEMBL1844	Homo sapiens	Inhibition	%	3.25
	8195283	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	3.2	CHEMBL1844	Homo sapiens	Inhibition	%	3.2
	8195447	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	26.34	CHEMBL1844	Homo sapiens	Inhibition	%	26.34
	8195586	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	67.33	CHEMBL1844	Homo sapiens	Inhibition	%	67.33
	8195810	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	3.57	CHEMBL1844	Homo sapiens	Inhibition	%	3.57
	8195908	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	3.03	CHEMBL1844	Homo sapiens	Inhibition	%	3.03
	8196249	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	4.66	CHEMBL1844	Homo sapiens	Inhibition	%	4.66
	8196399	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	6.91	CHEMBL1844	Homo sapiens	Inhibition	%	6.91
	8196623	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	10.54	CHEMBL1844	Homo sapiens	Inhibition	%	10.54
	8196751	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	0.46	CHEMBL1844	Homo sapiens	Inhibition	%	0.46
	8197116	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	4.09	CHEMBL1844	Homo sapiens	Inhibition	%	4.09
	8197253	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	2.34	CHEMBL1844	Homo sapiens	Inhibition	%	2.34
	8197477	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	17.21	CHEMBL1844	Homo sapiens	Inhibition	%	17.21
	8197528	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	2.97	CHEMBL1844	Homo sapiens	Inhibition	%	2.97
	8197752	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	15.42	CHEMBL1844	Homo sapiens	Inhibition	%	15.42
	8197892	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	1.91	CHEMBL1844	Homo sapiens	Inhibition	%	1.91
	8198049	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	25.14	CHEMBL1844	Homo sapiens	Inhibition	%	25.14
	8198273	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	0.95	CHEMBL1844	Homo sapiens	Inhibition	%	0.95
	8198411	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	0.02	CHEMBL1844	Homo sapiens	Inhibition	%	0.02
	8198765	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	6.14	CHEMBL1844	Homo sapiens	Inhibition	%	6.14
	8198896	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	4.95	CHEMBL1844	Homo sapiens	Inhibition	%	4.95
	8199120	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	4.62	CHEMBL1844	Homo sapiens	Inhibition	%	4.62
	8199268	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	4.7	CHEMBL1844	Homo sapiens	Inhibition	%	4.7
	8199626	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	3.32	CHEMBL1844	Homo sapiens	Inhibition	%	3.32
	8199789	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	73.97	CHEMBL1844	Homo sapiens	Inhibition	%	73.97
	8200151	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	4.35	CHEMBL1844	Homo sapiens	Inhibition	%	4.35
	8200255	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	2.25	CHEMBL1844	Homo sapiens	Inhibition	%	2.25
	8200479	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	4.3	CHEMBL1844	Homo sapiens	Inhibition	%	4.3
	8200594	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	5.24	CHEMBL1844	Homo sapiens	Inhibition	%	5.24
	8200968	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	45.09	CHEMBL1844	Homo sapiens	Inhibition	%	45.09
	8201098	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	1.28	CHEMBL1844	Homo sapiens	Inhibition	%	1.28
	8201322	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	11.68	CHEMBL1844	Homo sapiens	Inhibition	%	11.68
	8201457	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	-0.56	CHEMBL1844	Homo sapiens	Inhibition	%	-0.56
	8201814	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-1.13	CHEMBL1844	Homo sapiens	Inhibition	%	-1.13
	8202093	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	0.94	CHEMBL1844	Homo sapiens	Inhibition	%	0.94
	8202233	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	23.68	CHEMBL1844	Homo sapiens	Inhibition	%	23.68
	8202624	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	1.38	CHEMBL1844	Homo sapiens	Inhibition	%	1.38
	8202749	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	0.08	CHEMBL1844	Homo sapiens	Inhibition	%	0.08
	8203103	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	2.47	CHEMBL1844	Homo sapiens	Inhibition	%	2.47
	8203458	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	78.37	CHEMBL1844	Homo sapiens	Inhibition	%	78.37
	8203604	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	15.45	CHEMBL1844	Homo sapiens	Inhibition	%	15.45
	8203962	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	4.86	CHEMBL1844	Homo sapiens	Inhibition	%	4.86
	8204128	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	7.66	CHEMBL1844	Homo sapiens	Inhibition	%	7.66
	8204489	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	4.3	CHEMBL1844	Homo sapiens	Inhibition	%	4.3
	8204818	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	32.29	CHEMBL1844	Homo sapiens	Inhibition	%	32.29
	8204933	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	7.59	CHEMBL1844	Homo sapiens	Inhibition	%	7.59
	8205157	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	34.37	CHEMBL1844	Homo sapiens	Inhibition	%	34.37
	8205306	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	6.94	CHEMBL1844	Homo sapiens	Inhibition	%	6.94
	8205666	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	0.65	CHEMBL1844	Homo sapiens	Inhibition	%	0.65
	8205805	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	1.76	CHEMBL1844	Homo sapiens	Inhibition	%	1.76
	8206161	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	0.93	CHEMBL1844	Homo sapiens	Inhibition	%	0.93
	8206437	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	-0.75	CHEMBL1844	Homo sapiens	Inhibition	%	-0.75
	8206580	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-1.81	CHEMBL1844	Homo sapiens	Inhibition	%	-1.81
	8206804	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	2.56	CHEMBL1844	Homo sapiens	Inhibition	%	2.56
	8206984	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	2.34	CHEMBL1844	Homo sapiens	Inhibition	%	2.34
	8207110	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	3.27	CHEMBL1844	Homo sapiens	Inhibition	%	3.27
	8207334	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	1.82	CHEMBL1844	Homo sapiens	Inhibition	%	1.82
	8207464	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	4.84	CHEMBL1844	Homo sapiens	Inhibition	%	4.84
	8207820	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	91.74	CHEMBL1844	Homo sapiens	Inhibition	%	91.74
	8207965	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	-0.33	CHEMBL1844	Homo sapiens	Inhibition	%	-0.33
	8208189	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	5.17	CHEMBL1844	Homo sapiens	Inhibition	%	5.17
	8208321	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	6.09	CHEMBL1844	Homo sapiens	Inhibition	%	6.09
	8208487	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	38.58	CHEMBL1844	Homo sapiens	Inhibition	%	38.58
	8208711	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	7.17	CHEMBL1844	Homo sapiens	Inhibition	%	7.17
	8208844	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	20.38	CHEMBL1844	Homo sapiens	Inhibition	%	20.38
	8209173	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	4.55	CHEMBL1844	Homo sapiens	Inhibition	%	4.55
	8209513	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	2.04	CHEMBL1844	Homo sapiens	Inhibition	%	2.04
	8209663	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	33.73	CHEMBL1844	Homo sapiens	Inhibition	%	33.73
	8210023	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	2.68	CHEMBL1844	Homo sapiens	Inhibition	%	2.68
	8210164	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	2.08	CHEMBL1844	Homo sapiens	Inhibition	%	2.08
	8210388	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	-0.55	CHEMBL1844	Homo sapiens	Inhibition	%	-0.55
	8210524	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-2.02	CHEMBL1844	Homo sapiens	Inhibition	%	-2.02
	8210783	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	2.43	CHEMBL1844	Homo sapiens	Inhibition	%	2.43
	8211151	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	16.2	CHEMBL1844	Homo sapiens	Inhibition	%	16.2
	8211321	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	1.06	CHEMBL1844	Homo sapiens	Inhibition	%	1.06
	8211668	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	2.3	CHEMBL1844	Homo sapiens	Inhibition	%	2.3
	8211797	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	3.87	CHEMBL1844	Homo sapiens	Inhibition	%	3.87
	8212021	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	6.92	CHEMBL1844	Homo sapiens	Inhibition	%	6.92
	8212153	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	4.7	CHEMBL1844	Homo sapiens	Inhibition	%	4.7
	8212518	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	1.64	CHEMBL1844	Homo sapiens	Inhibition	%	1.64
	8212651	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	5.24	CHEMBL1844	Homo sapiens	Inhibition	%	5.24
	8213045	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	2.62	CHEMBL1844	Homo sapiens	Inhibition	%	2.62
	8213174	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	3.87	CHEMBL1844	Homo sapiens	Inhibition	%	3.87
	8213398	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	10.07	CHEMBL1844	Homo sapiens	Inhibition	%	10.07
	8213502	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	27.24	CHEMBL1844	Homo sapiens	Inhibition	%	27.24
	8213839	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	4.58	CHEMBL1844	Homo sapiens	Inhibition	%	4.58
	8213986	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	0.18	CHEMBL1844	Homo sapiens	Inhibition	%	0.18
	8214210	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	1.78	CHEMBL1844	Homo sapiens	Inhibition	%	1.78
	8214347	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	8.07	CHEMBL1844	Homo sapiens	Inhibition	%	8.07
	8214705	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	12.74	CHEMBL1844	Homo sapiens	Inhibition	%	12.74
	8214857	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	0.93	CHEMBL1844	Homo sapiens	Inhibition	%	0.93
	8215108	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	0.83	CHEMBL1844	Homo sapiens	Inhibition	%	0.83
	8215485	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	60.92	CHEMBL1844	Homo sapiens	Inhibition	%	60.92
	8215649	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	2.09	CHEMBL1844	Homo sapiens	Inhibition	%	2.09
	8215992	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	1.22	CHEMBL1844	Homo sapiens	Inhibition	%	1.22
	8216335	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	0.91	CHEMBL1844	Homo sapiens	Inhibition	%	0.91
	8216471	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	5.36	CHEMBL1844	Homo sapiens	Inhibition	%	5.36
	8216833	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	1.6	CHEMBL1844	Homo sapiens	Inhibition	%	1.6
	8216967	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	2.5	CHEMBL1844	Homo sapiens	Inhibition	%	2.5
	8217191	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	1.96	CHEMBL1844	Homo sapiens	Inhibition	%	1.96
	8217365	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%		CHEMBL1844	Homo sapiens	Inhibition	%	
	8217720	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	6.26	CHEMBL1844	Homo sapiens	Inhibition	%	6.26
	8217821	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	0.6	CHEMBL1844	Homo sapiens	Inhibition	%	0.6
	8218045	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	2.16	CHEMBL1844	Homo sapiens	Inhibition	%	2.16
	8218160	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	-1.89	CHEMBL1844	Homo sapiens	Inhibition	%	-1.89
	8218511	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	6.78	CHEMBL1844	Homo sapiens	Inhibition	%	6.78
	8218654	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	41.94	CHEMBL1844	Homo sapiens	Inhibition	%	41.94
	8219009	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	49.89	CHEMBL1844	Homo sapiens	Inhibition	%	49.89
	8219169	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	2.4	CHEMBL1844	Homo sapiens	Inhibition	%	2.4
	8219393	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	8.98	CHEMBL1844	Homo sapiens	Inhibition	%	8.98
	8219419	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	2.72	CHEMBL1844	Homo sapiens	Inhibition	%	2.72
	8219643	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	1.51	CHEMBL1844	Homo sapiens	Inhibition	%	1.51
	8219804	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	4.17	CHEMBL1844	Homo sapiens	Inhibition	%	4.17
	8219973	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	15.5	CHEMBL1844	Homo sapiens	Inhibition	%	15.5
	8220197	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	1.86	CHEMBL1844	Homo sapiens	Inhibition	%	1.86
	8220326	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	0.02	CHEMBL1844	Homo sapiens	Inhibition	%	0.02
	8220664	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	3.49	CHEMBL1844	Homo sapiens	Inhibition	%	3.49
	8220802	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	17.29	CHEMBL1844	Homo sapiens	Inhibition	%	17.29
	8221026	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	59.61	CHEMBL1844	Homo sapiens	Inhibition	%	59.61
	8221162	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	1.25	CHEMBL1844	Homo sapiens	Inhibition	%	1.25
	8221519	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	2.82	CHEMBL1844	Homo sapiens	Inhibition	%	2.82
	8221684	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	2.76	CHEMBL1844	Homo sapiens	Inhibition	%	2.76
	8222039	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	33.25	CHEMBL1844	Homo sapiens	Inhibition	%	33.25
	8222361	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	10.25	CHEMBL1844	Homo sapiens	Inhibition	%	10.25
	8222495	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	4.02	CHEMBL1844	Homo sapiens	Inhibition	%	4.02
	8222837	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	37.75	CHEMBL1844	Homo sapiens	Inhibition	%	37.75
	8222981	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	21.93	CHEMBL1844	Homo sapiens	Inhibition	%	21.93
	8223205	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	90.18	CHEMBL1844	Homo sapiens	Inhibition	%	90.18
	8223334	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	4.75	CHEMBL1844	Homo sapiens	Inhibition	%	4.75
	8223719	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	78.06	CHEMBL1844	Homo sapiens	Inhibition	%	78.06
	8223969	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	0.81	CHEMBL1844	Homo sapiens	Inhibition	%	0.81
	8224131	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	2.83	CHEMBL1844	Homo sapiens	Inhibition	%	2.83
	8224525	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	3.36	CHEMBL1844	Homo sapiens	Inhibition	%	3.36
	8224660	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	5.06	CHEMBL1844	Homo sapiens	Inhibition	%	5.06
	8224884	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	2.49	CHEMBL1844	Homo sapiens	Inhibition	%	2.49
	8224998	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	5.21	CHEMBL1844	Homo sapiens	Inhibition	%	5.21
	8225356	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	5.17	CHEMBL1844	Homo sapiens	Inhibition	%	5.17
	8225494	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	8.4	CHEMBL1844	Homo sapiens	Inhibition	%	8.4
	8225853	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	2.24	CHEMBL1844	Homo sapiens	Inhibition	%	2.24
	8226011	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	1.93	CHEMBL1844	Homo sapiens	Inhibition	%	1.93
	8226235	CHEMBL1962103	GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	3.61	CHEMBL1844	Homo sapiens	Inhibition	%	3.61
	8226360	CHEMBL1962102	GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	2.3	CHEMBL1844	Homo sapiens	Inhibition	%	2.3
inactive	9519321	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(-c2[nH]c(-c3ccnc(N)n3)cc2C(N)=O)c1C		CHEMBL1964290	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519322	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2onc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL213505	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519323	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1		CHEMBL202721	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519324	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519325	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519326	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#CCOc1ccc(Nc2nc(Nc3cccc(S(N)(=O)=O)c3)ncc2Br)cc1		CHEMBL1987034	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519327	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1993941	=	Ki	nM	3.162	CHEMBL1844	Homo sapiens	pKi		8.5
inactive	9519328	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519329	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12		CHEMBL2005886	=	Ki	nM	25.12	CHEMBL1844	Homo sapiens	pKi		7.6
active	9519330	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL481491	=	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
inactive	9519331	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682345	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519332	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)Nc1c(C(N)=O)sc2ccc(Cl)c(Cl)c12		CHEMBL1973142	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519333	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccc[nH]2)C(=O)N3)c1)Cc1ccccc1		CHEMBL1980407	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
active	9519334	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4nc(N)nc(N)c34)cc2)c1		CHEMBL1973145	=	Ki	nM	3.162	CHEMBL1844	Homo sapiens	pKi		8.5
inactive	9519335	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982924	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519336	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCC(=O)Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL2005936	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519337	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC1CCC(Nc2nccc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1966628	=	Ki	nM	100.0	CHEMBL1844	Homo sapiens	pKi		7.0
inactive	9519338	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)CCCN(C)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1964948	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519339	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc(C(N)=O)c3)cc2)c1		CHEMBL1971141	=	Ki	nM	398.11	CHEMBL1844	Homo sapiens	pKi		6.4
inactive	9519340	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC1CCCCC1Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL1995813	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519341	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1c(C)n(Cc2ccccc2)c2ccc(C(=O)Nc3nc[nH]n3)cc12		CHEMBL1979718	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519342	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(COCc1ccccc1)COc1cncc(C=Cc2ccncc2)c1		CHEMBL1993781	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519343	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH][nH]c2cccc(-c3ccccc3)c12		CHEMBL1989834	<	Ki	nM	39810.72	CHEMBL1844	Homo sapiens	pKi		4.4
inactive	9519344	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCn1c2cc(Cl)c(O)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL523823	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519345	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(-c2ccc(NC(=O)Nc3ccc(OC(F)(F)F)cc3)cc2)c2c(N)noc12		CHEMBL1973178	=	Ki	nM	5.012	CHEMBL1844	Homo sapiens	pKi		8.3
inactive	9519346	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1987430	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519347	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3cn[nH]c3c2)n1		CHEMBL244378	=	Ki	nM	316.23	CHEMBL1844	Homo sapiens	pKi		6.5
active	9519348	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)c(F)c2)c1		CHEMBL1988778	=	Ki	nM	3.162	CHEMBL1844	Homo sapiens	pKi		8.5
inactive	9519349	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(OCC(F)(F)F)nccn23)n1		CHEMBL2001957	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519350	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COCCNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1969372	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519351	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1ccccc1		CHEMBL1993413	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519352	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnn2ccc(C(=O)Nc3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1990583	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519353	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	199.53	CHEMBL1844	Homo sapiens	pKi		6.7
inactive	9519354	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(Nc2ncnc3ccccc23)cc1		CHEMBL289959	<	Ki	nM	63095.73	CHEMBL1844	Homo sapiens	pKi		4.2
inactive	9519355	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1nc2ccc(NS(=O)(=O)c3ccc(N)cc3)cc2nc1C		CHEMBL2006263	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519356	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	OC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1993584	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519357	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCn1c(C)c(-c2ccnc(Nc3cccc(OC)c3)n2)sc1=O		CHEMBL1986263	=	Ki	nM	398.11	CHEMBL1844	Homo sapiens	pKi		6.4
inactive	9519358	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CSc1c[nH]c2ncnc(NCCCO)c12		CHEMBL2000114	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519359	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519360	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(O)C1CN(Cc2ccc(OCc3cccc(C(F)(F)F)c3)cc2Cl)C1		CHEMBL1986265	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519361	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cccc12		CHEMBL1975647	=	Ki	nM	1000.0	CHEMBL1844	Homo sapiens	pKi		6.0
inactive	9519362	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1968380	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519363	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Fc1ccc(-c2ccc3nccn3n2)cn1		CHEMBL1967211	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
inactive	9519364	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NCc1ccccc1)Nc1ncc([N+](=O)[O-])s1		CHEMBL1964644	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519365	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN1c2ccc(N)cc2C(c2ccccc2)c2cc(N)ccc21		CHEMBL1991734	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
inactive	9519366	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NCc1ccc(Cl)c(Cl)c1)Nc1ccc2[nH]ncc2c1		CHEMBL1981782	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519367	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNC(=O)c1cc2c(-c3ccccc3F)n[nH]c2s1		CHEMBL1977681	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519368	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNC(=O)C(C)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(C)cc5)cc4)csc23)cn1		CHEMBL1970142	=	Ki	nM	10.0	CHEMBL1844	Homo sapiens	pKi		8.0
active	9519369	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	=	Ki	nM	199.53	CHEMBL1844	Homo sapiens	pKi		6.7
inactive	9519370	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	OCCNc1cc2cc(-c3cccnc3)ccc2cn1		CHEMBL1990912	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519371	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1NCc2c1cccc2-c1cccs1		CHEMBL1991782	<	Ki	nM	50118.72	CHEMBL1844	Homo sapiens	pKi		4.3
active	9519372	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2ncc(Br)cc12		CHEMBL2002105	=	Ki	nM	31622.78	CHEMBL1844	Homo sapiens	pKi		4.5
active	9519373	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	=	Ki	nM	7.943	CHEMBL1844	Homo sapiens	pKi		8.1
inactive	9519374	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCCN(CCC#N)C(=O)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1983348	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519375	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(-c2ccc3c(c2)C(=O)NC3)c1		CHEMBL1968394	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
inactive	9519376	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519377	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NS(=O)(=O)c1cccc(Nc2ncc3ccn(-c4ccccc4)c3n2)c1		CHEMBL1988163	=	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519378	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(O)ccc1-n1c2cc(Cl)ccc2c(=O)c2c(N)nc(N)nc21		CHEMBL1995592	=	Ki	nM	158.49	CHEMBL1844	Homo sapiens	pKi		6.8
active	9519379	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOC(=O)Cc1nc2c3cc(Br)ccc3[nH]c(=O)n2n1		CHEMBL1974480	=	Ki	nM	1000.0	CHEMBL1844	Homo sapiens	pKi		6.0
active	9519380	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2c1C(=O)Nc1ccccc1N2		CHEMBL1980671	=	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519381	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1CCCc2oc3cc(C(F)(F)F)ccc3c(=O)c21		CHEMBL2006493	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519382	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(Cl)c1)Nc1nc(CCNc2ncnc3ccsc23)cs1		CHEMBL1986177	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519383	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1C		CHEMBL1983449	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519384	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH]cnc2c1oc1ccc(Cl)cc12		CHEMBL1992323	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519385	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(Cl)nccn23)n1		CHEMBL1969735	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519386	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCc1nc2c(c3cc(OC)c(OC)cc13)C(=O)NC2=O		CHEMBL2003524	=	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
inactive	9519387	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc2c(c1)C(=Cc1c[nH]cn1)C(=O)N2		CHEMBL2002649	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519388	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc2c(c1)Cc1c[nH]nc1-2		CHEMBL1989423	<	Ki	nM	63095.73	CHEMBL1844	Homo sapiens	pKi		4.2
inactive	9519389	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccnc(Nc2cc(C)nc(-c3ccccc3)n2)c1		CHEMBL1985367	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519390	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	=	Ki	nM	316.23	CHEMBL1844	Homo sapiens	pKi		6.5
inactive	9519391	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1nc(N2CCNCC2)nc2ccccc12		CHEMBL1996510	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519392	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCn1c(C2CCNCC2)nc(-c2ccc(Cl)c(Cl)c2)c1-c1ccnc(NC2CCCCC2)n1		CHEMBL437747	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519393	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Brc1ccc2c(c1)-c1[nH]ncc1C2		CHEMBL1995172	<	Ki	nM	31622.78	CHEMBL1844	Homo sapiens	pKi		4.5
inactive	9519394	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1cc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2CO)cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c1=O		CHEMBL2001584	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519395	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL507936	=	Ki	nM	6.31	CHEMBL1844	Homo sapiens	pKi		8.2
inactive	9519396	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=S(=O)(NCCNCC=Cc1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL1987756	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519397	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1967998	=	Ki	nM	6.31	CHEMBL1844	Homo sapiens	pKi		8.2
active	9519398	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCNS(C)(=O)=O)cnc(N)c34)cc2)c1		CHEMBL1994321	=	Ki	nM	10.0	CHEMBL1844	Homo sapiens	pKi		8.0
active	9519399	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(C#N)ccc21		CHEMBL1978562	=	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
active	9519400	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1NCCc2[nH]c(-c3ccnc(C=Cc4ccccc4)c3)cc21		CHEMBL1997129	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
active	9519401	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc(Cl)cc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12		CHEMBL1984788	=	Ki	nM	398.11	CHEMBL1844	Homo sapiens	pKi		6.4
inactive	9519402	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	FC(F)(F)c1ccc(-c2nnc3ccc(NC4CC4)nn23)cc1		CHEMBL451964	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519403	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(O)c1csc2c1NCCNC2=O		CHEMBL1974875	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
active	9519404	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL1964307	=	Ki	nM	12.59	CHEMBL1844	Homo sapiens	pKi		7.9
active	9519405	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccnc2[nH]c3cc(C(C)C)ccc3c(=O)c12		CHEMBL1989471	=	Ki	nM	794.33	CHEMBL1844	Homo sapiens	pKi		6.1
inactive	9519406	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL2002099	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519407	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Fc1ccc(-c2nc3sccn3c2-c2ccncc2)cc1		CHEMBL2000508	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519408	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCCNc1n[s+]([O-])nc1Nc1ccc(F)cc1		CHEMBL1971694	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519409	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2001547	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519410	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519411	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc2c(-c3ccc(Br)cc3)cncc2s1		CHEMBL1978195	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519412	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1F		CHEMBL1994361	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519413	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(NC(=O)CCNC(=O)Nc2nc(C)c(-c3ccc(-n4cccn4)cc3)s2)no1		CHEMBL1986603	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519414	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519415	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(COc1cncc(-c2cc3cnccc3s2)c1)Cc1c[nH]c2ccccc12		CHEMBL1972840	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519416	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(CN(C)C)cc1Nc1nccc(-c2c(-c3cccc(NC(=O)Cc4ccccc4)c3)nc3sccn23)n1		CHEMBL1966842	=	Ki	nM	501.19	CHEMBL1844	Homo sapiens	pKi		6.3
inactive	9519417	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(C=C2SC(=O)NC2=O)ccc1O		CHEMBL2003286	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519418	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(O)Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL2002165	=	Ki	nM	3.162	CHEMBL1844	Homo sapiens	pKi		8.5
inactive	9519419	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1n[nH]c2c1C(c1ccccc1I)C(C#N)=C(N)O2		CHEMBL1979318	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519420	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1989518	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519421	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1998585	=	Ki	nM	19.95	CHEMBL1844	Homo sapiens	pKi		7.7
inactive	9519422	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1cncc1C(OCc1c(-c2ccc(OC(F)(F)F)cc2)cc(C#N)c(=O)n1C)c1ccc(C#N)cc1		CHEMBL127898	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519423	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2C		CHEMBL519697	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519424	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(F)c2)c1		CHEMBL2004934	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519425	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)c(F)c3)c12		CHEMBL2000652	=	Ki	nM	1.995	CHEMBL1844	Homo sapiens	pKi		8.7
active	9519426	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1973516	=	Ki	nM	19.95	CHEMBL1844	Homo sapiens	pKi		7.7
inactive	9519427	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(O)c1cc(-c2cccs2)n2nccc2n1		CHEMBL1977619	<	Ki	nM	25118.86	CHEMBL1844	Homo sapiens	pKi		4.6
inactive	9519428	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1ccc2nc(N)n(-c3nc4c(s3)CCCC4)c2c1		CHEMBL1996345	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519429	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12		CHEMBL1975128	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519430	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COCOc1cccc(OCOC)c1-c1ccc(NS(C)(=O)=O)cc1C(=O)OC		CHEMBL2004025	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
active	9519431	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(-c2cc3c(NCCN)ccc(C(N)=O)c3[nH]2)cc1		CHEMBL1996048	=	Ki	nM	794.33	CHEMBL1844	Homo sapiens	pKi		6.1
inactive	9519432	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL461876	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519433	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)cc1		CHEMBL1965033	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519434	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C(C)C(=O)N(C)C)c5)cnc(N)c34)cc2)cc1		CHEMBL2001485	=	Ki	nM	100.0	CHEMBL1844	Homo sapiens	pKi		7.0
active	9519435	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	=	Ki	nM	79.43	CHEMBL1844	Homo sapiens	pKi		7.1
active	9519436	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2cccc(-c3ccc(F)cc3)c12		CHEMBL1971519	=	Ki	nM	7943.28	CHEMBL1844	Homo sapiens	pKi		5.1
inactive	9519437	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(C)c2c(n1)sc1c(N)ncnc12		CHEMBL504950	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519438	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(C2=NNc3cccc4c(OC)ccc2c34)cc1OC		CHEMBL1997335	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519439	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)CCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1966425	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519440	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)ccc1F		CHEMBL1984363	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519441	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNC(=O)COc1ccc(Nc2nc(Nc3ccc(C)c(S(N)(=O)=O)c3)ncc2F)cc1		CHEMBL1978099	=	Ki	nM	251.19	CHEMBL1844	Homo sapiens	pKi		6.6
active	9519442	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COC(=O)c1c(-c2ccc(NC(=O)Nc3ccccc3)cc2)c2c(N)ncnn2c1C		CHEMBL1977041	=	Ki	nM	39.81	CHEMBL1844	Homo sapiens	pKi		7.4
inactive	9519443	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cccc2c1Nc1nnc(Cl)cc1C(=O)N2		CHEMBL1968070	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519444	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)Nc1cccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)c1		CHEMBL1988608	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519445	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)cc1C		CHEMBL184847	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519446	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)c1ccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)cc1		CHEMBL1984367	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519447	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1n[nH]c2cnc(-c3cncc(OCC(N)Cc4cccc(C(F)(F)F)c4)c3)cc12		CHEMBL1998159	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9519448	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COCC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(C)nccn23)n1		CHEMBL1982563	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9519449	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1CCCN1Cc1ccc2c(c1)[nH]c(=O)c1cccn12		CHEMBL539474	=	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
inactive	9523364	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(COc1cncc(-c2ccc3[nH]c(=O)oc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1987679	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523365	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(OC(F)F)cc5)cc4)csc23)cn1		CHEMBL1988387	=	Ki	nM	12.59	CHEMBL1844	Homo sapiens	pKi		7.9
inactive	9523366	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Oc1cnc2ccc(-c3ccncc3)cc2c1		CHEMBL1973868	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523367	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523368	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	=	Ki	nM	3.981	CHEMBL1844	Homo sapiens	pKi		8.4
active	9523369	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL1970074	=	Ki	nM	31.62	CHEMBL1844	Homo sapiens	pKi		7.5
inactive	9523370	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523371	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	=	Ki	nM	501.19	CHEMBL1844	Homo sapiens	pKi		6.3
inactive	9523372	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COCCN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1986970	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523373	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1cc(-c2ccncc2)nc(NC2CCCCC2)[nH]1		CHEMBL1958401	=	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523374	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	=	Ki	nM	19.95	CHEMBL1844	Homo sapiens	pKi		7.7
active	9523375	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN(CC)CCOc1ccc(-c2nc3c(C(N)=O)cccc3[nH]2)cc1		CHEMBL1984044	=	Ki	nM	501.19	CHEMBL1844	Homo sapiens	pKi		6.3
inactive	9523376	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH]c2cc(-c3ccccc3)cnc2[nH]1		CHEMBL2003456	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523377	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)cccc12		CHEMBL1966816	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
active	9523378	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
inactive	9523379	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL2002992	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523380	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1cnc(NC(=O)Nc2ccc3cc(C(=O)O)ccc3c2)cn1		CHEMBL560813	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523381	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCOn1c2ccc(Cl)cc2c(=O)c2c(C)nn(C)c21		CHEMBL207253	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
inactive	9523382	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCCNC(=O)c1cn(C(CC)CC)c(=O)c2cc(OC)c(OC)cc12		CHEMBL1982700	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523383	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CC(CN2CCCC2)C1		CHEMBL1968791	=	Ki	nM	125.89	CHEMBL1844	Homo sapiens	pKi		6.9
inactive	9523384	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1CC(c2ccc(Cl)cc2Cl)Cc2nc3cc(Cl)ccc3c(O)c21		CHEMBL326282	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523385	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(N)=O)cc2)n1		CHEMBL1977634	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523386	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOc1ccccc1C=NNC(=O)c1nnn(-c2nonc2N)c1N1CCCC1		CHEMBL1992732	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523387	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Fc1ccc(-c2nc3occn3c2-c2ccnc(NC3CCNCC3)n2)cc1		CHEMBL1971186	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523388	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Cc1ccc(Cl)cc1)Nc1[nH]nc2c1CCC2		CHEMBL2003482	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523389	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)Nc1cc2ccccn2n1		CHEMBL1976872	<	Ki	nM	63095.73	CHEMBL1844	Homo sapiens	pKi		4.2
inactive	9523390	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nccc2cnc(-c3ccccc3)n12		CHEMBL1969156	<	Ki	nM	63095.73	CHEMBL1844	Homo sapiens	pKi		4.2
active	9523391	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCCC5)cnc(N)c34)cc2)c1		CHEMBL1973211	=	Ki	nM	10.0	CHEMBL1844	Homo sapiens	pKi		8.0
inactive	9523392	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1984700	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523393	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	=	Ki	nM	1000.0	CHEMBL1844	Homo sapiens	pKi		6.0
active	9523394	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CCC(N2CCCC2)CC1		CHEMBL2007151	=	Ki	nM	501.19	CHEMBL1844	Homo sapiens	pKi		6.3
inactive	9523395	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)cc1		CHEMBL1998953	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523396	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2)c1		CHEMBL1971606	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523397	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1		CHEMBL1972125	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523398	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1ccc2[nH]ncc2c1)c1cccc(F)c1		CHEMBL1461728	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523399	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Ki	nM	158.49	CHEMBL1844	Homo sapiens	pKi		6.8
active	9523400	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)c1cc(=O)[nH]c2[nH][nH]c(=O)c12		CHEMBL1999120	=	Ki	nM	10000.0	CHEMBL1844	Homo sapiens	pKi		5.0
inactive	9523401	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1cc2cc(-c3ccc4cn[nH]c4c3)cnc2[nH]1		CHEMBL1976134	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523402	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(C(=O)Nc2c(C(N)=O)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL1965131	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523403	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL1972158	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523404	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(OC(F)F)ccc12		CHEMBL1981215	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523405	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL1974457	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523406	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	<	Ki	nM	1000.0	CHEMBL1844	Homo sapiens	pKi		6.0
active	9523407	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1999414	=	Ki	nM	2.512	CHEMBL1844	Homo sapiens	pKi		8.6
inactive	9523408	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cc(F)cc12		CHEMBL1967336	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523409	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1Cl)c1ccccc1F		CHEMBL2001228	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523410	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1Cl		CHEMBL2006581	=	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523411	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCC#N)c2)n1		CHEMBL1979855	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523412	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1noc2cccc(-c3cccc(O)c3)c12		CHEMBL1970340	<	Ki	nM	5011.87	CHEMBL1844	Homo sapiens	pKi		5.3
inactive	9523413	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1ccc(-c2ccncc2)cc1NCc1ccccc1		CHEMBL1967992	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523414	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	=	Ki	nM	50.12	CHEMBL1844	Homo sapiens	pKi		7.3
inactive	9523415	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL2005186	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523416	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL2006450	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523417	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NCC(O)C(O)Cn1cc(I)c2c(N)ncnc21		CHEMBL1975534	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523418	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NS(=O)(=O)c1cccc(Nc2ncc3ccn(Cc4ccccc4)c3n2)c1		CHEMBL1993424	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523419	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1n[nH]c2c1C(c1ccccc1F)C1=C(CC(C)(C)CC1=O)N2		CHEMBL1966703	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523420	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)ccc(F)c12		CHEMBL2001987	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523421	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)N(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1969561	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523422	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCc1c(-c2ccc(C(C)=O)cc2)[nH]c2nccnc12		CHEMBL1994555	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523423	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523424	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3coc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1983640	=	Ki	nM	5.012	CHEMBL1844	Homo sapiens	pKi		8.3
inactive	9523425	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)c1cc2sncc2cc1NC(=O)C(=O)O		CHEMBL1997023	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523426	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(C)cc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1964687	=	Ki	nM	19.95	CHEMBL1844	Homo sapiens	pKi		7.7
inactive	9523427	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523428	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc2c(-c3ccc(Br)c(F)c3F)cncc2s1		CHEMBL1999918	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523429	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1974254	=	Ki	nM	2.512	CHEMBL1844	Homo sapiens	pKi		8.6
active	9523430	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(CNc2nc(Nc3cc(C4CC4)[nH]n3)c3sccc3n2)cc1		CHEMBL1997924	=	Ki	nM	39.81	CHEMBL1844	Homo sapiens	pKi		7.4
inactive	9523431	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(C(=O)N2c3ccccc3Sc3c(Cl)cncc32)cc1		CHEMBL1988537	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523432	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(C)c2)c1		CHEMBL1969049	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523433	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)cc1		CHEMBL2005828	=	Ki	nM	501.19	CHEMBL1844	Homo sapiens	pKi		6.3
inactive	9523434	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)c1ccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)cc1NC(=O)c1ccccc1		CHEMBL1978267	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523435	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1		CHEMBL363648	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523436	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	=	Ki	nM	158.49	CHEMBL1844	Homo sapiens	pKi		6.8
active	9523437	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1sc2c(Br)ccc(Cl)c2c1N		CHEMBL1998611	=	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
inactive	9523438	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2CCC(N)=O		CHEMBL485556	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523439	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1c(NCc2ccc(Cl)c(Cl)c2)c(Nc2ccncc2)c1=O		CHEMBL1975900	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523440	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(C=C2SC(=S)NC2=O)ccc1O		CHEMBL1973098	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523441	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(=O)CC)c3c2)cc1		CHEMBL1972221	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523442	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNC(=O)C=Cc1cnc(N)c2c(-c3cc(F)c4[nH]c(C)cc4c3)csc12		CHEMBL2006778	=	Ki	nM	3.981	CHEMBL1844	Homo sapiens	pKi		8.4
inactive	9523443	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523444	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1c(F)cccc1F		CHEMBL1996979	=	Ki	nM	316.23	CHEMBL1844	Homo sapiens	pKi		6.5
active	9523445	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cccc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12		CHEMBL1997025	=	Ki	nM	794.33	CHEMBL1844	Homo sapiens	pKi		6.1
inactive	9523446	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1968406	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523447	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH]c2cc(Br)cnc2[nH]1		CHEMBL1975921	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
active	9523448	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)csc12		CHEMBL1982476	=	Ki	nM	1.585	CHEMBL1844	Homo sapiens	pKi		8.8
inactive	9523449	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1998545	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523450	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1csc(NC(=O)c2sc3nc(-c4ccncc4)ccc3c2N)n1		CHEMBL1986869	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523451	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(CCC(=O)O)(c1ccc(O)c(N)c1)c1ccc(O)c(N)c1		CHEMBL1975923	<	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
active	9523452	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(Nc2nc(Cl)cc(NCc3ccccc3)n2)n[nH]1		CHEMBL2005449	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
inactive	9523453	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(O)C1CN(Cc2ccc(OCc3ccccc3)cc2Cl)C1		CHEMBL1987998	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523454	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(Cl)c(Cl)ccc12		CHEMBL2006010	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523455	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Fc1ccc(-c2ncn(CCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1		CHEMBL1682558	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523456	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc2ccncc2s1		CHEMBL1971534	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
inactive	9523457	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O		CHEMBL1990496	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523458	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc([N+](=O)[O-])cc2)n1		CHEMBL242865	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523459	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2cc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)ccc12		CHEMBL1997623	=	Ki	nM	125.89	CHEMBL1844	Homo sapiens	pKi		6.9
inactive	9523460	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccc(Cl)cc5o4)cc3)c1)CNC2=O		CHEMBL2002479	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523461	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nc2ncc(-c3ccccc3)cn2n1		CHEMBL2002480	=	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
inactive	9523462	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=NNC(=N)N)c1cc(NC(=O)NCCCN(C)CCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL1993166	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523463	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NCc1ccc(Cl)cc1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL1967094	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523464	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1		CHEMBL1966035	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523465	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NC(CO)c1cc(Cl)cc(Cl)c1)c1ccc(-c2ccncc2)cc1		CHEMBL2003341	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523466	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NS(=O)(=O)c1ccc(NCCSc2ccc(O)cc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)cc1		CHEMBL1992645	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523467	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Oc1cccc(Nc2ncnc3scc(Cl)c23)c1		CHEMBL1982992	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523468	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	[2H]C([2H])([2H])Oc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1		CHEMBL1998110	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523469	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(-c2ccccc2)n(-c2cc(NN=Cc3ccco3)ncn2)n1		CHEMBL1999590	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523470	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1F		CHEMBL1981079	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523471	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	39.81	CHEMBL1844	Homo sapiens	pKi		7.4
inactive	9523472	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN(CC)CCCNc1cccc(-c2nc3c(C(N)=O)cccc3[nH]2)n1		CHEMBL1972276	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523473	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1c(NCc2ccc(Cl)cc2)c(Nc2ccncc2)c1=O		CHEMBL1980489	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523474	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCc4cccc(F)c4)cc2NC3=O)ccc1O		CHEMBL2000832	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523475	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)c1		CHEMBL1967116	=	Ki	nM	1.585	CHEMBL1844	Homo sapiens	pKi		8.8
inactive	9523476	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)n1ncc2cc(N)ccc21		CHEMBL1972454	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
inactive	9523477	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(O)nc2[nH]nc(-c3cccc(-c4ccc(Cl)cc4)c3)c12		CHEMBL1990590	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523478	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1Nc2ccccc2C1=Cc1ccc[nH]1		CHEMBL1996176	=	Ki	nM	316.23	CHEMBL1844	Homo sapiens	pKi		6.5
inactive	9523479	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NCc1ccc(Br)cc1)Nc1ccc2[nH]ncc2c1		CHEMBL1970709	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523480	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	OCc1cc(-c2ccc3[nH]ncc3c2)on1		CHEMBL1974617	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
inactive	9523481	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523482	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(Nc2ncnc(N3CCCc4cc(C)ccc43)n2)cc(OC)c1OC		CHEMBL1992125	=	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
inactive	9523483	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(-c2cc3nccn3c(Nc3ccccc3C(N)=O)n2)cc1OC		CHEMBL1998112	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523484	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(NC(=O)Nc2ccc(-c3c(F)ccc4[nH]nc(N)c34)cc2)ccc1F		CHEMBL1993996	=	Ki	nM	1.259	CHEMBL1844	Homo sapiens	pKi		8.9
inactive	9523485	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)n1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)cc21		CHEMBL1969126	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523486	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2sc(Br)c(-c3ccc(NC(=O)Cc4cccc(Cl)c4)cc3)c12		CHEMBL1980896	=	Ki	nM	25.12	CHEMBL1844	Homo sapiens	pKi		7.6
active	9523487	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	=	Ki	nM	316.23	CHEMBL1844	Homo sapiens	pKi		6.5
inactive	9523488	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1		CHEMBL1991429	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523489	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc2c(Oc3cccc(F)c3)cncc2s1		CHEMBL1964777	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523490	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)C(=O)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1971149	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523491	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc2c(c1)NC(=O)c1ccccc1N2		CHEMBL1999714	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523492	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Cc1ccccc1Cl)Nc1ccc2cn[nH]c2c1		CHEMBL1987533	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523493	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(O)CNc1nccc(-c2c(-c3ccc(F)cc3F)nc3c(CC4CC4)nccn23)n1		CHEMBL1994040	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523494	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL1980995	=	Ki	nM	7.943	CHEMBL1844	Homo sapiens	pKi		8.1
inactive	9523495	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(COc1cncc(-c2ccc3c(c2)CC(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL1967302	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523496	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)cn1		CHEMBL398951	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523497	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc2cnc3c(c2cc1OC)C(=O)NC3=O		CHEMBL1982506	=	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
active	9523498	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN(CC)CCNC(=O)C=Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2004716	=	Ki	nM	15.85	CHEMBL1844	Homo sapiens	pKi		7.8
inactive	9523499	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1		CHEMBL1968127	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523500	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(C)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1975233	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523501	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cccc(F)c3F)cc12		CHEMBL1985406	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523502	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1nc(C(F)(F)F)c2c(=O)c3cc(Cl)ccc3n(O)c21		CHEMBL207400	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523503	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(O)ccc1-n1cc(C(=O)NN)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL2000894	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523504	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Cc1cccs1)Nc1nc2ccccc2s1		CHEMBL1421720	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523505	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nnc2cncc(Cl)n12		CHEMBL1968130	=	Ki	nM	79432.82	CHEMBL1844	Homo sapiens	pKi		4.1
inactive	9523506	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccccc1NC(=O)Nc1ccc2c(c1)CCc1sc3ncnc(N)c3c1-2		CHEMBL1982135	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523507	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2c1sc1ncnc(N)c12		CHEMBL1976090	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523508	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4c(c3)OCO4)csc12		CHEMBL1993243	=	Ki	nM	31.62	CHEMBL1844	Homo sapiens	pKi		7.5
inactive	9523509	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3o2)cc1		CHEMBL2004771	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523510	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	OCC(CO)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1992922	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523511	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CC(CN2CCCC2)C1		CHEMBL1988370	=	Ki	nM	1000.0	CHEMBL1844	Homo sapiens	pKi		6.0
inactive	9523512	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1997597	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523513	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	S=c1[nH]nc2c3c4c(sc3n3c(=S)[nH]nc3n12)CCC4		CHEMBL1969537	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523514	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1976093	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523515	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(COc1cncc(-c2ccc(F)cc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1996543	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523516	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1cccs1		CHEMBL1975256	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523517	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3cnc4c(-c5cnn(C)c5)cnn4c3N)cc2)c1		CHEMBL508928	=	Ki	nM	31.62	CHEMBL1844	Homo sapiens	pKi		7.5
active	9523518	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(-c2cc3c(=O)[nH]c4ccccc4n3c2)c1		CHEMBL1991356	=	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523519	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL2004892	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523520	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH]cnc2c(Cl)cccc12		CHEMBL1949855	=	Ki	nM	39810.72	CHEMBL1844	Homo sapiens	pKi		4.4
inactive	9523521	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)Oc1ccc(-c2noc(-c3ccc(NC4CCC(C(=O)O)C4)cc3)n2)cc1Cl		CHEMBL1997503	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523522	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc2c(Oc3ccc(Br)cc3)cncc2s1		CHEMBL116070	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523523	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(C)c(C)c(OCCCc2c(C(=O)O)[nH]c3c(-c4ccccc4C)cccc23)c1		CHEMBL1990821	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523524	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc(-c2cccc(N)c2)cc2cccnc12		CHEMBL1970314	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523525	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	OCCCn1cnc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL2004871	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523526	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncn3)cc2)c1		CHEMBL2004872	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523527	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1Nc2ccccc2Nc2ccccc21		CHEMBL1727312	<	Ki	nM	79432.82	CHEMBL1844	Homo sapiens	pKi		4.1
inactive	9523528	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(OCc2ccc(Cl)c(Cl)c2)ccc1CN1CC(C(=O)O)C1		CHEMBL1990223	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523529	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC1CCN(C(=O)CO)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL1969879	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523530	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(c1cc(Br)c(O)c(I)c1)c1cc(Br)c(O)c(I)c1		CHEMBL1964382	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523531	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3Cl)n2)cc1		CHEMBL101311	=	Ki	nM	1000.0	CHEMBL1844	Homo sapiens	pKi		6.0
inactive	9523532	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cnccn1)Nc1ccnc2ccccc12		CHEMBL1981720	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523533	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(N)COc1cnc(Cl)c(C=Cc2ccncc2)c1		CHEMBL1993548	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523534	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3nsc4ncnc(N)c34)cc2)c1		CHEMBL262433	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
active	9523535	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL373798	=	Ki	nM	0.631	CHEMBL1844	Homo sapiens	pKi		9.2
active	9523536	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1		CHEMBL306380	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
inactive	9523537	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1nn(C)c2sc(C(N)=O)cc12		CHEMBL1986588	<	Ki	nM	25118.86	CHEMBL1844	Homo sapiens	pKi		4.6
inactive	9523538	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NNC(=S)Nc1ccc(Cl)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1966722	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523539	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(=O)n2ccc(CN(C)C)c(O)c2n1		CHEMBL1988581	=	Ki	nM	125.89	CHEMBL1844	Homo sapiens	pKi		6.9
inactive	9523540	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(=O)O)cc2)n1		CHEMBL2005699	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523541	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCNC(C)=O)cc2NC3=O)ccc1O		CHEMBL1975500	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523542	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4snc(N)c34)cc2)c1		CHEMBL1976328	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
active	9523543	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ccnc(N)c34)cc2)c1		CHEMBL394619	=	Ki	nM	6.31	CHEMBL1844	Homo sapiens	pKi		8.2
active	9523544	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN(C(C)=O)c1ccc(Nc2nc(NC3CC3)c3nc[nH]c3n2)cc1		CHEMBL2006564	=	Ki	nM	125.89	CHEMBL1844	Homo sapiens	pKi		6.9
active	9523545	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)cc1OC		CHEMBL1964399	=	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523546	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(O)c1c2c(nc3ccccc13)C(=C1CCCC1)CC2		CHEMBL1996831	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523547	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc1)CCN2		CHEMBL411903	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
active	9523548	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2c(-c3ccccc3)cccc12		CHEMBL1991008	=	Ki	nM	63095.73	CHEMBL1844	Homo sapiens	pKi		4.2
active	9523549	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	39.81	CHEMBL1844	Homo sapiens	pKi		7.4
inactive	9523550	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2ccccc21		CHEMBL1978167	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523551	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN)cnc(N)c34)cc2)c1		CHEMBL1965988	=	Ki	nM	5.012	CHEMBL1844	Homo sapiens	pKi		8.3
inactive	9523552	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523553	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL1989646	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523554	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(Cc2cc(-c3ccc4[nH]ncc4c3)on2)cc1		CHEMBL1682357	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523555	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523556	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOc1nc(C(=O)NCc2cccnc2)cc(N)c1C#N		CHEMBL209534	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
inactive	9523557	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1nccn2c(-c3ccnc(NCCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1978200	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523558	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Ki	nM	39.81	CHEMBL1844	Homo sapiens	pKi		7.4
active	9523559	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)c1cccc(-c2ccc3nccn3n2)c1		CHEMBL1994159	=	Ki	nM	63095.73	CHEMBL1844	Homo sapiens	pKi		4.2
active	9523560	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(C=C2SC(=Nc3ccccc3)NC2=O)ccc1O		CHEMBL1970522	=	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
active	9523561	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	=	Ki	nM	1.0	CHEMBL1844	Homo sapiens	pKi		9.0
inactive	9523562	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1n[nH]c2nc3ccccc3cc12)c1ccncc1		CHEMBL1990415	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523563	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	C(=Cc1cncc(OC2CCNC2)c1)c1ccncc1		CHEMBL1966087	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523564	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NC(CO)Cc1ccc(Cl)cc1)c1ccc(-c2ccncc2)cc1		CHEMBL1996931	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523565	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)cncc21		CHEMBL1964692	=	Ki	nM	316.23	CHEMBL1844	Homo sapiens	pKi		6.5
inactive	9523566	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	FC(F)(F)c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C(F)(F)F)c1		CHEMBL1964413	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523567	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL1973483	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523568	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1998470	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523569	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccccc3Cl)n2)c1		CHEMBL1995428	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
inactive	9523570	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C)c1		CHEMBL1984432	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523571	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL219722	=	Ki	nM	6.31	CHEMBL1844	Homo sapiens	pKi		8.2
inactive	9523572	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccccc1-c1ccnc(Nc2cccc(S(C)(=O)=O)c2)n1		CHEMBL1975903	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523573	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCC(O)C1		CHEMBL1997340	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523574	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(Nc2ncnc3ccccc23)c1		CHEMBL117697	<	Ki	nM	50118.72	CHEMBL1844	Homo sapiens	pKi		4.3
active	9523575	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
inactive	9523576	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1cc(-c2ccncn2)c(-c2ccc(F)cc2)n1		CHEMBL1989474	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523577	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1		CHEMBL1090360	=	Ki	nM	1000.0	CHEMBL1844	Homo sapiens	pKi		6.0
inactive	9523578	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1ccc2nc(N)n(-c3nccs3)c2c1		CHEMBL1988805	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523579	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
inactive	9523580	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C(F)(F)F)c2)c1		CHEMBL1971021	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523581	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(OC(F)(F)F)c4)c3)cc12		CHEMBL1965836	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523582	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH]cnc2c1sc1c(Cl)ccc(Cl)c12		CHEMBL583144	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523583	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc2c(-c3ccc(F)cc3)cncc2s1		CHEMBL1974310	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523584	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1ccc(-c2ccc3cn[nH]c3c2)cc1)Nc1cccc(F)c1		CHEMBL1969942	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523585	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1		CHEMBL1978567	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523586	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523587	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2sc3c(c12)-c1ccc(NC(=O)Nc2ccccc2)cc1CC3		CHEMBL1994693	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523588	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cccc(-c2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982957	=	Ki	nM	398.11	CHEMBL1844	Homo sapiens	pKi		6.4
active	9523589	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Ki	nM	125.89	CHEMBL1844	Homo sapiens	pKi		6.9
active	9523590	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1Nc2ccccc2C1=Cc1ccc[nH]1		CHEMBL1996176	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
active	9523591	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(CNc2cc(-c3c[nH]c4ncccc34)ncn2)cc1		CHEMBL2002346	=	Ki	nM	199.53	CHEMBL1844	Homo sapiens	pKi		6.7
inactive	9523592	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NNC(=S)Nc1ccc(F)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1975138	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523593	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N		CHEMBL424872	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
active	9523594	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#Cc5cccnc5)cnc(N)c34)cc2)c1		CHEMBL1971947	=	Ki	nM	15.85	CHEMBL1844	Homo sapiens	pKi		7.8
inactive	9523595	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1		CHEMBL412142	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523596	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523597	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc2nnc(SCc3cn4ccccc4n3)n2c2ccccc12		CHEMBL1980704	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523598	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1sc2ccc(Cl)c(Cl)c2c1NC(=O)c1ccc(Cl)cc1		CHEMBL2003271	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9523599	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1cc2nc(-c3ccccc3)cn2cn1		CHEMBL1972365	<	Ki	nM	25118.86	CHEMBL1844	Homo sapiens	pKi		4.6
inactive	9523600	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccncc4)nn12)CCCC3		CHEMBL1966808	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523601	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3c(F)ccc4[nH]nc(N)c34)cc2)c1		CHEMBL1996255	=	Ki	nM	1.259	CHEMBL1844	Homo sapiens	pKi		8.9
active	9523602	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1		CHEMBL49120	=	Ki	nM	0.631	CHEMBL1844	Homo sapiens	pKi		9.2
inactive	9523603	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)c1n[nH]c2c1C(c1ccccc1F)C(C#N)=C(N)O2		CHEMBL2004447	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523604	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Ki	nM	63.1	CHEMBL1844	Homo sapiens	pKi		7.2
inactive	9523605	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	OCCNc1cc2cc(-c3ccsc3)ccc2cn1		CHEMBL1973860	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9523606	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2nnc(-c3ccccc3)c(-c3ccccc3)c12		CHEMBL260135	=	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527511	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21		CHEMBL220241	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527512	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCC(=O)Nc1ccc(C(=O)N2CCNCC2)c(O)c1		CHEMBL1988141	=	Ki	nM	251.19	CHEMBL1844	Homo sapiens	pKi		6.6
inactive	9527513	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH]cc(I)c2nc(-c3cccc(Cl)c3)cn12		CHEMBL1982610	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527514	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)cnc2c(-c3ccc4c(c3)OCO4)cnn12		CHEMBL1977134	=	Ki	nM	63.1	CHEMBL1844	Homo sapiens	pKi		7.2
inactive	9527515	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(C2(c3cccc(C)c3)CC2C(=O)Nc2ccncc2)c1		CHEMBL1999496	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527516	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc2c(c1)C(=O)Nc1ccccc1N2		CHEMBL1970873	<	Ki	nM	39810.72	CHEMBL1844	Homo sapiens	pKi		4.4
inactive	9527517	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CSc1cnc2c(ccc3cnccc32)c1O		CHEMBL2006933	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527518	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COCC#Cc1cccc2c1Cc1c(-c3cccs3)n[nH]c1-2		CHEMBL1985206	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527519	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ccc(-c2csc3c(C=Cc4nc5ccccc5[nH]4)cnc(N)c23)cc1		CHEMBL1988300	=	Ki	nM	50.12	CHEMBL1844	Homo sapiens	pKi		7.3
inactive	9527520	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527521	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC		CHEMBL1991078	<	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
inactive	9527522	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCCNc1ccc2c3c(cccc13)C(=O)N(CCNCCO)C2=O		CHEMBL1987359	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527523	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	C=CCc1cccc2c(=NO)cc(-c3ccccc3)oc12		CHEMBL1977749	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527524	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2scc(-c3ccccc3)c12		CHEMBL1975212	=	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
inactive	9527525	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=NNC(=N)N)c1cc(NC(=O)c2cccc(C(=O)Nc3cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c3)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL2000685	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527526	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH][nH]c2ccc(Br)cc12		CHEMBL2001613	=	Ki	nM	39810.72	CHEMBL1844	Homo sapiens	pKi		4.4
inactive	9527527	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527528	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc2[nH]cc(C=C3C(=O)Nc4ccccc43)c2c1		CHEMBL1997275	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527529	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc2c(-c3ccc(Nc4nc5ccccc5o4)cc3)cnc(N)c2s1		CHEMBL1993904	=	Ki	nM	794.33	CHEMBL1844	Homo sapiens	pKi		6.1
active	9527530	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(-c2cccc3onc(N)c23)c1		CHEMBL1980376	=	Ki	nM	15848.93	CHEMBL1844	Homo sapiens	pKi		4.8
inactive	9527531	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2ccc(Cl)cc12		CHEMBL1967513	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527532	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(O)nc2[nH]nc(-c3cccc(-c4ccc(C#N)cc4)c3)c12		CHEMBL2000724	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527533	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(CO)ccc4F)cc3)c12		CHEMBL1985311	=	Ki	nM	5.012	CHEMBL1844	Homo sapiens	pKi		8.3
inactive	9527534	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527535	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC1CSc2c(C(=O)O)c(=O)c3cc(F)c(N4CCC(N)C4)cc3n21		CHEMBL1989265	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527536	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527537	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(Cc1cc(Cl)c(O)c2ncccc12)C1CCCCC1		CHEMBL1982413	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527538	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1NN=Cc2c[nH]c3cc(NC(=O)C4CC4c4ccccc4)cc1c23		CHEMBL1969502	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527539	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CCC(N2CCCC2)CC1		CHEMBL1965910	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
inactive	9527540	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)Nc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12		CHEMBL1682553	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527541	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(-c2c(-c3ccncc3)nc(NCC(N)Cc3ccccc3)n(C)c2=O)c1		CHEMBL1971430	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527542	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)c1		CHEMBL1983963	=	Ki	nM	1.995	CHEMBL1844	Homo sapiens	pKi		8.7
active	9527543	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)cc1		CHEMBL1997764	=	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
inactive	9527544	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1n[nH]c2ccc(-c3cncc(OCC(CN)Cc4ccccc4)c3)cc12		CHEMBL2000271	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527545	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH]cnc2ccc(Br)cc12		CHEMBL562488	<	Ki	nM	25118.86	CHEMBL1844	Homo sapiens	pKi		4.6
inactive	9527546	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(F)c(F)cc12		CHEMBL1981792	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527547	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NCCc1cccs1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1987535	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527548	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1ccccc1)Nc1ccccc1		CHEMBL354676	<	Ki	nM	63095.73	CHEMBL1844	Homo sapiens	pKi		4.2
inactive	9527549	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Oc1ccc(-c2n[nH]c(Nc3cccc(Cl)c3)c2-c2ccc(O)cc2)cc1		CHEMBL1985092	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527550	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1ccccc1		CHEMBL2004692	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527551	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL1981410	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527552	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Clc1cc(Nc2nc(NC3CC3)c3sccc3n2)ccc1N1CCOCC1		CHEMBL2002586	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527553	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc(-c2cccs2)n2nccc2n1		CHEMBL1987815	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
inactive	9527554	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC1(O)CC(c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn23)C1		CHEMBL1996234	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527555	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1981133	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527556	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)Oc1cc(Nc2nc(NC(C)c3ccc(F)cn3)ncc2Cl)n[nH]1		CHEMBL2007421	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527557	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(C=C2C(=O)ON=C2c2ccc(Br)cc2)cc1OC		CHEMBL1991434	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527558	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)c1cccc2c(S(=O)(=O)N(CCN)c3cncc(-c4ccc5cnccc5c4)c3)cccc12		CHEMBL1967544	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527559	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c(=O)n(C)c1		CHEMBL1973138	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527560	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2		CHEMBL223367	=	Ki	nM	19.95	CHEMBL1844	Homo sapiens	pKi		7.7
active	9527561	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH]c2ccc(Cl)cc2c2ncnn12		CHEMBL1992673	=	Ki	nM	19952.62	CHEMBL1844	Homo sapiens	pKi		4.7
active	9527562	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	=	Ki	nM	39.81	CHEMBL1844	Homo sapiens	pKi		7.4
active	9527563	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cn(-c2ccc(O)cc2Cl)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL340384	=	Ki	nM	398.11	CHEMBL1844	Homo sapiens	pKi		6.4
active	9527564	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)C1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1969151	=	Ki	nM	501.19	CHEMBL1844	Homo sapiens	pKi		6.3
inactive	9527565	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1996587	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527566	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COC(=O)c1c(N)nc2ccccn12		CHEMBL1981492	=	Ki	nM	79432.82	CHEMBL1844	Homo sapiens	pKi		4.1
active	9527567	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(F)ccc21		CHEMBL1993335	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
active	9527568	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)NC1=NNC(=O)C1=Cc1cc2ccccc2[nH]1		CHEMBL1988692	=	Ki	nM	794.33	CHEMBL1844	Homo sapiens	pKi		6.1
inactive	9527569	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1		CHEMBL2007574	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527570	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CS(=O)(=O)NCCOc1cncc(-c2ccc3cnccc3c2)c1		CHEMBL1964804	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527571	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(-c2cnc3c(Br)cnn3c2)cc1		CHEMBL443962	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527572	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(C=C2SC(=Nc3ccccc3)NC2=O)cc1O		CHEMBL2000354	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527573	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1965507	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527574	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527575	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)NCCO)c2)n1		CHEMBL1998680	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527576	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCC(=O)Nc1n[nH]c2nc3ccccc3cc12		CHEMBL1967564	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527577	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL592030	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527578	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	OCCCNc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL2000071	<	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
inactive	9527579	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc2c(NC(=O)Nc3cc(C(F)(F)F)ccn3)ccnc2c1		CHEMBL1979176	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527580	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1970317	=	Ki	nM	1.995	CHEMBL1844	Homo sapiens	pKi		8.7
active	9527581	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4c3c(N)nn4C)cc2)c1		CHEMBL1985491	=	Ki	nM	1.995	CHEMBL1844	Homo sapiens	pKi		8.7
inactive	9527582	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc2c(C)n1		CHEMBL2000408	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527583	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	=	Ki	nM	1.259	CHEMBL1844	Homo sapiens	pKi		8.9
inactive	9527584	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN1CCC(C(=O)n2nc(N)c3cc(-c4cn(Cc5ccccc5)nn4)ccc32)CC1		CHEMBL1978014	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527585	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCNC(=O)c1ccc(Nc2nc(CC)c3cc[nH]c3n2)cc1		CHEMBL1997007	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527586	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cnccn1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1994538	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527587	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1975490	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527588	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1964444	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527589	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1nc2c(O)cccc2s1)Nc1ccccc1-c1ccccc1		CHEMBL2002690	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527590	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccsc2)n1		CHEMBL2006567	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527591	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Clc1csc2ncnc(Nc3ccccc3)c12		CHEMBL1986139	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527592	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ccc(-c2cccn3c(=O)[nH]nc23)cc1		CHEMBL1975503	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
inactive	9527593	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(Cc1cccc2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1985580	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527594	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(Cl)cccc12		CHEMBL1980540	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527595	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	<	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
active	9527596	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN(C)C)cnc(N)c34)cc2)c1		CHEMBL1979883	=	Ki	nM	12.59	CHEMBL1844	Homo sapiens	pKi		7.9
active	9527597	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(C)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1984162	=	Ki	nM	63.1	CHEMBL1844	Homo sapiens	pKi		7.2
active	9527598	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(CN(C)C)cc1Nc1nccc(-c2c(-c3cccc(NC(=O)c4c(F)cccc4F)c3)nc3sccn23)n1		CHEMBL1997051	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
active	9527599	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Fc1cnc(Nc2ccccc2)nc1Nc1ccccc1		CHEMBL491758	=	Ki	nM	79.43	CHEMBL1844	Homo sapiens	pKi		7.1
active	9527600	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1Nc2ccccc2C1=Cc1c[nH]c2ccccc12		CHEMBL1986590	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
inactive	9527601	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C(C)(C)C		CHEMBL1986186	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527602	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1cc2[nH]ncc2cc1-c1cc(CN2CCCCC2)no1		CHEMBL1682360	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527603	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1n[nH]c2c1C(c1ccccc1Cl)C(C#N)=C(N)O2		CHEMBL1970189	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527604	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCC(N)C3)c21		CHEMBL1870106	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527605	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2c1c(I)nn2C1CCC(O)CC1		CHEMBL1996791	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527606	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3c(C)sc4ncnc(N)c34)cc2)c1		CHEMBL371206	=	Ki	nM	158.49	CHEMBL1844	Homo sapiens	pKi		6.8
active	9527607	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(C=NNc2ncnc3c2[nH]c2ccccc23)cc1OC		CHEMBL1974664	=	Ki	nM	10.0	CHEMBL1844	Homo sapiens	pKi		8.0
inactive	9527608	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21		CHEMBL406845	<	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
active	9527609	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	=	Ki	nM	316.23	CHEMBL1844	Homo sapiens	pKi		6.5
active	9527610	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(-c2ccnc3[nH]ccc23)cc1		CHEMBL482538	=	Ki	nM	10000.0	CHEMBL1844	Homo sapiens	pKi		5.0
inactive	9527611	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NC(CO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1974288	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527612	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)c1		CHEMBL196363	=	Ki	nM	1.995	CHEMBL1844	Homo sapiens	pKi		8.7
inactive	9527613	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1nn(C)c2sc(C(N)=O)c(N)c12		CHEMBL1996837	<	Ki	nM	63095.73	CHEMBL1844	Homo sapiens	pKi		4.2
active	9527614	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(-c2cc3nccn3c(Nc3ncccc3C(N)=O)n2)cc1OC		CHEMBL1190711	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
active	9527615	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2cccc(-c3ccc(Br)cc3)c12		CHEMBL1990346	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
inactive	9527616	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC1=CN2CC(=O)NN=C2C=C1		CHEMBL1964718	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
inactive	9527617	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1		CHEMBL1968705	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527618	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1c(F)cccc1F		CHEMBL1991410	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527619	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNCC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1964441	=	Ki	nM	5.012	CHEMBL1844	Homo sapiens	pKi		8.3
active	9527620	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(C(N)=O)n2nc(C(C)(C)C)cc2n1		CHEMBL1986684	=	Ki	nM	3981.07	CHEMBL1844	Homo sapiens	pKi		5.4
active	9527621	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	ON=C(c1nc2ccccc2[nH]1)c1nc2ccccc2[nH]1		CHEMBL546797	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
active	9527622	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL404367	=	Ki	nM	25.12	CHEMBL1844	Homo sapiens	pKi		7.6
inactive	9527623	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)Cc1cc(-c2ccc3[nH]nc(N)c3c2)on1		CHEMBL1966343	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527624	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCOCCO)c2)n1		CHEMBL1978271	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527625	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1n[nH]c2ccc(-c3cncc(OCCN)c3)cc12		CHEMBL1967887	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527626	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc(OCCCn4cccc4)c4[nH]nc(N)c34)cc2)c1		CHEMBL2007266	=	Ki	nM	15.85	CHEMBL1844	Homo sapiens	pKi		7.8
inactive	9527627	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL2000568	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527628	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)cc1C		CHEMBL2000335	=	Ki	nM	125.89	CHEMBL1844	Homo sapiens	pKi		6.9
active	9527629	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nc(=O)[nH]c2sccc12		CHEMBL2007097	=	Ki	nM	39810.72	CHEMBL1844	Homo sapiens	pKi		4.4
inactive	9527630	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527631	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1973516	=	Ki	nM	15.85	CHEMBL1844	Homo sapiens	pKi		7.8
active	9527632	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1cc(-c2cnn3c(N)c(-c4ccc(NC(=O)Nc5cccc(C(F)(F)F)c5)cc4)cnc23)cn1		CHEMBL1988717	=	Ki	nM	6.31	CHEMBL1844	Homo sapiens	pKi		8.2
active	9527633	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1		CHEMBL1974328	=	Ki	nM	1000.0	CHEMBL1844	Homo sapiens	pKi		6.0
active	9527634	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Ki	nM	398.11	CHEMBL1844	Homo sapiens	pKi		6.4
inactive	9527635	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1ccccc1)Nc1ccccn1		CHEMBL143703	<	Ki	nM	63095.73	CHEMBL1844	Homo sapiens	pKi		4.2
inactive	9527636	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1ccc2[nH]ncc2c1)c1ccc(Cl)cc1		CHEMBL1973808	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527637	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2000429	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527638	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)cc1		CHEMBL1972576	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527639	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527640	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1992342	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527641	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(Cl)ccc1NC(=S)NNC(=O)C(O)(c1ccccc1)c1ccccc1		CHEMBL1988173	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527642	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cnc(Nc2nc(NC(C)C)ncc2Br)s1		CHEMBL1973013	=	Ki	nM	501.19	CHEMBL1844	Homo sapiens	pKi		6.3
active	9527643	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	=	Ki	nM	398.11	CHEMBL1844	Homo sapiens	pKi		6.4
inactive	9527644	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#CC1=C(N)n2c(sc(=Cc3ccco3)c2=O)=C(C(N)=O)C1c1ccco1		CHEMBL1989805	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527645	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527646	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)Cn1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL1965423	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527647	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCC(N)(C#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12)CC		CHEMBL1983025	=	Ki	nM	31.62	CHEMBL1844	Homo sapiens	pKi		7.5
active	9527648	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)cc1		CHEMBL1975927	=	Ki	nM	5.012	CHEMBL1844	Homo sapiens	pKi		8.3
inactive	9527649	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1983945	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527650	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1977135	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527651	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1NC(=S)SC1=C1C(=O)Nc2ccc(Br)cc21		CHEMBL2001920	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527652	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc2c(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cncc2s1		CHEMBL2002322	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527653	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)c(F)c3)c12		CHEMBL1980904	=	Ki	nM	3.162	CHEMBL1844	Homo sapiens	pKi		8.5
active	9527654	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(Nc1cncc(-n2cnc3ccc(C#N)cc32)n1)c1ccccc1F		CHEMBL1977138	=	Ki	nM	251.19	CHEMBL1844	Homo sapiens	pKi		6.6
inactive	9527655	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(F)c(-c2ccc3nnc(N)n3c2)c1		CHEMBL2002323	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527656	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(N)=O)n2)cc(OC)c1OC		CHEMBL1241473	=	Ki	nM	12.59	CHEMBL1844	Homo sapiens	pKi		7.9
active	9527657	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(C2CCc3[nH]ncc3C2)cc1		CHEMBL2000879	=	Ki	nM	50118.72	CHEMBL1844	Homo sapiens	pKi		4.3
inactive	9527658	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CS(=O)(=O)N(Cc1ccc2[nH]c(=O)c3cccn3c2c1)C1CC1		CHEMBL1978448	<	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
inactive	9527659	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NCCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1972258	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527660	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COC(=O)c1ccccc1-c1ccc2c(c1)Nc1ccccc1NC2=O		CHEMBL2004513	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
active	9527661	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)c1ccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)cc1NC(=O)Cc1ccccc1		CHEMBL1969483	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
active	9527662	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1Nc2cc(-c3ccc(O)cc3)ccc2C1=Cc1ccc[nH]1		CHEMBL1980329	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
active	9527663	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1nc(-c2ccc3c(c2)OCO3)c2cc[nH]c2n1		CHEMBL2004515	=	Ki	nM	12589.25	CHEMBL1844	Homo sapiens	pKi		4.9
active	9527664	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN(CC)CC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2001257	=	Ki	nM	25.12	CHEMBL1844	Homo sapiens	pKi		7.6
inactive	9527665	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(C2Nc3ccc4ccccc4c3C3C=CCC32)c1)c1ccc(F)cc1		CHEMBL1992042	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527666	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(Cl)cc4Cl)c(=O)c3=O)ccc21		CHEMBL2005548	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527667	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4[nH]nc(N)c34)cc2)c1		CHEMBL271441	=	Ki	nM	0.7943	CHEMBL1844	Homo sapiens	pKi		9.1
inactive	9527668	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)cc1		CHEMBL1992536	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527669	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527670	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(-c2ncc3ccccn23)cc1		CHEMBL1380050	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
inactive	9527671	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN1CCN(CCCC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1		CHEMBL1992740	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527672	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)s2)c1		CHEMBL1994724	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527673	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(-c2csc3c(C=CC(=O)NCCN(C)C)cnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C		CHEMBL1989267	=	Ki	nM	79.43	CHEMBL1844	Homo sapiens	pKi		7.1
inactive	9527674	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	OCCCn1cnc(-c2ccccc2)c1-c1ccncc1		CHEMBL2002373	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527675	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1cccc(Cl)c1		CHEMBL1973348	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527676	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2NCCCN)c1		CHEMBL2006188	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527677	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN(CC)CCNC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1970290	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527678	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1967531	=	Ki	nM	199.53	CHEMBL1844	Homo sapiens	pKi		6.7
inactive	9527679	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCC(=O)Nc1nn(C(=O)CC)c2nc3ccccc3cc12		CHEMBL1970913	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527680	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(C)=O)c3c2)cc1		CHEMBL1973893	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527681	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	6.31	CHEMBL1844	Homo sapiens	pKi		8.2
inactive	9527682	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C(C)NC(=O)c2cc(C)c(-c3ccc4[nH]nc(C)c4c3)s2)c1		CHEMBL1997534	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527683	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	C#Cc1cn(C2CCCC2)c2ncnc(N)c12		CHEMBL1993877	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
inactive	9527684	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)Cn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL1985095	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527685	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1996500	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527686	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(NC(=O)Nc2ccc(-c3ccnc4[nH]nc(N)c34)cc2)ccc1F		CHEMBL273187	=	Ki	nM	0.3162	CHEMBL1844	Homo sapiens	pKi		9.5
inactive	9527687	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COCc1nnn(-c2nonc2N)c1C(=O)NN=C(C)c1ccc(O)cc1O		CHEMBL1991180	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527688	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	=	Ki	nM	31.62	CHEMBL1844	Homo sapiens	pKi		7.5
inactive	9527689	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)cn2c1		CHEMBL1682540	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527690	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12		CHEMBL1976420	=	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
active	9527691	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)c(F)c2)ccc1F		CHEMBL1986979	=	Ki	nM	1.585	CHEMBL1844	Homo sapiens	pKi		8.8
active	9527692	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCCO)c(Cl)cc1NC(=O)N2		CHEMBL413779	=	Ki	nM	25.12	CHEMBL1844	Homo sapiens	pKi		7.6
inactive	9527693	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1		CHEMBL1994864	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527694	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(Cl)ccc12		CHEMBL1981744	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527695	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOCC5CC5)c4)n[nH]c2-3)CC1		CHEMBL2002446	=	Ki	nM	3.162	CHEMBL1844	Homo sapiens	pKi		8.5
inactive	9527696	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1nc(-c2cc3c(Oc4ccc(I)cc4)cncc3s2)[nH]o1		CHEMBL497151	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527697	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccccc1-c1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL2000029	=	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
inactive	9527698	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(N2CCN(C)CC2)ccc1C(=O)Nc1n[nH]c2ccc(Cc3cc(F)cc(F)c3)cc12		CHEMBL1973961	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527699	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1		CHEMBL246970	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527700	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(O)ccc1-n1cc(C(N)=O)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL340921	=	Ki	nM	1000.0	CHEMBL1844	Homo sapiens	pKi		6.0
inactive	9527701	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCCCO)c2)n1		CHEMBL1994977	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527702	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCCCO)c(Cl)cc1NC(=O)N2		CHEMBL373598	=	Ki	nM	39.81	CHEMBL1844	Homo sapiens	pKi		7.4
inactive	9527703	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1ccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)nc1		CHEMBL1999718	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527704	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOc1ccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)cc1NC(=O)Cc1ccccc1		CHEMBL2000078	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
active	9527705	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1Nc2ccc3ncsc3c2C1=CNc1ccc(S(=O)(=O)Nc2ccccn2)cc1		CHEMBL1973540	=	Ki	nM	251.19	CHEMBL1844	Homo sapiens	pKi		6.6
active	9527706	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc2c(c1)c(-c1cc3nc(Br)cnc3[nH]1)cn2C		CHEMBL2005478	=	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
active	9527707	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(OC)c1CNc1nc(NC2CCCCC2)nc2ccc(Cl)cc12		CHEMBL1996646	=	Ki	nM	316.23	CHEMBL1844	Homo sapiens	pKi		6.5
inactive	9527708	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(CCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1979773	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527709	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1Nc2ccccc2Nc2nnc(I)cc21		CHEMBL1977346	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527710	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2003657	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527711	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL1971649	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527712	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(-c2cccc3nccn23)cc1		CHEMBL1992723	=	Ki	nM	79432.82	CHEMBL1844	Homo sapiens	pKi		4.1
active	9527713	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Cc1ccccc1)Nc1cc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)ccc1Cl		CHEMBL2005482	=	Ki	nM	158.49	CHEMBL1844	Homo sapiens	pKi		6.8
inactive	9527714	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCCN(C)C)cc2NC3=O)ccc1O		CHEMBL1996702	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527715	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527716	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccccc1Nc1nccc(-c2c(-c3cccc(NC(=O)Cc4ccccc4)c3)nc3sccn23)n1		CHEMBL1997909	=	Ki	nM	79.43	CHEMBL1844	Homo sapiens	pKi		7.1
inactive	9527717	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1ccc(-c2ccc(=O)[nH]n2)cc1)Nc1cccc(C(F)(F)F)c1		CHEMBL2007124	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527718	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCCCC2)n1		CHEMBL2006439	<	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
active	9527719	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1ccc2c(c1)C(c1ccc3c(n1)CCCC3O)C(=O)N2		CHEMBL1985681	=	Ki	nM	125.89	CHEMBL1844	Homo sapiens	pKi		6.9
inactive	9527720	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(-c2ccc(NC(=O)Nc3cc(F)cc(F)c3)cc2)c2c(N)noc12		CHEMBL1969190	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527721	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)n[nH]c12		CHEMBL1973937	=	Ki	nM	15.85	CHEMBL1844	Homo sapiens	pKi		7.8
inactive	9527722	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	<	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
inactive	9527723	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL2002099	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527724	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1991674	=	Ki	nM	199.53	CHEMBL1844	Homo sapiens	pKi		6.7
inactive	9527725	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1		CHEMBL1982711	<	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
inactive	9527726	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2c1N=C(c1ccccc1)CCN2		CHEMBL262623	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
inactive	9527727	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1984842	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527728	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1		CHEMBL1969102	=	Ki	nM	2.512	CHEMBL1844	Homo sapiens	pKi		8.6
active	9527729	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12		CHEMBL2004118	=	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
inactive	9527730	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1682346	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527731	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN(CC)CC#Cc1ccc2c(c1)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL2007044	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527732	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNC(=O)N1CCN(CCCOc2ccc3c(c2)-c2[nH]nc(-c4ccc(C#N)nc4)c2C3)CC1		CHEMBL2001998	=	Ki	nM	398.11	CHEMBL1844	Homo sapiens	pKi		6.4
active	9527733	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(C=C(C#N)c2nc3ccccc3[nH]2)c(Br)cc1O		CHEMBL1994241	=	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
active	9527734	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2		CHEMBL223460	=	Ki	nM	15.85	CHEMBL1844	Homo sapiens	pKi		7.8
inactive	9527735	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1ccc(Cl)cc1		CHEMBL1998829	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527736	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Ki	nM	1000.0	CHEMBL1844	Homo sapiens	pKi		6.0
inactive	9527737	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1995211	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527738	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc(OCC(N)=O)cc1		CHEMBL1988838	=	Ki	nM	316.23	CHEMBL1844	Homo sapiens	pKi		6.5
active	9527739	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN1CCN(c2ccc(Nc3nccc(-c4c(-c5cccc(C(=O)Nc6ccccc6F)c5)nc5ccccn45)n3)cc2)CC1		CHEMBL1981725	=	Ki	nM	31.62	CHEMBL1844	Homo sapiens	pKi		7.5
inactive	9527740	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1ccc(NC2CCCCC2N)nc1Nc1cccc(Cl)c1		CHEMBL1982753	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527741	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]ncc34)cc2)c1		CHEMBL375284	=	Ki	nM	2.512	CHEMBL1844	Homo sapiens	pKi		8.6
inactive	9527742	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2006299	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527743	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Oc1cc(O)cc(C=Cc2ccc(O)c(O)c2)c1		CHEMBL1972346	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527744	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(-c2cc3nc(Br)cnc3[nH]2)cc1		CHEMBL1965169	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527745	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Ki	nM	398.11	CHEMBL1844	Homo sapiens	pKi		6.4
active	9527746	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(O)CO)c5)cnc(N)c34)cc2)cc1		CHEMBL1965170	=	Ki	nM	3.981	CHEMBL1844	Homo sapiens	pKi		8.4
inactive	9527747	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COCCn1cc(-c2ccncn2)c(-c2ccc(Cl)cc2)n1		CHEMBL1982866	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527748	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1cnn2c(-c3ccccc3)ccnc12		CHEMBL1393571	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
inactive	9527749	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2005792	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9527750	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(CSc2nc(-c3ccncc3)n[nH]2)cc1		CHEMBL1968926	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9527751	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCNC(=O)c1n[nH]c(-c2cc(Cl)c(O)cc2O)c1-c1ccc(OC)cc1		CHEMBL365617	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
active	9527752	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOc1nc(C(=O)NCc2ccncc2)cc(N)c1C#N		CHEMBL1984206	=	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
active	9527753	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1c(-c2ccccc2)c2cc(Cl)ccc2[nH]c1=O		CHEMBL462120	=	Ki	nM	199.53	CHEMBL1844	Homo sapiens	pKi		6.7
inactive	9531654	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C1CCCCC1		CHEMBL1991577	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531655	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2nc(Cl)sc12		CHEMBL1991867	<	Ki	nM	63095.73	CHEMBL1844	Homo sapiens	pKi		4.2
inactive	9531656	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccccc4)nn12)CCCC3		CHEMBL2007592	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531657	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4ccccc4F)cc3)c12		CHEMBL1965570	=	Ki	nM	199.53	CHEMBL1844	Homo sapiens	pKi		6.7
active	9531658	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1c(-c2nc3ccccc3[nH]2)c(O)cc2oc(C)cc(=O)c12		CHEMBL1972355	=	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
inactive	9531659	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)c(Cl)c1		CHEMBL1997892	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531660	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(O)c1cn(-c2ccc3[nH]ncc3c2)nn1		CHEMBL2001641	=	Ki	nM	39810.72	CHEMBL1844	Homo sapiens	pKi		4.4
active	9531661	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(-c2cc(-c3cc(Br)ccc3O)[nH]c(=O)c2C#N)s1		CHEMBL1997193	=	Ki	nM	398.11	CHEMBL1844	Homo sapiens	pKi		6.4
inactive	9531662	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531663	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)O)c2)n1		CHEMBL1964902	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531664	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cncc2cccc(S(=O)(=O)N3CCCNCC3C)c12		CHEMBL1082440	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531665	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(CO)N1CCC(c2[nH]nc(-c3ccc(Cl)cc3F)c2-c2ccncn2)CC1		CHEMBL1614705	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531666	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CS(=O)(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1		CHEMBL1972362	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531667	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)s2)c1		CHEMBL1984633	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531668	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531669	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C(C)NC(=O)N2CC=C(c3c[nH]c4ncccc34)CC2)c1		CHEMBL1965845	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531670	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2007372	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531671	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)n2)s1		CHEMBL1983715	=	Ki	nM	25.12	CHEMBL1844	Homo sapiens	pKi		7.6
inactive	9531672	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL1971017	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531673	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1)c1c(F)cccc1F		CHEMBL2006715	=	Ki	nM	794.33	CHEMBL1844	Homo sapiens	pKi		6.1
active	9531674	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cccc2[nH]c(-c3ccc(NC(=O)c4cccc(S(=O)(=O)N5CCOCC5)c4)cc3)nc12		CHEMBL1986597	=	Ki	nM	1000.0	CHEMBL1844	Homo sapiens	pKi		6.0
inactive	9531675	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cccc2[nH]c(-c3ccncc3)nc12		CHEMBL1990482	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531676	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Fc1ccc(-c2nc3cnccn3c2-c2ccnc(NCC3CC3)n2)cc1		CHEMBL1990904	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531677	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCS(=O)(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1		CHEMBL2000104	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531678	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NCC1CCCCC1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL2005475	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531679	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531680	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	=	Ki	nM	1.0	CHEMBL1844	Homo sapiens	pKi		9.0
inactive	9531681	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2C)c1		CHEMBL183844	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531682	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL220057	=	Ki	nM	3.981	CHEMBL1844	Homo sapiens	pKi		8.4
inactive	9531683	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(Nc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682545	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531684	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1974935	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531685	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(OC2CCCC2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL2001224	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531686	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531687	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(O)Cc1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1976732	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531688	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(S(N)(=O)=O)cc4)c(=O)c3=O)ccc21		CHEMBL1969506	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531689	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)Cc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12		CHEMBL1980763	=	Ki	nM	501.19	CHEMBL1844	Homo sapiens	pKi		6.3
inactive	9531690	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NC(CO)c1ccccc1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1964937	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531691	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1		CHEMBL1980163	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531692	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL590109	=	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531693	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)c1ccccc1-c1ncnc2[nH]ccc12		CHEMBL1977931	=	Ki	nM	63095.73	CHEMBL1844	Homo sapiens	pKi		4.2
active	9531694	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(-c2nn(C3CCC(N4CCN(C(C)=O)CC4)CC3)c3ncnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C		CHEMBL1970879	=	Ki	nM	794.33	CHEMBL1844	Homo sapiens	pKi		6.1
inactive	9531695	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1c(C=O)c(O)n2c(nc3ccccc32)c1C#N		CHEMBL1989856	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531696	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)N(c1ccncc1)c1c(NC(C)C(C)(C)C)c(=O)c1=O		CHEMBL2005899	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531697	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)c(NC3CCCCC3)n2c1		CHEMBL1682552	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531698	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531699	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCCNc1nc(N)c(C(=O)c2ccccc2)s1		CHEMBL2007479	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531700	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(Cl)c4)c3)cc12		CHEMBL1974870	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531701	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(C)c(C=C2C(=O)Nc3ccccc32)[nH]1		CHEMBL2002702	=	Ki	nM	19.95	CHEMBL1844	Homo sapiens	pKi		7.7
inactive	9531702	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCc1cc(-c2ccc3[nH]ncc3c2)on1		CHEMBL1682359	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531703	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4ccc(OC(F)F)cc4)cc3)c12		CHEMBL1972220	=	Ki	nM	10.0	CHEMBL1844	Homo sapiens	pKi		8.0
inactive	9531704	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL1970903	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531705	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1ccccc1		CHEMBL1991846	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531706	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cnn2c(-c3ccccc3)ccnc12		CHEMBL1972583	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
active	9531707	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Fc1cccc(CNc2ncnc3[nH]cnc23)c1		CHEMBL2003785	=	Ki	nM	31622.78	CHEMBL1844	Homo sapiens	pKi		4.5
active	9531708	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	=	Ki	nM	125.89	CHEMBL1844	Homo sapiens	pKi		6.9
active	9531709	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)c1		CHEMBL1969523	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
inactive	9531710	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(C=O)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL207995	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531711	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1Nc2cc(CCOc3ccc(N4CCOCC4)cc3)ccc2Nc2cc(-c3cn(Cc4cc(F)c(F)c(F)c4)c4cnccc34)ccc21		CHEMBL2001923	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531712	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)N1CCC(Nc2nccc(-c3c(-c4ccc(F)cc4)nc4occn34)n2)CC1		CHEMBL1986781	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531713	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOc1ccccc1-c1cccc(-c2n[nH]c3nc(O)cc(C)c23)c1		CHEMBL1983070	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531714	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1nc(-c2ccc3[nH]ncc3c2)cc(-c2ccccc2)[nH]1		CHEMBL526133	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531715	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)nc2)c1		CHEMBL2003514	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531716	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531717	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4ccc(F)c(C(F)(F)F)c4)cc3)ccnc21		CHEMBL1966836	=	Ki	nM	3.981	CHEMBL1844	Homo sapiens	pKi		8.4
inactive	9531718	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21		CHEMBL1230122	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531719	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN1CCN(c2ccc(Nc3nc(N)c(C(=O)c4c(Cl)cccc4Cl)s3)cc2)CC1		CHEMBL1989043	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531720	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	<	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
inactive	9531721	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1nn(C)c2sc3c(=O)[nH]cnc3c12		CHEMBL1967538	<	Ki	nM	63095.73	CHEMBL1844	Homo sapiens	pKi		4.2
inactive	9531722	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3[nH]2)cc1		CHEMBL1979057	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531723	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(-c2ccc3c(c2)Nc2ccc(CCOc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1OCC(O)CO		CHEMBL1981045	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531724	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COCCOCC#Cc1cc(-c2n[nH]c3c2C(=O)c2cc(CN4CCN(C)CC4)ccc2-3)cs1		CHEMBL387971	=	Ki	nM	15.85	CHEMBL1844	Homo sapiens	pKi		7.8
inactive	9531725	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(Cn2nnc(-c3ccc4[nH]ncc4c3)c2C2CC2)cc1		CHEMBL1975418	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531726	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH]c2ccc(Cl)cc2c(-c2ccccc2)c1C1=NNC(c2ccccc2)C1		CHEMBL1992796	=	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531727	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1CN2C(=NN1)COc1ccccc12		CHEMBL1968515	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
active	9531728	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	=	Ki	nM	316.23	CHEMBL1844	Homo sapiens	pKi		6.5
inactive	9531729	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531730	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCC(O)CO)c(Cl)cc1NC(=O)N2		CHEMBL223257	=	Ki	nM	100.0	CHEMBL1844	Homo sapiens	pKi		7.0
active	9531731	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1999428	=	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531732	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1967560	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531733	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531734	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3noc4ncnc(N)c34)cc2)c1		CHEMBL211378	=	Ki	nM	15.85	CHEMBL1844	Homo sapiens	pKi		7.8
active	9531735	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1982465	=	Ki	nM	7.943	CHEMBL1844	Homo sapiens	pKi		8.1
inactive	9531736	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccco2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL2001751	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531737	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NCCCCCCNC(=O)NCc1cccnc1)NCc1cccnc1		CHEMBL2003420	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531738	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccccc1NC(=O)Nc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL1984586	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531739	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1c(Cl)c(N2CCC(CN)C2)nc2[nH]cc(C(=O)O)c(=O)c12		CHEMBL1999774	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531740	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3cncc4[nH]nc(N)c34)cc2)c1		CHEMBL272938	=	Ki	nM	0.631	CHEMBL1844	Homo sapiens	pKi		9.2
inactive	9531741	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1c(O)ccc2c1CCCC2=NNC(=O)Cc1cccc2ccccc12		CHEMBL1972659	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531742	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)Nc1ccc(-n2nc3ccc(N)nc3n2)cc1		CHEMBL2002723	=	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
inactive	9531743	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	OC1CCN(c2ncnc3[nH]cc(-c4ccccc4)c23)CC1		CHEMBL1973395	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531744	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(NC(=O)Nc2ccc(-c3cccc4onc(N)c34)cc2)cc1Cl		CHEMBL272453	=	Ki	nM	158.49	CHEMBL1844	Homo sapiens	pKi		6.8
inactive	9531745	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nnc2ccc(-c3ccccc3)cn12		CHEMBL1987143	<	Ki	nM	25118.86	CHEMBL1844	Homo sapiens	pKi		4.6
inactive	9531746	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3C)cc2)c1		CHEMBL1970217	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531747	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1Nc2ccccc2Nc2nnccc21		CHEMBL1971801	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531748	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1Nc2ccccc2Nc2nnc(Cl)cc21		CHEMBL1968850	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531749	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOC(=O)c1ccc2[nH]c3c(c2c1)CCNC3=O		CHEMBL2005528	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531750	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	=	Ki	nM	125.89	CHEMBL1844	Homo sapiens	pKi		6.9
inactive	9531751	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Brc1ccc2cnc(Nc3ccncn3)cc2c1		CHEMBL1984686	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531752	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)c1		CHEMBL185569	=	Ki	nM	63.1	CHEMBL1844	Homo sapiens	pKi		7.2
inactive	9531753	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1cc2[nH]ncc2cc1-c1cn(CC2CCOCC2)nn1		CHEMBL1969843	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531754	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(-c2ccc3[nH]nc(C(=O)Nc4ccccc4)c3c2)ccc1O		CHEMBL2007002	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531755	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN1CCC(NC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)CC1		CHEMBL1987007	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531756	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531757	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=S(=O)(Nc1ccc2c(c1)C(=NO)c1ccccc1-2)c1cccc(Br)c1		CHEMBL1973793	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531758	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Clc1cc(-c2c[nH]c3ncccc23)cc(NCc2ccccc2)n1		CHEMBL1969588	=	Ki	nM	158.49	CHEMBL1844	Homo sapiens	pKi		6.8
active	9531759	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(Nc2nccc(Nc3cc(C4CCCCC4)no3)n2)cc(OC)c1OC		CHEMBL1984711	=	Ki	nM	25.12	CHEMBL1844	Homo sapiens	pKi		7.6
active	9531760	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1		CHEMBL1967878	=	Ki	nM	125.89	CHEMBL1844	Homo sapiens	pKi		6.9
active	9531761	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCC1CC(NS(=O)(=O)C2CC2)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1992073	=	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
inactive	9531762	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL484390	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531763	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531764	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1c(NCc2cccc(C(F)(F)F)c2)c(Nc2ccncc2)c1=O		CHEMBL1979252	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531765	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NC(CCO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1986143	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531766	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2sccc12		CHEMBL1972934	=	Ki	nM	12589.25	CHEMBL1844	Homo sapiens	pKi		4.9
inactive	9531767	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3sccc3n2)cc1		CHEMBL2007559	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531768	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Cc1ccc(-c2cccnc2)cc1)Nc1ccc(SC(F)F)cc1		CHEMBL1992581	=	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
inactive	9531769	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(Cc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682341	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531770	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		CHEMBL2004290	=	Ki	nM	6.31	CHEMBL1844	Homo sapiens	pKi		8.2
active	9531771	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccc(F)cc3)cc12		CHEMBL1986499	=	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531772	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C=C2SC(=Nc3ccccc3)NC2=O)c1		CHEMBL1972937	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531773	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	C#Cc1cc2c(cc1OC)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL1972250	=	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531774	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1C1CCOc2c(F)cccc21		CHEMBL2000393	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531775	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2nccc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL403402	=	Ki	nM	1.585	CHEMBL1844	Homo sapiens	pKi		8.8
active	9531776	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cccc2[nH]c(-c3ccc(C4CCCCN4)cc3F)nc12		CHEMBL1089101	=	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
active	9531777	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	C=Cc1ccc(-c2cccc3nnc(N)n23)cc1		CHEMBL1983573	=	Ki	nM	6309.57	CHEMBL1844	Homo sapiens	pKi		5.2
active	9531778	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C)c2)c1		CHEMBL2004311	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
inactive	9531779	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Brc1cnc2[nH]cc(-c3ccccc3)c2c1		CHEMBL1992634	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531780	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1242373	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531781	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)OCCn1nc(-c2cccc(Br)c2)c2c(C(F)(F)F)cc(=O)[nH]c21		CHEMBL1984847	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531782	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)c1c(-c2ccccc2)nn(C)c(=O)c1N		CHEMBL1984402	=	Ki	nM	79432.82	CHEMBL1844	Homo sapiens	pKi		4.1
inactive	9531783	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Fc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL316264	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531784	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1988075	=	Ki	nM	10.0	CHEMBL1844	Homo sapiens	pKi		8.0
inactive	9531785	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Cc1ccc(OC(F)(F)F)cc1)N1CCC2(CC1)NCCc1c2[nH]c2ccccc12		CHEMBL1996576	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531786	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccccc1Nc1nccc(-c2c(-c3cccc(NC(=O)c4ccccc4)c3)nc3sccn23)n1		CHEMBL1988076	=	Ki	nM	125.89	CHEMBL1844	Homo sapiens	pKi		6.9
inactive	9531787	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1991678	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531788	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc(Nc2cc(CNC(=O)C(F)(F)F)c(O)c(-c3ccc(Cl)cc3)c2)n1		CHEMBL2001239	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531789	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2scc(C(=O)Nc3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1988594	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531790	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2c1c(I)nn2C1OC(CO)C(O)C1O		CHEMBL2001288	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531791	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL260092	=	Ki	nM	199.53	CHEMBL1844	Homo sapiens	pKi		6.7
inactive	9531792	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	<	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
inactive	9531793	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NN=Cc1ccc(O)cc1O)Nc1cccc2nsnc12		CHEMBL1999811	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531794	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1n[nH]c2ncc(C#N)c(-c3ccccc3)c12		CHEMBL1965495	=	Ki	nM	63.1	CHEMBL1844	Homo sapiens	pKi		7.2
inactive	9531795	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc2ncc3c(N)nc4c(C)c(N)ccc4c3c2cc1OC		CHEMBL235157	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531796	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CSc1ccc2nc3c(c(Cl)c2c1)CCNC3=O		CHEMBL1985074	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531797	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL2000481	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531798	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc2n1CC1CC1		CHEMBL1982874	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531799	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)CC(=O)NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1991725	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531800	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4sncc34)cc2)c1		CHEMBL1992242	=	Ki	nM	63.1	CHEMBL1844	Homo sapiens	pKi		7.2
inactive	9531801	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531802	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2007296	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531803	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL208637	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531804	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(CNC(=O)c2cnc(-c3ccncc3)nc2)c1		CHEMBL2004159	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531805	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ncc3c2)n1		CHEMBL396523	=	Ki	nM	501.19	CHEMBL1844	Homo sapiens	pKi		6.3
inactive	9531806	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#CC1=C(c2ccccc2)CC(c2ccc(Cl)cc2)C(C(=O)c2ccccc2)C1=O		CHEMBL1978371	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531807	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(C)cc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1970203	=	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
inactive	9531808	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(c1cc(Cc2n[nH]c(=O)c3c2CCCC3)ccc1F)N1CCN(c2ncccn2)CC1		CHEMBL1986530	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531809	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531810	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1c(NCCc2ccc(Oc3ccccc3)cc2)c(Nc2ccncc2)c1=O		CHEMBL1999321	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531811	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4sc(C)nc4c3)csc12		CHEMBL1968590	=	Ki	nM	3.981	CHEMBL1844	Homo sapiens	pKi		8.4
active	9531812	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1cnc2[nH]cc(-c3ccnc(NC4CCCCC4)n3)c2c1		CHEMBL385478	=	Ki	nM	100.0	CHEMBL1844	Homo sapiens	pKi		7.0
inactive	9531813	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(Nc2ncnc3ccc(-c4ccc(CN5CC6C(CO)C6C5)cc4)cc23)ccc1Oc1ccccc1		CHEMBL1999749	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531814	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCCCC4)cc3OC)nc2N1C1CCCC1		CHEMBL2005375	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531815	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Clc1ccc(-c2n[nH]cc2-c2ccncn2)cc1Cl		CHEMBL1984191	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531816	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(C(=O)O)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1983006	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531817	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Br		CHEMBL1971029	=	Ki	nM	158.49	CHEMBL1844	Homo sapiens	pKi		6.8
active	9531818	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL394790	=	Ki	nM	1000.0	CHEMBL1844	Homo sapiens	pKi		6.0
inactive	9531819	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1NCCc2[nH]c(-c3ccnc(-c4ccccc4F)c3)cc21		CHEMBL226471	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531820	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1nc2c(sc3c(Br)ccc(Cl)c32)c(=O)o1		CHEMBL1974702	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531821	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1996111	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531822	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC1CCN(C(=O)CC#N)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1966175	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531823	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1nccn2c(-c3ccnc(NCC4(O)CC4)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1965589	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531824	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC#Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL2007375	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531825	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NCCCCCCNC(=O)Nc1cccnc1)Nc1cccnc1		CHEMBL1998193	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531826	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1[nH]c3ccc(O)cc3c21		CHEMBL379975	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531827	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(NC(=O)Nc2ccc(-c3ccnc4[nH]nc(N)c34)cc2)ccc1F		CHEMBL273187	=	Ki	nM	0.3162	CHEMBL1844	Homo sapiens	pKi		9.5
active	9531828	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)O)s3)c2cc1OC		CHEMBL474432	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
active	9531829	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2c(OCCCn3cccc3)ccc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL1965387	=	Ki	nM	31.62	CHEMBL1844	Homo sapiens	pKi		7.5
inactive	9531830	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1cc2c(s1)CCc1cn[nH]c1-2		CHEMBL2001539	<	Ki	nM	39810.72	CHEMBL1844	Homo sapiens	pKi		4.4
active	9531831	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(-c2ncnc3[nH]ccc23)ccc1F		CHEMBL1997041	=	Ki	nM	3162.28	CHEMBL1844	Homo sapiens	pKi		5.5
inactive	9531832	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1nnc(-c2cc3c(Oc4ccc(C(F)(F)F)cc4)cncc3s2)o1		CHEMBL1988153	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531833	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(-c2ccc3c(c2)Nc2c(O)cccc2NC3=O)ccc1O		CHEMBL550418	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531834	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
inactive	9531835	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1		CHEMBL1969664	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531836	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOc1ccc(C=C2SC(=N)NC2=O)c(O)c1		CHEMBL1971289	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531837	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc2c(-c3ccccc3)cncc2s1		CHEMBL1999556	=	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531838	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1		CHEMBL1988437	=	Ki	nM	79.43	CHEMBL1844	Homo sapiens	pKi		7.1
inactive	9531839	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(COc1cc(C=Cc2ccncc2)cnc1Cl)Cc1c[nH]c2ccccc12		CHEMBL1968245	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531840	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CC(C)(C)N)cnc(N)c34)cc2)c1		CHEMBL1979577	=	Ki	nM	7.943	CHEMBL1844	Homo sapiens	pKi		8.1
inactive	9531841	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NCCC(C(=O)Nc1ccc2[nH]ncc2c1)c1ccc(Cl)c(Cl)c1		CHEMBL1998121	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531842	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc2c(c1)c(-c1cc3nccnc3[nH]1)cn2C		CHEMBL1233887	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531843	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2c1C(=O)NCCN2		CHEMBL1992607	=	Ki	nM	79432.82	CHEMBL1844	Homo sapiens	pKi		4.1
inactive	9531844	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CC4CC4)nccn23)n1		CHEMBL1991800	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531845	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCC(CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL52387	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531846	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1nn(-c2ccccc2)c2c1c(=O)c1cc(Cl)ccc1n2O		CHEMBL379835	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531847	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1cc(C(CN)c2cncc(C=Cc3ccncc3)c2)c2ccccc21		CHEMBL1979357	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531848	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1ncc2nc1OCC(O)C(O)COc1ccc(Cl)cc1NC(=O)N2		CHEMBL1980802	=	Ki	nM	158.49	CHEMBL1844	Homo sapiens	pKi		6.8
active	9531849	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1996649	=	Ki	nM	2.512	CHEMBL1844	Homo sapiens	pKi		8.6
active	9531850	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCCOc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1996817	=	Ki	nM	316.23	CHEMBL1844	Homo sapiens	pKi		6.5
inactive	9531851	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1c(NCc2ccc(Cl)cc2Cl)c(Nc2ccc3[nH]ncc3c2)c1=O		CHEMBL1979554	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531852	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1986756	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531853	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4onc(N)c34)cc2)c1		CHEMBL409349	=	Ki	nM	3.981	CHEMBL1844	Homo sapiens	pKi		8.4
active	9531854	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOc1nc(C(=O)NCc2ccc(S(N)(=O)=O)cc2)cc(N)c1C#N		CHEMBL2004355	=	Ki	nM	199.53	CHEMBL1844	Homo sapiens	pKi		6.7
inactive	9531855	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	<	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
inactive	9531856	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCn1c2cc(Cl)c(F)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL468280	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531857	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(C)c2oc(Nc3ccc(-c4cccc(C(N)=O)c4N)cc3F)nc2c1		CHEMBL1990884	=	Ki	nM	398.11	CHEMBL1844	Homo sapiens	pKi		6.4
active	9531858	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C		CHEMBL1990885	=	Ki	nM	2.512	CHEMBL1844	Homo sapiens	pKi		8.6
inactive	9531859	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL256835	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531860	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1980142	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531861	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL41783	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531862	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccc2nccnc12		CHEMBL2004438	=	Ki	nM	25.12	CHEMBL1844	Homo sapiens	pKi		7.6
inactive	9531863	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc2c1Nc1cc(Nc3ccncc3)ccc1C(=O)N2		CHEMBL2006276	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531864	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
active	9531865	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)noc12		CHEMBL271381	=	Ki	nM	79.43	CHEMBL1844	Homo sapiens	pKi		7.1
inactive	9531866	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(C(=O)Nc2c(C#N)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL2006785	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531867	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1982466	=	Ki	nM	7.943	CHEMBL1844	Homo sapiens	pKi		8.1
active	9531868	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1ccc2nc(-c3ccc([N+](=O)[O-])o3)cn2c1		CHEMBL1973359	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
active	9531869	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)c(F)c2)c1		CHEMBL1994638	=	Ki	nM	1.585	CHEMBL1844	Homo sapiens	pKi		8.8
inactive	9531870	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(-c2ccc3c(c2)Nc2ccc([N+](=O)[O-])cc2NC3=O)ccc1O		CHEMBL1995740	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531871	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)ccnc21		CHEMBL1985888	=	Ki	nM	2.512	CHEMBL1844	Homo sapiens	pKi		8.6
inactive	9531872	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(O)c1cc2c(-c3ccccc3)cncc2s1		CHEMBL1996390	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531873	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	199.53	CHEMBL1844	Homo sapiens	pKi		6.7
active	9531874	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1979690	=	Ki	nM	15.85	CHEMBL1844	Homo sapiens	pKi		7.8
inactive	9531875	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL234085	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531876	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1995832	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531877	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Oc1ccc(Nc2[nH]nc(-c3ccc(O)cc3)c2-c2ccc(O)cc2)cc1		CHEMBL1969042	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531878	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(C=C(C#N)c2nc3cc(C)ccc3[nH]2)c(Br)cc1O		CHEMBL2000345	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
inactive	9531879	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccccc1		CHEMBL1999931	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531880	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncnc2c1c(-c1ccc(Oc3ccc(CO)cc3)cc1)cn2C1CCOC1		CHEMBL1976376	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531881	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH]sc2c1c(=O)c1cc(F)c(NCc3ccccc3)c(F)c1n2C1CC1		CHEMBL1991640	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531882	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	C(=Cc1ccc2nccn2n1)c1ccccc1		CHEMBL1988622	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
active	9531883	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NN=Cc1cc(Br)c(O)c(Br)c1)Nc1ccccc1		CHEMBL1983575	=	Ki	nM	31.62	CHEMBL1844	Homo sapiens	pKi		7.5
inactive	9531884	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1cccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)n1		CHEMBL1968868	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531885	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(CNc2ccc3nnc(-c4ccccc4)n3n2)cc1		CHEMBL1375418	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531886	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
active	9531887	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1[nH]c(C=C2C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL2007064	=	Ki	nM	100.0	CHEMBL1844	Homo sapiens	pKi		7.0
active	9531888	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COC(C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL1981047	=	Ki	nM	158.49	CHEMBL1844	Homo sapiens	pKi		6.8
inactive	9531889	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccc(Cl)c(Cl)c4)c3)cc12		CHEMBL1991063	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531890	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1ccc([N+](=O)[O-])cc1)N1CCc2[nH]c3c(Cl)cc(Cl)cc3c2C1		CHEMBL1976196	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531891	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)Nc1nccc(Nc2ncc(-c3ccccc3)s2)n1		CHEMBL2002432	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
inactive	9531892	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C(CN)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1976240	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9531893	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccccc1CNC(=N)Nc1nccc(-c2cccs2)n1		CHEMBL1997197	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531894	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1Cc2cc(-c3ccccc3)cnc2N1		CHEMBL1983630	=	Ki	nM	63095.73	CHEMBL1844	Homo sapiens	pKi		4.2
inactive	9531895	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH]c2sccc2c2nc(-c3ccncc3)nn12		CHEMBL1968151	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9531896	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(-c2ccc(NC(=O)Nc3ccc(F)c(C)c3)cc2)c2c(N)noc12		CHEMBL1979093	=	Ki	nM	501.19	CHEMBL1844	Homo sapiens	pKi		6.3
inactive	9535798	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Clc1ccc(CNc2ccc3nnc(-c4ccccc4)n3n2)cc1		CHEMBL1381197	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535799	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1NCc2ccc(-c3ccccc3)cc21		CHEMBL1973795	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
inactive	9535800	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)c1		CHEMBL1987009	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535801	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccccc4)c3)cc12		CHEMBL2002726	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535802	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cnccn1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL2003817	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535803	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ncccc2N1		CHEMBL336961	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535804	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nnc(-c2cc3c(Oc4ccc(Cl)cc4)cncc3s2)o1		CHEMBL1994830	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535805	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(Cl)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1987054	=	Ki	nM	100.0	CHEMBL1844	Homo sapiens	pKi		7.0
active	9535806	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncc(-c2ccncc2)c2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1970083	=	Ki	nM	19.95	CHEMBL1844	Homo sapiens	pKi		7.7
inactive	9535807	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1NCCc2[nH]c(-c3ccnc(-c4cnc5ccccc5c4)c3)cc21		CHEMBL226403	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535808	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cc(C)ccc4F)cc3)csc12		CHEMBL2005631	=	Ki	nM	3.162	CHEMBL1844	Homo sapiens	pKi		8.5
active	9535809	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncc(C=CC(=O)NCCCn2ccnc2)c2scc(-c3ccc(Br)cc3)c12		CHEMBL1994938	=	Ki	nM	50.12	CHEMBL1844	Homo sapiens	pKi		7.3
inactive	9535810	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535811	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1977223	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535812	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1cc(=O)[nH]n1-c1ccccn1		CHEMBL1995765	=	Ki	nM	15848.93	CHEMBL1844	Homo sapiens	pKi		4.8
inactive	9535813	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(-c2ccc3c(c2)CNC3=O)ccc1F		CHEMBL1976290	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
inactive	9535814	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NCCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL1966279	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535815	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)C(=O)Oc1ccc2c(c1)nc(NC(=O)c1cccc([N+](=O)[O-])c1)n2CCCO		CHEMBL1236126	=	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
inactive	9535816	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Clc1cc(NC2CCCCC2)nc(-c2c[nH]c3ncccc23)n1		CHEMBL1997846	<	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
active	9535817	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCNC(=O)c1ccc(Nc2nc(CCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL1984760	=	Ki	nM	1000.0	CHEMBL1844	Homo sapiens	pKi		6.0
inactive	9535818	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)Cn1c(N)nc2c(F)cc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2004419	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535819	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(=NNC(=N)N)c1cc(NC(=O)NCCCCCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL1991728	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535820	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)CC1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL360847	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535821	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cc(F)ccc1F		CHEMBL1995811	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535822	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cc2c(-c3ccc(F)cc3F)cncc2s1		CHEMBL1975787	=	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
inactive	9535823	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNC(=O)c1cc(-c2ccccc2)[nH]n1		CHEMBL1995916	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
inactive	9535824	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(C=C(C#N)c2n[nH]c(N)c2C#N)ccc1O		CHEMBL2002407	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535825	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1ccc2cn[nH]c2c1)c1ccc(Cl)cc1		CHEMBL1972489	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535826	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Brc1ccc2[nH]nc(-c3ccccc3)c2c1		CHEMBL1994074	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
active	9535827	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1		CHEMBL1992937	=	Ki	nM	794.33	CHEMBL1844	Homo sapiens	pKi		6.1
active	9535828	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1cccc2cn[nH]c12		CHEMBL451401	=	Ki	nM	15848.93	CHEMBL1844	Homo sapiens	pKi		4.8
inactive	9535829	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(-c2ccc3c(c2)Nc2ccc(CCOc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1CC#N		CHEMBL1985566	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535830	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(N2CCOCC2)n1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1972119	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535831	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1		CHEMBL1986328	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535832	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL95692	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535833	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1		CHEMBL1090356	<	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
inactive	9535834	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(-c2ccc(N)cc2)c2cnoc12		CHEMBL2002450	<	Ki	nM	100000.0	CHEMBL1844	Homo sapiens	pKi		4.0
active	9535835	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3ccnc4c3c(N)nn4C)cc2)c1		CHEMBL1986507	=	Ki	nM	1.995	CHEMBL1844	Homo sapiens	pKi		8.7
inactive	9535836	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(C(F)(F)F)cc12		CHEMBL1976455	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535837	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Ki	nM	39.81	CHEMBL1844	Homo sapiens	pKi		7.4
active	9535838	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1		CHEMBL1983923	=	Ki	nM	125.89	CHEMBL1844	Homo sapiens	pKi		6.9
inactive	9535839	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535840	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(CNc2nc3ccc(-c4ccncc4)cc3s2)cc1		CHEMBL1983534	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535841	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1c(NCc2ccccc2F)c(Nc2ccncc2)c1=O		CHEMBL1982361	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535842	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOC(=O)C1=c2sc(=Cc3ccco3)c(=O)n2C(N)=C(C#N)C1c1ccco1		CHEMBL1999112	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535843	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1ccc(-c2cccc3sncc23)cc1)Nc1ccc(F)c(C(F)(F)F)c1		CHEMBL2000801	=	Ki	nM	316.23	CHEMBL1844	Homo sapiens	pKi		6.5
inactive	9535844	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	OCCC(Nc1nc2ccc(-c3ccncc3)cc2s1)c1ccccc1		CHEMBL1982122	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535845	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682546	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535846	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1991395	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535847	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN1CCN(c2cccc(Nc3nccc(-c4c(C(N)=O)nc5ccccn45)n3)c2)CC1		CHEMBL1971245	=	Ki	nM	794.33	CHEMBL1844	Homo sapiens	pKi		6.1
inactive	9535848	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1987648	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535849	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOC(=O)c1cn(-c2ccc(O)cc2C)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL1996780	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535850	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NCc1ccccc1)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL1972142	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535851	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1966514	=	Ki	nM	15.85	CHEMBL1844	Homo sapiens	pKi		7.8
inactive	9535852	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(F)c1		CHEMBL2003638	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535853	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
active	9535854	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1ccc2nc(N)n(-c3nc(-c4ccccc4)cs3)c2c1		CHEMBL1996066	=	Ki	nM	398.11	CHEMBL1844	Homo sapiens	pKi		6.4
inactive	9535855	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cccc(F)c1)Nc1cccc(-c2ccc3cn[nH]c3c2)c1		CHEMBL1983393	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535856	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(COc1cncc(-c2cc3ccncc3s2)c1)Cc1c[nH]c2ccccc12		CHEMBL1966524	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535857	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=c1[nH]c2sc3c(c2c2nc(-c4cccnc4)nn12)CCCC3		CHEMBL1970806	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535858	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(C(=O)O)ccc4F)cc3)c12		CHEMBL1993722	=	Ki	nM	1000.0	CHEMBL1844	Homo sapiens	pKi		6.0
inactive	9535859	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCCC3CCO)nc12		CHEMBL2006674	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535860	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)c1ccc(Nc2cc(-c3csc(Br)c3)[nH]n2)cc1		CHEMBL1984236	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535861	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cnccn1)Nc1cccc2c(O)cccc12		CHEMBL1992371	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535862	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1nc(COc2ccccc2Cl)sc1-c1ccnc(N)n1		CHEMBL1375640	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535863	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL1979970	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535864	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(N3CC4COCC4C3)cc12		CHEMBL2002599	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535865	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCN4CCOCC4)cc2-3)cn1		CHEMBL249282	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535866	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1n[nH]c2ccc(-c3cccnc3)cc12		CHEMBL1967252	=	Ki	nM	31622.78	CHEMBL1844	Homo sapiens	pKi		4.5
inactive	9535867	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN(CCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL2004637	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535868	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)C(C)Nc1ncc(Cl)c(Nc2nccs2)n1		CHEMBL1993374	=	Ki	nM	501.19	CHEMBL1844	Homo sapiens	pKi		6.3
inactive	9535869	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C)NC(=O)c1ccc2nc3[nH]c4ccccc4c3nc2c1		CHEMBL1969264	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535870	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	N#Cc1c(O)[nH]c(=O)c2c(=N)oc3ccc(Cl)cc3c12		CHEMBL1973711	=	Ki	nM	398.11	CHEMBL1844	Homo sapiens	pKi		6.4
inactive	9535871	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN1CCN(CCCNc2cccc(-c3nc4c(C(N)=O)cccc4[nH]3)n2)CC1		CHEMBL2006237	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535872	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(C(N)=O)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1967720	=	Ki	nM	5.012	CHEMBL1844	Homo sapiens	pKi		8.3
inactive	9535873	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC1C2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)CC12		CHEMBL1624529	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535874	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nccn2c(C3CC(CN4CCCC4)C3)nc(-c3cccc(OCc4ccccc4)c3)c12		CHEMBL1991138	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535875	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1979516	=	Ki	nM	50.12	CHEMBL1844	Homo sapiens	pKi		7.3
inactive	9535876	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1F		CHEMBL1969755	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535877	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(O)c1ccc(N2C(=O)c3ccccc3C2=O)cc1O		CHEMBL1972820	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535878	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535879	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)OC1=NNC(=O)C1=Cc1c[nH]c2ccccc12		CHEMBL1989029	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535880	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1		CHEMBL392642	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535881	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)c(F)c3)c12		CHEMBL2000652	=	Ki	nM	1.995	CHEMBL1844	Homo sapiens	pKi		8.7
active	9535882	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Ki	nM	501.19	CHEMBL1844	Homo sapiens	pKi		6.3
inactive	9535883	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOC(=O)c1c(C)n(-c2ccc(I)cc2)c2c1cc(O)c1ccccc12		CHEMBL1970352	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535884	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)CC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1965631	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535885	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccccc1NC(=O)Nc1ccc(NC(=O)c2csc3ncnc(N)c23)cc1		CHEMBL1980144	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535886	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2OC)c1		CHEMBL1991188	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535887	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN(C)c1ccc(-c2cc(-c3ccc([N+](=O)[O-])cc3)nc(NS(=O)(=O)c3ccc(N)cc3)n2)cc1		CHEMBL1980167	=	Ki	nM	1995.26	CHEMBL1844	Homo sapiens	pKi		5.7
inactive	9535888	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1972849	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535889	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N		CHEMBL377408	=	Ki	nM	630.96	CHEMBL1844	Homo sapiens	pKi		6.2
inactive	9535890	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535891	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL231209	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535892	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Br)c4)cc3)c12		CHEMBL1976220	=	Ki	nM	794.33	CHEMBL1844	Homo sapiens	pKi		6.1
inactive	9535893	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535894	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL259922	=	Ki	nM	25.12	CHEMBL1844	Homo sapiens	pKi		7.6
active	9535895	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CN1CCN(C2CCC(n3cc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1997617	=	Ki	nM	15.85	CHEMBL1844	Homo sapiens	pKi		7.8
inactive	9535896	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CCCCn1c(NC(=O)c2cccc(C#N)c2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL1969301	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535897	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CCN)nccn23)n1		CHEMBL1982383	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535898	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CSc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17370	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535899	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NCc1cc(Nc2ncnc(-c3ccccc3)n2)ccc1O		CHEMBL1980246	=	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
active	9535900	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)ccc1F		CHEMBL374044	=	Ki	nM	1.0	CHEMBL1844	Homo sapiens	pKi		9.0
active	9535901	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4ccccc4C(F)(F)F)cc3)c12		CHEMBL1987910	=	Ki	nM	199.53	CHEMBL1844	Homo sapiens	pKi		6.7
inactive	9535902	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1ccc2c(NC(=O)Nc3cccc(Br)n3)ccnc2c1		CHEMBL1983932	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535903	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1nc2ccccc2s1)c1cccc2c1CN(c1nc(C(=O)O)c(-c3ccc(CO)cc3)s1)CC2		CHEMBL1983980	=	Ki	nM	1584.89	CHEMBL1844	Homo sapiens	pKi		5.8
active	9535904	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)s1		CHEMBL1999484	=	Ki	nM	63.1	CHEMBL1844	Homo sapiens	pKi		7.2
active	9535905	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	=	Ki	nM	3.162	CHEMBL1844	Homo sapiens	pKi		8.5
active	9535906	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cncc21		CHEMBL404366	=	Ki	nM	0.3162	CHEMBL1844	Homo sapiens	pKi		9.5
inactive	9535907	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	NC(=O)c1csc2c1NCCC2=O		CHEMBL1973399	<	Ki	nM	63095.73	CHEMBL1844	Homo sapiens	pKi		4.2
inactive	9535908	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	c1ccc2c(c1)nnn2Cc1cn(-c2ccc3[nH]ncc3c2)nn1		CHEMBL1966069	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
inactive	9535909	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535910	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1ccc(NCc2ccc(-c3ccc(F)cc3)nc2)cc1		CHEMBL1986899	=	Ki	nM	100.0	CHEMBL1844	Homo sapiens	pKi		7.0
active	9535911	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc(OCC2CCC(C(=O)O)C2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL1991285	=	Ki	nM	1000.0	CHEMBL1844	Homo sapiens	pKi		6.0
active	9535912	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	Cc1cc2cc(-c3csc4c(-c5cccc(S(C)(=O)=O)c5)cnc(N)c34)ccc2[nH]1		CHEMBL1997822	=	Ki	nM	39.81	CHEMBL1844	Homo sapiens	pKi		7.4
active	9535913	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1		CHEMBL243088	=	Ki	nM	316.23	CHEMBL1844	Homo sapiens	pKi		6.5
inactive	9535914	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc(-c2ccc3c(c2)NC(=O)c2ccc(-c4ccccc4NS(C)(=O)=O)cc2N3)cc(OC)c1OC		CHEMBL1984038	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
active	9535915	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1cccc(F)c1F		CHEMBL1974416	=	Ki	nM	1258.93	CHEMBL1844	Homo sapiens	pKi		5.9
active	9535916	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl		CHEMBL1993661	=	Ki	nM	158.49	CHEMBL1844	Homo sapiens	pKi		6.8
active	9535917	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2		CHEMBL1980391	=	Ki	nM	794.33	CHEMBL1844	Homo sapiens	pKi		6.1
inactive	9535918	CHEMBL1964104	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSF1R	F	O=C(c1cccc(-c2cnc3[nH]ccc3c2)c1)N1CCOCC1		CHEMBL1997872	<	Ki	nM	2511.89	CHEMBL1844	Homo sapiens	pKi		5.6
	10838592	CHEMBL2014432	Inhibition of FMS at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	6.0	CHEMBL1844	Homo sapiens	INH	%	6.0
	10843854	CHEMBL2016114	Inhibition of human FMS using ATP as substrate	B	CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3		CHEMBL2010872	=	IC50	nM	78.0	CHEMBL1844	Homo sapiens	IC50	nM	78.0
	10850679	CHEMBL2019799	Inhibition of human Fms at 1 uM	B	Cn1cc(-c2cccc(-c3cnc(N)c(C(=O)N[C@H]4C5CC6CC4C[C@@](O)(C6)C5)n3)c2)cn1		CHEMBL2018022	>	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	10863745	CHEMBL2024900	Inhibition of CSF1R by TR-FRET assay	B	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	=	IC50	nM	16.0	CHEMBL1844	Homo sapiens	IC50	nM	16.0
	10868263	CHEMBL2027407	Inhibition of CSF-1R	B	CCn1cc(NC(=O)Cc2ccc(Oc3ccnc4cc(OC)c(OC)cc34)cc2OC)cn1		CHEMBL2023117	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	uM	0.003
	10868269	CHEMBL2027407	Inhibition of CSF-1R	B	CCc1cc(NC(=O)Cc2ccc(Oc3ccnc4cc(OC)ccc34)cc2OC)no1		CHEMBL2023482	=	IC50	nM	4.0	CHEMBL1844	Homo sapiens	IC50	uM	0.004
	10868275	CHEMBL2027407	Inhibition of CSF-1R	B	CCn1cc(NC(=O)Cc2ccc(Oc3ccnc4cc(OC)ccc34)cc2OC)cn1		CHEMBL2023118	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	uM	0.005
	10868276	CHEMBL2027407	Inhibition of CSF-1R	B	CCc1cc(NC(=O)Cc2ccc(Oc3ccnc4cc(OC)ccc34)cc2OC)n[nH]1		CHEMBL2023486	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	uM	0.005
	10868284	CHEMBL2027407	Inhibition of CSF-1R	B	COc1ccc2c(Oc3ccc(CC(=O)Nc4cc(C)cc(CN(C)C)c4)c(OC)c3)ccnc2c1		CHEMBL2023494	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	uM	0.009
	10868286	CHEMBL2027407	Inhibition of CSF-1R	B	COc1ccc2c(Oc3ccc(CC(=O)Nc4ncc(C)s4)c(OC)c3)ccnc2c1		CHEMBL2023476	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	uM	0.01
	10868291	CHEMBL2027407	Inhibition of CSF-1R	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1CC(=O)Nc1noc(C)c1C		CHEMBL2023477	=	IC50	nM	20.0	CHEMBL1844	Homo sapiens	IC50	uM	0.02
	10868292	CHEMBL2027407	Inhibition of CSF-1R	B	CCn1cc(NC(=O)Cc2ncc(Oc3ccnc4cc(OC)ccc34)cc2OC)cn1		CHEMBL2023495	=	IC50	nM	20.0	CHEMBL1844	Homo sapiens	IC50	uM	0.02
	10868295	CHEMBL2027407	Inhibition of CSF-1R	B	COc1ccc2c(Oc3ccc(CC(=O)Nc4noc(C)c4C)c(OC)c3)ccnc2c1		CHEMBL2023478	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	uM	0.03
	10868300	CHEMBL2027407	Inhibition of CSF-1R	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1CC(=O)Nc1cn(C)nc1C		CHEMBL2023488	=	IC50	nM	50.0	CHEMBL1844	Homo sapiens	IC50	uM	0.05
	10868303	CHEMBL2027407	Inhibition of CSF-1R	B	COc1ccc2c(Oc3cnc(CC(=O)Nc4cn(C)nc4C)c(OC)c3)ccnc2c1		CHEMBL2023496	=	IC50	nM	80.0	CHEMBL1844	Homo sapiens	IC50	uM	0.08
	10868306	CHEMBL2027407	Inhibition of CSF-1R	B	COc1cc2ncnc(Oc3ccc(CC(=O)Nc4cnn(C(C)C)c4)cc3)c2cc1OC		CHEMBL1940274	=	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	uM	0.1
	10868307	CHEMBL2027407	Inhibition of CSF-1R	B	COc1ccc2c(Oc3ccc(CC(=O)Nc4n[nH]c(C)c4C)c(OC)c3)ccnc2c1		CHEMBL2023483	=	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	uM	0.1
	10868308	CHEMBL2027407	Inhibition of CSF-1R	B	CCc1c[nH]nc1NC(=O)Cc1ccc(Oc2ccnc3cc(OC)ccc23)cc1OC		CHEMBL2023484	=	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	uM	0.1
	10868309	CHEMBL2027407	Inhibition of CSF-1R	B	COc1ccc2c(Oc3ccc(CC(=O)Nc4cnn(C)c4)c(OC)c3)ccnc2c1		CHEMBL2023492	=	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	uM	0.1
	10868310	CHEMBL2027407	Inhibition of CSF-1R	B	COc1ccc2c(Oc3ccc(CC(=O)Nc4cc(C)nn4C)c(OC)c3)ccnc2c1		CHEMBL2023493	=	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	uM	0.1
	10868312	CHEMBL2027407	Inhibition of CSF-1R	B	CCn1cc(NC(=O)Cc2ccc(Oc3ccnc4ccc(OC)cc34)cc2OC)cn1		CHEMBL2023119	=	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	uM	0.2
	10868313	CHEMBL2027407	Inhibition of CSF-1R	B	COc1ccc2c(Oc3ccc(CC(=O)Nc4cn(C)nc4C)c(OC)c3)ccnc2c1		CHEMBL2023489	=	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	uM	0.2
	10868314	CHEMBL2027407	Inhibition of CSF-1R	B	CCOc1cc2nccc(Oc3cnc(CC(=O)Nc4n[nH]c(CC)c4C)c(OC)c3)c2cc1OC		CHEMBL2023802	=	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	uM	0.2
	10868318	CHEMBL2027407	Inhibition of CSF-1R	B	COc1cc2nccc(Oc3ccc(CC(=O)Nc4cn(C)nc4C)cc3)c2cc1OC		CHEMBL2023490	=	IC50	nM	300.0	CHEMBL1844	Homo sapiens	IC50	uM	0.3
	10868319	CHEMBL2027407	Inhibition of CSF-1R	B	CCn1cc(NC(=O)Cc2ccc(Oc3ccnc4cc(OC)c(OC)cc34)cn2)cn1		CHEMBL2023800	=	IC50	nM	300.0	CHEMBL1844	Homo sapiens	IC50	uM	0.3
	10868323	CHEMBL2027407	Inhibition of CSF-1R	B	CCn1cc(NC(=O)Cc2ccc(Oc3ncnc4cc(OC)c(OC)cc34)cc2OC)cn1		CHEMBL2023115	=	IC50	nM	500.0	CHEMBL1844	Homo sapiens	IC50	uM	0.5
	10868324	CHEMBL2027407	Inhibition of CSF-1R	B	CCn1cc(NC(=O)Cc2ccc(Oc3ccnc4cc(F)ccc34)cc2OC)cn1		CHEMBL2023474	=	IC50	nM	500.0	CHEMBL1844	Homo sapiens	IC50	uM	0.5
	10868325	CHEMBL2027407	Inhibition of CSF-1R	B	COc1ccc2c(Oc3ccc(CC(=O)Nc4cnn(C)c4C)c(OC)c3)ccnc2c1		CHEMBL2023491	=	IC50	nM	500.0	CHEMBL1844	Homo sapiens	IC50	uM	0.5
	10868328	CHEMBL2027407	Inhibition of CSF-1R	B	COc1ccc2nccc(Oc3ccc(CC(=O)Nc4noc(C)c4C)c(OC)c3)c2c1		CHEMBL2023479	=	IC50	nM	600.0	CHEMBL1844	Homo sapiens	IC50	uM	0.6
	10868329	CHEMBL2027407	Inhibition of CSF-1R	B	CCc1[nH]nc(NC(=O)Cc2ncc(Oc3ccnc4cc(OC)c(OC)cc34)cc2OC)c1C		CHEMBL2023801	=	IC50	nM	600.0	CHEMBL1844	Homo sapiens	IC50	uM	0.6
	10868330	CHEMBL2027407	Inhibition of CSF-1R	B	CCn1cc(NC(=O)Cc2ccc(Oc3ccnc4ccc(F)cc34)cc2OC)cn1		CHEMBL2023475	=	IC50	nM	700.0	CHEMBL1844	Homo sapiens	IC50	uM	0.7
	10868387	CHEMBL2027407	Inhibition of CSF-1R	B	CCc1cc(NC(=O)Cc2ccc(Oc3ccnc4cc(OC)c(OC)cc34)cc2OC)n[nH]1		CHEMBL2023485	<	IC50	nM	0.3	CHEMBL1844	Homo sapiens	IC50	uM	0.0003
	10868391	CHEMBL2027407	Inhibition of CSF-1R	B	COc1cc(Oc2ccnc3cc(F)ccc23)ccc1CC(=O)Nc1noc(C)c1C		CHEMBL2023480	>	IC50	nM	900.0	CHEMBL1844	Homo sapiens	IC50	uM	0.9
	10868393	CHEMBL2027407	Inhibition of CSF-1R	B	COc1cc2ncnc(Nc3ccc(CC(=O)Nc4cnn(C(C)C)c4)cc3)c2cc1OC		CHEMBL1940275	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	10868394	CHEMBL2027407	Inhibition of CSF-1R	B	CCn1cc(NC(=O)Cc2ccc(Oc3ncnc4cc(OC)c(OC)cc34)c(OC)c2)cn1		CHEMBL2023116	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	10868395	CHEMBL2027407	Inhibition of CSF-1R	B	COc1cc(Oc2ccnc3ccc(F)cc23)ccc1CC(=O)Nc1noc(C)c1C		CHEMBL2023481	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	10868396	CHEMBL2027407	Inhibition of CSF-1R	B	COc1cc(Oc2ncnc3cc(OC)c(OC)cc23)ccc1CC(=O)Nc1cn(C)nc1C		CHEMBL2023487	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	uM	1.0
	10886022	CHEMBL2033408	Inhibition of CSF1R in human HEK293 cells after 1 hr by competition binding assay	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	=	Kd	nM	9.0	CHEMBL1844	Homo sapiens	Kd	nM	9.0
	10910720	CHEMBL2040160	Inhibition of c-fms	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1		CHEMBL2035185	=	IC50	nM	69.0	CHEMBL1844	Homo sapiens	IC50	nM	69.0
	10921348	CHEMBL2046168	Inhibition of CSF1R at 1 uM	B	CCN1C(=O)CCCc2c1ccc(Nc1ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n1)c2OC		CHEMBL2042829	=	Inhibition	%	91.0	CHEMBL1844	Homo sapiens	INH	%	91.0
	10921349	CHEMBL2046166	Inhibition of CSF1R at 0.1 uM	B	CCN1C(=O)CCCc2c1ccc(Nc1ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n1)c2OC		CHEMBL2042829	<	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	10934980	CHEMBL2051516	Inhibition of FMS at 10 uM	B	O=C(Nc1ccc(Oc2ccnc(-c3ncc(C(F)(F)F)[nH]3)c2)cc1)Nc1ccc(Cl)c(C(F)(F)F)c1		CHEMBL2047981	=	Inhibition	%	50.8	CHEMBL1844	Homo sapiens	INH	%	50.8
	10936264	CHEMBL2050057	Inhibition of human FMS	B	Cc1ccc(NC(=O)Nc2nnc(Sc3ncnc4cc(OCCCN5CCOCC5)ccc34)s2)cc1		CHEMBL2046883	=	IC50	nM	2800.0	CHEMBL1844	Homo sapiens	IC50	uM	2.8
	10978314	CHEMBL2065349	Inhibition of CSF1R	B	C[C@@H](O)Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL2022856	=	Ki	nM	3.162	CHEMBL1844	Homo sapiens	pKi		8.5
	10978315	CHEMBL2065349	Inhibition of CSF1R	B	CNCC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1964441	=	Ki	nM	5.012	CHEMBL1844	Homo sapiens	pKi		8.3
	10978316	CHEMBL2065349	Inhibition of CSF1R	B	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CC(C)(C)N)cnc(N)c34)cc2)c1		CHEMBL1979577	=	Ki	nM	7.943	CHEMBL1844	Homo sapiens	pKi		8.1
	10978317	CHEMBL2065349	Inhibition of CSF1R	B	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1970317	=	Ki	nM	1.995	CHEMBL1844	Homo sapiens	pKi		8.7
	10978318	CHEMBL2065349	Inhibition of CSF1R	B	CC(C)(C(N)=O)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1967720	=	Ki	nM	5.012	CHEMBL1844	Homo sapiens	pKi		8.3
	10978319	CHEMBL2065349	Inhibition of CSF1R	B	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	=	Ki	nM	3.162	CHEMBL1844	Homo sapiens	pKi		8.5
	10984744	CHEMBL2072040	Inhibition of human Fms at 1 uM	B	Nc1cc(Nc2cnccn2)nc(-c2ccnc(N3CCNCC3)c2)c1		CHEMBL2069349	<	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	12046277	CHEMBL2156514	Inhibition of CSF1R at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	-3.3	CHEMBL1844	Homo sapiens	INH	%	-3.3
	12068078	CHEMBL2162579	Inhibition of CSF1R at 0.1 uM	B	Cc1nc2cnc3[nH]ccc3c2n1[C@@H]1CCC[C@@H](O)C1		CHEMBL2159210	=	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	12073586	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCNCC3)cc2C2=CCCCC2)n1.O=C(O)C(F)(F)F		CHEMBL2158221	=	IC50	nM	1.1	CHEMBL1844	Homo sapiens	IC50	nM	1.1
	12073587	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(c4ccccn4)CC3)cc2C2=CCCCC2)n1		CHEMBL2158222	=	IC50	nM	22.0	CHEMBL1844	Homo sapiens	IC50	nM	22.0
	12073588	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#CCCN1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL2158223	=	IC50	nM	1.8	CHEMBL1844	Homo sapiens	IC50	nM	1.8
	12073589	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(Cc4ccccn4)CC3)cc2C2=CCCCC2)n1		CHEMBL2158224	=	IC50	nM	2.4	CHEMBL1844	Homo sapiens	IC50	nM	2.4
	12073590	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1cnc(C(=O)Nc2ccc(C3CCN(CCO)CC3)cc2C2=CCCCC2)[nH]1		CHEMBL2158225	=	IC50	nM	1.1	CHEMBL1844	Homo sapiens	IC50	nM	1.1
	12073591	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(CO)CO)CC3)cc2C2=CCCCC2)n1		CHEMBL2158226	=	IC50	nM	1.6	CHEMBL1844	Homo sapiens	IC50	nM	1.6
	12073592	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	CS(=O)(=O)CCN1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL2158227	=	IC50	nM	1.5	CHEMBL1844	Homo sapiens	IC50	nM	1.5
	12073593	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(CC(N)=O)CC3)cc2C2=CCCCC2)n1		CHEMBL2158228	=	IC50	nM	1.4	CHEMBL1844	Homo sapiens	IC50	nM	1.4
	12073594	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(CC(=O)O)CC3)cc2C2=CCCCC2)n1		CHEMBL2158229	=	IC50	nM	1.3	CHEMBL1844	Homo sapiens	IC50	nM	1.3
	12073595	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1cnc(C(=O)Nc2ccc(C3CCN(CCN4CCOCC4)CC3)cc2C2=CCCCC2)[nH]1		CHEMBL2158230	=	IC50	nM	1.1	CHEMBL1844	Homo sapiens	IC50	nM	1.1
	12073596	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	CC(=O)N1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL256712	=	IC50	nM	2.4	CHEMBL1844	Homo sapiens	IC50	nM	2.4
	12073597	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)c4cccnc4)CC3)cc2C2=CCCCC2)n1		CHEMBL2158231	=	IC50	nM	2.7	CHEMBL1844	Homo sapiens	IC50	nM	2.7
	12073598	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL1908842	=	IC50	nM	0.69	CHEMBL1844	Homo sapiens	IC50	nM	0.69
	12073599	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)[C@H](O)CO)CC3)cc2C2=CCCCC2)n1		CHEMBL2158287	=	IC50	nM	1.2	CHEMBL1844	Homo sapiens	IC50	nM	1.2
	12073600	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)CNCCO)CC3)cc2C2=CCCCC2)n1		CHEMBL2158288	=	IC50	nM	0.83	CHEMBL1844	Homo sapiens	IC50	nM	0.83
	12073601	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	CN(CCO)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL2158289	=	IC50	nM	1.0	CHEMBL1844	Homo sapiens	IC50	nM	1.0
	12073602	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	CS(=O)(=O)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL2158290	=	IC50	nM	2.6	CHEMBL1844	Homo sapiens	IC50	nM	2.6
	12073603	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)c4ccc[n+]([O-])c4)CC3)cc2C2=CCCCC2)n1		CHEMBL2158291	=	IC50	nM	1.4	CHEMBL1844	Homo sapiens	IC50	nM	1.4
	12073604	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)c4cc[n+]([O-])cc4)CC3)cc2C2=CCCCC2)n1		CHEMBL2158292	=	IC50	nM	1.3	CHEMBL1844	Homo sapiens	IC50	nM	1.3
	12073605	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)Cc4c[nH]cn4)CC3)cc2C2=CCCCC2)n1		CHEMBL2158293	=	IC50	nM	1.1	CHEMBL1844	Homo sapiens	IC50	nM	1.1
	12073606	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	Cn1cnc(CC(=O)N2CCC(c3ccc(NC(=O)c4nc(C#N)c[nH]4)c(C4=CCCCC4)c3)CC2)c1		CHEMBL2158294	=	IC50	nM	1.6	CHEMBL1844	Homo sapiens	IC50	nM	1.6
	12073607	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)Cc4ccccn4)CC3)cc2C2=CCCCC2)n1		CHEMBL2158295	=	IC50	nM	2.5	CHEMBL1844	Homo sapiens	IC50	nM	2.5
	12073608	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)Cc4cccnc4)CC3)cc2C2=CCCCC2)n1		CHEMBL2158296	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	nM	1.7
	12073609	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)Cc4ccncc4)CC3)cc2C2=CCCCC2)n1		CHEMBL2158297	=	IC50	nM	1.3	CHEMBL1844	Homo sapiens	IC50	nM	1.3
	12073610	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)CCN4CCOCC4)CC3)cc2C2=CCCCC2)n1		CHEMBL2158298	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	nM	1.7
	12073611	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)CN4CCOCC4)CC3)cc2C2=CCCCC2)n1		CHEMBL2158299	=	IC50	nM	3.8	CHEMBL1844	Homo sapiens	IC50	nM	3.8
	12073612	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	CC(C)(N)CC(=O)N1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL2158300	=	IC50	nM	0.62	CHEMBL1844	Homo sapiens	IC50	nM	0.62
	12073613	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	CC(C)(N)C(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL2158301	=	IC50	nM	1.3	CHEMBL1844	Homo sapiens	IC50	nM	1.3
	12073614	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)NCCO)CC3)cc2C2=CCCCC2)n1		CHEMBL2158302	=	IC50	nM	0.7	CHEMBL1844	Homo sapiens	IC50	nM	0.7
	12073615	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(N)=O)CC3)cc2C2=CCCCC2)n1		CHEMBL2158303	=	IC50	nM	3.3	CHEMBL1844	Homo sapiens	IC50	nM	3.3
	12073616	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	O=C(Nc1ccccc1N1CCCCC1)c1ccno1		CHEMBL253864	=	IC50	nM	400.0	CHEMBL1844	Homo sapiens	IC50	uM	0.4
	12073617	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	O=C(Nc1ccccc1N1CCCCC1)c1ccc([N+](=O)[O-])o1		CHEMBL428056	=	IC50	nM	47.0	CHEMBL1844	Homo sapiens	IC50	uM	0.047
	12073618	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	CC1CCN(c2ccc(CO)cc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL400754	=	IC50	nM	24.0	CHEMBL1844	Homo sapiens	IC50	uM	0.024
	12073619	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	CN1CCN(c2ccc(NC(=O)c3ccc(C#N)o3)c(N3CCCCC3)c2)CC1		CHEMBL398509	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	uM	0.0008
	12073620	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	CN1CCN(c2ccc(NC(=O)c3cc(C#N)c[nH]3)c(N3CCCCC3)c2)CC1		CHEMBL399763	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	uM	0.002
	12073621	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	CC1CCN(c2cc(N3CCN(C)CC3)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL252436	=	IC50	nM	1.0	CHEMBL1844	Homo sapiens	IC50	uM	0.001
	12073622	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	CC1CCN(c2cc(N3CCN(C)CC3)ccc2NC(=O)c2cc(C#N)c[nH]2)CC1		CHEMBL254702	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	uM	0.0008
	12073623	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	CC1CCN(c2cc(C3CCNCC3)ccc2NC(=O)c2ccc(C#N)o2)CC1		CHEMBL438533	=	IC50	nM	0.3	CHEMBL1844	Homo sapiens	IC50	uM	0.0003
	12074588	CHEMBL2160985	Inhibition of FMS at 0.1 uM	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL1908842	>	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	12074712	CHEMBL2161432	Inhibition of FMS	B	CS(=O)(=O)CCN1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL2158227	=	IC50	nM	1.5	CHEMBL1844	Homo sapiens	IC50	nM	1.5
	12074713	CHEMBL2161432	Inhibition of FMS	B	N#Cc1cnc(C(=O)Nc2ccc(C3CCN(CCN4CCOCC4)CC3)cc2C2=CCCCC2)[nH]1		CHEMBL2158230	=	IC50	nM	1.1	CHEMBL1844	Homo sapiens	IC50	nM	1.1
	12074714	CHEMBL2161432	Inhibition of FMS	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL1908842	=	IC50	nM	0.69	CHEMBL1844	Homo sapiens	IC50	nM	0.69
	12075460	CHEMBL2163155	Inhibition of FMS mediated phosphorylation using SYEGNSYTFIDPTQ as substrate after 80 mins by fluorescence polarization	B	CN1CCN(c2ccc(NC(=O)c3ccc(C#N)o3)c(C3=CCCCC3)c2)CC1		CHEMBL265432	=	IC50	nM	18.0	CHEMBL1844	Homo sapiens	IC50	uM	0.018
	12145257	CHEMBL2182678	Inhibition of FMS using fluorescent labelled substrate at 5 uM by caliper method	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177819	>	Inhibition	%	25.0	CHEMBL1844	Homo sapiens	INH	%	25.0
	12145258	CHEMBL2182678	Inhibition of FMS using fluorescent labelled substrate at 5 uM by caliper method	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177818	>	Inhibition	%	25.0	CHEMBL1844	Homo sapiens	INH	%	25.0
	12173681	CHEMBL2209318	Inhibition of autoinhibited CSF1R assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	100.0	CHEMBL1844	Homo sapiens	Activity	%	100.0
	12173682	CHEMBL2209317	Inhibition of CSF1R assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	68.0	CHEMBL1844	Homo sapiens	Activity	%	68.0
	12177069	CHEMBL2213411	Inhibition of M-CSF-induced FK506 -fussed CSF1R phosphorylation expressed in HEK293 cells after 2 hrs by sandwich ELISA	B	CCN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C		CHEMBL2206278	=	IC50	nM	10.5	CHEMBL1844	Homo sapiens	IC50	nM	10.5
	12177076	CHEMBL2213411	Inhibition of M-CSF-induced FK506 -fussed CSF1R phosphorylation expressed in HEK293 cells after 2 hrs by sandwich ELISA	B	CN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C		CHEMBL2206277	=	IC50	nM	15.0	CHEMBL1844	Homo sapiens	IC50	nM	15.0
	12177083	CHEMBL2213411	Inhibition of M-CSF-induced FK506 -fussed CSF1R phosphorylation expressed in HEK293 cells after 2 hrs by sandwich ELISA	B	CCN1CCC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1		CHEMBL2203434	=	IC50	nM	6.9	CHEMBL1844	Homo sapiens	IC50	nM	6.9
	12177092	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	CN1CCN(Cc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1		CHEMBL2203428	=	Kd	nM	4.9	CHEMBL1844	Homo sapiens	Kd	nM	4.9
	12177098	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	CCN1CCC(Cc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1		CHEMBL2203427	=	Kd	nM	1.0	CHEMBL1844	Homo sapiens	Kd	nM	1.0
	12177104	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	CCN1CCC(c2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1		CHEMBL2203426	=	Kd	nM	3.1	CHEMBL1844	Homo sapiens	Kd	nM	3.1
	12177110	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	CC1(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC(C)(C)N1		CHEMBL2206279	=	Kd	nM	1.8	CHEMBL1844	Homo sapiens	Kd	nM	1.8
	12177116	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	CCN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C		CHEMBL2206278	=	Kd	nM	1.57	CHEMBL1844	Homo sapiens	Kd	nM	1.57
	12177122	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	CN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C		CHEMBL2206277	=	Kd	nM	1.0	CHEMBL1844	Homo sapiens	Kd	nM	1.0
	12177128	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(NC(=O)c3ccc(OC4CCN(C5CC5)CC4)cn3)cc2)no1		CHEMBL2203438	=	Kd	nM	1.28	CHEMBL1844	Homo sapiens	Kd	nM	1.28
	12177134	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(NC(=O)c3ccc(OC4CCN(C(C)(C)C)CC4)cn3)cc2)no1		CHEMBL2203437	=	Kd	nM	1.12	CHEMBL1844	Homo sapiens	Kd	nM	1.12
	12177140	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(NC(=O)c3ccc(OC4CCN(CC(F)(F)F)CC4)cn3)cc2)no1		CHEMBL2203436	=	Kd	nM	3.4	CHEMBL1844	Homo sapiens	Kd	nM	3.4
	12177146	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	CC(C)N1CCC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1		CHEMBL2203435	=	Kd	nM	1.2	CHEMBL1844	Homo sapiens	Kd	nM	1.2
	12177152	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	CCN1CCC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1		CHEMBL2203434	=	Kd	nM	0.8	CHEMBL1844	Homo sapiens	Kd	nM	0.8
	12177158	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(NC(=O)c3ccc(OC4CCNCC4)cn3)cc2)no1		CHEMBL2203433	=	Kd	nM	0.6	CHEMBL1844	Homo sapiens	Kd	nM	0.6
	12177164	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	CCN1CCC(Oc2ccnc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)c2)CC1		CHEMBL2203432	=	Kd	nM	3.0	CHEMBL1844	Homo sapiens	Kd	nM	3.0
	12177170	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(NC(=O)c3cc(OC4CCNCC4)ccn3)cc2)no1		CHEMBL2203431	=	Kd	nM	1.8	CHEMBL1844	Homo sapiens	Kd	nM	1.8
	12177176	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	Cc1ccc(C(=O)Nc2ccc(NC(=O)Nc3cc(C(C)(C)C)on3)cc2)nc1		CHEMBL2203430	=	Kd	nM	1.6	CHEMBL1844	Homo sapiens	Kd	nM	1.6
	12177182	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	Cc1ccnc(C(=O)Nc2ccc(NC(=O)Nc3cc(C(C)(C)C)on3)cc2)c1		CHEMBL2203429	=	Kd	nM	2.0	CHEMBL1844	Homo sapiens	Kd	nM	2.0
	12177188	CHEMBL2213418	Binding affinity to CSF1R expressed in HEK-293 cells after 1 hr	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(NC(=O)c3cc4ccccc4cn3)cc2)no1		CHEMBL1081509	=	Kd	nM	8.5	CHEMBL1844	Homo sapiens	Kd	nM	8.5
	12195388	CHEMBL2210926	Inhibition of recombinant CSF1R after 1 hr by scintillation counter analysis in presence of gamma-[33P]ATP	B	CC(C)(C)Nc1c(Nc2ccnc(Nc3ccc(-c4ccncc4)cc3)n2)c(=O)c1=O		CHEMBL2205426	=	Ki	nM	2100.0	CHEMBL1844	Homo sapiens	Ki	nM	2100.0
	12196683	CHEMBL2214817	Inhibition of CSF1R at 0.1 uM	B	CS(=O)(=O)NCc1nc2cnc3[nH]ccc3c2n1[C@@H]1C[C@H]2CC[C@@H]1C2		CHEMBL2206059	>	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	12248099	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	97.0	CHEMBL1844	Homo sapiens	Residual Activity	%	97.0
	12248100	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	82.0	CHEMBL1844	Homo sapiens	Residual Activity	%	82.0
	12248101	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	71.0	CHEMBL1844	Homo sapiens	Residual Activity	%	71.0
	12248102	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	89.0	CHEMBL1844	Homo sapiens	Residual Activity	%	89.0
	12248103	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	88.0	CHEMBL1844	Homo sapiens	Residual Activity	%	88.0
	12248104	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	77.0	CHEMBL1844	Homo sapiens	Residual Activity	%	77.0
	12248105	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	52.0	CHEMBL1844	Homo sapiens	Residual Activity	%	52.0
	12248106	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	88.0	CHEMBL1844	Homo sapiens	Residual Activity	%	88.0
	12248107	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	52.0	CHEMBL1844	Homo sapiens	Residual Activity	%	52.0
	12248108	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	94.0	CHEMBL1844	Homo sapiens	Residual Activity	%	94.0
	12248109	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	88.0	CHEMBL1844	Homo sapiens	Residual Activity	%	88.0
	12248110	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	8.0	CHEMBL1844	Homo sapiens	Residual Activity	%	8.0
	12248111	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	94.0	CHEMBL1844	Homo sapiens	Residual Activity	%	94.0
	12248112	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	59.0	CHEMBL1844	Homo sapiens	Residual Activity	%	59.0
	12248113	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	57.0	CHEMBL1844	Homo sapiens	Residual Activity	%	57.0
	12248114	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	20.0	CHEMBL1844	Homo sapiens	Residual Activity	%	20.0
	12248115	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	93.0	CHEMBL1844	Homo sapiens	Residual Activity	%	93.0
	12248116	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	87.0	CHEMBL1844	Homo sapiens	Residual Activity	%	87.0
	12248117	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	39.0	CHEMBL1844	Homo sapiens	Residual Activity	%	39.0
	12248118	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	54.0	CHEMBL1844	Homo sapiens	Residual Activity	%	54.0
	12248119	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	78.0	CHEMBL1844	Homo sapiens	Residual Activity	%	78.0
	12248120	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	75.0	CHEMBL1844	Homo sapiens	Residual Activity	%	75.0
	12248121	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	87.0	CHEMBL1844	Homo sapiens	Residual Activity	%	87.0
	12248122	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	1.0
	12248123	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	93.0	CHEMBL1844	Homo sapiens	Residual Activity	%	93.0
	12248124	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	73.0	CHEMBL1844	Homo sapiens	Residual Activity	%	73.0
	12248125	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	54.0	CHEMBL1844	Homo sapiens	Residual Activity	%	54.0
	12248126	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	63.0	CHEMBL1844	Homo sapiens	Residual Activity	%	63.0
	12248127	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	7.0	CHEMBL1844	Homo sapiens	Residual Activity	%	7.0
	12248128	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	66.0	CHEMBL1844	Homo sapiens	Residual Activity	%	66.0
	12248129	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	71.0	CHEMBL1844	Homo sapiens	Residual Activity	%	71.0
	12248130	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	0.0	CHEMBL1844	Homo sapiens	Residual Activity	%	0.0
	12248131	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	55.0	CHEMBL1844	Homo sapiens	Residual Activity	%	55.0
	12248132	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	111.0	CHEMBL1844	Homo sapiens	Residual Activity	%	111.0
	12248133	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	1.0
	12248134	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	115.0	CHEMBL1844	Homo sapiens	Residual Activity	%	115.0
	12248135	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	1.0
	12248136	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	85.0	CHEMBL1844	Homo sapiens	Residual Activity	%	85.0
	12248137	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	119.0	CHEMBL1844	Homo sapiens	Residual Activity	%	119.0
	12248138	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	11.0	CHEMBL1844	Homo sapiens	Residual Activity	%	11.0
	12248139	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	124.0	CHEMBL1844	Homo sapiens	Residual Activity	%	124.0
	12248140	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	123.0	CHEMBL1844	Homo sapiens	Residual Activity	%	123.0
	12248141	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	14.0	CHEMBL1844	Homo sapiens	Residual Activity	%	14.0
	12248142	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	42.0	CHEMBL1844	Homo sapiens	Residual Activity	%	42.0
	12248143	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	0.0	CHEMBL1844	Homo sapiens	Residual Activity	%	0.0
	12248144	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	110.0	CHEMBL1844	Homo sapiens	Residual Activity	%	110.0
	12248145	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	73.0	CHEMBL1844	Homo sapiens	Residual Activity	%	73.0
	12248146	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	2.0	CHEMBL1844	Homo sapiens	Residual Activity	%	2.0
	12248147	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	78.0	CHEMBL1844	Homo sapiens	Residual Activity	%	78.0
	12248148	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	78.0	CHEMBL1844	Homo sapiens	Residual Activity	%	78.0
	12248149	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	59.0	CHEMBL1844	Homo sapiens	Residual Activity	%	59.0
	12248150	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	18.0	CHEMBL1844	Homo sapiens	Residual Activity	%	18.0
	12248151	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	22.0	CHEMBL1844	Homo sapiens	Residual Activity	%	22.0
	12248152	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	73.0	CHEMBL1844	Homo sapiens	Residual Activity	%	73.0
	12248153	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	67.0	CHEMBL1844	Homo sapiens	Residual Activity	%	67.0
	12248154	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	28.0	CHEMBL1844	Homo sapiens	Residual Activity	%	28.0
	12248155	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	84.0	CHEMBL1844	Homo sapiens	Residual Activity	%	84.0
	12248156	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	69.0	CHEMBL1844	Homo sapiens	Residual Activity	%	69.0
	12248157	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	6.0	CHEMBL1844	Homo sapiens	Residual Activity	%	6.0
	12248158	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	66.0	CHEMBL1844	Homo sapiens	Residual Activity	%	66.0
	12248159	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	7.0	CHEMBL1844	Homo sapiens	Residual Activity	%	7.0
	12248160	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	0.0	CHEMBL1844	Homo sapiens	Residual Activity	%	0.0
	12248161	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	79.0	CHEMBL1844	Homo sapiens	Residual Activity	%	79.0
	12248162	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	75.0	CHEMBL1844	Homo sapiens	Residual Activity	%	75.0
	12248163	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	74.0	CHEMBL1844	Homo sapiens	Residual Activity	%	74.0
	12248164	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	8.0	CHEMBL1844	Homo sapiens	Residual Activity	%	8.0
	12248165	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	131.0	CHEMBL1844	Homo sapiens	Residual Activity	%	131.0
	12248166	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	61.0	CHEMBL1844	Homo sapiens	Residual Activity	%	61.0
	12248167	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	126.0	CHEMBL1844	Homo sapiens	Residual Activity	%	126.0
	12248168	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	49.0	CHEMBL1844	Homo sapiens	Residual Activity	%	49.0
	12248169	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	36.0	CHEMBL1844	Homo sapiens	Residual Activity	%	36.0
	12248170	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	14.0	CHEMBL1844	Homo sapiens	Residual Activity	%	14.0
	12248171	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	50.0	CHEMBL1844	Homo sapiens	Residual Activity	%	50.0
	12248172	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	20.0	CHEMBL1844	Homo sapiens	Residual Activity	%	20.0
	12248173	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	1.0
	12248174	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	17.0	CHEMBL1844	Homo sapiens	Residual Activity	%	17.0
	12248175	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	56.0	CHEMBL1844	Homo sapiens	Residual Activity	%	56.0
	12248176	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	0.0	CHEMBL1844	Homo sapiens	Residual Activity	%	0.0
	12248177	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	30.0	CHEMBL1844	Homo sapiens	Residual Activity	%	30.0
	12248178	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	1.0
	12248179	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	93.0	CHEMBL1844	Homo sapiens	Residual Activity	%	93.0
	12248180	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	30.0	CHEMBL1844	Homo sapiens	Residual Activity	%	30.0
	12248181	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	78.0	CHEMBL1844	Homo sapiens	Residual Activity	%	78.0
	12248182	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	98.0	CHEMBL1844	Homo sapiens	Residual Activity	%	98.0
	12248183	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	4.0	CHEMBL1844	Homo sapiens	Residual Activity	%	4.0
	12248184	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	97.0	CHEMBL1844	Homo sapiens	Residual Activity	%	97.0
	12248185	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	112.0	CHEMBL1844	Homo sapiens	Residual Activity	%	112.0
	12248186	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	109.0	CHEMBL1844	Homo sapiens	Residual Activity	%	109.0
	12248187	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	101.0	CHEMBL1844	Homo sapiens	Residual Activity	%	101.0
	12248188	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	15.0	CHEMBL1844	Homo sapiens	Residual Activity	%	15.0
	12248189	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	84.0	CHEMBL1844	Homo sapiens	Residual Activity	%	84.0
	12248190	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	67.0	CHEMBL1844	Homo sapiens	Residual Activity	%	67.0
	12248191	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	4.0	CHEMBL1844	Homo sapiens	Residual Activity	%	4.0
	12248192	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	94.0	CHEMBL1844	Homo sapiens	Residual Activity	%	94.0
	12248193	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	103.0	CHEMBL1844	Homo sapiens	Residual Activity	%	103.0
	12248194	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	120.0	CHEMBL1844	Homo sapiens	Residual Activity	%	120.0
	12248195	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	89.0	CHEMBL1844	Homo sapiens	Residual Activity	%	89.0
	12248196	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	84.0	CHEMBL1844	Homo sapiens	Residual Activity	%	84.0
	12248197	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	96.0	CHEMBL1844	Homo sapiens	Residual Activity	%	96.0
	12248198	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	49.0	CHEMBL1844	Homo sapiens	Residual Activity	%	49.0
	12248199	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	26.0	CHEMBL1844	Homo sapiens	Residual Activity	%	26.0
	12248200	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	2.0	CHEMBL1844	Homo sapiens	Residual Activity	%	2.0
	12248201	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	114.0	CHEMBL1844	Homo sapiens	Residual Activity	%	114.0
	12248202	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	30.0	CHEMBL1844	Homo sapiens	Residual Activity	%	30.0
	12248203	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	33.0	CHEMBL1844	Homo sapiens	Residual Activity	%	33.0
	12248204	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	101.0	CHEMBL1844	Homo sapiens	Residual Activity	%	101.0
	12248205	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	81.0	CHEMBL1844	Homo sapiens	Residual Activity	%	81.0
	12248206	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	68.0	CHEMBL1844	Homo sapiens	Residual Activity	%	68.0
	12248207	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	87.0	CHEMBL1844	Homo sapiens	Residual Activity	%	87.0
	12248208	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	49.0	CHEMBL1844	Homo sapiens	Residual Activity	%	49.0
	12248209	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	81.0	CHEMBL1844	Homo sapiens	Residual Activity	%	81.0
	12248210	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	90.0	CHEMBL1844	Homo sapiens	Residual Activity	%	90.0
	12248211	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	24.0	CHEMBL1844	Homo sapiens	Residual Activity	%	24.0
	12248212	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	79.0	CHEMBL1844	Homo sapiens	Residual Activity	%	79.0
	12248213	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	84.0	CHEMBL1844	Homo sapiens	Residual Activity	%	84.0
	12248214	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	91.0	CHEMBL1844	Homo sapiens	Residual Activity	%	91.0
	12248215	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	11.0	CHEMBL1844	Homo sapiens	Residual Activity	%	11.0
	12248216	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	78.0	CHEMBL1844	Homo sapiens	Residual Activity	%	78.0
	12248217	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	93.0	CHEMBL1844	Homo sapiens	Residual Activity	%	93.0
	12248218	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	90.0	CHEMBL1844	Homo sapiens	Residual Activity	%	90.0
	12248219	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	13.0	CHEMBL1844	Homo sapiens	Residual Activity	%	13.0
	12248220	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	54.0	CHEMBL1844	Homo sapiens	Residual Activity	%	54.0
	12248221	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	83.0	CHEMBL1844	Homo sapiens	Residual Activity	%	83.0
	12248222	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	71.0	CHEMBL1844	Homo sapiens	Residual Activity	%	71.0
	12248223	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	1.0
	12248224	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	91.0	CHEMBL1844	Homo sapiens	Residual Activity	%	91.0
	12248225	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	70.0	CHEMBL1844	Homo sapiens	Residual Activity	%	70.0
	12248226	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	72.0	CHEMBL1844	Homo sapiens	Residual Activity	%	72.0
	12248227	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	14.0	CHEMBL1844	Homo sapiens	Residual Activity	%	14.0
	12248228	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	5.0	CHEMBL1844	Homo sapiens	Residual Activity	%	5.0
	12248229	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	91.0	CHEMBL1844	Homo sapiens	Residual Activity	%	91.0
	12248230	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	77.0	CHEMBL1844	Homo sapiens	Residual Activity	%	77.0
	12248231	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	36.0	CHEMBL1844	Homo sapiens	Residual Activity	%	36.0
	12248232	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	73.0	CHEMBL1844	Homo sapiens	Residual Activity	%	73.0
	12248233	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	3.0	CHEMBL1844	Homo sapiens	Residual Activity	%	3.0
	12248234	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	55.0	CHEMBL1844	Homo sapiens	Residual Activity	%	55.0
	12248235	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	74.0	CHEMBL1844	Homo sapiens	Residual Activity	%	74.0
	12248236	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	1.0
	12248237	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	5.0	CHEMBL1844	Homo sapiens	Residual Activity	%	5.0
	12248238	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	72.0	CHEMBL1844	Homo sapiens	Residual Activity	%	72.0
	12248239	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	86.0	CHEMBL1844	Homo sapiens	Residual Activity	%	86.0
	12248240	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	116.0	CHEMBL1844	Homo sapiens	Residual Activity	%	116.0
	12248241	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	102.0	CHEMBL1844	Homo sapiens	Residual Activity	%	102.0
	12248242	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	3.0	CHEMBL1844	Homo sapiens	Residual Activity	%	3.0
	12248243	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	74.0	CHEMBL1844	Homo sapiens	Residual Activity	%	74.0
	12248244	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	62.0	CHEMBL1844	Homo sapiens	Residual Activity	%	62.0
	12248245	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	33.0	CHEMBL1844	Homo sapiens	Residual Activity	%	33.0
	12248246	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	70.0	CHEMBL1844	Homo sapiens	Residual Activity	%	70.0
	12248247	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	69.0	CHEMBL1844	Homo sapiens	Residual Activity	%	69.0
	12248248	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	78.0	CHEMBL1844	Homo sapiens	Residual Activity	%	78.0
	12248249	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	41.0	CHEMBL1844	Homo sapiens	Residual Activity	%	41.0
	12248250	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	79.0	CHEMBL1844	Homo sapiens	Residual Activity	%	79.0
	12248251	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	67.0	CHEMBL1844	Homo sapiens	Residual Activity	%	67.0
	12248252	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	54.0	CHEMBL1844	Homo sapiens	Residual Activity	%	54.0
	12248253	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	69.0	CHEMBL1844	Homo sapiens	Residual Activity	%	69.0
	12248254	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	72.0	CHEMBL1844	Homo sapiens	Residual Activity	%	72.0
	12248255	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	79.0	CHEMBL1844	Homo sapiens	Residual Activity	%	79.0
	12248256	CHEMBL2219082	Millipore: Percentage of residual kinase activity of CSF1R at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	58.0	CHEMBL1844	Homo sapiens	Residual Activity	%	58.0
	12248257	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	76.0	CHEMBL1844	Homo sapiens	Residual Activity	%	76.0
	12248258	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	32.0	CHEMBL1844	Homo sapiens	Residual Activity	%	32.0
	12248259	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	37.0	CHEMBL1844	Homo sapiens	Residual Activity	%	37.0
	12250925	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	73.0	CHEMBL1844	Homo sapiens	Residual Activity	%	73.0
	12250926	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	59.0	CHEMBL1844	Homo sapiens	Residual Activity	%	59.0
	12250927	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	67.0	CHEMBL1844	Homo sapiens	Residual Activity	%	67.0
	12250928	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	12.0	CHEMBL1844	Homo sapiens	Residual Activity	%	12.0
	12250929	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	38.0	CHEMBL1844	Homo sapiens	Residual Activity	%	38.0
	12250930	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	8.0	CHEMBL1844	Homo sapiens	Residual Activity	%	8.0
	12250931	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	37.0	CHEMBL1844	Homo sapiens	Residual Activity	%	37.0
	12250932	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	83.0	CHEMBL1844	Homo sapiens	Residual Activity	%	83.0
	12250933	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	5.0	CHEMBL1844	Homo sapiens	Residual Activity	%	5.0
	12250934	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	61.0	CHEMBL1844	Homo sapiens	Residual Activity	%	61.0
	12250935	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	6.0	CHEMBL1844	Homo sapiens	Residual Activity	%	6.0
	12250936	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	4.0	CHEMBL1844	Homo sapiens	Residual Activity	%	4.0
	12250937	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	9.0	CHEMBL1844	Homo sapiens	Residual Activity	%	9.0
	12250938	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	71.0	CHEMBL1844	Homo sapiens	Residual Activity	%	71.0
	12250939	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	74.0	CHEMBL1844	Homo sapiens	Residual Activity	%	74.0
	12250940	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	43.0	CHEMBL1844	Homo sapiens	Residual Activity	%	43.0
	12250941	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	18.0	CHEMBL1844	Homo sapiens	Residual Activity	%	18.0
	12250942	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	83.0	CHEMBL1844	Homo sapiens	Residual Activity	%	83.0
	12250943	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	54.0	CHEMBL1844	Homo sapiens	Residual Activity	%	54.0
	12250944	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	100.0	CHEMBL1844	Homo sapiens	Residual Activity	%	100.0
	12250945	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	0.0	CHEMBL1844	Homo sapiens	Residual Activity	%	0.0
	12250946	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	102.0	CHEMBL1844	Homo sapiens	Residual Activity	%	102.0
	12250947	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	27.0	CHEMBL1844	Homo sapiens	Residual Activity	%	27.0
	12250948	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	10.0	CHEMBL1844	Homo sapiens	Residual Activity	%	10.0
	12250949	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	22.0	CHEMBL1844	Homo sapiens	Residual Activity	%	22.0
	12250950	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	2.0	CHEMBL1844	Homo sapiens	Residual Activity	%	2.0
	12250951	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	40.0	CHEMBL1844	Homo sapiens	Residual Activity	%	40.0
	12250952	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	76.0	CHEMBL1844	Homo sapiens	Residual Activity	%	76.0
	12250953	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	0.0	CHEMBL1844	Homo sapiens	Residual Activity	%	0.0
	12250954	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	51.0	CHEMBL1844	Homo sapiens	Residual Activity	%	51.0
	12250955	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	102.0	CHEMBL1844	Homo sapiens	Residual Activity	%	102.0
	12250956	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	0.0	CHEMBL1844	Homo sapiens	Residual Activity	%	0.0
	12250957	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	125.0	CHEMBL1844	Homo sapiens	Residual Activity	%	125.0
	12250958	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	0.0	CHEMBL1844	Homo sapiens	Residual Activity	%	0.0
	12250959	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	65.0	CHEMBL1844	Homo sapiens	Residual Activity	%	65.0
	12250960	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	120.0	CHEMBL1844	Homo sapiens	Residual Activity	%	120.0
	12250961	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	3.0	CHEMBL1844	Homo sapiens	Residual Activity	%	3.0
	12250962	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	127.0	CHEMBL1844	Homo sapiens	Residual Activity	%	127.0
	12250963	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	110.0	CHEMBL1844	Homo sapiens	Residual Activity	%	110.0
	12250964	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	5.0	CHEMBL1844	Homo sapiens	Residual Activity	%	5.0
	12250965	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	8.0	CHEMBL1844	Homo sapiens	Residual Activity	%	8.0
	12250966	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	-1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	-1.0
	12250967	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	92.0	CHEMBL1844	Homo sapiens	Residual Activity	%	92.0
	12250968	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	109.0	CHEMBL1844	Homo sapiens	Residual Activity	%	109.0
	12250969	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	0.0	CHEMBL1844	Homo sapiens	Residual Activity	%	0.0
	12250970	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	92.0	CHEMBL1844	Homo sapiens	Residual Activity	%	92.0
	12250971	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	80.0	CHEMBL1844	Homo sapiens	Residual Activity	%	80.0
	12250972	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	36.0	CHEMBL1844	Homo sapiens	Residual Activity	%	36.0
	12250973	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	1.0
	12250974	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	3.0	CHEMBL1844	Homo sapiens	Residual Activity	%	3.0
	12250975	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	78.0	CHEMBL1844	Homo sapiens	Residual Activity	%	78.0
	12250976	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	81.0	CHEMBL1844	Homo sapiens	Residual Activity	%	81.0
	12250977	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	5.0	CHEMBL1844	Homo sapiens	Residual Activity	%	5.0
	12250978	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	79.0	CHEMBL1844	Homo sapiens	Residual Activity	%	79.0
	12250979	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	84.0	CHEMBL1844	Homo sapiens	Residual Activity	%	84.0
	12250980	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	1.0
	12250981	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	62.0	CHEMBL1844	Homo sapiens	Residual Activity	%	62.0
	12250982	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	1.0
	12250983	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	1.0
	12250984	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	86.0	CHEMBL1844	Homo sapiens	Residual Activity	%	86.0
	12250985	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	55.0	CHEMBL1844	Homo sapiens	Residual Activity	%	55.0
	12250986	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	73.0	CHEMBL1844	Homo sapiens	Residual Activity	%	73.0
	12250987	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	2.0	CHEMBL1844	Homo sapiens	Residual Activity	%	2.0
	12250988	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	112.0	CHEMBL1844	Homo sapiens	Residual Activity	%	112.0
	12250989	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	78.0	CHEMBL1844	Homo sapiens	Residual Activity	%	78.0
	12250990	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	112.0	CHEMBL1844	Homo sapiens	Residual Activity	%	112.0
	12250991	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	53.0	CHEMBL1844	Homo sapiens	Residual Activity	%	53.0
	12250992	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	6.0	CHEMBL1844	Homo sapiens	Residual Activity	%	6.0
	12250993	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	2.0	CHEMBL1844	Homo sapiens	Residual Activity	%	2.0
	12250994	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	30.0	CHEMBL1844	Homo sapiens	Residual Activity	%	30.0
	12250995	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	11.0	CHEMBL1844	Homo sapiens	Residual Activity	%	11.0
	12250996	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	1.0
	12250997	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	4.0	CHEMBL1844	Homo sapiens	Residual Activity	%	4.0
	12250998	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	72.0	CHEMBL1844	Homo sapiens	Residual Activity	%	72.0
	12250999	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	0.0	CHEMBL1844	Homo sapiens	Residual Activity	%	0.0
	12251000	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	7.0	CHEMBL1844	Homo sapiens	Residual Activity	%	7.0
	12251001	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	0.0	CHEMBL1844	Homo sapiens	Residual Activity	%	0.0
	12251002	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	91.0	CHEMBL1844	Homo sapiens	Residual Activity	%	91.0
	12251003	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	7.0	CHEMBL1844	Homo sapiens	Residual Activity	%	7.0
	12251004	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	68.0	CHEMBL1844	Homo sapiens	Residual Activity	%	68.0
	12251005	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	110.0	CHEMBL1844	Homo sapiens	Residual Activity	%	110.0
	12251006	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	0.0	CHEMBL1844	Homo sapiens	Residual Activity	%	0.0
	12251007	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	43.0	CHEMBL1844	Homo sapiens	Residual Activity	%	43.0
	12251008	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	41.0	CHEMBL1844	Homo sapiens	Residual Activity	%	41.0
	12251009	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	52.0	CHEMBL1844	Homo sapiens	Residual Activity	%	52.0
	12251010	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	74.0	CHEMBL1844	Homo sapiens	Residual Activity	%	74.0
	12251011	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	8.0	CHEMBL1844	Homo sapiens	Residual Activity	%	8.0
	12251012	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	62.0	CHEMBL1844	Homo sapiens	Residual Activity	%	62.0
	12251013	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	28.0	CHEMBL1844	Homo sapiens	Residual Activity	%	28.0
	12251014	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	0.0	CHEMBL1844	Homo sapiens	Residual Activity	%	0.0
	12251015	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	53.0	CHEMBL1844	Homo sapiens	Residual Activity	%	53.0
	12251016	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	61.0	CHEMBL1844	Homo sapiens	Residual Activity	%	61.0
	12251017	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	94.0	CHEMBL1844	Homo sapiens	Residual Activity	%	94.0
	12251018	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	71.0	CHEMBL1844	Homo sapiens	Residual Activity	%	71.0
	12251019	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	89.0	CHEMBL1844	Homo sapiens	Residual Activity	%	89.0
	12251020	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	79.0	CHEMBL1844	Homo sapiens	Residual Activity	%	79.0
	12251021	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	15.0	CHEMBL1844	Homo sapiens	Residual Activity	%	15.0
	12251022	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	23.0	CHEMBL1844	Homo sapiens	Residual Activity	%	23.0
	12251023	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	1.0
	12251024	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	88.0	CHEMBL1844	Homo sapiens	Residual Activity	%	88.0
	12251025	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	26.0	CHEMBL1844	Homo sapiens	Residual Activity	%	26.0
	12251026	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	26.0	CHEMBL1844	Homo sapiens	Residual Activity	%	26.0
	12251027	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	77.0	CHEMBL1844	Homo sapiens	Residual Activity	%	77.0
	12251028	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	66.0	CHEMBL1844	Homo sapiens	Residual Activity	%	66.0
	12251029	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	58.0	CHEMBL1844	Homo sapiens	Residual Activity	%	58.0
	12251030	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	69.0	CHEMBL1844	Homo sapiens	Residual Activity	%	69.0
	12251031	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	23.0	CHEMBL1844	Homo sapiens	Residual Activity	%	23.0
	12251032	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	54.0	CHEMBL1844	Homo sapiens	Residual Activity	%	54.0
	12251033	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	86.0	CHEMBL1844	Homo sapiens	Residual Activity	%	86.0
	12251034	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	19.0	CHEMBL1844	Homo sapiens	Residual Activity	%	19.0
	12251035	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	27.0	CHEMBL1844	Homo sapiens	Residual Activity	%	27.0
	12251036	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	59.0	CHEMBL1844	Homo sapiens	Residual Activity	%	59.0
	12251037	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	80.0	CHEMBL1844	Homo sapiens	Residual Activity	%	80.0
	12251038	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	2.0	CHEMBL1844	Homo sapiens	Residual Activity	%	2.0
	12251039	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	64.0	CHEMBL1844	Homo sapiens	Residual Activity	%	64.0
	12251040	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	58.0	CHEMBL1844	Homo sapiens	Residual Activity	%	58.0
	12251041	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	84.0	CHEMBL1844	Homo sapiens	Residual Activity	%	84.0
	12251042	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	6.0	CHEMBL1844	Homo sapiens	Residual Activity	%	6.0
	12251043	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	11.0	CHEMBL1844	Homo sapiens	Residual Activity	%	11.0
	12251044	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	39.0	CHEMBL1844	Homo sapiens	Residual Activity	%	39.0
	12251045	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	53.0	CHEMBL1844	Homo sapiens	Residual Activity	%	53.0
	12251046	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	1.0
	12251047	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	51.0	CHEMBL1844	Homo sapiens	Residual Activity	%	51.0
	12251048	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	34.0	CHEMBL1844	Homo sapiens	Residual Activity	%	34.0
	12251049	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	43.0	CHEMBL1844	Homo sapiens	Residual Activity	%	43.0
	12251050	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	8.0	CHEMBL1844	Homo sapiens	Residual Activity	%	8.0
	12251051	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	0.0	CHEMBL1844	Homo sapiens	Residual Activity	%	0.0
	12251052	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	69.0	CHEMBL1844	Homo sapiens	Residual Activity	%	69.0
	12251053	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	58.0	CHEMBL1844	Homo sapiens	Residual Activity	%	58.0
	12251054	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	9.0	CHEMBL1844	Homo sapiens	Residual Activity	%	9.0
	12251055	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	65.0	CHEMBL1844	Homo sapiens	Residual Activity	%	65.0
	12251056	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	-1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	-1.0
	12251057	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	21.0	CHEMBL1844	Homo sapiens	Residual Activity	%	21.0
	12251058	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	66.0	CHEMBL1844	Homo sapiens	Residual Activity	%	66.0
	12251059	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	2.0	CHEMBL1844	Homo sapiens	Residual Activity	%	2.0
	12251060	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	8.0	CHEMBL1844	Homo sapiens	Residual Activity	%	8.0
	12251061	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	51.0	CHEMBL1844	Homo sapiens	Residual Activity	%	51.0
	12251062	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	68.0	CHEMBL1844	Homo sapiens	Residual Activity	%	68.0
	12251063	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	92.0	CHEMBL1844	Homo sapiens	Residual Activity	%	92.0
	12251064	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	75.0	CHEMBL1844	Homo sapiens	Residual Activity	%	75.0
	12251065	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	1.0	CHEMBL1844	Homo sapiens	Residual Activity	%	1.0
	12251066	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	64.0	CHEMBL1844	Homo sapiens	Residual Activity	%	64.0
	12251067	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	51.0	CHEMBL1844	Homo sapiens	Residual Activity	%	51.0
	12251068	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	16.0	CHEMBL1844	Homo sapiens	Residual Activity	%	16.0
	12251069	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	31.0	CHEMBL1844	Homo sapiens	Residual Activity	%	31.0
	12251070	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	27.0	CHEMBL1844	Homo sapiens	Residual Activity	%	27.0
	12251071	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	71.0	CHEMBL1844	Homo sapiens	Residual Activity	%	71.0
	12251072	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	14.0	CHEMBL1844	Homo sapiens	Residual Activity	%	14.0
	12251073	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	62.0	CHEMBL1844	Homo sapiens	Residual Activity	%	62.0
	12251074	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	65.0	CHEMBL1844	Homo sapiens	Residual Activity	%	65.0
	12251075	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	49.0	CHEMBL1844	Homo sapiens	Residual Activity	%	49.0
	12251076	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	74.0	CHEMBL1844	Homo sapiens	Residual Activity	%	74.0
	12251077	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	60.0	CHEMBL1844	Homo sapiens	Residual Activity	%	60.0
	12251078	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	58.0	CHEMBL1844	Homo sapiens	Residual Activity	%	58.0
	12251079	CHEMBL2219083	Millipore: Percentage of residual kinase activity of CSF1R at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	60.0	CHEMBL1844	Homo sapiens	Residual Activity	%	60.0
	12626713	CHEMBL2316987	Inhibition of FMS (unknown origin) at 1 uM	B	COc1cc(Nc2cc(-c3cccc(C#N)c3)ccn2)ccc1N1CCN(C)CC1		CHEMBL2312142	=	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	12626714	CHEMBL2316987	Inhibition of FMS (unknown origin) at 1 uM	B	COc1cc(Nc2ncc(Cl)c(-c3cccc(CC#N)c3)n2)ccc1N1CCN(C)CC1		CHEMBL2312140	>=	Inhibition	%	80.0	CHEMBL1844	Homo sapiens	INH	%	80.0
	12671070	CHEMBL2345084	Inhibition of CSF1R (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2cc(N3CCOCC3)ccc12		CHEMBL2333120	=	Inhibition	%	97.0	CHEMBL1844	Homo sapiens	INH	%	97.0
	12671071	CHEMBL2345084	Inhibition of CSF1R (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333115	=	Inhibition	%	96.0	CHEMBL1844	Homo sapiens	INH	%	96.0
	12671072	CHEMBL2345084	Inhibition of CSF1R (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2ccc(-c3ccncc3)cc12		CHEMBL2333114	=	Inhibition	%	90.0	CHEMBL1844	Homo sapiens	INH	%	90.0
	12671073	CHEMBL2345084	Inhibition of CSF1R (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2cc(-c3ccncc3)ccc12		CHEMBL2333112	=	Inhibition	%	99.0	CHEMBL1844	Homo sapiens	INH	%	99.0
	12671074	CHEMBL2345084	Inhibition of CSF1R (unknown origin) at 10 uM relative to control	B	CS(=O)(=O)c1ccc(-c2ccc3c(NC4CCC4)c(C(N)=O)nnc3c2)cc1		CHEMBL2333129	=	Inhibition	%	100.0	CHEMBL1844	Homo sapiens	INH	%	100.0
	12671075	CHEMBL2345084	Inhibition of CSF1R (unknown origin) at 10 uM relative to control	B	C[C@@H](Nc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12)C1CC1		CHEMBL2333128	=	Inhibition	%	100.0	CHEMBL1844	Homo sapiens	INH	%	100.0
	12671076	CHEMBL2345084	Inhibition of CSF1R (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12		CHEMBL2333125	=	Inhibition	%	98.0	CHEMBL1844	Homo sapiens	INH	%	98.0
	12671140	CHEMBL2345522	Inhibition of CSF1R (unknown origin) by TR-FRET assay in presence of ATP	B	CC(C)Nc1c(C(N)=O)nnc2cc(N3CCOCC3)ccc12		CHEMBL2333120	=	IC50	nM	22.0	CHEMBL1844	Homo sapiens	IC50	uM	0.022
	12671141	CHEMBL2345522	Inhibition of CSF1R (unknown origin) by TR-FRET assay in presence of ATP	B	CS(=O)(=O)c1ccc(-c2ccc3c(NC4CCC4)c(C(N)=O)nnc3c2)cc1		CHEMBL2333129	<	IC50	nM	40.0	CHEMBL1844	Homo sapiens	IC50	uM	0.04
	12671142	CHEMBL2345522	Inhibition of CSF1R (unknown origin) by TR-FRET assay in presence of ATP	B	C[C@@H](Nc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12)C1CC1		CHEMBL2333128	=	IC50	nM	17.0	CHEMBL1844	Homo sapiens	IC50	uM	0.017
	12671143	CHEMBL2345522	Inhibition of CSF1R (unknown origin) by TR-FRET assay in presence of ATP	B	CC(C)Nc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12		CHEMBL2333126	=	IC50	nM	12.0	CHEMBL1844	Homo sapiens	IC50	uM	0.012
	12723666	CHEMBL2350765	Inhibition of CSF1R (unknown origin) at 10 uM by single point assay	B	C[C@@H](Nc1c(C#N)cnc2cc(-c3ccc(-n4ccoc4=O)cc3)ccc12)C1CC1		CHEMBL2347818	=	Inhibition	%	39.0	CHEMBL1844	Homo sapiens	INH	%	39.0
	12724774	CHEMBL2352285	Inhibition of CSF1R (unknown origin) at 1 uM by single point assay	B	CC(C)Nc1c(C#N)cnc2cc(-c3cnn(C)c3)ccc12		CHEMBL2347824	=	Inhibition	%	67.0	CHEMBL1844	Homo sapiens	INH	%	67.0
	12724775	CHEMBL2352285	Inhibition of CSF1R (unknown origin) at 1 uM by single point assay	B	CC(C)Nc1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12		CHEMBL2347823	=	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	12728824	CHEMBL2352897	Inhibition of FMS (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	68.0	CHEMBL1844	Homo sapiens	Activity	%	68.0
	12729069	CHEMBL2352247	Inhibition of FMS (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	70.0	CHEMBL1844	Homo sapiens	Activity	%	70.0
	12729354	CHEMBL2351454	Inhibition of CSF1R (unknown origin) at 1 uM	B	FC(F)(F)c1cccc(Sc2ccc3nnc(-c4ccccc4)n3n2)c1		CHEMBL2348936	>	Inhibition	%	18.0	CHEMBL1844	Homo sapiens	INH	%	18.0
	12729953	CHEMBL2352189	Inhibition of FMS (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	96.0	CHEMBL1844	Homo sapiens	Activity	%	96.0
	12730212	CHEMBL2352897	Inhibition of FMS (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	19.0	CHEMBL1844	Homo sapiens	Activity	%	19.0
	12730625	CHEMBL2353584	Inhibition of human FMS	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	12731233	CHEMBL2352061	Inhibition of FMS (unknown origin)	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	IC50	nM	2700.0	CHEMBL1844	Homo sapiens	IC50	uM	2.7
	13301269	CHEMBL2384610	Inhibition of Fms (unknown origin)	B	O=C(Nc1ccc(Nc2ccnc3[nH]c(=O)c4ccccc4c23)cc1)c1ccc(F)cc1C(F)(F)F		CHEMBL2380834	=	IC50	nM	575.0	CHEMBL1844	Homo sapiens	IC50	nM	575.0
	13327690	CHEMBL2389842	Inhibition of CSF1R (unknown origin) at 1 uM	B	CC(C)(C)c1cc(NC(=O)NCc2ccc(-c3cc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)[nH]n3)cc2)no1		CHEMBL2386802	=	Inhibition	%	95.0	CHEMBL1844	Homo sapiens	INH	%	95.0
	13327691	CHEMBL2389842	Inhibition of CSF1R (unknown origin) at 1 uM	B	Cc1cc(-c2cc(NC(=O)c3ccc(CN4CCN(C)CC4)cc3)[nH]n2)ccc1NC(=O)Nc1cc(C(C)(C)C)on1		CHEMBL2386796	=	Inhibition	%	97.0	CHEMBL1844	Homo sapiens	INH	%	97.0
	13329900	CHEMBL2390176	Inhibition of CSF1R (unknown origin) at 1 uM	B	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@@H](NCC(F)(F)F)C1		CHEMBL2385096	=	Inhibition	%	75.0	CHEMBL1844	Homo sapiens	INH	%	75.0
	13375908	CHEMBL2405318	Inhibition of CSF1R (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	-4.0	CHEMBL1844	Homo sapiens	INH	%	-4.0
	13418829	CHEMBL2422663	Inhibition of CSF1R (unknown origin)	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	IC50	nM	5.012	CHEMBL1844	Homo sapiens	pIC50		8.3
	13418830	CHEMBL2422663	Inhibition of CSF1R (unknown origin)	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	IC50	nM	50.12	CHEMBL1844	Homo sapiens	pIC50		7.3
	13439723	CHEMBL2427772	Competitive binding affinity to CSF1R (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	<	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	13442589	CHEMBL2427772	Competitive binding affinity to CSF1R (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-c3n[nH]c4ccccc34)n2)CC1		CHEMBL2425644	=	Inhibition	%	97.0	CHEMBL1844	Homo sapiens	INH	%	97.0
	13445556	CHEMBL2427772	Competitive binding affinity to CSF1R (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	=	Inhibition	%	74.0	CHEMBL1844	Homo sapiens	INH	%	74.0
	13451543	CHEMBL2427772	Competitive binding affinity to CSF1R (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	<	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	13829784	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(C)(C)CN3CCN(CCO)CC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085975	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
	13829785	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(C)(C)CNCCS(C)(=O)=O)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085974	=	IC50	nM	1.5	CHEMBL1844	Homo sapiens	IC50	nM	1.5
	13829786	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	COCCNCC(C)(C)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3085973	=	IC50	nM	0.6	CHEMBL1844	Homo sapiens	IC50	nM	0.6
	13829787	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(C)(C)CN3CCS(=O)(=O)CC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3085972	=	IC50	nM	3.5	CHEMBL1844	Homo sapiens	IC50	nM	3.5
	13829788	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC(=O)N1CCN(CC(C)(C)c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3085971	=	IC50	nM	5.7	CHEMBL1844	Homo sapiens	IC50	nM	5.7
	13829789	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(C)(C)CN3CCOCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085970	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	nM	8.0
	13829790	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(C)(C)CO)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3085969	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
	13829791	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	COCCN1CCN(C(C)(C)c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3085834	=	IC50	nM	1.3	CHEMBL1844	Homo sapiens	IC50	nM	1.3
	13829792	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCN(CCO)CC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085833	=	IC50	nM	0.7	CHEMBL1844	Homo sapiens	IC50	nM	0.7
	13829793	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC(=O)N1CCN(C(C)(C)c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3085832	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	nM	1.7
	13829794	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CCN1CCN(C(C)(C)c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3085831	=	IC50	nM	1.5	CHEMBL1844	Homo sapiens	IC50	nM	1.5
	13829795	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CN1CCN(C(C)(C)c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3085830	=	IC50	nM	2.3	CHEMBL1844	Homo sapiens	IC50	nM	2.3
	13829796	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCS(=O)(=O)CC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3085829	=	IC50	nM	3.5	CHEMBL1844	Homo sapiens	IC50	nM	3.5
	13829797	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCOCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085828	=	IC50	nM	0.9	CHEMBL1844	Homo sapiens	IC50	nM	0.9
	13829798	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(C)(C)Nc3ccccn3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085827	=	IC50	nM	19.0	CHEMBL1844	Homo sapiens	IC50	nM	19.0
	13829799	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC(=O)NCCNC(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3085977	=	IC50	nM	0.7	CHEMBL1844	Homo sapiens	IC50	nM	0.7
	13829800	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(C)(C)NCCN3CCOCC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3085976	=	IC50	nM	1.2	CHEMBL1844	Homo sapiens	IC50	nM	1.2
	13829801	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CN(CCS(C)(=O)=O)C(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3086323	=	IC50	nM	7.2	CHEMBL1844	Homo sapiens	IC50	nM	7.2
	13829802	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(C)(C)NCCS(C)(=O)=O)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086322	=	IC50	nM	1.5	CHEMBL1844	Homo sapiens	IC50	nM	1.5
	13829803	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	COCCN(C)C(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3086321	=	IC50	nM	2.1	CHEMBL1844	Homo sapiens	IC50	nM	2.1
	13829804	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	COCCNC(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3086320	=	IC50	nM	0.6	CHEMBL1844	Homo sapiens	IC50	nM	0.6
Not Determined	13829805	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(C)(C)NCCO)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086319		IC50			CHEMBL1844	Homo sapiens	IC50		
	13829806	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(C)(C)OCCN3CCOCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3086318	=	IC50	nM	1.9	CHEMBL1844	Homo sapiens	IC50	nM	1.9
	13829807	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(C)(C)OCCN3CCCC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086317	=	IC50	nM	1.2	CHEMBL1844	Homo sapiens	IC50	nM	1.2
	13829808	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CN(C)CCOC(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3086316	=	IC50	nM	2.1	CHEMBL1844	Homo sapiens	IC50	nM	2.1
	13829809	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(C)(C)O)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086315	=	IC50	nM	1.9	CHEMBL1844	Homo sapiens	IC50	nM	1.9
	13829810	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(CCS(=O)(=O)N3CCOCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3086314	=	IC50	nM	4.5	CHEMBL1844	Homo sapiens	IC50	nM	4.5
	13829811	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	N#Cc1c[nH]c(C(=O)Nc2ccc(CCS(=O)(=O)N3CCOCC3)cc2C2=CCCCC2)n1		CHEMBL3086179	=	IC50	nM	3.5	CHEMBL1844	Homo sapiens	IC50	nM	3.5
	13829812	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(CCS(=O)(=O)NN)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086178	=	IC50	nM	2.6	CHEMBL1844	Homo sapiens	IC50	nM	2.6
	13829813	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	N#Cc1c[nH]c(C(=O)Nc2ccc(CCS(=O)(=O)NN)cc2C2=CCCCC2)n1		CHEMBL3086177	=	IC50	nM	5.6	CHEMBL1844	Homo sapiens	IC50	nM	5.6
	13829814	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(CCS(N)(=O)=O)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086176	=	IC50	nM	1.6	CHEMBL1844	Homo sapiens	IC50	nM	1.6
	13829815	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	N#Cc1c[nH]c(C(=O)Nc2ccc(CCS(N)(=O)=O)cc2C2=CCCCC2)n1		CHEMBL3085982	=	IC50	nM	2.4	CHEMBL1844	Homo sapiens	IC50	nM	2.4
	13829816	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(CCC(N)=O)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3085981	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	nM	1.7
	13829817	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	N#Cc1c[nH]c(C(=O)Nc2ccc(CCC(N)=O)cc2C2=CCCCC2)n1		CHEMBL3085980	=	IC50	nM	2.7	CHEMBL1844	Homo sapiens	IC50	nM	2.7
	13829818	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	N#Cc1c[nH]c(C(=O)Nc2ccc(CCC(=O)O)cc2C2=CCCCC2)n1		CHEMBL3085979	=	IC50	nM	5.9	CHEMBL1844	Homo sapiens	IC50	nM	5.9
	13829819	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(CCN3CCOCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085978	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	nM	0.8
	13829820	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	N#Cc1cnc(C(=O)Nc2ccc(CCN3CCOCC3)cc2C2=CCCCC2)[nH]1		CHEMBL3086175	=	IC50	nM	1.4	CHEMBL1844	Homo sapiens	IC50	nM	1.4
	13829821	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(CCO)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086174	=	IC50	nM	4.6	CHEMBL1844	Homo sapiens	IC50	nM	4.6
	13829822	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	N#Cc1c[nH]c(C(=O)Nc2ccc(CCO)cc2C2=CCCCC2)n1		CHEMBL3086173	=	IC50	nM	6.8	CHEMBL1844	Homo sapiens	IC50	nM	6.8
	13829823	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(CC(=O)NCCCO)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3086172	=	IC50	nM	2.4	CHEMBL1844	Homo sapiens	IC50	nM	2.4
	13829824	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC(C)(O)Cc1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCCCC2)c1		CHEMBL3086171	=	IC50	nM	3.7	CHEMBL1844	Homo sapiens	IC50	nM	3.7
	13829825	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(Cc3nnn[nH]3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086160	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
	13829826	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	N#Cc1c[nH]c(C(=O)Nc2ccc(Cc3nnn[nH]3)cc2C2=CCCCC2)n1		CHEMBL3085986	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	nM	13.0
	13829827	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	N#Cc1cnc(C(=O)Nc2ccc(CS(=O)(=O)N3CCOCC3)cc2C2=CCCCC2)[nH]1		CHEMBL3085985	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	nM	13.0
	13829828	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(CN3CCN(CCO)CC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3085984	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	nM	0.8
	13829829	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	N#Cc1cnc(C(=O)Nc2ccc(CN3CCOCC3)cc2C2=CCCCC2)[nH]1		CHEMBL3085983	=	IC50	nM	3.2	CHEMBL1844	Homo sapiens	IC50	nM	3.2
	13829830	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(-c3nnn[nH]3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086170	=	IC50	nM	3.7	CHEMBL1844	Homo sapiens	IC50	nM	3.7
	13829831	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	N#Cc1c[nH]c(C(=O)Nc2ccc(-c3nnn[nH]3)cc2C2=CCCCC2)n1		CHEMBL3086169	=	IC50	nM	23.0	CHEMBL1844	Homo sapiens	IC50	nM	23.0
	13829832	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	N#Cc1c[nH]c(C(=O)Nc2ccc(S(=O)(=O)N3CCOCC3)cc2C2=CCCCC2)n1		CHEMBL3086168	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	13829833	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(S(N)(=O)=O)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086167	=	IC50	nM	1.9	CHEMBL1844	Homo sapiens	IC50	nM	1.9
	13829834	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	N#Cc1c[nH]c(C(=O)Nc2ccc(S(N)(=O)=O)cc2C2=CCCCC2)n1		CHEMBL3086161	=	IC50	nM	6.9	CHEMBL1844	Homo sapiens	IC50	nM	6.9
	13829835	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(S(C)(=O)=O)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086166	=	IC50	nM	2.3	CHEMBL1844	Homo sapiens	IC50	nM	2.3
	13829836	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC(O)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3086165	=	IC50	nM	1.4	CHEMBL1844	Homo sapiens	IC50	nM	1.4
	13829837	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(=O)O)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086164	=	IC50	nM	1.5	CHEMBL1844	Homo sapiens	IC50	nM	1.5
	13829838	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CN(C)C(=O)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3086163	=	IC50	nM	2.8	CHEMBL1844	Homo sapiens	IC50	nM	2.8
	13829839	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	CC1(C)CC=C(c2cc(C(N)=O)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086162	=	IC50	nM	2.2	CHEMBL1844	Homo sapiens	IC50	nM	2.2
	13829840	CHEMBL3088374	Inhibition of FMS (unknown origin)	B	N#Cc1c[nH]c(C(=O)Nc2ccc(C(N)=O)cc2C2=CCCCC2)n1		CHEMBL3086325	=	IC50	nM	3.6	CHEMBL1844	Homo sapiens	IC50	nM	3.6
	13872139	CHEMBL3101764	Inhibition of human Fms assessed as residual activity at 1 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	91.0	CHEMBL1844	Homo sapiens	Activity	%	91.0
	13890636	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(OCCN)c4n3)cnc2c1		CHEMBL3109355	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	13890637	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(OCc5cnc[nH]5)c4n3)cnc2c1		CHEMBL3109354	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	13890638	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CN[C@H](C(=O)OC)C5)c4n3)cnc2c1		CHEMBL3109353	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	13890639	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(O[C@H]5CN[C@H](C(=O)OC)C5)c4n3)cnc2c1		CHEMBL3109352	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	13890640	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CNC[C@H]5OC)c4n3)cnc2c1		CHEMBL3109351	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	13890641	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(OCC5CCNC5)c4n3)cnc2c1		CHEMBL3109350	=	IC50	nM	301.0	CHEMBL1844	Homo sapiens	IC50	nM	301.0
	13890642	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(OCC5CNCCO5)c4n3)cnc2c1		CHEMBL3109349	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	13890643	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(O[C@H]5CC[C@H](N)CC5)c4n3)cnc2c1		CHEMBL3109348	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	13890644	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@@H]5O)c4n3)cnc2c1		CHEMBL3109347	=	IC50	nM	384.0	CHEMBL1844	Homo sapiens	IC50	nM	384.0
	13890645	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@H]5O)c4n3)cnc2c1		CHEMBL3109346	=	IC50	nM	131.0	CHEMBL1844	Homo sapiens	IC50	nM	131.0
	13890646	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCCNC5)c4n3)cnc2c1		CHEMBL3109345	=	IC50	nM	873.0	CHEMBL1844	Homo sapiens	IC50	nM	873.0
	13890647	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(O[C@H]5CCCNC5)c4n3)cnc2c1		CHEMBL3109344	=	IC50	nM	21.0	CHEMBL1844	Homo sapiens	IC50	nM	21.0
	13890648	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(OCC5(F)CCNCC5)c4n3)cnc2c1		CHEMBL3109343	=	IC50	nM	88.0	CHEMBL1844	Homo sapiens	IC50	nM	88.0
	13890649	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(OCC5CCNCC5)c4n3)cnc2c1		CHEMBL3109342	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	13890650	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(OC5CCN(C)CC5)c4n3)cnc2c1		CHEMBL3109341	=	IC50	nM	312.0	CHEMBL1844	Homo sapiens	IC50	nM	312.0
	13890737	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@H]5F)c4n3)cnc2c1		CHEMBL3109337	=	IC50	nM	767.0	CHEMBL1844	Homo sapiens	IC50	nM	767.0
	13890738	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@@H]5F)c4n3)cnc2c1		CHEMBL3109356	=	IC50	nM	282.0	CHEMBL1844	Homo sapiens	IC50	nM	282.0
	13890739	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(O[C@H]5CCNC[C@@H]5F)c4n3)cnc2c1		CHEMBL3109338	=	IC50	nM	499.0	CHEMBL1844	Homo sapiens	IC50	nM	499.0
	13890740	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@H]5F)c4n3)cnc2c1		CHEMBL3109337	=	IC50	nM	322.0	CHEMBL1844	Homo sapiens	IC50	nM	322.0
	13890741	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(OCC(C)(C)CN)c4n3)cnc2c1		CHEMBL3109339	=	IC50	nM	73.0	CHEMBL1844	Homo sapiens	IC50	nM	73.0
	13890768	CHEMBL3111863	Inhibition of cFMS (unknown origin)	B	COCCOc1ccn2c(-c3ccc4cccc(OC5CCNCC5)c4n3)cnc2c1		CHEMBL3109340	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	13917427	CHEMBL3117356	Inhibition of FMS (unknown origin)	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	nM	10000.0
	13917483	CHEMBL3117356	Inhibition of FMS (unknown origin)	B	CN1CCN(c2ccc(Nc3ncc4cc(C#N)c(=O)n(C5CCCC5)c4n3)cc2)CC1		CHEMBL3115681	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	13954563	CHEMBL3132484	Inhibition of human FMS assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125726	=	Activity	%	70.0	CHEMBL1844	Homo sapiens	Activity	%	70.0
	13954750	CHEMBL3132484	Inhibition of human FMS assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125728	=	Activity	%	70.0	CHEMBL1844	Homo sapiens	Activity	%	70.0
	13954761	CHEMBL3132484	Inhibition of human FMS assessed as residual activity at 1 uM relative to control	B	COc1ccc(-c2nc3cc(-c4csc(C(=O)NCC(C)C)c4)cnc3[nH]2)cc1		CHEMBL3125727	=	Activity	%	63.0	CHEMBL1844	Homo sapiens	Activity	%	63.0
	14526847	CHEMBL3223956	Inhibition of FMS (unknown origin) at 10 uM assessed as residual enzyme activity	B	COc1ccc(-c2n[nH]c3ncc(-c4ccc(Cl)cc4N)cc23)cc1		CHEMBL3220823	=	Activity	%	101.5	CHEMBL1844	Homo sapiens	Activity	%	101.5
	14544036	CHEMBL3226045	Inhibition of FMS (unknown origin) at 10 uM	B	CC1(C)C(=O)Nc2cc3nccc(Oc4ccc(NC(=O)Nc5ccc(F)c(C(F)(F)F)c5)cc4Cl)c3cc21		CHEMBL3218350	=	Inhibition	%	46.9	CHEMBL1844	Homo sapiens	INH	%	46.9
	14582507	CHEMBL3242359	Inhibition of human Fms assessed as enzyme activity at 1 uM relative to control	B	CCCS(=O)(=O)Nc1cccc(Nc2ccc3ncn(C)c(=O)c3c2)c1C#N		CHEMBL3236464	=	Activity	%	99.0	CHEMBL1844	Homo sapiens	Activity	%	99.0
	14713704	CHEMBL3296769	Binding affinity to FMS (unknown origin)	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1NC(=O)CCN1CCN(C)CC1		CHEMBL3288854	=	Ki	nM	230.0	CHEMBL1844	Homo sapiens	Ki	uM	0.23
	14713740	CHEMBL3296858	Inhibition of FMS (unknown origin) at 1 uM relative to control	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1NC(=O)CCN1CCN(C)CC1		CHEMBL3288854	=	Inhibition	%	84.0	CHEMBL1844	Homo sapiens	INH	%	84.0
Not Determined	14713761	CHEMBL3296769	Binding affinity to FMS (unknown origin)	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535		Ki			CHEMBL1844	Homo sapiens	Ki		
	14979248	CHEMBL3379617	Inhibition of CSF1R (unknown origin) at 1 uM	B	CNc1cc2ccc(C#CCOc3ccc(CN4CCNCC4)c(C(F)(F)F)c3)cc2cn1		CHEMBL3355065	=	Inhibition	%	94.0	CHEMBL1844	Homo sapiens	INH	%	94.0
	14979249	CHEMBL3379618	Inhibition of CSF1R (unknown origin)	B	CNc1cc2ccc(C#CCOc3ccc(CN4CCNCC4)c(C(F)(F)F)c3)cc2cn1		CHEMBL3355065	=	IC50	nM	46.0	CHEMBL1844	Homo sapiens	IC50	nM	46.0
	14981084	CHEMBL3375433	Inhibition of FMS (unknown origin) at 1 uM	B	CC(C)(O)[C@H]1CC[C@H](Nc2ccn3ncc(-c4cccc(Cl)c4)c3n2)CC1		CHEMBL3355987	>	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	15009828	CHEMBL3361646	Inhibition of FMS (unknown origin) at 10 uM	B	C[C@H](O)CNc1nccc(-n2ccnc2Cc2cccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c2)n1		CHEMBL3309549	=	Inhibition	%	33.6	CHEMBL1844	Homo sapiens	INH	%	33.6
	15018569	CHEMBL3361883	Inhibition of CSF1R (unknown origin) at 100 nM	B	O=C(N[C@H](CO)c1ccc(Cl)c(F)c1)N1CCc2cnc(NC3CCOCC3)nc2C1		CHEMBL3298678	=	Inhibition	%	4.4	CHEMBL1844	Homo sapiens	INH	%	4.4
	15055373	CHEMBL3371390	Inhibition of CSF1-R (unknown origin) assessed as residual activity at 1 uM by radiometric protein kinase assay	B	COc1cc(-c2c[nH]c(=O)c(-c3cc(OC)c(OC)c(OC)c3)n2)ccc1O		CHEMBL3358999	=	Activity	%	28.0	CHEMBL1844	Homo sapiens	Activity	%	28.0
	15100462	CHEMBL3384721	Inhibition of CSF1R kinase (unknown origin)	B	CCN1CCN(CC(=O)Nc2cc(Oc3ccc4c(c3)nc(Nc3cc(C(F)(F)F)ccc3F)n4C)ccn2)CC1		CHEMBL3335387	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	15116722	CHEMBL3382757	Inhibition of human CSF1R (unknown origin)	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	=	IC50	nM	489.0	CHEMBL1844	Homo sapiens	IC50	nM	489.0
	15250384	CHEMBL3430288	Binding affinity to human CSF1R at 10 uM relative to control	B	COc1cc(-c2cnc3c(N4CCOCC4)snc3c2)cc(OC)c1OC		CHEMBL3425865	<	Activity	%	10.0	CHEMBL1844	Homo sapiens	Activity	%	10.0
	15250391	CHEMBL3430295	Binding affinity to human CSF1R	B	COc1cc(-c2cnc3c(N4CCOCC4)snc3c2)cc(OC)c1OC		CHEMBL3425865	=	Kd	nM	320.0	CHEMBL1844	Homo sapiens	Kd	nM	320.0
	15616256	CHEMBL3583128	Inhibition of Tel-fused FMS (unknown origin) expressed in mouse BA/F3 cells after 48 hrs by luciferase reporter gene assay in absence of recombinant mouse IL3	B	OC1CCN(c2cc(-c3cnc4ccc(N5CCC[C@@H]5c5cccc(F)c5)nn34)ccn2)CC1		CHEMBL3582442	=	IC50	nM	5300.0	CHEMBL1844	Homo sapiens	IC50	uM	5.3
	15616257	CHEMBL3583128	Inhibition of Tel-fused FMS (unknown origin) expressed in mouse BA/F3 cells after 48 hrs by luciferase reporter gene assay in absence of recombinant mouse IL3	B	O=C(O)CN1CCN(c2cc(-c3cnc4ccc(N5CCC[C@@H]5c5cccc(F)c5)nn34)ccn2)CC1		CHEMBL3582441	=	IC50	nM	2500.0	CHEMBL1844	Homo sapiens	IC50	uM	2.5
	15616258	CHEMBL3583128	Inhibition of Tel-fused FMS (unknown origin) expressed in mouse BA/F3 cells after 48 hrs by luciferase reporter gene assay in absence of recombinant mouse IL3	B	Fc1cccc([C@H]2CCCN2c2ccc3ncc(-c4ccccn4)n3n2)c1		CHEMBL3582439	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	15616259	CHEMBL3583128	Inhibition of Tel-fused FMS (unknown origin) expressed in mouse BA/F3 cells after 48 hrs by luciferase reporter gene assay in absence of recombinant mouse IL3	B	N#Cc1ccc(-c2cnc3ccc(NCc4ccccc4)nn23)cc1		CHEMBL3582427	=	IC50	nM	3400.0	CHEMBL1844	Homo sapiens	IC50	uM	3.4
	15625305	CHEMBL3588376	Inhibition of recombinant human cFMS at 3 uM relative to control	B	CCN1C(=O)CNc2ncc(-c3ccc(-c4nc[nH]n4)nc3C)nc21		CHEMBL3586573	=	Inhibition	%	57.0	CHEMBL1844	Homo sapiens	INH	%	57.0
	15625306	CHEMBL3588377	Inhibition of recombinant human cFMS	B	CCN1C(=O)CNc2ncc(-c3ccc(-c4nc[nH]n4)nc3C)nc21		CHEMBL3586573	=	IC50	nM	2000.0	CHEMBL1844	Homo sapiens	IC50	uM	2.0
	15632699	CHEMBL3587471	Inhibition of cFMS (unknown origin)	B	CO[C@H]1CC[C@H](N2C(=O)CNc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1		CHEMBL3586404	=	IC50	nM	28.0	CHEMBL1844	Homo sapiens	IC50	uM	0.028
	15649718	CHEMBL3595387	Inhibition of human CSF1R at 0.1 uM relative to control	B	CCc1cc(NC(=O)Nc2ccc(-c3cnc(Nc4cc(N5CCN(CC)CC5)nc(C)n4)s3)cc2)no1		CHEMBL3593290	=	Inhibition	%	94.0	CHEMBL1844	Homo sapiens	INH	%	94.0
	15723391	CHEMBL3620000	Inhibition of FMS (unknown origin) at 10 uM after 40 mins by scintillation counting analysis	B	Cc1ccc(NC(=O)c2cc(N3CCN(C)CC3)cc(C(F)(F)F)c2)cc1NC(=O)c1cnoc1C		CHEMBL3616960	=	Inhibition	%	98.7	CHEMBL1844	Homo sapiens	INH	%	98.7
Not Active	15723392	CHEMBL3620000	Inhibition of FMS (unknown origin) at 10 uM after 40 mins by scintillation counting analysis	B	Cc1ccccc1C(=O)Nc1cnoc1C		CHEMBL3616990		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
	15723438	CHEMBL3620030	Inhibition of FMS (unknown origin) after 40 mins by scintillation counting analysis	B	Cc1ccc(NC(=O)c2cc(N3CCN(C)CC3)cc(C(F)(F)F)c2)cc1NC(=O)c1cnoc1C		CHEMBL3616960	=	IC50	nM	9.95	CHEMBL1844	Homo sapiens	IC50	nM	9.95
	15723439	CHEMBL3620030	Inhibition of FMS (unknown origin) after 40 mins by scintillation counting analysis	B	Cc1ccccc1C(=O)Nc1cnoc1C		CHEMBL3616990	=	IC50	nM	216.0	CHEMBL1844	Homo sapiens	IC50	nM	216.0
	15723440	CHEMBL3620030	Inhibition of FMS (unknown origin) after 40 mins by scintillation counting analysis	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	1.14	CHEMBL1844	Homo sapiens	IC50	nM	1.14
	15736637	CHEMBL3625814	Inhibition of human recombinant Fms	B	CN(C)CCCNC(=O)c1csc2nc(-c3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)cn12		CHEMBL3623375	=	IC50	nM	43.0	CHEMBL1844	Homo sapiens	IC50	uM	0.043
	15754928	CHEMBL3631711	Inhibition of CSF1R (unknown origin) at 1 uM by FRET method	B	N#Cc1ccnc(Nc2cc(C3CCN(C4COC4)CC3)n(C3CCCC3)n2)c1		CHEMBL3629013	=	Inhibition	%	51.8	CHEMBL1844	Homo sapiens	INH	%	51.8
	15754947	CHEMBL3631839	Inhibition of CSF1R (unknown origin) by FRET method	B	N#Cc1ccnc(Nc2cc(C3CCN(C4COC4)CC3)n(C3CCCC3)n2)c1		CHEMBL3629013	=	IC50	nM	57000.0	CHEMBL1844	Homo sapiens	IC50	mM	0.057
	15755221	CHEMBL3630645	Inhibition of CSF1R (unknown origin) assessed as remaining activity at 10 uM by high-throughput assay relative to control	B	O=C1c2ccccc2-c2c1oc1ccccc1c2=O		CHEMBL3629616	=	Activity	%	77.0	CHEMBL1844	Homo sapiens	Activity	%	77.0
	15756979	CHEMBL3630504	Inhibition of FMS (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	98.25	CHEMBL1844	Homo sapiens	INH	%	98.25
	15757744	CHEMBL3630504	Inhibition of FMS (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	43.92	CHEMBL1844	Homo sapiens	INH	%	43.92
	15758723	CHEMBL3630504	Inhibition of FMS (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	5.32	CHEMBL1844	Homo sapiens	INH	%	5.32
249764	16269784	CHEMBL3707499	Homogenous Time-Resolved Fluorescence Assay (HTRF): To determine the activity of the various kinases, a homogenous time-resolved fluorescence (HTRF) in vitro kinase assay was used. (Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6): p. 309-314; Alfred J. Kolb, Paul V. Kaplita, David J. Hayes, Young-Whan Park, Christine Pernell, John S. Major and Gerard Mathis, Drug Discovery Today, 1998, 3, 333-342.). For example for KDR, cKIT, FLT1, CSF1R and FTL3, purified enzyme was mixed with 0.5 μM N-biotinylated substrate (Biotin-Ahx-AEEEYFFLA-amide (SEQ. ID. 1)), various concentrations of inhibitor in reaction buffer (50 mM HEPES, pH 7.1, 10 mM MgCl2, 2 mM MnCl2, 0.1% BSA and 1 mM DTT, 40 μL final volume), ATP (1 mM final conc.) in a black 384-well plate. After 60 minutes incubation at room temperature, the reaction was quenched by addition of a buffered EDTA solution.	B	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C[C@H](O)CO)c5)cnc(N)c34)cc2)cc1		CHEMBL3646211	=	IC50	nM	1.34	CHEMBL1844	Homo sapiens	IC50	nM	1.34
249765	16273908	CHEMBL3707499	Homogenous Time-Resolved Fluorescence Assay (HTRF): To determine the activity of the various kinases, a homogenous time-resolved fluorescence (HTRF) in vitro kinase assay was used. (Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6): p. 309-314; Alfred J. Kolb, Paul V. Kaplita, David J. Hayes, Young-Whan Park, Christine Pernell, John S. Major and Gerard Mathis, Drug Discovery Today, 1998, 3, 333-342.). For example for KDR, cKIT, FLT1, CSF1R and FTL3, purified enzyme was mixed with 0.5 μM N-biotinylated substrate (Biotin-Ahx-AEEEYFFLA-amide (SEQ. ID. 1)), various concentrations of inhibitor in reaction buffer (50 mM HEPES, pH 7.1, 10 mM MgCl2, 2 mM MnCl2, 0.1% BSA and 1 mM DTT, 40 μL final volume), ATP (1 mM final conc.) in a black 384-well plate. After 60 minutes incubation at room temperature, the reaction was quenched by addition of a buffered EDTA solution.	B	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1		CHEMBL1969102	=	IC50	nM	2.74	CHEMBL1844	Homo sapiens	IC50	nM	2.74
249763	16327463	CHEMBL3707499	Homogenous Time-Resolved Fluorescence Assay (HTRF): To determine the activity of the various kinases, a homogenous time-resolved fluorescence (HTRF) in vitro kinase assay was used. (Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6): p. 309-314; Alfred J. Kolb, Paul V. Kaplita, David J. Hayes, Young-Whan Park, Christine Pernell, John S. Major and Gerard Mathis, Drug Discovery Today, 1998, 3, 333-342.). For example for KDR, cKIT, FLT1, CSF1R and FTL3, purified enzyme was mixed with 0.5 μM N-biotinylated substrate (Biotin-Ahx-AEEEYFFLA-amide (SEQ. ID. 1)), various concentrations of inhibitor in reaction buffer (50 mM HEPES, pH 7.1, 10 mM MgCl2, 2 mM MnCl2, 0.1% BSA and 1 mM DTT, 40 μL final volume), ATP (1 mM final conc.) in a black 384-well plate. After 60 minutes incubation at room temperature, the reaction was quenched by addition of a buffered EDTA solution.	B	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		CHEMBL2004290	=	IC50	nM	7.87	CHEMBL1844	Homo sapiens	IC50	nM	7.87
249760	16328038	CHEMBL3707499	Homogenous Time-Resolved Fluorescence Assay (HTRF): To determine the activity of the various kinases, a homogenous time-resolved fluorescence (HTRF) in vitro kinase assay was used. (Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6): p. 309-314; Alfred J. Kolb, Paul V. Kaplita, David J. Hayes, Young-Whan Park, Christine Pernell, John S. Major and Gerard Mathis, Drug Discovery Today, 1998, 3, 333-342.). For example for KDR, cKIT, FLT1, CSF1R and FTL3, purified enzyme was mixed with 0.5 μM N-biotinylated substrate (Biotin-Ahx-AEEEYFFLA-amide (SEQ. ID. 1)), various concentrations of inhibitor in reaction buffer (50 mM HEPES, pH 7.1, 10 mM MgCl2, 2 mM MnCl2, 0.1% BSA and 1 mM DTT, 40 μL final volume), ATP (1 mM final conc.) in a black 384-well plate. After 60 minutes incubation at room temperature, the reaction was quenched by addition of a buffered EDTA solution.	B	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	=	IC50	nM	3.42	CHEMBL1844	Homo sapiens	IC50	nM	3.42
249761	16332700	CHEMBL3707499	Homogenous Time-Resolved Fluorescence Assay (HTRF): To determine the activity of the various kinases, a homogenous time-resolved fluorescence (HTRF) in vitro kinase assay was used. (Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6): p. 309-314; Alfred J. Kolb, Paul V. Kaplita, David J. Hayes, Young-Whan Park, Christine Pernell, John S. Major and Gerard Mathis, Drug Discovery Today, 1998, 3, 333-342.). For example for KDR, cKIT, FLT1, CSF1R and FTL3, purified enzyme was mixed with 0.5 μM N-biotinylated substrate (Biotin-Ahx-AEEEYFFLA-amide (SEQ. ID. 1)), various concentrations of inhibitor in reaction buffer (50 mM HEPES, pH 7.1, 10 mM MgCl2, 2 mM MnCl2, 0.1% BSA and 1 mM DTT, 40 μL final volume), ATP (1 mM final conc.) in a black 384-well plate. After 60 minutes incubation at room temperature, the reaction was quenched by addition of a buffered EDTA solution.	B	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	=	IC50	nM	2.22	CHEMBL1844	Homo sapiens	IC50	nM	2.22
249762	16333521	CHEMBL3707499	Homogenous Time-Resolved Fluorescence Assay (HTRF): To determine the activity of the various kinases, a homogenous time-resolved fluorescence (HTRF) in vitro kinase assay was used. (Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6): p. 309-314; Alfred J. Kolb, Paul V. Kaplita, David J. Hayes, Young-Whan Park, Christine Pernell, John S. Major and Gerard Mathis, Drug Discovery Today, 1998, 3, 333-342.). For example for KDR, cKIT, FLT1, CSF1R and FTL3, purified enzyme was mixed with 0.5 μM N-biotinylated substrate (Biotin-Ahx-AEEEYFFLA-amide (SEQ. ID. 1)), various concentrations of inhibitor in reaction buffer (50 mM HEPES, pH 7.1, 10 mM MgCl2, 2 mM MnCl2, 0.1% BSA and 1 mM DTT, 40 μL final volume), ATP (1 mM final conc.) in a black 384-well plate. After 60 minutes incubation at room temperature, the reaction was quenched by addition of a buffered EDTA solution.	B	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C[C@H](C)O)c5)cnc(N)c34)cc2)c1		CHEMBL3646210	=	IC50	nM	5.62	CHEMBL1844	Homo sapiens	IC50	nM	5.62
	16369078	CHEMBL3734113	Inhibition of Fms (unknown origin)	B	O=S(=O)(Nc1ccc(F)c(C(O)c2c[nH]c3ncnc(C4CC4)c23)c1F)c1ccc(C(F)(F)F)cc1		CHEMBL3730651	<=	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	16369079	CHEMBL3734113	Inhibition of Fms (unknown origin)	B	COc1ncnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c12		CHEMBL3727846	<=	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	16369080	CHEMBL3734113	Inhibition of Fms (unknown origin)	B	O=C(c1c(F)ccc(NS(=O)(=O)c2ccc(F)cc2F)c1F)c1c[nH]c2ncncc12		CHEMBL3732327	<=	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	16369081	CHEMBL3734113	Inhibition of Fms (unknown origin)	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncnc(C)c23)c1F		CHEMBL3730594	<=	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	16369082	CHEMBL3734113	Inhibition of Fms (unknown origin)	B	O=C(c1c(F)ccc(NS(=O)(=O)N2CCOCC2)c1F)c1c[nH]c2ncncc12		CHEMBL3728645	<=	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	16369083	CHEMBL3734113	Inhibition of Fms (unknown origin)	B	O=C(c1c(F)ccc(NS(=O)(=O)C2CCCCC2)c1F)c1c[nH]c2ncncc12		CHEMBL3732716	<=	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	16369084	CHEMBL3734113	Inhibition of Fms (unknown origin)	B	O=C(c1c(F)ccc(NS(=O)(=O)C2CCCC2)c1F)c1c[nH]c2ncncc12		CHEMBL3732892	<=	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	16370658	CHEMBL3734191	Inhibition of Fms (unknown origin)	B	CCCS(=O)(=O)Nc1ccc(F)c(COc2cnc3ccccc3c2)c1F		CHEMBL3730296	<=	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	16370659	CHEMBL3734191	Inhibition of Fms (unknown origin)	B	CCCS(=O)(=O)Nc1ccc(Cl)c(C(=O)Nc2cc(-c3ccc(Cl)cc3)n[nH]2)c1F		CHEMBL3729881	<=	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	16387311	CHEMBL3737986	Inhibition of CSF1R (unknown origin) at 50 nM	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	40.0	CHEMBL1844	Homo sapiens	INH	%	40.0
	16413434	CHEMBL3743710	Inhibition of CSF1R (unknown origin)	B	O=C(O)C1CN(Cc2ccc(OCc3ccc(Cl)c(Cl)c3)cc2)C1		CHEMBL3741589	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	16425378	CHEMBL3751214	Inhibition of CSF1R (unknown origin) at 1 uM	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	=	Inhibition	%	13.0	CHEMBL1844	Homo sapiens	INH	%	13.0
	16431840	CHEMBL3748194	Inhibition of human FMS using poly[Glu:Tyr] (4:1) as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	16450799	CHEMBL3762317	Inhibition of CSF1R (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	17.5	CHEMBL1844	Homo sapiens	INH	%	17.5
	16451706	CHEMBL3762317	Inhibition of CSF1R (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4c(Cl)cccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758602	=	Inhibition	%	19.1	CHEMBL1844	Homo sapiens	INH	%	19.1
	16457634	CHEMBL3761564	Inhibition of CSF1R (unknown origin) at 500 nM	B	C[C@@H](Nc1ncnc2sc(-c3ccccc3C(N)=O)cc12)c1ccccc1		CHEMBL3759085	=	Inhibition	%	3.0	CHEMBL1844	Homo sapiens	INH	%	3.0
	16457635	CHEMBL3761564	Inhibition of CSF1R (unknown origin) at 500 nM	B	C[C@@H](Nc1ncnc2sc(-c3ccc(C(=O)NCCN(C)C)cc3)cc12)c1ccccc1		CHEMBL3758800	=	Inhibition	%	8.0	CHEMBL1844	Homo sapiens	INH	%	8.0
	16457636	CHEMBL3761564	Inhibition of CSF1R (unknown origin) at 500 nM	B	CN(C)CCNC(=O)c1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3s2)cc1		CHEMBL3758376	=	Inhibition	%	0.0	CHEMBL1844	Homo sapiens	INH	%	0.0
	16457637	CHEMBL3761564	Inhibition of CSF1R (unknown origin) at 500 nM	B	COc1cc(C(N)=O)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2s1		CHEMBL3759480	=	Inhibition	%	6.0	CHEMBL1844	Homo sapiens	INH	%	6.0
	16457638	CHEMBL3761564	Inhibition of CSF1R (unknown origin) at 500 nM	B	COc1ccc(C(=O)NCCN(C)C)cc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1		CHEMBL3758582	=	Inhibition	%	6.0	CHEMBL1844	Homo sapiens	INH	%	6.0
	16457639	CHEMBL3761564	Inhibition of CSF1R (unknown origin) at 500 nM	B	COc1cc(CO)ccc1-c1cc2c(N[C@H](C)c3ccccc3)ncnc2s1		CHEMBL3759559	=	Inhibition	%	2.0	CHEMBL1844	Homo sapiens	INH	%	2.0
	16457640	CHEMBL3761564	Inhibition of CSF1R (unknown origin) at 500 nM	B	COc1cc(CO)ccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2s1		CHEMBL3758682	=	Inhibition	%	3.0	CHEMBL1844	Homo sapiens	INH	%	3.0
	16457641	CHEMBL3761564	Inhibition of CSF1R (unknown origin) at 500 nM	B	COc1cc(CO)ccc1-c1cc2c(Nc3ccccc3)ncnc2s1		CHEMBL3758768	=	Inhibition	%	15.0	CHEMBL1844	Homo sapiens	INH	%	15.0
	16457642	CHEMBL3761564	Inhibition of CSF1R (unknown origin) at 500 nM	B	C#Cc1cccc(Nc2ncnc3sc(-c4ccc(CO)cc4OC)cc23)c1		CHEMBL3758802	=	Inhibition	%	-1.0	CHEMBL1844	Homo sapiens	INH	%	-1.0
	16457643	CHEMBL3761564	Inhibition of CSF1R (unknown origin) at 500 nM	B	COc1cc(CO)ccc1-c1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2s1		CHEMBL3758351	=	Inhibition	%	4.0	CHEMBL1844	Homo sapiens	INH	%	4.0
	16457644	CHEMBL3761564	Inhibition of CSF1R (unknown origin) at 500 nM	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	=	Inhibition	%	38.0	CHEMBL1844	Homo sapiens	INH	%	38.0
	16465829	CHEMBL3767842	Inhibition of human FMS at 10 uM	B	Cc1cncn1-c1cc(C(=O)Nc2cccc(CNc3ccc4c(C(=O)N[C@@H](C)C(N)=O)[nH]nc4c3)c2)cc(C(F)(F)F)c1		CHEMBL3764798	=	Inhibition	%	10.56	CHEMBL1844	Homo sapiens	INH	%	10.56
	16485713	CHEMBL3771441	Inhibition of human recombinant CSF1R assessed as residual activity at 10 uM after 1 hr by qPCR analysis relative to control	B	Cc1c(Cl)cccc1NC(=O)c1sc2nc3c(cc2c1N)C(=O)CC3		CHEMBL3771285	=	Activity	%	100.0	CHEMBL1844	Homo sapiens	Activity	%	100.0
	16496002	CHEMBL3779697	Inhibition of N-terminal His6-tagged recombinant human FMS expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	8.0	CHEMBL1844	Homo sapiens	Activity	%	8.0
	16496003	CHEMBL3779698	Inhibition of N-terminal His6-tagged recombinant human FMS Y969C mutant expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	-20.0	CHEMBL1844	Homo sapiens	Activity	%	-20.0
	16508189	CHEMBL3779697	Inhibition of N-terminal His6-tagged recombinant human FMS expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	9.0	CHEMBL1844	Homo sapiens	Activity	%	9.0
	16508190	CHEMBL3779698	Inhibition of N-terminal His6-tagged recombinant human FMS Y969C mutant expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	1.0	CHEMBL1844	Homo sapiens	Activity	%	1.0
	16509166	CHEMBL3779697	Inhibition of N-terminal His6-tagged recombinant human FMS expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	8.0	CHEMBL1844	Homo sapiens	Activity	%	8.0
	16509167	CHEMBL3779698	Inhibition of N-terminal His6-tagged recombinant human FMS Y969C mutant expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	-1.0	CHEMBL1844	Homo sapiens	Activity	%	-1.0
Not Active	16514112	CHEMBL3782160	Inhibition of partial length human CSF1R expressed in bacterial system at 1 uM	B	Cc1cnc(N)nc1OCC(C)(C)CO		CHEMBL3780032		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
	16593592	CHEMBL3811550	Inhibition of His-tagged human recombinant CSF1R (538 to 910 residues) expressed in baculovirus using Fluorescein-Poly GT as substrate at 100 nM	B	COC(=O)c1cc2cc(NCc3cc(NC(=O)c4cc(-n5cnc(C)c5)cc(C(F)(F)F)c4)ccc3C)cnc2[nH]1		CHEMBL3808884	<	Inhibition	%	40.0	CHEMBL1844	Homo sapiens	INH	%	40.0
	16593741	CHEMBL3812305	Inhibition of human wild type partial length CSF1R expressed in bacterial expression system assessed as residual activity at 1 uM by KinomeScan method	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1OC1CCN(C(=O)c2ccncc2)CC1		CHEMBL3809935	=	Activity	%	0.6	CHEMBL1844	Homo sapiens	Activity	%	0.6
	16593745	CHEMBL3812309	Inhibition of His-tagged recombinant human CSF1R expressed in baculovirus expression system after 1 hr by Z-lyte assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1OC1CCN(C(=O)c2ccncc2)CC1		CHEMBL3809935	=	IC50	nM	133.0	CHEMBL1844	Homo sapiens	IC50	nM	133.0
	16594902	CHEMBL3812237	Inhibition of human CSF1R (564 to 939 amino acid residues) assessed as enzyme activity at 10 uM by KINOMEScan assay expressed in bacterial system assessed as enzyme activity at 10 uM by KINOMEScan assay	B	O=C1C2=C(C(=O)c3c(O)ccc(O)c31)[C@@H](O)[C@@H](O)[C@@H](O)C2		CHEMBL1987813	=	Activity	%	77.0	CHEMBL1844	Homo sapiens	Activity	%	77.0
	16614483	CHEMBL3816681	Inhibition of human FMS at 1 uM using poly[Glu:Tyr] (4:1) as substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	-5.0	CHEMBL1844	Homo sapiens	INH	%	-5.0
	16618252	CHEMBL3817072	Inhibition of recombinant human His-tagged cytoplasmic CSF1R (538 to 910 residues) expressed in baculovirus expression system at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	16737942	CHEMBL3856659	Inhibition of recombinant human FMS expressed in insect Sf21 cells assessed as remaining activity at 10 uM preincubated for 15 mins followed by poly(Glu:Tyr) substrate addition for 30 mins in presence of [gamma-32P]ATP by TR-FRET assay	B	CNCCOc1ccc(-c2sc3nc(-c4cccs4)nc(NN4C(=O)C=C(C)C4=O)c3c2C)cc1.Cl		CHEMBL3966536	=	Activity	%	78.0	CHEMBL1844	Homo sapiens	Activity	%	78.0
	16739471	CHEMBL3857040	Inhibition of His tagged recombinant human FMS cytoplasmic domain (538 to 910 residues) expressed in baculovirus at 500 nM by Z'-LYTE assay	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	=	Inhibition	%	38.0	CHEMBL1844	Homo sapiens	INH	%	38.0
	16739472	CHEMBL3857040	Inhibition of His tagged recombinant human FMS cytoplasmic domain (538 to 910 residues) expressed in baculovirus at 500 nM by Z'-LYTE assay	B	C[C@@H](Nc1ncnc2oc(-c3ccc(NCCN4CCCCC4)cc3)cc12)c1ccccc1		CHEMBL3891846	=	Inhibition	%	78.0	CHEMBL1844	Homo sapiens	INH	%	78.0
	16739473	CHEMBL3857040	Inhibition of His tagged recombinant human FMS cytoplasmic domain (538 to 910 residues) expressed in baculovirus at 500 nM by Z'-LYTE assay	B	C[C@@H](Nc1ncnc2oc(-c3ccc(NCCN(C)C)cc3)cc12)c1ccccc1		CHEMBL3901622	=	Inhibition	%	79.0	CHEMBL1844	Homo sapiens	INH	%	79.0
	16763145	CHEMBL3862734	Binding affinity to auto-inhibited human CSF1R expressed in Escherichia coli BL21 cells incubated for 1 hr by active site directed binding competition assay	B	CCc1ccc(/N=C2\S/C(=C\c3ccnc(Nc4ccc(C(=O)O)cn4)c3)C(=O)N2C)cc1		CHEMBL3921246	=	Kd	nM	120.0	CHEMBL1844	Homo sapiens	Kd	nM	120.0
	16804162	CHEMBL3869753	Inhibition of human recombinant His-tagged FMS cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system at 200 nM by Z'-LYTE assay	B	Cn1cc(-c2nc(N[C@@H]3CCCC[C@@H]3N)c(F)c3c2C(=O)NC3)cn1		CHEMBL3979920	=	Inhibition	%	63.0	CHEMBL1844	Homo sapiens	INH	%	63.0
	16837381	CHEMBL3876042	Inhibition of human recombinant His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system	B	CC1(C)C(=O)N([C@H]2CCc3c(O)cccc32)c2nc(Nc3ccccc3)ncc21		CHEMBL3884319	=	IC50	nM	12.0	CHEMBL1844	Homo sapiens	IC50	nM	12.0
	16854249	CHEMBL3878998	Inhibition of Tel-fused CSF1R (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	B	Cc1ccc(C(=O)N2CCC(Oc3cc(NC(=O)c4ccc(CN5CCN(C)CC5)c(C(F)(F)F)c4)ccc3C)CC2)cn1		CHEMBL3939150	=	GI50	nM	162.0	CHEMBL1844	Homo sapiens	GI50	uM	0.162
	16854250	CHEMBL3878998	Inhibition of Tel-fused CSF1R (unknown origin) expressed in BAF3 cells assessed as growth inhibition measured after 72 hrs by CellTiter-Glo or CCK8 assay	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	GI50	nM	110.0	CHEMBL1844	Homo sapiens	GI50	uM	0.11
	16854267	CHEMBL3878985	Inhibition of recombinant His-tagged human CSF1R cytoplasmic domain expressed in baculovirus expression system measured after 1 hr by FRET based Z'Lyte assay	B	Cc1ccc(C(=O)N2CCC(Oc3cc(NC(=O)c4ccc(CN5CCN(C)CC5)c(C(F)(F)F)c4)ccc3C)CC2)cn1		CHEMBL3939150	=	IC50	nM	227.0	CHEMBL1844	Homo sapiens	IC50	nM	227.0
	16854268	CHEMBL3878984	Inhibition of recombinant His-tagged human CSF1R cytoplasmic domain expressed in baculovirus expression system assessed as residual activity at 1 uM measured after 1 hr by FRET based Z'Lyte assay relative to control	B	Cc1ccc(C(=O)N2CCC(Oc3cc(NC(=O)c4ccc(CN5CCN(C)CC5)c(C(F)(F)F)c4)ccc3C)CC2)cn1		CHEMBL3939150	=	Activity	%	0.3	CHEMBL1844	Homo sapiens	Activity	%	0.3
264403	17646895	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	COCCOc1ccn2c(C(=O)Nc3cccc4c3c(I)nn4Cc3ccccc3)cnc2c1		CHEMBL3642058	=	IC50	nM	112.0	CHEMBL1844	Homo sapiens	IC50	nM	112.0
264404	17646896	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccccc2)c2cccc(NC(=O)c3cnc4cc(OCCOC)ccn34)c12		CHEMBL3642059	=	IC50	nM	117.9	CHEMBL1844	Homo sapiens	IC50	nM	117.9
264405	17646897	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	COCCOc1ccn2c(C(=O)Nc3cccc4c3c(C3CC3)nn4Cc3ccccc3)cnc2c1		CHEMBL3642060	=	IC50	nM	57.9	CHEMBL1844	Homo sapiens	IC50	nM	57.9
264406	17646898	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccccc2)c2ccc(Cl)c(NC(=O)c3cnc4cc(OCCOC)ccn34)c12		CHEMBL3642061	=	IC50	nM	42.0	CHEMBL1844	Homo sapiens	IC50	nM	42.0
264407	17646899	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642062	=	IC50	nM	137.0	CHEMBL1844	Homo sapiens	IC50	nM	137.0
264408	17646900	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccc(C)nc2OC)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642063	=	IC50	nM	515.8	CHEMBL1844	Homo sapiens	IC50	nM	515.8
264409	17646901	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccn(CCN3CCNCC3)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642064	=	IC50	nM	3066.9	CHEMBL1844	Homo sapiens	IC50	nM	3066.9
264410	17646902	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccnn2CC(O)CO)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642065	=	IC50	nM	3002.7	CHEMBL1844	Homo sapiens	IC50	nM	3002.7
264411	17646903	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(OCCN)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642066	=	IC50	nM	454.9	CHEMBL1844	Homo sapiens	IC50	nM	454.9
264412	17646904	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(OCCCN)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642067	=	IC50	nM	395.4	CHEMBL1844	Homo sapiens	IC50	nM	395.4
264413	17646905	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(OCCCN(C)C)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642068	=	IC50	nM	4876.5	CHEMBL1844	Homo sapiens	IC50	nM	4876.5
264414	17646906	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(C(=O)N5CCNCC5)ccn34)c12		CHEMBL3642069	=	IC50	nM	903.2	CHEMBL1844	Homo sapiens	IC50	nM	903.2
264415	17646907	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(C(=O)N5CCN(C)CC5)ccn34)c12		CHEMBL3642070	=	IC50	nM	2558.8	CHEMBL1844	Homo sapiens	IC50	nM	2558.8
264416	17646908	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(CN3CCNCC3)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642071	=	IC50	nM	3844.8	CHEMBL1844	Homo sapiens	IC50	nM	3844.8
264417	17646909	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(OC)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642072	=	IC50	nM	138.2	CHEMBL1844	Homo sapiens	IC50	nM	138.2
264418	17646910	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCOCC5)ccn34)c12		CHEMBL3642073	=	IC50	nM	145.1	CHEMBL1844	Homo sapiens	IC50	nM	145.1
264419	17646911	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(OC3CCNC3)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642074	=	IC50	nM	1396.9	CHEMBL1844	Homo sapiens	IC50	nM	1396.9
264420	17646912	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(OC3CCNC[C@H]3F)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642075	=	IC50	nM	1136.4	CHEMBL1844	Homo sapiens	IC50	nM	1136.4
264421	17646913	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(OC3CCNCC3)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642076	=	IC50	nM	860.1	CHEMBL1844	Homo sapiens	IC50	nM	860.1
264422	17646914	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cnn(Cc3ccc(OC)cc3)c2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642077	=	IC50	nM	1037.9	CHEMBL1844	Homo sapiens	IC50	nM	1037.9
264423	17646915	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cnn(CCO)c2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642078	=	IC50	nM	2907.5	CHEMBL1844	Homo sapiens	IC50	nM	2907.5
264424	17646916	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cnn(C3CCNC[C@H]3F)c2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642079	=	IC50	nM	2256.2	CHEMBL1844	Homo sapiens	IC50	nM	2256.2
264425	17646917	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1ccn2c(C(=O)Nc3cccc4c3c(CC)nn4Cc3cccc(C)n3)cnc2c1		CHEMBL3642080	=	IC50	nM	141.2	CHEMBL1844	Homo sapiens	IC50	nM	141.2
264426	17646918	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1cccc(Cn2nc(CC)c3c(NC(=O)c4cnc5ccccn45)cccc32)n1		CHEMBL3642081	=	IC50	nM	409.9	CHEMBL1844	Homo sapiens	IC50	nM	409.9
264427	17646919	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(=O)n2C)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642082	=	IC50	nM	1973.5	CHEMBL1844	Homo sapiens	IC50	nM	1973.5
264428	17646920	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(=O)n2CC)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642083	=	IC50	nM	4910.5	CHEMBL1844	Homo sapiens	IC50	nM	4910.5
264429	17646921	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCOc1cccc(Cn2nc(CC)c3c(NC(=O)c4cnc5ccccn45)cccc32)n1		CHEMBL3642084	=	IC50	nM	100.8	CHEMBL1844	Homo sapiens	IC50	nM	100.8
264430	17646922	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(-c5nnco5)ccn34)c12		CHEMBL3642085	=	IC50	nM	176.2	CHEMBL1844	Homo sapiens	IC50	nM	176.2
264431	17646923	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(-c5nnc(C)o5)ccn34)c12		CHEMBL3639409	=	IC50	nM	555.6	CHEMBL1844	Homo sapiens	IC50	nM	555.6
264432	17646924	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(CN5CCNCC5)ccn34)c12		CHEMBL3642086	=	IC50	nM	191.3	CHEMBL1844	Homo sapiens	IC50	nM	191.3
264433	17646925	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(CN5CCN(C)CC5)ccn34)c12		CHEMBL3642087	=	IC50	nM	333.1	CHEMBL1844	Homo sapiens	IC50	nM	333.1
264434	17646926	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(O[C@H]5CNC[C@@H]5O)ccn34)c12		CHEMBL3642088	=	IC50	nM	341.5	CHEMBL1844	Homo sapiens	IC50	nM	341.5
264435	17646927	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(O[C@@H]5CNC[C@H]5O)ccn34)c12		CHEMBL3642089	=	IC50	nM	286.8	CHEMBL1844	Homo sapiens	IC50	nM	286.8
264436	17646928	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(O[C@H]5CN(C)C[C@@H]5O)ccn34)c12		CHEMBL3642090	=	IC50	nM	688.5	CHEMBL1844	Homo sapiens	IC50	nM	688.5
264437	17646929	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(O[C@@H]5CN(C)C[C@H]5O)ccn34)c12		CHEMBL3642091	=	IC50	nM	488.2	CHEMBL1844	Homo sapiens	IC50	nM	488.2
264438	17646930	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(OC[C@H]3NCC[C@@H]3O)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642092	=	IC50	nM	554.6	CHEMBL1844	Homo sapiens	IC50	nM	554.6
264439	17646931	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CC[N+](C)([O-])CC5)ccn34)c12		CHEMBL3642093	=	IC50	nM	725.3	CHEMBL1844	Homo sapiens	IC50	nM	725.3
264440	17646932	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OC[C@H]5NCC[C@@H]5O)ccn34)c12		CHEMBL3642094	=	IC50	nM	98.3	CHEMBL1844	Homo sapiens	IC50	nM	98.3
264441	17646933	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccnn2CC)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642095	=	IC50	nM	331.8	CHEMBL1844	Homo sapiens	IC50	nM	331.8
264442	17646934	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccn(CC)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642096	=	IC50	nM	358.5	CHEMBL1844	Homo sapiens	IC50	nM	358.5
264443	17646935	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(OC[C@@H]3[C@@H](O)CCN3C)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642097	=	IC50	nM	931.9	CHEMBL1844	Homo sapiens	IC50	nM	931.9
264444	17646936	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OC[C@@H]5[C@@H](O)CCN5C)ccn34)c12		CHEMBL3642098	=	IC50	nM	275.1	CHEMBL1844	Homo sapiens	IC50	nM	275.1
264445	17646937	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(OCCN3CCNCC3)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642099	=	IC50	nM	395.7	CHEMBL1844	Homo sapiens	IC50	nM	395.7
264446	17646938	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(-c5nncs5)ccn34)c12		CHEMBL3642100	=	IC50	nM	232.6	CHEMBL1844	Homo sapiens	IC50	nM	232.6
264447	17646939	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCN(C)CC5)ccn34)c12		CHEMBL3642101	=	IC50	nM	172.1	CHEMBL1844	Homo sapiens	IC50	nM	172.1
264448	17646940	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(C(=O)NC5CCNC5)ccn34)c12		CHEMBL3642102	=	IC50	nM	264.6	CHEMBL1844	Homo sapiens	IC50	nM	264.6
264449	17646941	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(C(=O)NCCN)ccn34)c12		CHEMBL3642103	=	IC50	nM	310.6	CHEMBL1844	Homo sapiens	IC50	nM	310.6
264450	17646942	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(C(=O)NC)ccn34)c12		CHEMBL3642104	=	IC50	nM	426.4	CHEMBL1844	Homo sapiens	IC50	nM	426.4
264451	17646943	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(C(=O)N(C)C)ccn34)c12		CHEMBL3642105	=	IC50	nM	738.2	CHEMBL1844	Homo sapiens	IC50	nM	738.2
264452	17646944	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(C(=O)NC5CCN(C)C5)ccn34)c12		CHEMBL3642106	=	IC50	nM	348.1	CHEMBL1844	Homo sapiens	IC50	nM	348.1
264453	17646945	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(C(=O)NCCN(C)C)ccn34)c12		CHEMBL3642107	=	IC50	nM	430.1	CHEMBL1844	Homo sapiens	IC50	nM	430.1
264454	17646946	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(-c5cnc(C)n5C)ccn34)c12		CHEMBL3642108	=	IC50	nM	134.6	CHEMBL1844	Homo sapiens	IC50	nM	134.6
264455	17646947	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccc(C)n(C)c2=O)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642109	=	IC50	nM	1617.8	CHEMBL1844	Homo sapiens	IC50	nM	1617.8
264456	17646948	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(OCCN3CCN(C)CC3)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642110	=	IC50	nM	1253.3	CHEMBL1844	Homo sapiens	IC50	nM	1253.3
264457	17646949	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cc(C)n(C)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642111	=	IC50	nM	936.5	CHEMBL1844	Homo sapiens	IC50	nM	936.5
264458	17646950	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cc(C)n(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCN(C)CC5)ccn34)c12		CHEMBL3642112	=	IC50	nM	313.5	CHEMBL1844	Homo sapiens	IC50	nM	313.5
264459	17646951	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccn(C)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3642113	=	IC50	nM	1611.6	CHEMBL1844	Homo sapiens	IC50	nM	1611.6
264460	17646952	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccn(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCN(C)CC5)ccn34)c12		CHEMBL3642114	=	IC50	nM	492.1	CHEMBL1844	Homo sapiens	IC50	nM	492.1
264461	17646953	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(-c5cnc6n5CCNC6)ccn34)c12		CHEMBL3642115	=	IC50	nM	250.1	CHEMBL1844	Homo sapiens	IC50	nM	250.1
264462	17646954	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(-c5cnc6n5CCN(C)C6)ccn34)c12		CHEMBL3642116	=	IC50	nM	391.2	CHEMBL1844	Homo sapiens	IC50	nM	391.2
264463	17646955	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCn1ccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCN(C)CC6)ccn45)cccc32)n1		CHEMBL3644151	=	IC50	nM	95.1	CHEMBL1844	Homo sapiens	IC50	nM	95.1
264464	17646956	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCn1ccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCN(C(C)C)CC6)ccn45)cccc32)n1		CHEMBL3644152	=	IC50	nM	92.8	CHEMBL1844	Homo sapiens	IC50	nM	92.8
264465	17646957	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CC(C)n1ccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCN(C)CC6)ccn45)cccc32)n1		CHEMBL3644153	=	IC50	nM	94.7	CHEMBL1844	Homo sapiens	IC50	nM	94.7
264466	17646958	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CC(C)N1CCN(CCOc2ccn3c(C(=O)Nc4cccc5c4c(C4CC4)nn5Cc4ccn(C(C)C)n4)cnc3c2)CC1		CHEMBL3644154	=	IC50	nM	121.9	CHEMBL1844	Homo sapiens	IC50	nM	121.9
264467	17646959	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(Cl)ccn45)cccc32)n1		CHEMBL3644155	=	IC50	nM	283.7	CHEMBL1844	Homo sapiens	IC50	nM	283.7
264468	17646960	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(OCC(O)CO)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3644156	=	IC50	nM	591.8	CHEMBL1844	Homo sapiens	IC50	nM	591.8
264469	17646961	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(N3CCNCC3)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3644157	=	IC50	nM	1721.2	CHEMBL1844	Homo sapiens	IC50	nM	1721.2
264470	17646962	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(N3CCC(N)CC3)n2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3644158	=	IC50	nM	1215.7	CHEMBL1844	Homo sapiens	IC50	nM	1215.7
264471	17646963	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cnn(CC)c2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3644159	=	IC50	nM	1718.9	CHEMBL1844	Homo sapiens	IC50	nM	1718.9
264472	17646964	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cnn(CC3CC3)c2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3644160	=	IC50	nM	977.1	CHEMBL1844	Homo sapiens	IC50	nM	977.1
264473	17646965	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CC[N+](C)([O-])CC6)ccn45)cccc32)n1		CHEMBL3644161	=	IC50	nM	621.2	CHEMBL1844	Homo sapiens	IC50	nM	621.2
264474	17646966	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCNCC6)ccn45)cccc32)n1		CHEMBL3644162	=	IC50	nM	102.3	CHEMBL1844	Homo sapiens	IC50	nM	102.3
264475	17646967	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4ccc(C#N)cn34)c12		CHEMBL3644163	=	IC50	nM	1229.0	CHEMBL1844	Homo sapiens	IC50	nM	1229.0
264476	17646968	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCN(C(C)C)CC5)ccn34)c12		CHEMBL3644164	=	IC50	nM	157.6	CHEMBL1844	Homo sapiens	IC50	nM	157.6
264477	17646969	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCN(C(C)C)CC6)ccn45)cccc32)n1		CHEMBL3639430	=	IC50	nM	106.8	CHEMBL1844	Homo sapiens	IC50	nM	106.8
264478	17646970	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CN1CCN(CCOc2ccn3c(C(=O)Nc4cccc5c4c(C4CC4)nn5Cc4cccn(C)c4=O)cnc3c2)CC1		CHEMBL3644165	=	IC50	nM	266.9	CHEMBL1844	Homo sapiens	IC50	nM	266.9
264479	17646971	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(F)ccn45)cccc32)n1		CHEMBL3644166	=	IC50	nM	497.0	CHEMBL1844	Homo sapiens	IC50	nM	497.0
264480	17646972	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCC5CCN(C)CC5)ccn34)c12		CHEMBL3644167	=	IC50	nM	82.5	CHEMBL1844	Homo sapiens	IC50	nM	82.5
264481	17646973	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCN(CC)CC5)ccn34)c12		CHEMBL3644168	=	IC50	nM	120.4	CHEMBL1844	Homo sapiens	IC50	nM	120.4
264482	17646974	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(O[C@@H]5CCN(C)C5)ccn34)c12		CHEMBL3644169	=	IC50	nM	184.6	CHEMBL1844	Homo sapiens	IC50	nM	184.6
264483	17646975	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OC5CCN(C)CC5)ccn34)c12		CHEMBL3644170	=	IC50	nM	163.7	CHEMBL1844	Homo sapiens	IC50	nM	163.7
264484	17646976	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCCC5)ccn34)c12		CHEMBL3644171	=	IC50	nM	172.6	CHEMBL1844	Homo sapiens	IC50	nM	172.6
264485	17646977	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCOCC6)ccn45)cccc32)n1		CHEMBL3644172	=	IC50	nM	305.2	CHEMBL1844	Homo sapiens	IC50	nM	305.2
264486	17646978	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(O[C@H]5CCN(C)C5)ccn34)c12		CHEMBL3644173	=	IC50	nM	188.2	CHEMBL1844	Homo sapiens	IC50	nM	188.2
264487	17646979	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCC5CN(C(=O)OC(C)(C)C)CCO5)ccn34)c12		CHEMBL3644174	=	IC50	nM	379.9	CHEMBL1844	Homo sapiens	IC50	nM	379.9
264488	17646980	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCC(F)(F)CNC(=O)OC(C)(C)C)ccn34)c12		CHEMBL3644175	=	IC50	nM	876.7	CHEMBL1844	Homo sapiens	IC50	nM	876.7
264489	17646981	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccn(CC)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCN(C(C)C)CC5)ccn34)c12		CHEMBL3644176	=	IC50	nM	167.7	CHEMBL1844	Homo sapiens	IC50	nM	167.7
264490	17646982	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCCC6)ccn45)cccc32)n1		CHEMBL3644177	=	IC50	nM	141.0	CHEMBL1844	Homo sapiens	IC50	nM	141.0
264491	17646983	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CC[C@@H](OC)C5)ccn34)c12		CHEMBL3644178	=	IC50	nM	155.9	CHEMBL1844	Homo sapiens	IC50	nM	155.9
264492	17646984	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CC6CCC(C5)N6C)ccn34)c12		CHEMBL3644179	=	IC50	nM	163.5	CHEMBL1844	Homo sapiens	IC50	nM	163.5
264493	17646985	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CC[C@H](OC)C5)ccn34)c12		CHEMBL3644180	=	IC50	nM	183.3	CHEMBL1844	Homo sapiens	IC50	nM	183.3
264494	17646986	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccn(CC)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCCC5)ccn34)c12		CHEMBL3644181	=	IC50	nM	193.5	CHEMBL1844	Homo sapiens	IC50	nM	193.5
264495	17646987	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OC6CCN(C)CC6)ccn45)cccc32)n1		CHEMBL3644182	=	IC50	nM	198.2	CHEMBL1844	Homo sapiens	IC50	nM	198.2
264496	17646988	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CC[C@H](F)C5)ccn34)c12		CHEMBL3644183	=	IC50	nM	219.3	CHEMBL1844	Homo sapiens	IC50	nM	219.3
264497	17646989	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCS(=O)(=O)CC6)ccn45)cccc32)n1		CHEMBL3644184	=	IC50	nM	238.7	CHEMBL1844	Homo sapiens	IC50	nM	238.7
264498	17646990	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccn(CC)n2)c2cccc(NC(=O)c3cnc4cc(OC5CCN(C)CC5)ccn34)c12		CHEMBL3644185	=	IC50	nM	267.7	CHEMBL1844	Homo sapiens	IC50	nM	267.7
264499	17646991	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CC7CCC(C6)O7)ccn45)cccc32)n1		CHEMBL3644186	=	IC50	nM	271.3	CHEMBL1844	Homo sapiens	IC50	nM	271.3
264500	17646992	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cn1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCCC6)ccn45)cccc32)c1=O		CHEMBL3644187	=	IC50	nM	497.2	CHEMBL1844	Homo sapiens	IC50	nM	497.2
264501	17646993	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccn(CC)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCOCC5)ccn34)c12		CHEMBL3644188	=	IC50	nM	325.9	CHEMBL1844	Homo sapiens	IC50	nM	325.9
264502	17646994	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cn1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCOCC6)ccn45)cccc32)c1=O		CHEMBL3644189	=	IC50	nM	558.4	CHEMBL1844	Homo sapiens	IC50	nM	558.4
264503	17646995	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cn1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCC6)ccn45)cccc32)c1=O		CHEMBL3644190	=	IC50	nM	703.3	CHEMBL1844	Homo sapiens	IC50	nM	703.3
264504	17646996	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCNCC5)ccn34)c12		CHEMBL3644191	=	IC50	nM	276.2	CHEMBL1844	Homo sapiens	IC50	nM	276.2
264505	17646997	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCO)ccn34)c12		CHEMBL3644192	=	IC50	nM	192.4	CHEMBL1844	Homo sapiens	IC50	nM	192.4
264506	17646998	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCC(F)(F)CN)ccn34)c12		CHEMBL3644193	=	IC50	nM	380.0	CHEMBL1844	Homo sapiens	IC50	nM	380.0
264507	17646999	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OC5CNC5)ccn34)c12		CHEMBL3644194	=	IC50	nM	187.4	CHEMBL1844	Homo sapiens	IC50	nM	187.4
264508	17647000	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCC5CNCCO5)ccn34)c12		CHEMBL3644195	=	IC50	nM	141.2	CHEMBL1844	Homo sapiens	IC50	nM	141.2
264509	17647001	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CC[C@@H](F)C5)ccn34)c12		CHEMBL3644196	=	IC50	nM	371.1	CHEMBL1844	Homo sapiens	IC50	nM	371.1
264510	17647002	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(N5CCNCC5)ccn34)c12		CHEMBL3644197	=	IC50	nM	87.9	CHEMBL1844	Homo sapiens	IC50	nM	87.9
264511	17647003	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(N5CCOCC5)ccn34)c12		CHEMBL3644198	=	IC50	nM	96.6	CHEMBL1844	Homo sapiens	IC50	nM	96.6
264512	17647004	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(N5CC[C@@H](O)C5)ccn34)c12		CHEMBL3644199	=	IC50	nM	184.6	CHEMBL1844	Homo sapiens	IC50	nM	184.6
264513	17647005	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(N5CCN(CCO)CC5)ccn34)c12		CHEMBL3644200	=	IC50	nM	152.3	CHEMBL1844	Homo sapiens	IC50	nM	152.3
264514	17647006	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(N5CCC(O)CC5)ccn34)c12		CHEMBL3644201	=	IC50	nM	170.5	CHEMBL1844	Homo sapiens	IC50	nM	170.5
264515	17647007	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(N5CC[C@H](O)C5)ccn34)c12		CHEMBL3644202	=	IC50	nM	218.7	CHEMBL1844	Homo sapiens	IC50	nM	218.7
264516	17647008	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(N5CCN(CC)CC5)ccn34)c12		CHEMBL3644203	=	IC50	nM	91.4	CHEMBL1844	Homo sapiens	IC50	nM	91.4
264517	17647009	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(N5CCNC(=O)C5)ccn34)c12		CHEMBL3644204	=	IC50	nM	204.9	CHEMBL1844	Homo sapiens	IC50	nM	204.9
264518	17647010	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(N5CCCNCC5)ccn34)c12		CHEMBL3644205	=	IC50	nM	173.7	CHEMBL1844	Homo sapiens	IC50	nM	173.7
264519	17647011	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccn(CC)n2)c2cccc(NC(=O)c3cnc4cc(F)ccn34)c12		CHEMBL3644206	=	IC50	nM	633.0	CHEMBL1844	Homo sapiens	IC50	nM	633.0
264520	17647012	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(-n5cncn5)ccn34)c12		CHEMBL3644207	=	IC50	nM	235.8	CHEMBL1844	Homo sapiens	IC50	nM	235.8
264521	17647013	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(-n5cnc(C)n5)ccn34)c12		CHEMBL3644208	=	IC50	nM	232.2	CHEMBL1844	Homo sapiens	IC50	nM	232.2
264522	17647014	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(-n5ncnc5C)ccn34)c12		CHEMBL3644209	=	IC50	nM	522.6	CHEMBL1844	Homo sapiens	IC50	nM	522.6
264523	17647015	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(-n5cnnc5C)ccn34)c12		CHEMBL3644210	=	IC50	nM	929.2	CHEMBL1844	Homo sapiens	IC50	nM	929.2
264524	17647016	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCC(O)CO)ccn34)c12		CHEMBL3644211	=	IC50	nM	280.0	CHEMBL1844	Homo sapiens	IC50	nM	280.0
264525	17647017	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccn(CC)n2)c2cccc(NC(=O)c3cnc4cc(-c5cnn(C)c5)ccn34)c12		CHEMBL3644212	=	IC50	nM	72.8	CHEMBL1844	Homo sapiens	IC50	nM	72.8
264526	17647018	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cc(C)n(C)n2)c2cccc(NC(=O)c3cnc4cc(-c5cnn(C)c5)ccn34)c12		CHEMBL3644213	=	IC50	nM	155.8	CHEMBL1844	Homo sapiens	IC50	nM	155.8
264527	17647019	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cc(C)n(C)n2)c2cccc(NC(=O)c3cnc4cc(-c5ccc(CN(C)C)o5)ccn34)c12		CHEMBL3644214	=	IC50	nM	141.1	CHEMBL1844	Homo sapiens	IC50	nM	141.1
264528	17647020	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(CCN5CC[C@@H](F)C5)ccn34)c12		CHEMBL3644215	=	IC50	nM	278.4	CHEMBL1844	Homo sapiens	IC50	nM	278.4
264529	17647021	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(CCN5CCN(C)CC5)ccn34)c12		CHEMBL3644216	=	IC50	nM	157.4	CHEMBL1844	Homo sapiens	IC50	nM	157.4
264530	17647022	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(CCN5CC(F)C5)ccn34)c12		CHEMBL3644217	=	IC50	nM	217.3	CHEMBL1844	Homo sapiens	IC50	nM	217.3
264531	17647023	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(CCN(C)C)ccn34)c12		CHEMBL3644218	=	IC50	nM	6551.3	CHEMBL1844	Homo sapiens	IC50	nM	6551.3
264532	17647024	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(CCN5CC(OC)C5)ccn34)c12		CHEMBL3644219	=	IC50	nM	2135.6	CHEMBL1844	Homo sapiens	IC50	nM	2135.6
264533	17647025	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(CN(C)C)ccn34)c12		CHEMBL3644220	=	IC50	nM	1893.7	CHEMBL1844	Homo sapiens	IC50	nM	1893.7
264534	17647026	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccn(CC)n2)c2cccc(NC(=O)c3cnc4cc(CN(C)C)ccn34)c12		CHEMBL3644221	=	IC50	nM	4121.9	CHEMBL1844	Homo sapiens	IC50	nM	4121.9
264535	17647027	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1ncc(Cn2nc(I)c3c(NC(=O)c4cnc5cc(OCCN6CCN(C)CC6)ccn45)cccc32)s1		CHEMBL3644222	=	IC50	nM	183.3	CHEMBL1844	Homo sapiens	IC50	nM	183.3
264536	17647028	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1nnc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCN(C)CC6)ccn45)cccc32)s1		CHEMBL3644223	=	IC50	nM	449.3	CHEMBL1844	Homo sapiens	IC50	nM	449.3
264537	17647029	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1nc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCN(C)CC6)ccn45)cccc32)co1		CHEMBL3644224	=	IC50	nM	1171.4	CHEMBL1844	Homo sapiens	IC50	nM	1171.4
264538	17647030	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(-c5cncnc5)ccn34)c12		CHEMBL3644225	=	IC50	nM	400.6	CHEMBL1844	Homo sapiens	IC50	nM	400.6
264539	17647031	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(-c5ccc(C)nc5)ccn34)c12		CHEMBL3644226	=	IC50	nM	54.6	CHEMBL1844	Homo sapiens	IC50	nM	54.6
264540	17647032	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(CCCN5CCN(C)CC5)ccn34)c12		CHEMBL3644227	=	IC50	nM	274.8	CHEMBL1844	Homo sapiens	IC50	nM	274.8
264541	17647033	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	COCCOc1ccn2c(C(=O)Nc3cccc4c3c(OC)nn4Cc3ccc(C)nc3)cnc2c1		CHEMBL3644228	=	IC50	nM	137.5	CHEMBL1844	Homo sapiens	IC50	nM	137.5
264542	17647034	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	COCCOc1ccn2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3ccc(C)nc3)cnc2c1		CHEMBL3644229	=	IC50	nM	108.4	CHEMBL1844	Homo sapiens	IC50	nM	108.4
264543	17647035	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	COc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCN(C)CC5)ccn34)c12		CHEMBL3644230	=	IC50	nM	32.7	CHEMBL1844	Homo sapiens	IC50	nM	32.7
264544	17647036	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2nccs2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3644231	=	IC50	nM	1563.4	CHEMBL1844	Homo sapiens	IC50	nM	1563.4
264545	17647037	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccc(C)nc2)c2cccc(NC(=O)c3cnc4ccccn34)c12		CHEMBL3644232	=	IC50	nM	711.3	CHEMBL1844	Homo sapiens	IC50	nM	711.3
264546	17647038	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccc(C)nc2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCN(C)CC5)ccn34)c12		CHEMBL3644233	=	IC50	nM	276.2	CHEMBL1844	Homo sapiens	IC50	nM	276.2
264547	17647039	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2nccs2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCN(C)CC5)ccn34)c12		CHEMBL3644234	=	IC50	nM	178.8	CHEMBL1844	Homo sapiens	IC50	nM	178.8
264548	17647040	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2nc(C)cs2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCN(C)CC5)ccn34)c12		CHEMBL3644235	=	IC50	nM	102.4	CHEMBL1844	Homo sapiens	IC50	nM	102.4
264549	17647041	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1ccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCN(C)CC6)ccn45)cccc32)cn1		CHEMBL3644236	=	IC50	nM	123.0	CHEMBL1844	Homo sapiens	IC50	nM	123.0
264550	17647042	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2csc(C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCN(C)CC5)ccn34)c12		CHEMBL3644237	=	IC50	nM	259.5	CHEMBL1844	Homo sapiens	IC50	nM	259.5
264551	17647043	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccc(F)cn2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCN(C)CC5)ccn34)c12		CHEMBL3644238	=	IC50	nM	200.7	CHEMBL1844	Homo sapiens	IC50	nM	200.7
264552	17647044	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CN1CCN(CCOc2ccn3c(C(=O)Nc4cccc5c4c(C4CC4)nn5Cc4ccc(F)cn4)cnc3c2)CC1		CHEMBL3644239	=	IC50	nM	136.1	CHEMBL1844	Homo sapiens	IC50	nM	136.1
264553	17647045	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1nc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCN(C)CC6)ccn45)cccc32)cs1		CHEMBL3644240	=	IC50	nM	148.5	CHEMBL1844	Homo sapiens	IC50	nM	148.5
264554	17647046	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2csc(C(C)C)n2)c2cccc(NC(=O)c3cnc4cc(OCCN5CCN(C)CC5)ccn34)c12		CHEMBL3644241	=	IC50	nM	79.5	CHEMBL1844	Homo sapiens	IC50	nM	79.5
264555	17647047	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CC(C)c1nc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCN(C)CC6)ccn45)cccc32)cs1		CHEMBL3644242	=	IC50	nM	118.3	CHEMBL1844	Homo sapiens	IC50	nM	118.3
264556	17647048	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CC(C)N1CCN(CCOc2ccn3c(C(=O)Nc4cccc5c4c(C4CC4)nn5Cc4ccc(F)cn4)cnc3c2)CC1		CHEMBL3644243	=	IC50	nM	131.7	CHEMBL1844	Homo sapiens	IC50	nM	131.7
264557	17647049	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3cnc4cc(SCCNC(C)=O)ccn34)c12		CHEMBL3644244	=	IC50	nM	217.8	CHEMBL1844	Homo sapiens	IC50	nM	217.8
264558	17647050	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1nc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCN(C)CC6)ccn45)cccc32)ccc1O		CHEMBL3644245	=	IC50	nM	86.75	CHEMBL1844	Homo sapiens	IC50	nM	86.75
264559	17647051	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCc6ccccc6)ccn45)cccc32)n1		CHEMBL3644246	=	IC50	nM	493.5	CHEMBL1844	Homo sapiens	IC50	nM	493.5
264560	17647052	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(O)ccn45)cccc32)n1		CHEMBL3644247	=	IC50	nM	227.05	CHEMBL1844	Homo sapiens	IC50	nM	227.05
264561	17647053	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CSc1ccn2c(C(=O)Nc3cccc4c3c(C3CC3)nn4Cc3cccc(C)n3)cnc2c1		CHEMBL3644248	=	IC50	nM	18.5	CHEMBL1844	Homo sapiens	IC50	nM	18.5
264562	17647054	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	C=COCCOCCOc1ccn2c(C(=O)Nc3cccc4c3c(C3CC3)nn4Cc3cccc(C)n3)cnc2c1		CHEMBL3644249	=	IC50	nM	90.4	CHEMBL1844	Homo sapiens	IC50	nM	90.4
264563	17647055	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCOCCO)ccn45)cccc32)n1		CHEMBL3644250	=	IC50	nM	753.2	CHEMBL1844	Homo sapiens	IC50	nM	753.2
264564	17647056	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(Br)ccn45)cccc32)n1		CHEMBL3644251	=	IC50	nM	74.4	CHEMBL1844	Homo sapiens	IC50	nM	74.4
264565	17647057	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCN(C)CC6)ccn45)cccc32)n1		CHEMBL3644252	=	IC50	nM	93.6	CHEMBL1844	Homo sapiens	IC50	nM	93.6
264566	17647058	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCC6)ccn45)cccc32)n1		CHEMBL3644253	=	IC50	nM	149.8	CHEMBL1844	Homo sapiens	IC50	nM	149.8
264567	17647059	CHEMBL3705963	LANCE Ultra TR-FRET Assay: The ability of compounds of Formula I to inhibit cFMS was determined by the following assay. cFMS enzymatic activity was measured using the LANCE Ultra TR-FRET assay technology from PerkinElmer (Waltham, Mass.). Incubation mixtures contained the following: 50 mM NaHEPES, pH 7.3, 10 mM MgCl2, 0.5 mM MnCl2, 0.01% Triton X-100, 1 mM DTT, 1% DMSO, 10 uM ATP, 25 nM LANCE Ultra ULight-poly GAT and 0.5 nM cFMS in a total volume of 10 uL. The concentration of compounds of Formula I was varied over 10-point, 3-fold dilution series with 10,000 nM typically being the highest dose. Incubations were carried out in white ProxyPlate-384 Plus plates (PerkinElmer) at 22 C. for 20 minutes, after which 10 uL of a quench/detection solution was added containing 1x LANCE Detection Buffer, 2 nM LANCE EuW1024 Anti-phosphotyrosine (PY20) and 36 mM EDTA. After an additional 60 minutes incubation at 22 C., the assay plate was read on an EnVision 2103 Multilabel Reader (PerkinElmer).	B	CCc1nn(Cc2ccn(CC)n2)c2cccc(NC(=O)c3cnc4cc(-n5cncn5)ccn34)c12		CHEMBL3644254	=	IC50	nM	462.7	CHEMBL1844	Homo sapiens	IC50	nM	462.7
308525	17689193	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5cnn(C)c5)ccc43)cc2OC)cc1		CHEMBL3673436	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
308526	17689194	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5cncnc5)ccc43)cc2OC)cc1		CHEMBL3673437	=	IC50	nM	4.0	CHEMBL1844	Homo sapiens	IC50	nM	4.0
308527	17689195	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5ccncc5)ccc43)cc2OC)cc1		CHEMBL3673438	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
308528	17689196	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5cnn(CCN6CCOCC6)c5)ccc43)cc2OC)cc1		CHEMBL3673439	=	IC50	nM	4.0	CHEMBL1844	Homo sapiens	IC50	nM	4.0
308529	17689197	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5ccc(P(C)(C)=O)nc5)ccc43)cc2OC)cc1		CHEMBL3673440	=	IC50	nM	1.0	CHEMBL1844	Homo sapiens	IC50	nM	1.0
308530	17689198	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(-c5ccnnc5)ccc43)cc2OC)cn1		CHEMBL3673441	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	nM	30.0
308531	17689199	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(-c5cnn(C6CCNCC6)c5)ccc43)cc2OC)cn1		CHEMBL3673442	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
308532	17689200	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(-n5cc(C6CCCNC6)nn5)ccc43)cc2OC)cn1		CHEMBL3673443	=	IC50	nM	6.0	CHEMBL1844	Homo sapiens	IC50	nM	6.0
308533	17689201	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(-c5nnc(C6CCCNC6)o5)ccc43)cc2OC)cn1		CHEMBL3673444	=	IC50	nM	28.0	CHEMBL1844	Homo sapiens	IC50	nM	28.0
308534	17689202	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(C5CCNCC5)ccc43)cc2OC)cn1		CHEMBL3673445	=	IC50	nM	359.0	CHEMBL1844	Homo sapiens	IC50	nM	359.0
308535	17689203	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(C5CCOCC5)ccc43)cc2OC)cn1		CHEMBL3673446	=	IC50	nM	27.0	CHEMBL1844	Homo sapiens	IC50	nM	27.0
308536	17689204	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(N5CCC(C(C)(C)N)CC5)ccc43)cc2OC)cn1		CHEMBL3673447	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	nM	13.0
308537	17689205	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(N5CC6(CCNCC6)C5)ccc43)cc2OC)cn1		CHEMBL3673448	=	IC50	nM	12.0	CHEMBL1844	Homo sapiens	IC50	nM	12.0
308538	17689206	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(N5CCC(N)CC5)ccc43)cc2OC)cn1		CHEMBL3673449	=	IC50	nM	31.0	CHEMBL1844	Homo sapiens	IC50	nM	31.0
308539	17689207	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(N5CCN(C)CC5)ccc43)cc2OC)cn1		CHEMBL3673450	=	IC50	nM	32.0	CHEMBL1844	Homo sapiens	IC50	nM	32.0
308540	17689208	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(N5CCN(C)CC5=O)ccc43)cc2OC)cn1		CHEMBL3673451	=	IC50	nM	330.0	CHEMBL1844	Homo sapiens	IC50	nM	330.0
308541	17689209	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5cnn(C)c5)cnc43)cc2OC)cc1		CHEMBL3673452	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
308542	17689210	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5ccc(P(C)(C)=O)nc5)cnc43)cc2OC)cc1		CHEMBL3673453	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
308543	17689211	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(N5CCN(C)CC5)cnc43)cc2OC)cn1		CHEMBL3673454	=	IC50	nM	16.0	CHEMBL1844	Homo sapiens	IC50	nM	16.0
308544	17689212	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(N5CCC(C(C)(C)N)CC5)cnc43)cc2OC)cn1		CHEMBL3673455	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	nM	5.0
308545	17689213	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(N5CCOCC5)cnc43)cc2OC)cn1		CHEMBL3673456	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	nM	8.0
308546	17689214	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(N5CCN(C6CC6)CC5)cnc43)cc2OC)cn1		CHEMBL3673457	=	IC50	nM	16.0	CHEMBL1844	Homo sapiens	IC50	nM	16.0
308547	17689215	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(N5CCN6CCC5CC6)cnc43)cc2OC)cn1		CHEMBL3673458	=	IC50	nM	36.0	CHEMBL1844	Homo sapiens	IC50	nM	36.0
308548	17689216	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(N5CC6(CCNCC6)C5)cnc43)cc2OC)cn1		CHEMBL3673459	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	nM	7.0
308549	17689217	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(N5CCC(N)CC5)cnc43)cc2OC)cn1		CHEMBL3673460	=	IC50	nM	12.0	CHEMBL1844	Homo sapiens	IC50	nM	12.0
308550	17689218	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(N5CCC[C@H]5C(=O)O)cnc43)cc2OC)cn1		CHEMBL3673461	=	IC50	nM	32.0	CHEMBL1844	Homo sapiens	IC50	nM	32.0
308551	17689219	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(-c5cnn(C6CCNCC6)c5)cnc43)cc2OC)cn1		CHEMBL3673462	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
308552	17689220	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(Cn2cnc3cc(-c4cnn(C5CCNCC5)c4)cnc32)ccc1OCc1ccc(C)nc1		CHEMBL3673463	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	nM	3.0
308553	17689221	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(-c5noc(C6CCNCC6)n5)cnc43)cc2OC)cn1		CHEMBL3673464	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	nM	7.0
308554	17689222	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(-c5noc(C6CCNCC6)n5)ccc43)cc2OC)cn1		CHEMBL3673465	=	IC50	nM	15.0	CHEMBL1844	Homo sapiens	IC50	nM	15.0
308555	17689223	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(-c5nnc(C6CCNCC6)o5)cnc43)cc2OC)cn1		CHEMBL3673466	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	nM	13.0
308556	17689224	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(-n5cc(C(C)(C)N)nn5)cnc43)cc2OC)cn1		CHEMBL3673467	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	nM	7.0
308557	17689225	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(-n5cc(C6CCCNC6)nn5)cnc43)cc2OC)cn1		CHEMBL3673468	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	nM	3.0
308558	17689226	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(N5CCN(C)CC5)ccc43)cc2OC)cn1		CHEMBL3639723	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	nM	30.0
308559	17689227	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2cc(F)c(Cn3cnc4cc(N5CCN(C)CC5)ccc43)cc2OC)cn1		CHEMBL3673469	=	IC50	nM	379.0	CHEMBL1844	Homo sapiens	IC50	nM	379.0
308560	17689228	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(N5CCN(C)CC5)cnc43)cc2OC)cn1		CHEMBL3673454	=	IC50	nM	12.0	CHEMBL1844	Homo sapiens	IC50	nM	12.0
308561	17689229	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(N5CCN(C)CC5=O)ccc43)cc2OC)cn1		CHEMBL3673470	=	IC50	nM	431.0	CHEMBL1844	Homo sapiens	IC50	nM	431.0
308562	17689230	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(C5=CC6(C)CCCN5C6)cnc43)cc2OC)cn1		CHEMBL3673471	=	IC50	nM	15.0	CHEMBL1844	Homo sapiens	IC50	nM	15.0
308563	17689231	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(C5=CC6(C)CCCN5C6)ccc43)cc2OC)cn1		CHEMBL3673472	=	IC50	nM	161.0	CHEMBL1844	Homo sapiens	IC50	nM	161.0
308564	17689232	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(C5=CC6(O)CCCN5C6)cnc43)cc2OC)cn1		CHEMBL3673473	=	IC50	nM	41.0	CHEMBL1844	Homo sapiens	IC50	nM	41.0
308565	17689233	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3cnc4cc(C5=CC6(O)CCCN5C6)ccc43)cc2OC)cn1		CHEMBL3673474	=	IC50	nM	151.0	CHEMBL1844	Homo sapiens	IC50	nM	151.0
308566	17689234	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	CCC(Oc1ccc(Cn2c(N)nc3cc(-c4cnn(C)c4)cnc32)cc1OC)c1ccc(OC)nc1		CHEMBL3673475	=	IC50	nM	59.0	CHEMBL1844	Homo sapiens	IC50	nM	59.0
308567	17689235	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5cnn(C)c5)cnc43)cc2OC)cn1		CHEMBL3673476	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	nM	3.0
308568	17689236	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(Cn2c(N)nc3cc(-c4cnn(C)c4)cnc32)ccc1OCc1ccc(C(F)(F)F)nc1		CHEMBL3673477	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	nM	5.0
308569	17689237	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(Cn2c(N)nc3cc(-c4cnn(C)c4)cnc32)ccc1OCc1ccc(C(F)(F)F)cc1		CHEMBL3673478	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	nM	5.0
308570	17689238	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(Cn2c(N)nc3cc(-c4cnn(C)c4)cnc32)ccc1OCc1ccc(C2CC2)nc1		CHEMBL3673479	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	nM	3.0
308571	17689239	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(Cn2c(N)nc3cc(-c4cnn(C)c4)cnc32)ccc1OCc1csc(C)n1		CHEMBL3673480	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	nM	5.0
308572	17689240	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5ccccc5)cnc43)cc2OC)cn1		CHEMBL3673481	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	nM	7.0
308573	17689241	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5ccc(F)cc5)cnc43)cc2OC)cn1		CHEMBL3673482	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	nM	9.0
308574	17689242	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5ccn(C)n5)cnc43)cc2OC)cn1		CHEMBL3673483	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	nM	5.0
308575	17689243	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5cncnc5)cnc43)cc2OC)cn1		CHEMBL3673484	=	IC50	nM	11.0	CHEMBL1844	Homo sapiens	IC50	nM	11.0
308576	17689244	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5c(C)nn(C)c5C)cnc43)cc2OC)cn1		CHEMBL3673485	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	nM	5.0
308577	17689245	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5ccncc5)cnc43)cc2OC)cn1		CHEMBL3673486	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
308578	17689246	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5cccnc5)cnc43)cc2OC)cn1		CHEMBL3673487	=	IC50	nM	6.0	CHEMBL1844	Homo sapiens	IC50	nM	6.0
308579	17689247	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5ccccn5)cnc43)cc2OC)cn1		CHEMBL3673488	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	nM	5.0
308580	17689248	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(Cn2c(N)nc3cc(-c4cnn(C)c4)cnc32)ccc1OCc1ccc(C(F)(F)C(F)(F)F)cc1		CHEMBL3673489	=	IC50	nM	28.0	CHEMBL1844	Homo sapiens	IC50	nM	28.0
308581	17689249	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(Cn2c(N)nc3cc(-c4cnn(C)c4)cnc32)ccc1OCc1ccc(OC(F)(F)F)cc1		CHEMBL3678283	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	nM	8.0
308582	17689250	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(Cn2c(N)nc3cc(-c4cnn(C)c4)cnc32)ccc1OCc1ccc(SC(F)(F)F)cc1		CHEMBL3678284	=	IC50	nM	18.0	CHEMBL1844	Homo sapiens	IC50	nM	18.0
308583	17689251	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(Cn2c(N)nc3cc(-c4cnn(C)c4)cnc32)ccc1OCc1ccc(C(C)C)nc1		CHEMBL3678285	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	nM	5.0
308584	17689252	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(Cn2c(N)nc3cc(-c4cnn(C)c4)cnc32)ccc1OCc1ccc(CC(F)(F)F)cc1		CHEMBL3678286	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
308585	17689253	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(Cn2c(N)nc3cc(-c4cnn(C)c4)cnc32)ccc1OCc1csc(C(F)(F)F)n1		CHEMBL3678287	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	nM	7.0
308586	17689254	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(C#CC5CCCCC5)cnc43)cc2OC)cn1		CHEMBL3678288	=	IC50	nM	213.0	CHEMBL1844	Homo sapiens	IC50	nM	213.0
308587	17689255	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(Cn3c(N)nc4cc(C#CCCO)cnc43)cc2OC)cn1		CHEMBL3678289	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	nM	13.0
308588	17689256	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(C(Oc2ccc(Cn3c(N)nc4cc(-c5cnn(C)c5)cnc43)cc2OC)C2CC2)cn1		CHEMBL3678290	=	IC50	nM	794.0	CHEMBL1844	Homo sapiens	IC50	nM	794.0
308589	17689257	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc2c(cn1)C(Oc1ccc(Cn3c(N)nc4cc(-c5cnn(C)c5)cnc43)cc1OC)CCC2		CHEMBL3678291	=	IC50	nM	765.0	CHEMBL1844	Homo sapiens	IC50	nM	765.0
308590	17689258	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(C(C)n3c(N)nc4cc(-c5cnn(C)c5)ccc43)cc2OC)cn1		CHEMBL3678292	=	IC50	nM	73.0	CHEMBL1844	Homo sapiens	IC50	nM	73.0
308591	17689259	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(COc2ccc(C(C)n3c(N)nc4cc(-c5ccc(F)cc5)ccc43)cc2OC)cn1		CHEMBL3678293	=	IC50	nM	686.0	CHEMBL1844	Homo sapiens	IC50	nM	686.0
308592	17689260	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(C(C)n2cnc3cc(-c4ccc(F)cc4)ccc32)ccc1OCc1ccc(C(F)(F)F)nc1		CHEMBL3678294	=	IC50	nM	4130.0	CHEMBL1844	Homo sapiens	IC50	nM	4130.0
308593	17689261	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(C(C)n2cnc3cc(-c4cnn(C)c4)ccc32)ccc1OCc1ccc(C(F)(F)F)nc1		CHEMBL3678295	=	IC50	nM	160.0	CHEMBL1844	Homo sapiens	IC50	nM	160.0
308594	17689262	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(C(C)n2cnc3cc(C#CCCO)ccc32)ccc1OCc1ccc(C(F)(F)F)nc1		CHEMBL3678296	=	IC50	nM	4680.0	CHEMBL1844	Homo sapiens	IC50	nM	4680.0
308595	17689263	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc([C@H](C)n2c(N)nc3cc(-c4cnn(C)c4)cnc32)ccc1OCc1ccc(C(F)(F)F)cc1		CHEMBL3678297	=	IC50	nM	19.0	CHEMBL1844	Homo sapiens	IC50	nM	19.0
308596	17689264	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc([C@@H](C)n2c(N)nc3cc(-c4cnn(C)c4)cnc32)ccc1OCc1ccc(C(F)(F)F)cc1		CHEMBL3678298	=	IC50	nM	96.0	CHEMBL1844	Homo sapiens	IC50	nM	96.0
308597	17689265	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(C(C)n2cnc3cc(-c4cnn(C)c4)cnc32)ccc1OCc1ccc(C(F)(F)F)nc1		CHEMBL3678299	=	IC50	nM	56.0	CHEMBL1844	Homo sapiens	IC50	nM	56.0
308598	17689266	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(C(C)n2c(N)nc3cc(-c4cnn(C)c4)cnc32)ccc1OCc1ccc(C(F)(F)F)nc1		CHEMBL3678300	=	IC50	nM	19.0	CHEMBL1844	Homo sapiens	IC50	nM	19.0
308599	17689267	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(C(C)n2c(N)nc3cc(C#CCCO)cnc32)ccc1OCc1ccc(C(F)(F)F)nc1		CHEMBL3678301	=	IC50	nM	137.0	CHEMBL1844	Homo sapiens	IC50	nM	137.0
308600	17689268	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1cc(Cn2cnc3cc(C#CCCO)cnc32)ccc1OCc1ccc(C(F)F)nc1		CHEMBL3678302	=	IC50	nM	25.0	CHEMBL1844	Homo sapiens	IC50	nM	25.0
308601	17689269	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(C(C)Oc2ccc(Cn3cnc4cc(-c5cnn(C)c5)cnc43)cc2OC)cn1		CHEMBL3678303	=	IC50	nM	58.0	CHEMBL1844	Homo sapiens	IC50	nM	58.0
308602	17689270	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(C(C)Oc2ccc(Cn3cnc4cc(-c5ccnn5C)cnc43)cc2OC)cn1		CHEMBL3678304	=	IC50	nM	82.0	CHEMBL1844	Homo sapiens	IC50	nM	82.0
308603	17689271	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(-c2cnc3c(c2)ncn3Cc2ccc(OC(C)c3ccc(OC)nc3)c(OC)c2)cn1		CHEMBL3678305	=	IC50	nM	103.0	CHEMBL1844	Homo sapiens	IC50	nM	103.0
308604	17689272	CHEMBL3705886	Inhibition Assay: Reagents and consumables were purchased from Sigma Aldrich, Carna Biosciences, or Caliper Life Sciences. All assay reaction conditions for IC50 determinations were within the linear range with respect to time and enzyme concentration. In a 384 well polypropylene plate, c-FMS (0.14 nM, Carna 08-155) was pre-incubated in a 100 mM Hepes-NaOH pH 7.5 buffer containing 0.01% Triton X-100, 10 mM MgCl2, 0.1% BSA, 1 mM DTT, 10 uM sodium orthovanadate and 10 uM beta-glycerophosphate and compound with a concentration of 2.5% DMSO for 15 minutes at room temperature. The reaction was initiated with an equal volume of peptide substrate (Caliper Life Sciences catalog no. 760430) and ATP in the aforementioned buffer. The final concentrations in the reaction were 70 pM c-FMS, 1.5 uM peptide substrate and 500 uM ATP (ATP Km). The reaction was incubated at room temperature for 120 minutes and terminated with a buffer containing excess EDTA (100 mM Hepes-NaOH pH 7.5, 0.02% Brij, 0.1% CR-3.	B	COc1ccc(C(C)Oc2ccc(Cn3cnc4cc(-c5ccnc(F)c5)cnc43)cc2OC)cn1		CHEMBL3678306	=	IC50	nM	102.0	CHEMBL1844	Homo sapiens	IC50	nM	102.0
320299	17700220	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)c(OC)n1		CHEMBL3668997	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320300	17700221	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cc2C)cn1		CHEMBL3673956	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320301	17700222	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cc2F)cn1		CHEMBL3673957	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320302	17700223	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(F)cc34)c(F)n2)cn1		CHEMBL3673950	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320303	17700224	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	CS(=O)(=O)Nc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1		CHEMBL3673954	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320304	17700225	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Fc1cncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)c1		CHEMBL3673943	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320305	17700226	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Clc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3)c2c1		CHEMBL3673980	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320306	17700227	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Fc1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3673981	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320307	17700228	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Fc1ccc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cc1F		CHEMBL3668998	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320308	17700229	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1cccc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)c1		CHEMBL3669000	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320309	17700230	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3)c2c1		CHEMBL3673952	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320310	17700231	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1cnc2[nH]cc(Cc3ccc(NCc4cncc(F)c4)nc3F)c2c1		CHEMBL3673944	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320311	17700232	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cn1		CHEMBL3673945	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320312	17700233	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(OC)nc4)nc3F)c2c1		CHEMBL3673946	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320313	17700234	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3F)c2c1		CHEMBL3673947	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320314	17700235	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c2c1		CHEMBL3673948	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320315	17700236	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ccnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c12		CHEMBL3673958	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320316	17700237	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3673959	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320317	17700238	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4OC)nc3F)c2c1		CHEMBL3673960	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320318	17700239	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ncccc1CNc1ccc(Cc2c[nH]c3ncccc23)c(F)n1		CHEMBL3673962	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320319	17700240	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1cnc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cc1F		CHEMBL3673963	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320320	17700241	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1		CHEMBL3639728	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320321	17700242	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ncccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1		CHEMBL3673964	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320322	17700243	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cn1		CHEMBL3673965	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320323	17700244	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1		CHEMBL3673934	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320324	17700245	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1cnc2[nH]cc(Cc3ccc(NCc4cnccc4C(F)(F)F)nc3F)c2c1		CHEMBL3673966	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320325	17700246	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	FC(F)(F)c1ccncc1CNc1ccc(Cc2c[nH]c3ncc(Cl)cc23)cn1		CHEMBL3673967	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320326	17700247	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(Cl)cc23)cn1		CHEMBL3673935	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320327	17700248	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(C)c4)nc3F)c2c1		CHEMBL3673968	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320328	17700249	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1cnc2[nH]cc(Cc3ccc(NCc4cnccc4C(F)(F)F)nc3)c2c1		CHEMBL3673969	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320329	17700250	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1cc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(F)cn1		CHEMBL3673970	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320330	17700251	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ncc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cc1F		CHEMBL3673971	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320331	17700252	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1cc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)ccn1		CHEMBL3673972	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320332	17700253	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(Cl)nc4)nc3)c2c1		CHEMBL3669001	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320333	17700254	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(C)n4)nc3)c2c1		CHEMBL3669002	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320334	17700255	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCOCC5)n4)nc3)c2c1		CHEMBL3669003	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320335	17700256	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCCC5)n4)nc3)c2c1		CHEMBL3669004	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320336	17700257	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1		CHEMBL3673936	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320337	17700258	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(OC)n1		CHEMBL3673937	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320338	17700259	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4F)nc3F)c2c1		CHEMBL3673938	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320339	17700260	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(F)c4)nc3F)c2c1		CHEMBL3673939	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320340	17700261	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)nc1		CHEMBL3673940	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320341	17700262	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ncccc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1		CHEMBL3669005	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320342	17700263	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1		CHEMBL3673973	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320343	17700264	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1		CHEMBL3673974	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320344	17700265	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cc1cnc2[nH]cc(Cc3cnc(NCc4cccnc4OC4CCCC4)nc3)c2c1		CHEMBL3673932	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320345	17700266	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)s2)cn1		CHEMBL3673975	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320346	17700267	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Cn1cc(F)cc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)c1=O		CHEMBL3673976	>	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320347	17700268	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1cccc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)s2)n1		CHEMBL3673977	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320348	17700269	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)cc1F		CHEMBL3673978	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320349	17700270	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Fc1cc(Cc2c[nH]c3ncc(Cl)cc23)cnc1NCc1ccc(C(F)(F)F)nc1		CHEMBL3673979	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320350	17700271	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Fc1cncc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)c1		CHEMBL3673949	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320351	17700272	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C#N)cc23)c(F)n1		CHEMBL3673982	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320352	17700273	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	CCS(=O)(=O)Nc1ccccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1		CHEMBL3673941	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320353	17700274	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	CCS(=O)(=O)Nc1cc(F)cc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c1		CHEMBL3673942	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320408	17700329	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	FC(F)(F)c1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3)c2c1		CHEMBL3673951	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320409	17700330	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1ncc(CNc2ccc(Cc3c[nH]c4ncc(C(F)(F)F)cc34)c(F)n2)cc1F		CHEMBL3673933	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320410	17700331	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Fc1cc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cc(C(F)(F)F)c1		CHEMBL3668999	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320411	17700332	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	COc1cnc2[nH]cc(Cc3ccc(NCc4ccccc4Cl)nc3F)c2c1		CHEMBL3673955	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
320412	17700333	CHEMBL3706095	Biochemical Assay: In one assay the biochemical activity IC50 values are determined with respect to inhibition of Fms kinase activity, where inhibition of phosphorylation of a peptide substrate is measured as a function of compound concentration. Compounds to be tested, dissolved in DMSO (1 uL), are added to a white 384-well plate (Costar #3705). Working stocks of Fms kinase (Invitrogen #PV3249), biotin-(E4Y)10 substrate (Upstate Biotech, Cat#12-440), and ATP (Sigma, Cat#A-3377) are prepared in 25 mM Hepes pH 7.5, 0.5 mM MgCl2, 2 mM MnCl2, 2 mM DTT, 0.01% BSA, and 0.01% Tween-20. All components are added to the 384-well plate for a final concentration of 1 ng/well Fms, 30 nM biotin-(E4Y)10 (Upstate Biotechnology) and 100 uM ATP in a volume of 20 uL. Each sample is at 5% DMSO. The plate is then incubated for 20 minutes at 30 C. Just before use, working stocks of donor and acceptor beads from the AlphaScreen PY20 Detection Kit (PerkinElmer, Cat#676601M) are prepared in 25 mM Hepes pH 7.5.	B	Fc1nc(NCc2ccc(Cl)cn2)ccc1Cc1c[nH]c2ncccc12		CHEMBL3673961	<	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
327865	17706564	CHEMBL3887276	Enzymatic Assay: Activity of unphosphorylated c-FMS kinase (uFMS, Seq. ID no. 1) was determined by following the production of ADP from the FMS kinase reaction with ATP and poly E4Y as substrates through coupling with the pyruvate kinase/lactate dehydrogenase system (e.g., Schindler et al. Science (2000) 289: 1938-1942). In this assay, the oxidation of NADH (thus the decrease at A340 nm) was continuously monitored spectrophometrically. The reaction mixture (100 .mu.L) contained FMS (purchased from Millipore) (10 nM), polyE4Y (1 mg/mL), MgCl.sub.2 (10 mM), pyruvate kinase (4 units), lactate dehydrogenase (0.7 units), phosphoenol pyruvate (1 mM), NADH (0.28 mM) and ATP (500 .mu.M) in 90 mM Tris buffer containing 0.2% octyl-glucoside and 1% DMSO, pH 7.5. The inhibition reaction was started by mixing serial diluted test compound with the above reaction mixture. The absorption at 340 nm was monitored continuously for 4 hours at 30.degree. C. on Synergy 2 plate reader.	B	Cn1cc(-c2cc(Oc3ccc(NC(=O)N4CCN(c5ccc(F)cc5)C4=O)nc3)ccn2)cn1		CHEMBL3908700	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	nM	13.0
327866	17706565	CHEMBL3887276	Enzymatic Assay: Activity of unphosphorylated c-FMS kinase (uFMS, Seq. ID no. 1) was determined by following the production of ADP from the FMS kinase reaction with ATP and poly E4Y as substrates through coupling with the pyruvate kinase/lactate dehydrogenase system (e.g., Schindler et al. Science (2000) 289: 1938-1942). In this assay, the oxidation of NADH (thus the decrease at A340 nm) was continuously monitored spectrophometrically. The reaction mixture (100 .mu.L) contained FMS (purchased from Millipore) (10 nM), polyE4Y (1 mg/mL), MgCl.sub.2 (10 mM), pyruvate kinase (4 units), lactate dehydrogenase (0.7 units), phosphoenol pyruvate (1 mM), NADH (0.28 mM) and ATP (500 .mu.M) in 90 mM Tris buffer containing 0.2% octyl-glucoside and 1% DMSO, pH 7.5. The inhibition reaction was started by mixing serial diluted test compound with the above reaction mixture. The absorption at 340 nm was monitored continuously for 4 hours at 30.degree. C. on Synergy 2 plate reader.	B	Cn1cc(-c2cc(Oc3ccc(NC(=O)N4CCN(C5CCOCC5)C4=O)nc3)ccn2)cn1		CHEMBL3891316	=	IC50	nM	6.0	CHEMBL1844	Homo sapiens	IC50	nM	6.0
327867	17706566	CHEMBL3887276	Enzymatic Assay: Activity of unphosphorylated c-FMS kinase (uFMS, Seq. ID no. 1) was determined by following the production of ADP from the FMS kinase reaction with ATP and poly E4Y as substrates through coupling with the pyruvate kinase/lactate dehydrogenase system (e.g., Schindler et al. Science (2000) 289: 1938-1942). In this assay, the oxidation of NADH (thus the decrease at A340 nm) was continuously monitored spectrophometrically. The reaction mixture (100 .mu.L) contained FMS (purchased from Millipore) (10 nM), polyE4Y (1 mg/mL), MgCl.sub.2 (10 mM), pyruvate kinase (4 units), lactate dehydrogenase (0.7 units), phosphoenol pyruvate (1 mM), NADH (0.28 mM) and ATP (500 .mu.M) in 90 mM Tris buffer containing 0.2% octyl-glucoside and 1% DMSO, pH 7.5. The inhibition reaction was started by mixing serial diluted test compound with the above reaction mixture. The absorption at 340 nm was monitored continuously for 4 hours at 30.degree. C. on Synergy 2 plate reader.	B	Cn1cc(-c2cc(Oc3cc(F)c(NC(=O)N4CCN(C5CCOCC5)C4=O)cc3F)ccn2)cn1		CHEMBL3948615	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	nM	7.0
327868	17706567	CHEMBL3887276	Enzymatic Assay: Activity of unphosphorylated c-FMS kinase (uFMS, Seq. ID no. 1) was determined by following the production of ADP from the FMS kinase reaction with ATP and poly E4Y as substrates through coupling with the pyruvate kinase/lactate dehydrogenase system (e.g., Schindler et al. Science (2000) 289: 1938-1942). In this assay, the oxidation of NADH (thus the decrease at A340 nm) was continuously monitored spectrophometrically. The reaction mixture (100 .mu.L) contained FMS (purchased from Millipore) (10 nM), polyE4Y (1 mg/mL), MgCl.sub.2 (10 mM), pyruvate kinase (4 units), lactate dehydrogenase (0.7 units), phosphoenol pyruvate (1 mM), NADH (0.28 mM) and ATP (500 .mu.M) in 90 mM Tris buffer containing 0.2% octyl-glucoside and 1% DMSO, pH 7.5. The inhibition reaction was started by mixing serial diluted test compound with the above reaction mixture. The absorption at 340 nm was monitored continuously for 4 hours at 30.degree. C. on Synergy 2 plate reader.	B	Cn1cc(-c2cc(Oc3ccc(NC(=O)N4CCN(C5CCCCC5)C4=O)nc3)ccn2)cn1		CHEMBL3893595	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	nM	3.0
327869	17706568	CHEMBL3887276	Enzymatic Assay: Activity of unphosphorylated c-FMS kinase (uFMS, Seq. ID no. 1) was determined by following the production of ADP from the FMS kinase reaction with ATP and poly E4Y as substrates through coupling with the pyruvate kinase/lactate dehydrogenase system (e.g., Schindler et al. Science (2000) 289: 1938-1942). In this assay, the oxidation of NADH (thus the decrease at A340 nm) was continuously monitored spectrophometrically. The reaction mixture (100 .mu.L) contained FMS (purchased from Millipore) (10 nM), polyE4Y (1 mg/mL), MgCl.sub.2 (10 mM), pyruvate kinase (4 units), lactate dehydrogenase (0.7 units), phosphoenol pyruvate (1 mM), NADH (0.28 mM) and ATP (500 .mu.M) in 90 mM Tris buffer containing 0.2% octyl-glucoside and 1% DMSO, pH 7.5. The inhibition reaction was started by mixing serial diluted test compound with the above reaction mixture. The absorption at 340 nm was monitored continuously for 4 hours at 30.degree. C. on Synergy 2 plate reader.	B	COCCN1CCN(C(=O)Nc2ccc(Oc3ccnc(-c4cnn(C)c4)c3)c(C)n2)C1=O		CHEMBL3983027	=	IC50	nM	20.0	CHEMBL1844	Homo sapiens	IC50	nM	20.0
327870	17706569	CHEMBL3887276	Enzymatic Assay: Activity of unphosphorylated c-FMS kinase (uFMS, Seq. ID no. 1) was determined by following the production of ADP from the FMS kinase reaction with ATP and poly E4Y as substrates through coupling with the pyruvate kinase/lactate dehydrogenase system (e.g., Schindler et al. Science (2000) 289: 1938-1942). In this assay, the oxidation of NADH (thus the decrease at A340 nm) was continuously monitored spectrophometrically. The reaction mixture (100 .mu.L) contained FMS (purchased from Millipore) (10 nM), polyE4Y (1 mg/mL), MgCl.sub.2 (10 mM), pyruvate kinase (4 units), lactate dehydrogenase (0.7 units), phosphoenol pyruvate (1 mM), NADH (0.28 mM) and ATP (500 .mu.M) in 90 mM Tris buffer containing 0.2% octyl-glucoside and 1% DMSO, pH 7.5. The inhibition reaction was started by mixing serial diluted test compound with the above reaction mixture. The absorption at 340 nm was monitored continuously for 4 hours at 30.degree. C. on Synergy 2 plate reader.	B	Cc1nc(NC(=O)N2CCN(C3CCCC3)C2=O)ccc1Oc1ccnc(-c2cnn(C)c2)c1		CHEMBL3931177	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
327871	17706570	CHEMBL3887276	Enzymatic Assay: Activity of unphosphorylated c-FMS kinase (uFMS, Seq. ID no. 1) was determined by following the production of ADP from the FMS kinase reaction with ATP and poly E4Y as substrates through coupling with the pyruvate kinase/lactate dehydrogenase system (e.g., Schindler et al. Science (2000) 289: 1938-1942). In this assay, the oxidation of NADH (thus the decrease at A340 nm) was continuously monitored spectrophometrically. The reaction mixture (100 .mu.L) contained FMS (purchased from Millipore) (10 nM), polyE4Y (1 mg/mL), MgCl.sub.2 (10 mM), pyruvate kinase (4 units), lactate dehydrogenase (0.7 units), phosphoenol pyruvate (1 mM), NADH (0.28 mM) and ATP (500 .mu.M) in 90 mM Tris buffer containing 0.2% octyl-glucoside and 1% DMSO, pH 7.5. The inhibition reaction was started by mixing serial diluted test compound with the above reaction mixture. The absorption at 340 nm was monitored continuously for 4 hours at 30.degree. C. on Synergy 2 plate reader.	B	CCN1CCN(C(=O)Nc2ccc(Oc3ccnc(-c4cnn(C)c4)c3)c(C)n2)C1=O		CHEMBL3936132	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	nM	8.0
327872	17706571	CHEMBL3887276	Enzymatic Assay: Activity of unphosphorylated c-FMS kinase (uFMS, Seq. ID no. 1) was determined by following the production of ADP from the FMS kinase reaction with ATP and poly E4Y as substrates through coupling with the pyruvate kinase/lactate dehydrogenase system (e.g., Schindler et al. Science (2000) 289: 1938-1942). In this assay, the oxidation of NADH (thus the decrease at A340 nm) was continuously monitored spectrophometrically. The reaction mixture (100 .mu.L) contained FMS (purchased from Millipore) (10 nM), polyE4Y (1 mg/mL), MgCl.sub.2 (10 mM), pyruvate kinase (4 units), lactate dehydrogenase (0.7 units), phosphoenol pyruvate (1 mM), NADH (0.28 mM) and ATP (500 .mu.M) in 90 mM Tris buffer containing 0.2% octyl-glucoside and 1% DMSO, pH 7.5. The inhibition reaction was started by mixing serial diluted test compound with the above reaction mixture. The absorption at 340 nm was monitored continuously for 4 hours at 30.degree. C. on Synergy 2 plate reader.	B	CN(C)C(=O)Nc1cc(Oc2cc(F)c(NC(=O)N3CCN(C4CCOCC4)C3=O)cc2Cl)ccn1		CHEMBL3974611	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	nM	8.0
327873	17706572	CHEMBL3887276	Enzymatic Assay: Activity of unphosphorylated c-FMS kinase (uFMS, Seq. ID no. 1) was determined by following the production of ADP from the FMS kinase reaction with ATP and poly E4Y as substrates through coupling with the pyruvate kinase/lactate dehydrogenase system (e.g., Schindler et al. Science (2000) 289: 1938-1942). In this assay, the oxidation of NADH (thus the decrease at A340 nm) was continuously monitored spectrophometrically. The reaction mixture (100 .mu.L) contained FMS (purchased from Millipore) (10 nM), polyE4Y (1 mg/mL), MgCl.sub.2 (10 mM), pyruvate kinase (4 units), lactate dehydrogenase (0.7 units), phosphoenol pyruvate (1 mM), NADH (0.28 mM) and ATP (500 .mu.M) in 90 mM Tris buffer containing 0.2% octyl-glucoside and 1% DMSO, pH 7.5. The inhibition reaction was started by mixing serial diluted test compound with the above reaction mixture. The absorption at 340 nm was monitored continuously for 4 hours at 30.degree. C. on Synergy 2 plate reader.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)N3CCN(C(C)(C)C)C3=O)nc2)ccn1		CHEMBL3957739	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	nM	5.0
334770	17713012	CHEMBL3887351	Kinase Activity: The compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profiling Service (Invitrogen, U.S.).	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1NC(=O)c1csc2c(N)ncnc12		CHEMBL3969260	=	IC50	nM	1.0	CHEMBL1844	Homo sapiens	IC50	nM	1.0
334771	17713013	CHEMBL3887351	Kinase Activity: The compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profiling Service (Invitrogen, U.S.).	B	Cc1ccc2c(Nc3cccc(Cl)c3)nccc2c1NC(=O)c1csc2c(N)ncnc12		CHEMBL3954810	=	IC50	nM	57.0	CHEMBL1844	Homo sapiens	IC50	nM	57.0
334772	17713014	CHEMBL3887351	Kinase Activity: The compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profiling Service (Invitrogen, U.S.).	B	CC(=O)c1ccc(Nc2nccc3c(NC(=O)c4csc5c(N)ncnc45)c(C)ccc23)cc1		CHEMBL3944137	=	IC50	nM	4.0	CHEMBL1844	Homo sapiens	IC50	nM	4.0
334773	17713015	CHEMBL3887351	Kinase Activity: The compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profiling Service (Invitrogen, U.S.).	B	Cc1ccc2c(Nc3ccc(F)c(Cl)c3)nccc2c1NC(=O)c1csc2c(N)ncnc12		CHEMBL3915720	=	IC50	nM	50.0	CHEMBL1844	Homo sapiens	IC50	nM	50.0
334774	17713016	CHEMBL3887351	Kinase Activity: The compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profiling Service (Invitrogen, U.S.).	B	Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12		CHEMBL3977543	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
353827	17729829	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC(C)(NS(C)(=O)=O)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCCCC2)c1		CHEMBL3660753	=	IC50	nM	4.7	CHEMBL1844	Homo sapiens	IC50	nM	4.7
353828	17729830	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	C=C(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCCCC2)c1		CHEMBL3660803	=	IC50	nM	32.9	CHEMBL1844	Homo sapiens	IC50	nM	32.9
353829	17729831	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC(=O)NC(C)(C)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCCCC2)c1		CHEMBL3660754	=	IC50	nM	6.1	CHEMBL1844	Homo sapiens	IC50	nM	6.1
353830	17729832	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC(C)(NC(N)=O)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCCCC2)c1		CHEMBL3660755	=	IC50	nM	12.4	CHEMBL1844	Homo sapiens	IC50	nM	12.4
353831	17729833	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC(C)(NC(=O)NCCO)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCCCC2)c1		CHEMBL3660756	=	IC50	nM	31.7	CHEMBL1844	Homo sapiens	IC50	nM	31.7
353832	17729834	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC(C)(NC(=O)C(N)=O)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCCCC2)c1		CHEMBL3660757	=	IC50	nM	8.6	CHEMBL1844	Homo sapiens	IC50	nM	8.6
353833	17729835	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	N#Cc1c[nH]c(C(=O)Nc2ccc(CCC(N)=O)cc2C2=CCCCC2)n1		CHEMBL3085980	=	IC50	nM	2.7	CHEMBL1844	Homo sapiens	IC50	nM	2.7
353834	17729836	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	N#Cc1c[nH]c(C(=O)Nc2ccc(CCC(=O)O)cc2C2=CCCCC2)n1		CHEMBL3085979	=	IC50	nM	5.9	CHEMBL1844	Homo sapiens	IC50	nM	5.9
353835	17729837	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	NC(=O)c1c[nH]c(C(=O)Nc2ccc(CCC(=O)O)cc2C2=CCCCC2)n1		CHEMBL3660804	=	IC50	nM	79.0	CHEMBL1844	Homo sapiens	IC50	nM	79.0
353836	17729838	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(CCC(N)=O)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3085981	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	nM	1.7
353837	17729839	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	N#Cc1cnc(C(=O)Nc2ccc(C(CO)CO)cc2C2=CCCCC2)[nH]1		CHEMBL3660758	>	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	nM	60.0
353838	17729840	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC(=O)OCC(COC(C)=O)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCCCC2)c1		CHEMBL3660759	=	IC50	nM	4.4	CHEMBL1844	Homo sapiens	IC50	nM	4.4
353839	17729841	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC(C)(C(=O)O)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCCCC2)c1		CHEMBL3660760	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	nM	8.0
353840	17729842	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCSCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3660761	=	IC50	nM	9.3	CHEMBL1844	Homo sapiens	IC50	nM	9.3
353841	17729843	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)N3CC[S+]([O-])CC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3660762	=	IC50	nM	1.1	CHEMBL1844	Homo sapiens	IC50	nM	1.1
353842	17729844	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCS(=O)(=O)CC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3085829	=	IC50	nM	3.3	CHEMBL1844	Homo sapiens	IC50	nM	3.3
353843	17729845	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CSCCNC(C)(C)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3660763	=	IC50	nM	1.4	CHEMBL1844	Homo sapiens	IC50	nM	1.4
353844	17729846	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)NCCS(C)(=O)=O)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086322	=	IC50	nM	1.8	CHEMBL1844	Homo sapiens	IC50	nM	1.8
353845	17729847	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CN(CCS(C)(=O)=O)C(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3086323	=	IC50	nM	7.2	CHEMBL1844	Homo sapiens	IC50	nM	7.2
353846	17729848	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	COCCNC(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3086320	=	IC50	nM	0.44	CHEMBL1844	Homo sapiens	IC50	nM	0.44
353847	17729849	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	COCCN(C)C(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3086321	=	IC50	nM	2.6	CHEMBL1844	Homo sapiens	IC50	nM	2.6
353848	17729850	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	COCCN(C)C(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3086321	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	nM	1.7
353849	17729851	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCOCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085828	=	IC50	nM	0.94	CHEMBL1844	Homo sapiens	IC50	nM	0.94
353850	17729852	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CN1CCN(C(C)(C)c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3085830	=	IC50	nM	2.9	CHEMBL1844	Homo sapiens	IC50	nM	2.9
353851	17729853	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CN1CCN(C(C)(C)c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3085830	=	IC50	nM	5.1	CHEMBL1844	Homo sapiens	IC50	nM	5.1
353852	17729854	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)NCCN3CCOCC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3085976	=	IC50	nM	1.2	CHEMBL1844	Homo sapiens	IC50	nM	1.2
353853	17729855	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	C[C@H]1CN(S(=O)(=O)Cc2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)C[C@@H](C)N1		CHEMBL3660764	=	IC50	nM	7.74	CHEMBL1844	Homo sapiens	IC50	nM	7.74
353854	17729856	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	N#Cc1c[nH]c(C(=O)Nc2ccc(CCS(=O)(=O)N3CCOCC3)cc2C2=CCCCC2)n1		CHEMBL3086179	=	IC50	nM	3.2	CHEMBL1844	Homo sapiens	IC50	nM	3.2
353855	17729857	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	N#Cc1c[nH]c(C(=O)Nc2ccc(CCS(=O)(=O)N3CCOCC3)cc2C2=CCCCC2)n1		CHEMBL3086179	=	IC50	nM	3.7	CHEMBL1844	Homo sapiens	IC50	nM	3.7
353856	17729858	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	N#Cc1c[nH]c(C(=O)Nc2ccc(CCS(=O)(=O)N3CCOCC3)cc2C2=CCCCC2)n1		CHEMBL3086179	=	IC50	nM	3.6	CHEMBL1844	Homo sapiens	IC50	nM	3.6
353857	17729859	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(CCS(=O)(=O)N3CCOCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3086314	=	IC50	nM	4.5	CHEMBL1844	Homo sapiens	IC50	nM	4.5
353858	17729860	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CN(C)S(=O)(=O)CCc1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCCCC2)c1		CHEMBL3660765	=	IC50	nM	9.4	CHEMBL1844	Homo sapiens	IC50	nM	9.4
353859	17729861	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CN(C)S(=O)(=O)CCc1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3660766	=	IC50	nM	2.9	CHEMBL1844	Homo sapiens	IC50	nM	2.9
353860	17729862	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CNS(=O)(=O)CCc1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCCCC2)c1		CHEMBL3660767	=	IC50	nM	5.6	CHEMBL1844	Homo sapiens	IC50	nM	5.6
353861	17729863	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CNS(=O)(=O)CCc1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3660768	=	IC50	nM	2.6	CHEMBL1844	Homo sapiens	IC50	nM	2.6
353862	17729864	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	N#Cc1cnc(C(=O)Nc2ccc(CS(=O)(=O)N3CCOCC3)cc2C2=CCCCC2)[nH]1		CHEMBL3085985	=	IC50	nM	12.8	CHEMBL1844	Homo sapiens	IC50	nM	12.8
353863	17729865	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	Cc1nc(C(=O)Nc2ccc(CCN3CCOCC3)cc2C2=CCCCC2)[nH]c1C#N		CHEMBL3660769	>	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	nM	60.0
353864	17729866	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CSc1ncc(C(=O)Nc2ccc(CCN3CCOCC3)cc2C2=CCCCC2)[nH]1		CHEMBL3660770	=	IC50	nM	373.0	CHEMBL1844	Homo sapiens	IC50	nM	373.0
353865	17729867	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	C[S+]([O-])c1ncc(C(=O)Nc2ccc(CCN3CCOCC3)cc2C2=CCCCC2)[nH]1		CHEMBL3660771	>	IC50	nM	500.0	CHEMBL1844	Homo sapiens	IC50	nM	500.0
353866	17729868	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CS(=O)(=O)c1ncc(C(=O)Nc2ccc(CCN3CCOCC3)cc2C2=CCCCC2)[nH]1		CHEMBL3660772	>	IC50	nM	500.0	CHEMBL1844	Homo sapiens	IC50	nM	500.0
353867	17729869	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	Cc1c[nH]c(C(=O)Nc2ccc(CCN3CCOCC3)cc2C2=CCCCC2)n1		CHEMBL3660773	=	IC50	nM	300.0	CHEMBL1844	Homo sapiens	IC50	nM	300.0
353868	17729870	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	O=C(Nc1ccc(CCN2CCOCC2)cc1C1=CCCCC1)c1nc(Cl)c(Cl)[nH]1		CHEMBL3660774	>	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	nM	60.0
353869	17729871	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	O=C(Nc1ccc(CCN2CCOCC2)cc1C1=CCCCC1)c1nc2ccccc2[nH]1		CHEMBL3660775	>	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	nM	60.0
353870	17729872	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	O=C(Nc1ccc(CCN2CCOCC2)cc1C1=CCCCC1)c1ncc(Br)[nH]1		CHEMBL3660776	=	IC50	nM	27.9	CHEMBL1844	Homo sapiens	IC50	nM	27.9
353871	17729873	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	O=C(Nc1ccc(CCN2CCOCC2)cc1C1=CCCCC1)c1ncc(Cl)[nH]1		CHEMBL3912812	=	IC50	nM	8.2	CHEMBL1844	Homo sapiens	IC50	nM	8.2
353872	17729874	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	N#Cc1cnc(C(=O)Nc2ccc(CCN3CCOCC3)cc2C2=CCCCC2)[nH]1		CHEMBL3086175	=	IC50	nM	1.43	CHEMBL1844	Homo sapiens	IC50	nM	1.43
353873	17729875	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	N#Cc1cnc(C(=O)Nc2ccc(CN3CCOCC3)cc2C2=CCCCC2)[nH]1		CHEMBL3085983	=	IC50	nM	4.6	CHEMBL1844	Homo sapiens	IC50	nM	4.6
353874	17729876	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1=C(c2cc(C(C)(C)N3CCCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CCCC1C		CHEMBL3937254	=	IC50	nM	0.6	CHEMBL1844	Homo sapiens	IC50	nM	0.6
353875	17729877	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(O)C(=O)O)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3660781	=	IC50	nM	2.5	CHEMBL1844	Homo sapiens	IC50	nM	2.5
353876	17729878	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	COC[C@H](O)Cc1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3967115	=	IC50	nM	1.5	CHEMBL1844	Homo sapiens	IC50	nM	1.5
353877	17729879	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	N#Cc1cnc(C(=O)Nc2ccc(/C=C/C(=O)O)cc2C2=CCCCC2)[nH]1		CHEMBL3889904	=	IC50	nM	3.9	CHEMBL1844	Homo sapiens	IC50	nM	3.9
353878	17729880	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	N#Cc1cnc(C(=O)Nc2ccc(/C=C/C(=O)O)cc2C2=CCCCC2)[nH]1		CHEMBL3889904	=	IC50	nM	5.3	CHEMBL1844	Homo sapiens	IC50	nM	5.3
353879	17729881	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2nc(CC(=O)O)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3660784	=	IC50	nM	26.0	CHEMBL1844	Homo sapiens	IC50	nM	26.0
353880	17729882	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CCOC(=O)Cc1ccc(NC(=O)c2cc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)n1		CHEMBL3660785	=	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	nM	60.0
353881	17729883	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2nc(CC(=O)O)ccc2NC(=O)c2cc(C#N)c[nH]2)CC1		CHEMBL3660786	=	IC50	nM	36.2	CHEMBL1844	Homo sapiens	IC50	nM	36.2
353882	17729884	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CN(C)CCOC(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3086316	=	IC50	nM	5.6	CHEMBL1844	Homo sapiens	IC50	nM	5.6
353883	17729885	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CN(C)CCOC(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3086316	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	nM	0.8
353884	17729886	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CN(C)CCNC(=O)Cc1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3660787	=	IC50	nM	2.9	CHEMBL1844	Homo sapiens	IC50	nM	2.9
353885	17729887	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(CC(=O)NCCCO)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3086172	=	IC50	nM	2.4	CHEMBL1844	Homo sapiens	IC50	nM	2.4
353886	17729888	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CCN(C)CCCc1ccc(NC(=O)c2ccc(C#N)o2)c(N2CCC(C)CC2)c1		CHEMBL3660788	=	IC50	nM	50.0	CHEMBL1844	Homo sapiens	IC50	nM	50.0
353887	17729889	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(CCN3CCOCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085978	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	nM	0.8
353888	17729890	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)OCCN3CCOCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3086318	=	IC50	nM	1.9	CHEMBL1844	Homo sapiens	IC50	nM	1.9
353889	17729891	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCN(CCO)CC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085833	=	IC50	nM	0.88	CHEMBL1844	Homo sapiens	IC50	nM	0.88
353890	17729892	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCN(CCO)CC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085833	=	IC50	nM	0.69	CHEMBL1844	Homo sapiens	IC50	nM	0.69
353891	17729893	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCN(CC(=O)O)CC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3705040	=	IC50	nM	0.93	CHEMBL1844	Homo sapiens	IC50	nM	0.93
353892	17729894	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	C=C(CN1CCOCC1)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCCCC2)c1		CHEMBL3660790	=	IC50	nM	3.9	CHEMBL1844	Homo sapiens	IC50	nM	3.9
353893	17729895	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	C=C(CNCCOC)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCCCC2)c1		CHEMBL3660791	=	IC50	nM	1.3	CHEMBL1844	Homo sapiens	IC50	nM	1.3
353894	17729896	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	C=C(CNC)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCCCC2)c1		CHEMBL3660792	=	IC50	nM	1.6	CHEMBL1844	Homo sapiens	IC50	nM	1.6
353895	17729897	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	COCCNC(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3086320	=	IC50	nM	0.51	CHEMBL1844	Homo sapiens	IC50	nM	0.51
353896	17729898	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	COc1ccc(CSC(C)(C)c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCC(C)(C)CC3)c2)cc1		CHEMBL3660793	=	IC50	nM	140.0	CHEMBL1844	Homo sapiens	IC50	nM	140.0
353897	17729899	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC(=O)SC(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3660794	=	IC50	nM	33.0	CHEMBL1844	Homo sapiens	IC50	nM	33.0
353898	17729900	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)Nc3ccccn3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085827	=	IC50	nM	19.0	CHEMBL1844	Homo sapiens	IC50	nM	19.0
353899	17729901	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	Cc1cccc(NC(C)(C)c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCC(C)(C)CC3)c2)n1		CHEMBL3660795	=	IC50	nM	8.8	CHEMBL1844	Homo sapiens	IC50	nM	8.8
353900	17729902	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CCN1CCN(C(C)(C)c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3085831	=	IC50	nM	1.5	CHEMBL1844	Homo sapiens	IC50	nM	1.5
353901	17729903	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC(=O)N1CCN(C(C)(C)c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3085832	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	nM	1.7
353902	17729904	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC(=O)NCCNC(C)(C)c1ccc(C(=O)NOC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3958194	=	IC50	nM	0.68	CHEMBL1844	Homo sapiens	IC50	nM	0.68
353903	17729905	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	COCCN1CCN(C(C)(C)c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3085834	=	IC50	nM	1.3	CHEMBL1844	Homo sapiens	IC50	nM	1.3
353904	17729906	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CCOC(=O)CN1CCN(C(C)(C)c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3660796	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
353905	17729907	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)OCCN3CCCC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086317	=	IC50	nM	1.2	CHEMBL1844	Homo sapiens	IC50	nM	1.2
353906	17729908	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CSCCNCC(C)(C)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3639596	=	IC50	nM	1.3	CHEMBL1844	Homo sapiens	IC50	nM	1.3
353907	17729909	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)CNCCS(C)(=O)=O)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085974	=	IC50	nM	1.6	CHEMBL1844	Homo sapiens	IC50	nM	1.6
353908	17729910	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)CN3CC4OC(C)(C)OC4C3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3942293	>	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
353909	17729911	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)CN3CC(O)C(O)C3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3956347	=	IC50	nM	18.0	CHEMBL1844	Homo sapiens	IC50	nM	18.0
353910	17729912	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)CN3CCOCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085970	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	nM	8.0
353911	17729913	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC(=O)N1CCN(CC(C)(C)c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3085971	=	IC50	nM	5.7	CHEMBL1844	Homo sapiens	IC50	nM	5.7
353912	17729914	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)CN3CCSCC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3660799	=	IC50	nM	36.0	CHEMBL1844	Homo sapiens	IC50	nM	36.0
353913	17729915	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)CN3CCS(=O)(=O)CC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3085972	=	IC50	nM	3.5	CHEMBL1844	Homo sapiens	IC50	nM	3.5
353914	17729916	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(C(C)(C)CN3CCN(CCO)CC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085975	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
353915	17729917	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	COCCNCC(C)(C)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3085973	=	IC50	nM	0.64	CHEMBL1844	Homo sapiens	IC50	nM	0.64
353916	17729918	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1CN(C(C)c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCC(C)(C)CC3)c2)CC(C)N1		CHEMBL3906636	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	nM	1.7
353917	17729919	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1=C(c2cc(C(C)(C)N3CCCCC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CCCC1C		CHEMBL3982086	=	IC50	nM	1.5	CHEMBL1844	Homo sapiens	IC50	nM	1.5
353918	17729920	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(CN3CCN(CCO)CC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3085984	=	IC50	nM	0.75	CHEMBL1844	Homo sapiens	IC50	nM	0.75
353919	17729921	CHEMBL3887764	Fluorescence Polarization Competition Immunoassay: A fluorescence polarization competition immunoassay was used to measure compound inhibition of CSF-1R phosphorylation of tyrosine on a synthetic CSF-1R555-568 peptide (SYEGNSYTFIDPTQ). The assay was performed in black 96-well microplates (Cat #42-000-0117, Molecular Devices, Sunnyvale, Calif.). To each well, 5 uL of compound (in 4% DMSO) were mixed with 2 uL of 3.5 nM CSF-1R, 25 mM MgCl2 in assay buffer (100 mM HEPES (hydroxyethylpiperazineethylsodiumsulfonate), pH 7.5, 1 mM DTT (dithiothreitol), 0.01% Tween-20), and 2 uL of 1540 uM peptide in assay buffer. The kinase reaction was initiated by adding 1 Î¼L of 10 mM ATP in assay buffer. The final concentrations in the 10 uL reaction mixture were 100 mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween-20, 2% DMSO, 308 uM SYEGNSYTFIDPTQ, 1 mM ATP, 5 mM MgCl2, and 0.7 nM CSF-1R. Positive and negative control wells were included on each plate, where 4% DMSO in assay buffer was substituted for the compound; in addition, positive control wells received 1.2 uL of 50 mM EDTA (ethylenediaminetetraacetic acid) before the start of the reaction.	B	CC1(C)CC=C(c2cc(CN3CCNCC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3660802	=	IC50	nM	0.82	CHEMBL1844	Homo sapiens	IC50	nM	0.82
364061	17739254	CHEMBL3887938	Competitive Binding Assay (KINOMEscan): For the competitive binding assay, test compounds were screened at 10 uM against 70 diverse kinase targets for competitive binding using the KINOMEscan technology (Ambit Biosciences) (Karaman, et al. (2008) Nature biotechnology 26:127-132). 11-point Kd curves were determined for hits identified during the initial screen.	B	CSc1nc(N)cc(Oc2ccc(-c3nnc(Nc4cccc(C(F)(F)F)c4)[nH]3)cc2)n1		CHEMBL3932957	>	Kd	nM	10000.0	CHEMBL1844	Homo sapiens	Kd	nM	10000.0
	17964887	CHEMBL3994996	Inhibition of human CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by KINOMEscan assay relative to control	B	CNc1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)on3)c(C)c2)ncn1		CHEMBL4060295	=	Activity	%	48.0	CHEMBL1844	Homo sapiens	Activity	%	48.0
	17979967	CHEMBL3998356	Inhibition of CSF-1R (unknown origin)	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	IC50	nM	1.0	CHEMBL1844	Homo sapiens	IC50	nM	1.0
	17996249	CHEMBL4001398	Inhibition of human wild type partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system at 10 uM by KinomeScan method relative to control	B	Cc1nc2nc(Sc3ccccc3)cnc2cc1NC(=O)Nc1ccccc1		CHEMBL4083528	=	Inhibition	%	0.0	CHEMBL1844	Homo sapiens	INH	%	0.0
	18008686	CHEMBL4003783	Inhibition of human Fms using KKKSPGEYVNIEFG as substrate in presence of [gamma-33P]ATP at 1 uM after 40 mins by scintillation counter method	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(N[C@H]3CCCC[C@@H]3N)nc21		CHEMBL4088144	=	Inhibition	%	-1.0	CHEMBL1844	Homo sapiens	INH	%	-1.0
	18008687	CHEMBL4003783	Inhibition of human Fms using KKKSPGEYVNIEFG as substrate in presence of [gamma-33P]ATP at 1 uM after 40 mins by scintillation counter method	B	CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21	Outside typical range	CHEMBL4066861	=	Inhibition	%	-16.0	CHEMBL1844	Homo sapiens	INH	%	-16.0
	18008688	CHEMBL4003783	Inhibition of human Fms using KKKSPGEYVNIEFG as substrate in presence of [gamma-33P]ATP at 1 uM after 40 mins by scintillation counter method	B	CC(C)n1cnc2c(Nc3cc(N)cc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL4078898	=	Inhibition	%	9.0	CHEMBL1844	Homo sapiens	INH	%	9.0
	18031671	CHEMBL4007700	Inhibition of CSF1R (unknown origin) after 60 mins by TR-FRET assay	B	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	=	IC50	nM	9060.0	CHEMBL1844	Homo sapiens	IC50	uM	9.06
	18031672	CHEMBL4007700	Inhibition of CSF1R (unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2ccoc12		CHEMBL4078893	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	18031673	CHEMBL4007700	Inhibition of CSF1R (unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc3cn[nH]c3c2)nc2ccoc12		CHEMBL4066664	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	18031674	CHEMBL4007700	Inhibition of CSF1R (unknown origin) after 60 mins by TR-FRET assay	B	CC1(C)OCC(=O)Nc2cc(Nc3nc(NCC(F)(F)F)c4occc4n3)ccc21		CHEMBL4069365	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	18031675	CHEMBL4007700	Inhibition of CSF1R (unknown origin) after 60 mins by TR-FRET assay	B	Cc1n[nH]c2cc(Nc3nc(NC4CC4)c4occc4n3)ccc12		CHEMBL4062803	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	18057679	CHEMBL4012652	Inhibition of human CSF1R (564 to 939 residues) expressed in bacterial expression system assessed as activity remaining at 1 uM by KINOMEscan assay relative to control	B	Cc1cc(NC(=O)Nc2ccc(-c3ccnc4[nH]nc(C)c34)cc2)ccc1N1CCOCC1		CHEMBL4072731	=	Activity	%	0.0	CHEMBL1844	Homo sapiens	Activity	%	0.0
	18057749	CHEMBL4012658	Inhibition of human full length His-tagged CSF1R expressed in baculovirus by Z'Lyte assay	B	Cc1cc(NC(=O)Nc2ccc(-c3ccnc4[nH]nc(C)c34)cc2)ccc1N1CCOCC1		CHEMBL4072731	=	IC50	nM	160.0	CHEMBL1844	Homo sapiens	IC50	nM	160.0
	18057943	CHEMBL4012657	Inhibition of human full length His-tagged CSF1R expressed in baculovirus assessed as activity remaining at 1 uM by Z'Lyte assay relative to control	B	Cc1cc(NC(=O)Nc2ccc(-c3ccnc4[nH]nc(C)c34)cc2)ccc1N1CCOCC1		CHEMBL4072731	=	Activity	%	0.0	CHEMBL1844	Homo sapiens	Activity	%	0.0
	18064284	CHEMBL4013833	Inhibition of human CSF1R preincubated for 15 mins followed by peptide substrate addition measured after 3 hrs by caliper capillary electrophoresis method	B	C=CC(=O)N1CCN(CCCn2c(=O)c(-c3c(Cl)c(OC)cc(OC)c3Cl)cc3cnc(NC)nc32)CC1		CHEMBL4068509	=	IC50	nM	8.1	CHEMBL1844	Homo sapiens	IC50	nM	8.1
	18064298	CHEMBL4013853	Inhibition of human CSF1R at 1 uM preincubated for 15 mins followed by peptide substrate addition measured after 3 hrs by caliper capillary electrophoresis method relative to control	B	C=CC(=O)N1CCN(CCCn2c(=O)c(-c3c(Cl)c(OC)cc(OC)c3Cl)cc3cnc(NC)nc32)CC1		CHEMBL4068509	>	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	18064307	CHEMBL4013862	Inhibition of human CSF1R by cell based assay	B	C=CC(=O)N1CCN(CCCn2c(=O)c(-c3c(Cl)c(OC)cc(OC)c3Cl)cc3cnc(NC)nc32)CC1		CHEMBL4068509	>	IC50	nM	1500.0	CHEMBL1844	Homo sapiens	IC50	nM	1500.0
	18081915	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cccnc2)c1		CHEMBL4060882	=	IC50	nM	20.0	CHEMBL1844	Homo sapiens	IC50	uM	0.02
	18081916	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cncnc2)c1		CHEMBL4081527	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	uM	0.01
	18081917	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(C(=O)N(C)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cccs2)c1		CHEMBL4083705	=	IC50	nM	630.0	CHEMBL1844	Homo sapiens	IC50	uM	0.63
	18081918	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1N(C)C(=O)c1cccc(-c2cccs2)c1		CHEMBL4090750	=	IC50	nM	1800.0	CHEMBL1844	Homo sapiens	IC50	uM	1.8
	18081919	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cccs2)c1		CHEMBL4064012	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	uM	0.03
	18081920	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NCc1cccc(-c2cccs2)c1		CHEMBL4072863	=	IC50	nM	350.0	CHEMBL1844	Homo sapiens	IC50	uM	0.35
	18081921	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(CNc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cccs2)c1		CHEMBL4099012	=	IC50	nM	11700.0	CHEMBL1844	Homo sapiens	IC50	uM	11.7
	18081922	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cnn(C)c2)c1		CHEMBL4095856	=	IC50	nM	1.0	CHEMBL1844	Homo sapiens	IC50	uM	0.001
	18081923	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cn[nH]c2)c1		CHEMBL4068526	<	IC50	nM	0.5	CHEMBL1844	Homo sapiens	IC50	uM	0.0005
	18081924	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2nn[nH]n2)c1		CHEMBL4084299	=	IC50	nM	20.0	CHEMBL1844	Homo sapiens	IC50	uM	0.02
	18081925	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cccnc2)c1		CHEMBL4059858	=	IC50	nM	4.0	CHEMBL1844	Homo sapiens	IC50	uM	0.004
	18081926	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2ccccn2)c1		CHEMBL4104586	=	IC50	nM	12.0	CHEMBL1844	Homo sapiens	IC50	uM	0.012
	18081927	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2ccncc2)c1		CHEMBL4063659	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	uM	0.01
	18081928	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cncnc2)c1		CHEMBL4100838	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	uM	0.009
	18081929	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(NC(=O)c2ccc(CN3CCNCC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cnn(C)c2)c1		CHEMBL4074076	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	nM	1.7
	18081930	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cnn(C)c2)c1		CHEMBL4062707	=	IC50	nM	370.0	CHEMBL1844	Homo sapiens	IC50	uM	0.37
	18081931	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1NC(=O)c1cncc(-c2cnn(C)c2)c1		CHEMBL4084391	=	IC50	nM	0.5	CHEMBL1844	Homo sapiens	IC50	uM	0.0005
	18081932	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ncc(NC(=O)c2cccc(C(F)(F)F)c2)cc1NC(=O)c1cncc(-c2cnn(C)c2)c1		CHEMBL4085366	=	IC50	nM	0.9	CHEMBL1844	Homo sapiens	IC50	uM	0.0009
	18081933	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1NC(=O)c1cnc(N)nc1		CHEMBL4103299	=	IC50	nM	32.0	CHEMBL1844	Homo sapiens	IC50	uM	0.032
	18081948	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	CN1CCN(Cc2ccc(NC(=O)c3ccc(Cl)c(NC(=O)c4cccc(-c5cccs5)c4)c3)cc2C(F)(F)F)CC1		CHEMBL4082748	=	IC50	nM	40.0	CHEMBL1844	Homo sapiens	IC50	uM	0.04
	18081949	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(Cl)c2)cc1NC(=O)c1cccc(-c2cccs2)c1		CHEMBL4099220	=	IC50	nM	230.0	CHEMBL1844	Homo sapiens	IC50	uM	0.23
	18081950	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)cc2)cc1NC(=O)c1cccc(-c2cccs2)c1		CHEMBL4072266	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	18081951	CHEMBL4017683	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate incubated for 2 hrs in presence of [33gammaP]ATP by P81 ion exchange chromatographic method	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cccs2)c1		CHEMBL4079932	=	IC50	nM	80.0	CHEMBL1844	Homo sapiens	IC50	uM	0.08
	18081974	CHEMBL4017711	Ratio of IC50 for inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system in presence of 167 uM ATP to IC50 for inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system in presence of 18 uM ATP	B	CNC(=O)c1cc(Oc2ccc3nc(N[C@H]4CCCC[C@@H]4O)sc3c2)ccn1		CHEMBL4065459	=	Ratio IC50		15.0	CHEMBL1844	Homo sapiens	Ratio IC50		15.0
	18081975	CHEMBL4017711	Ratio of IC50 for inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system in presence of 167 uM ATP to IC50 for inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system in presence of 18 uM ATP	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1NC(=O)c1cncc(-c2cnn(C)c2)c1		CHEMBL4084391	=	Ratio IC50		1.77	CHEMBL1844	Homo sapiens	Ratio IC50		1.77
	18081976	CHEMBL4017711	Ratio of IC50 for inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system in presence of 167 uM ATP to IC50 for inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system in presence of 18 uM ATP	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cnn(C)c2)c1		CHEMBL4095856	=	Ratio IC50		4.88	CHEMBL1844	Homo sapiens	Ratio IC50		4.88
	18081977	CHEMBL4017710	Ratio of IC50 for inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system in presence of 500 uM ATP to IC50 for inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system in presence of 18 uM ATP	B	CNC(=O)c1cc(Oc2ccc3nc(N[C@H]4CCCC[C@@H]4O)sc3c2)ccn1		CHEMBL4065459	=	Ratio IC50		29.0	CHEMBL1844	Homo sapiens	Ratio IC50		29.0
	18081978	CHEMBL4017710	Ratio of IC50 for inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system in presence of 500 uM ATP to IC50 for inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system in presence of 18 uM ATP	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1NC(=O)c1cncc(-c2cnn(C)c2)c1		CHEMBL4084391	=	Ratio IC50		2.66	CHEMBL1844	Homo sapiens	Ratio IC50		2.66
	18081979	CHEMBL4017710	Ratio of IC50 for inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system in presence of 500 uM ATP to IC50 for inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system in presence of 18 uM ATP	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cnn(C)c2)c1		CHEMBL4095856	=	Ratio IC50		6.42	CHEMBL1844	Homo sapiens	Ratio IC50		6.42
	18081982	CHEMBL4017707	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system using fluorescent-polyGT as substrate preincubated for 10 mins followed by substrate measured after 1 hr in presence of 18 uM ATP by LanthaScreen TR-FRET assay	B	CNC(=O)c1cc(Oc2ccc3nc(N[C@H]4CCCC[C@@H]4O)sc3c2)ccn1		CHEMBL4065459	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	uM	0.002
	18081983	CHEMBL4017707	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system using fluorescent-polyGT as substrate preincubated for 10 mins followed by substrate measured after 1 hr in presence of 18 uM ATP by LanthaScreen TR-FRET assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1NC(=O)c1cncc(-c2cnn(C)c2)c1		CHEMBL4084391	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	uM	0.009
	18081984	CHEMBL4017707	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system using fluorescent-polyGT as substrate preincubated for 10 mins followed by substrate measured after 1 hr in presence of 18 uM ATP by LanthaScreen TR-FRET assay	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cnn(C)c2)c1		CHEMBL4095856	=	IC50	nM	69.0	CHEMBL1844	Homo sapiens	IC50	uM	0.069
	18081985	CHEMBL4017706	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system using fluorescent-polyGT as substrate preincubated for 10 mins followed by substrate measured after 1 hr in presence of 167 uM ATP by LanthaScreen TR-FRET assay	B	CNC(=O)c1cc(Oc2ccc3nc(N[C@H]4CCCC[C@@H]4O)sc3c2)ccn1		CHEMBL4065459	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	uM	0.03
	18081986	CHEMBL4017706	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system using fluorescent-polyGT as substrate preincubated for 10 mins followed by substrate measured after 1 hr in presence of 167 uM ATP by LanthaScreen TR-FRET assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1NC(=O)c1cncc(-c2cnn(C)c2)c1		CHEMBL4084391	=	IC50	nM	16.0	CHEMBL1844	Homo sapiens	IC50	uM	0.016
	18081987	CHEMBL4017706	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system using fluorescent-polyGT as substrate preincubated for 10 mins followed by substrate measured after 1 hr in presence of 167 uM ATP by LanthaScreen TR-FRET assay	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cnn(C)c2)c1		CHEMBL4095856	=	IC50	nM	337.0	CHEMBL1844	Homo sapiens	IC50	uM	0.337
	18081988	CHEMBL4017705	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system using fluorescent-polyGT as substrate preincubated for 10 mins followed by substrate measured after 1 hr in presence of 500 uM ATP by LanthaScreen TR-FRET assay	B	CNC(=O)c1cc(Oc2ccc3nc(N[C@H]4CCCC[C@@H]4O)sc3c2)ccn1		CHEMBL4065459	=	IC50	nM	58.0	CHEMBL1844	Homo sapiens	IC50	uM	0.058
	18081989	CHEMBL4017705	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system using fluorescent-polyGT as substrate preincubated for 10 mins followed by substrate measured after 1 hr in presence of 500 uM ATP by LanthaScreen TR-FRET assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1NC(=O)c1cncc(-c2cnn(C)c2)c1		CHEMBL4084391	=	IC50	nM	24.0	CHEMBL1844	Homo sapiens	IC50	uM	0.024
	18081990	CHEMBL4017705	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system using fluorescent-polyGT as substrate preincubated for 10 mins followed by substrate measured after 1 hr in presence of 500 uM ATP by LanthaScreen TR-FRET assay	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1NC(=O)c1cccc(-c2cnn(C)c2)c1		CHEMBL4095856	=	IC50	nM	443.0	CHEMBL1844	Homo sapiens	IC50	uM	0.443
	18084575	CHEMBL4018336	Inhibition of human FMS using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method	B	C=CC(=O)Nc1cccc(C)c1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1		CHEMBL4089245	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	18084607	CHEMBL4018329	Inhibition of human FMS at 10 uM using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method relative to control	B	C=CC(=O)Nc1cccc(C)c1Nc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)ccc2n1		CHEMBL4068896	=	Inhibition	%	78.0	CHEMBL1844	Homo sapiens	INH	%	78.0
	18084614	CHEMBL4018336	Inhibition of human FMS using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method	B	C=CC(=O)Nc1cccc(C)c1Nc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)ccc2n1		CHEMBL4068896	=	IC50	nM	1100.0	CHEMBL1844	Homo sapiens	IC50	uM	1.1
	18084621	CHEMBL4018329	Inhibition of human FMS at 10 uM using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method relative to control	B	C=CC(=O)Nc1cccc(C)c1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1		CHEMBL4089245	=	Inhibition	%	4.0	CHEMBL1844	Homo sapiens	INH	%	4.0
	18084667	CHEMBL4018329	Inhibition of human FMS at 10 uM using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method relative to control	B	C=CC(=O)N[C@H]1COC[C@H]1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1		CHEMBL4077859	=	Inhibition	%	6.0	CHEMBL1844	Homo sapiens	INH	%	6.0
	18084674	CHEMBL4018336	Inhibition of human FMS using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method	B	C=CC(=O)N[C@H]1COC[C@H]1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1		CHEMBL4077859	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	18084683	CHEMBL4018336	Inhibition of human FMS using poly[Glu:Tyr] (4:1) as substrate measured after 120 mins in presence of [gamma33P]ATP by P81 ion exchange chromatographic method	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	970.0	CHEMBL1844	Homo sapiens	IC50	uM	0.97
	18114422	CHEMBL4025072	Inhibition of wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	100.0	CHEMBL1844	Homo sapiens	Activity	%	100.0
	18114423	CHEMBL4025071	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	86.0	CHEMBL1844	Homo sapiens	Activity	%	86.0
	18141781	CHEMBL4031396	Inhibition of human CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-n3nc(-c4ccc(OCCN5CCOCC5)cc4)c4c(N)ncnc43)cc2)no1		CHEMBL4101411	=	Activity	%	0.05	CHEMBL1844	Homo sapiens	Activity	%	0.05
	18141804	CHEMBL4031417	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in Baculovirus expression system by Z'Lyte assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-n3nc(-c4ccc(OCCN5CCOCC5)cc4)c4c(N)ncnc43)cc2)no1		CHEMBL4101411	=	IC50	nM	154.0	CHEMBL1844	Homo sapiens	IC50	nM	154.0
	18141851	CHEMBL4031449	Binding affinity to CSF1R (unknown origin) by KinomeSCan assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	=	Kd	nM	12.0	CHEMBL1844	Homo sapiens	Kd	nM	12.0
	18172176	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C(C)=O)CC5)c(C)c4)nc32)C1		CHEMBL4078026	=	IC50	nM	25.9	CHEMBL1844	Homo sapiens	IC50	nM	25.9
	18172177	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCOCC5)c(C)c4)nc32)C1		CHEMBL4102288	=	IC50	nM	25.2	CHEMBL1844	Homo sapiens	IC50	nM	25.2
	18172178	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCCCC5)c(C)c4)nc32)C1		CHEMBL4062192	=	IC50	nM	41.2	CHEMBL1844	Homo sapiens	IC50	nM	41.2
	18172179	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C(C)C)c4)nc32)C1		CHEMBL4083916	=	IC50	nM	25.8	CHEMBL1844	Homo sapiens	IC50	nM	25.8
	18172180	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(CC)c4)nc32)C1		CHEMBL4096014	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	18172181	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C(F)(F)F)c4)nc32)C1		CHEMBL4068695	=	IC50	nM	31.9	CHEMBL1844	Homo sapiens	IC50	nM	31.9
	18172182	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(Cl)c4)nc32)C1		CHEMBL4103761	=	IC50	nM	14.8	CHEMBL1844	Homo sapiens	IC50	nM	14.8
	18172183	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(F)c4)nc32)C1		CHEMBL4079506	=	IC50	nM	17.1	CHEMBL1844	Homo sapiens	IC50	nM	17.1
	18172184	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(OC)c4)nc32)C1		CHEMBL4065984	=	IC50	nM	5.8	CHEMBL1844	Homo sapiens	IC50	nM	5.8
	18172185	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)C1		CHEMBL4087383	=	IC50	nM	30.4	CHEMBL1844	Homo sapiens	IC50	nM	30.4
	18172186	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4C)nc32)C1		CHEMBL4074615	=	IC50	nM	20.2	CHEMBL1844	Homo sapiens	IC50	nM	20.2
	18172187	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4)nc32)C1		CHEMBL4095071	=	IC50	nM	13.6	CHEMBL1844	Homo sapiens	IC50	nM	13.6
	18172188	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4084726	=	IC50	nM	2.1	CHEMBL1844	Homo sapiens	IC50	nM	2.1
	18172189	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cccc(OC)c3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4063067	=	IC50	nM	4.4	CHEMBL1844	Homo sapiens	IC50	nM	4.4
	18172190	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4096822	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
	18172191	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cccc(OC)c3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4078801	=	IC50	nM	4.5	CHEMBL1844	Homo sapiens	IC50	nM	4.5
	18172192	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cccc(OC(F)(F)F)c3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4089120	=	IC50	nM	151.0	CHEMBL1844	Homo sapiens	IC50	nM	151.0
	18172193	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cccc(OC(F)F)c3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4067916	=	IC50	nM	28.0	CHEMBL1844	Homo sapiens	IC50	nM	28.0
	18172194	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3ccc(OC)cc3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4081252	=	IC50	nM	5.8	CHEMBL1844	Homo sapiens	IC50	nM	5.8
	18172195	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cccc(OC)c3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4105503	=	IC50	nM	4.5	CHEMBL1844	Homo sapiens	IC50	nM	4.5
	18172196	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3ccccc3OC)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4070640	=	IC50	nM	5.1	CHEMBL1844	Homo sapiens	IC50	nM	5.1
	18172197	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3ccc(C)cc3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4097770	=	IC50	nM	20.6	CHEMBL1844	Homo sapiens	IC50	nM	20.6
	18172198	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cccc(C)c3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4087525	=	IC50	nM	16.4	CHEMBL1844	Homo sapiens	IC50	nM	16.4
	18172199	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3ccc(Cl)cc3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4105392	=	IC50	nM	14.8	CHEMBL1844	Homo sapiens	IC50	nM	14.8
	18172200	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cccc(Cl)c3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4079649	=	IC50	nM	13.2	CHEMBL1844	Homo sapiens	IC50	nM	13.2
	18172201	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3ccc(F)cc3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4097682	=	IC50	nM	18.1	CHEMBL1844	Homo sapiens	IC50	nM	18.1
	18172202	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cccc(F)c3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4070404	=	IC50	nM	15.2	CHEMBL1844	Homo sapiens	IC50	nM	15.2
	18172203	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3ccccc3C)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4089951	=	IC50	nM	5.6	CHEMBL1844	Homo sapiens	IC50	nM	5.6
	18172204	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3ccccc3F)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4060198	=	IC50	nM	5.2	CHEMBL1844	Homo sapiens	IC50	nM	5.2
	18172205	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	=	IC50	nM	10.8	CHEMBL1844	Homo sapiens	IC50	nM	10.8
	18172206	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@@H](N2C(=O)N(c3ccccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4098591	=	IC50	nM	20.9	CHEMBL1844	Homo sapiens	IC50	nM	20.9
	18172207	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCCN1CC[C@H](N2C(=O)N(c3ccccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4062830	=	IC50	nM	180.7	CHEMBL1844	Homo sapiens	IC50	nM	180.7
	18172208	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)CN(C)C)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1		CHEMBL4083904	=	IC50	nM	22.7	CHEMBL1844	Homo sapiens	IC50	nM	22.7
	18172209	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)CO)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1		CHEMBL4062178	=	IC50	nM	20.0	CHEMBL1844	Homo sapiens	IC50	nM	20.0
	18172210	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)C4CCCCC4)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1		CHEMBL4102822	=	IC50	nM	30.6	CHEMBL1844	Homo sapiens	IC50	nM	30.6
	18172211	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)C4CCCC4)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1		CHEMBL4084868	=	IC50	nM	28.4	CHEMBL1844	Homo sapiens	IC50	nM	28.4
	18172212	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)C4CC4)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1		CHEMBL4064937	=	IC50	nM	20.7	CHEMBL1844	Homo sapiens	IC50	nM	20.7
	18172213	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)C(C)(C)C)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1		CHEMBL4092632	=	IC50	nM	20.1	CHEMBL1844	Homo sapiens	IC50	nM	20.1
	18172214	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)CC(C)C)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1		CHEMBL4087375	=	IC50	nM	10.3	CHEMBL1844	Homo sapiens	IC50	nM	10.3
	18172215	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCCC(=O)N1CC[C@H](N2C(=O)N(c3ccccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4065970	=	IC50	nM	10.1	CHEMBL1844	Homo sapiens	IC50	nM	10.1
	18172216	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	Cc1cc(Nc2ncc3c(n2)N([C@H]2CCN(C(=O)C(C)C)C2)C(=O)N(c2ccccc2Cl)C3)ccc1N1CCN(C)CC1		CHEMBL4095063	=	IC50	nM	6.7	CHEMBL1844	Homo sapiens	IC50	nM	6.7
	18172217	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CC(=O)N1CC[C@H](N2C(=O)N(c3ccccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4074601	=	IC50	nM	5.5	CHEMBL1844	Homo sapiens	IC50	nM	5.5
	18172218	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3ccccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4098507	=	IC50	nM	5.0	CHEMBL1844	Homo sapiens	IC50	nM	5.0
	18172219	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	C=CC(=O)N1CC[C@H](N2C(=O)N(c3ccccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4071474	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	nM	30.0
	18172220	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCCN(C)CC5)c(C)c4)nc32)C1		CHEMBL4083224	=	IC50	nM	4.9	CHEMBL1844	Homo sapiens	IC50	nM	4.9
	18172221	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCC(N(C)C)CC5)c(C)c4)nc32)C1		CHEMBL4076405	=	IC50	nM	4.7	CHEMBL1844	Homo sapiens	IC50	nM	4.7
	18172222	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCC6(CCN(C)C6)C5)c(C)c4)nc32)C1		CHEMBL4086821	=	IC50	nM	6.8	CHEMBL1844	Homo sapiens	IC50	nM	6.8
	18172223	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCC6(CCN(C)CC6)CC5)c(C)c4)nc32)C1		CHEMBL4104717	=	IC50	nM	6.2	CHEMBL1844	Homo sapiens	IC50	nM	6.2
	18172224	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CC6(CCN(C)CC6)C5)c(C)c4)nc32)C1		CHEMBL4078973	=	IC50	nM	6.5	CHEMBL1844	Homo sapiens	IC50	nM	6.5
	18172225	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5C[C@@H]6CN(C)C[C@@H]6C5)c(C)c4)nc32)C1		CHEMBL4096988	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	nM	7.0
	18172226	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N(C)CCN(C)C)c(C)c4)nc32)C1		CHEMBL4076515	=	IC50	nM	10.3	CHEMBL1844	Homo sapiens	IC50	nM	10.3
	18172227	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C)C(C)C5)c(C)c4)nc32)C1		CHEMBL4093535	=	IC50	nM	7.2	CHEMBL1844	Homo sapiens	IC50	nM	7.2
	18172228	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5C[C@H](C)N(C)[C@H](C)C5)c(C)c4)nc32)C1		CHEMBL4103893	=	IC50	nM	7.8	CHEMBL1844	Homo sapiens	IC50	nM	7.8
	18172229	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3F)Cc3cnc(Nc4ccc(N5CCN(C6COC6)CC5)c(C)c4)nc32)C1		CHEMBL4072688	=	IC50	nM	3.4	CHEMBL1844	Homo sapiens	IC50	nM	3.4
	18172230	CHEMBL4038016	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus using tyr4 peptide as substrate after 1 hr by FRET-based Z'-Lyte assay	B	CCC(=O)N1CC[C@H](N2C(=O)N(c3cc(OC)ccc3Cl)Cc3cnc(Nc4ccc(N5CCN(C6COC6)CC5)c(C)c4)nc32)C1		CHEMBL4066141	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	nM	3.0
	18203595	CHEMBL4043882	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	0.4	CHEMBL1844	Homo sapiens	Activity	%	0.4
	18203596	CHEMBL4043883	Inhibition of wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in HEK293 cells assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	74.0	CHEMBL1844	Homo sapiens	Activity	%	74.0
	18212541	CHEMBL4046277	Inhibition of recombinant human N-terminal GST-tagged FMS cytoplasmic domain (538 to 972 residues) expressed in baculovirus expression system at 10 uM by TR-FRET assay relative to control	B	NC(=O)c1c(NC(=O)c2ccc(CN3CCOCC3)cc2)sc2c1CCC(CO)C2		CHEMBL4088423	>	Inhibition	%	80.0	CHEMBL1844	Homo sapiens	INH	%	80.0
	18218984	CHEMBL4047239	Inhibition of FMS (unknown origin) assessed as residual activity at 1 uM relative to control	B	C=CC(=O)Nc1cccc(CNc2cc(Nc3ccccc3)ncc2C(N)=O)c1		CHEMBL4065693	<	Activity	%	10.0	CHEMBL1844	Homo sapiens	Activity	%	10.0
	18218996	CHEMBL4047251	Inhibition of FMS (unknown origin) by caliper assay	B	C=CC(=O)Nc1cccc(CNc2cc(Nc3ccccc3)ncc2C(N)=O)c1		CHEMBL4065693	=	IC50	nM	180.0	CHEMBL1844	Homo sapiens	IC50	nM	180.0
	18253331	CHEMBL4054949	Inhibition of wild-type human partial length FMS (I564 to S939 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	57.0	CHEMBL1844	Homo sapiens	Activity	%	57.0
	18253332	CHEMBL4054949	Inhibition of wild-type human partial length FMS (I564 to S939 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	74.0	CHEMBL1844	Homo sapiens	Activity	%	74.0
	18265867	CHEMBL4057317	Inhibition of FMS (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1	Outside typical range	CHEMBL4095072	=	Inhibition	%	-22.7	CHEMBL1844	Homo sapiens	INH	%	-22.7
	18266061	CHEMBL4057511	Inhibition of FMS (unknown origin) at 0.49 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(NC(=O)C3CC3)noc2c1	Outside typical range	CHEMBL4088455	=	Inhibition	%	-14.7	CHEMBL1844	Homo sapiens	INH	%	-14.7
	18269013	CHEMBL4058143	Inhibition of recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus Sf21 insect cells preincubated for 5 mins followed by substrate addition after 30 to 60 mins in presence of ATP by fluorescence assay	B	C=CS(=O)(=O)N1CCC[C@@H]1Cn1cc(-c2ccc3c(c2)OCO3)c2c(N)ncnc21		CHEMBL4095253	=	IC50	nM	4701.0	CHEMBL1844	Homo sapiens	IC50	nM	4701.0
	18274421	CHEMBL4059352	Inhibition of human CSF1R assessed as remaining activity at 1 uM after 30 mins by qPCR method	B	CNCc1cc(Oc2ccc3c(ccn3C(=O)Nc3cc(C(F)(F)F)n(C)n3)c2)ncn1		CHEMBL4076112	<=	Activity	%	10.0	CHEMBL1844	Homo sapiens	Activity	%	10.0
	18274428	CHEMBL4059359	Inhibition of human FMS assessed as remaining activity at 1 uM after 30 mins by qPCR method	B	CNCc1cc(Oc2ccc3c(ccn3C(=O)Nc3cc(C(F)(F)F)n(C)n3)c2)ncn1		CHEMBL4076112	<=	Activity	%	10.0	CHEMBL1844	Homo sapiens	Activity	%	10.0
	18274893	CHEMBL4118343	Inhibition of FMS in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled VAVKMLK probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1Cl		CHEMBL3883384	=	Inhibition	%	33.7	CHEMBL1844	Homo sapiens	INH	%	33.7
	18274894	CHEMBL4118343	Inhibition of FMS in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled VAVKMLK probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Oc1nc(Nc2cnn(CCOC)c2)ncc1Cl		CHEMBL3884839	=	Inhibition	%	7.6	CHEMBL1844	Homo sapiens	INH	%	7.6
	18274895	CHEMBL4118343	Inhibition of FMS in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled VAVKMLK probe by mass-spectrometric analysis relative to control	B	COc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O		CHEMBL1077979	=	Inhibition	%	18.4	CHEMBL1844	Homo sapiens	INH	%	18.4
	18282012	CHEMBL4119967	Inhibition of recombinant His-tagged human CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@@H]1[C@H]2CN(C3COC3)C[C@H]21		CHEMBL3719135	=	Inhibition	%	46.3	CHEMBL1844	Homo sapiens	INH	%	46.3
	18282331	CHEMBL4119967	Inhibition of recombinant His-tagged human CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	Nc1ncc(-c2cc([C@@H]3[C@H]4CN(C5COC5)C[C@H]43)n(CC3CC3)n2)cc1C(F)(F)F		CHEMBL3715238	=	Inhibition	%	54.1	CHEMBL1844	Homo sapiens	INH	%	54.1
	18282544	CHEMBL4120182	Inhibition of recombinant His-tagged human CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system by FRET assay	B	Nc1ncc(-c2cc([C@@H]3[C@H]4CN(C5COC5)C[C@H]43)n(CC3CC3)n2)cc1C(F)(F)F		CHEMBL3715238	=	IC50	nM	1220.0	CHEMBL1844	Homo sapiens	IC50	uM	1.22
	18282825	CHEMBL4120410	Inhibition of FMS (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1	Outside typical range	CHEMBL4095072	=	Inhibition	%	-22.7	CHEMBL1844	Homo sapiens	INH	%	-22.7
	18282995	CHEMBL4120580	Inhibition of FMS (unknown origin) at 0.19 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2c1		CHEMBL4125807	=	Inhibition	%	21.3	CHEMBL1844	Homo sapiens	INH	%	21.3
	18283219	CHEMBL4120804	Inhibition of FMS (unknown origin) at 0.164 uM relative to control	B	COC(=O)Nc1cc(-c2c(C3CC3)n[nH]c2C)cc2[nH]ncc12		CHEMBL4129737	=	Inhibition	%	-0.7	CHEMBL1844	Homo sapiens	INH	%	-0.7
	18380190	CHEMBL4145922	Inhibition of FMS (unknown origin) assessed as remaining activity at 1 x 10'-6 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2cccc(OC)c2)cc(OC)c1		CHEMBL4172190	=	Activity	%	8.38	CHEMBL1844	Homo sapiens	Activity	%	8.38
	18380191	CHEMBL4145922	Inhibition of FMS (unknown origin) assessed as remaining activity at 1 x 10'-6 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(C(F)(F)F)cc2)cc(OC)c1		CHEMBL4160898	=	Activity	%	9.11	CHEMBL1844	Homo sapiens	Activity	%	9.11
	18380192	CHEMBL4145922	Inhibition of FMS (unknown origin) assessed as remaining activity at 1 x 10'-6 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2/N=C/c2cc(OC)cc(OC)c2)cc1		CHEMBL4165412	=	Activity	%	4.79	CHEMBL1844	Homo sapiens	Activity	%	4.79
	18380193	CHEMBL4145922	Inhibition of FMS (unknown origin) assessed as remaining activity at 1 x 10'-6 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(F)cc2)cc(OC)c1		CHEMBL4161971	=	Activity	%	6.81	CHEMBL1844	Homo sapiens	Activity	%	6.81
	18380194	CHEMBL4145923	Inhibition of FMS (unknown origin) assessed as remaining activity at 3.33 x 10'-7 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2cccc(OC)c2)cc(OC)c1		CHEMBL4172190	=	Activity	%	15.22	CHEMBL1844	Homo sapiens	Activity	%	15.22
	18380195	CHEMBL4145923	Inhibition of FMS (unknown origin) assessed as remaining activity at 3.33 x 10'-7 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(C(F)(F)F)cc2)cc(OC)c1		CHEMBL4160898	=	Activity	%	13.49	CHEMBL1844	Homo sapiens	Activity	%	13.49
	18380196	CHEMBL4145923	Inhibition of FMS (unknown origin) assessed as remaining activity at 3.33 x 10'-7 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2/N=C/c2cc(OC)cc(OC)c2)cc1		CHEMBL4165412	=	Activity	%	8.7	CHEMBL1844	Homo sapiens	Activity	%	8.7
	18380197	CHEMBL4145923	Inhibition of FMS (unknown origin) assessed as remaining activity at 3.33 x 10'-7 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(F)cc2)cc(OC)c1		CHEMBL4161971	=	Activity	%	14.88	CHEMBL1844	Homo sapiens	Activity	%	14.88
	18380198	CHEMBL4145924	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.11 x 10'-7 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2cccc(OC)c2)cc(OC)c1		CHEMBL4172190	=	Activity	%	21.09	CHEMBL1844	Homo sapiens	Activity	%	21.09
	18380199	CHEMBL4145924	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.11 x 10'-7 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(C(F)(F)F)cc2)cc(OC)c1		CHEMBL4160898	=	Activity	%	22.91	CHEMBL1844	Homo sapiens	Activity	%	22.91
	18380200	CHEMBL4145924	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.11 x 10'-7 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2/N=C/c2cc(OC)cc(OC)c2)cc1		CHEMBL4165412	=	Activity	%	14.86	CHEMBL1844	Homo sapiens	Activity	%	14.86
	18380201	CHEMBL4145924	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.11 x 10'-7 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(F)cc2)cc(OC)c1		CHEMBL4161971	=	Activity	%	26.78	CHEMBL1844	Homo sapiens	Activity	%	26.78
	18380202	CHEMBL4145925	Inhibition of FMS (unknown origin) assessed as remaining activity at 3.7 x 10'-8 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2cccc(OC)c2)cc(OC)c1		CHEMBL4172190	=	Activity	%	33.67	CHEMBL1844	Homo sapiens	Activity	%	33.67
	18380203	CHEMBL4145925	Inhibition of FMS (unknown origin) assessed as remaining activity at 3.7 x 10'-8 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(C(F)(F)F)cc2)cc(OC)c1		CHEMBL4160898	=	Activity	%	36.55	CHEMBL1844	Homo sapiens	Activity	%	36.55
	18380204	CHEMBL4145925	Inhibition of FMS (unknown origin) assessed as remaining activity at 3.7 x 10'-8 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2/N=C/c2cc(OC)cc(OC)c2)cc1		CHEMBL4165412	=	Activity	%	23.33	CHEMBL1844	Homo sapiens	Activity	%	23.33
	18380205	CHEMBL4145925	Inhibition of FMS (unknown origin) assessed as remaining activity at 3.7 x 10'-8 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(F)cc2)cc(OC)c1		CHEMBL4161971	=	Activity	%	38.37	CHEMBL1844	Homo sapiens	Activity	%	38.37
	18380206	CHEMBL4145926	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.23 x 10'-8 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2cccc(OC)c2)cc(OC)c1		CHEMBL4172190	=	Activity	%	40.62	CHEMBL1844	Homo sapiens	Activity	%	40.62
	18380207	CHEMBL4145926	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.23 x 10'-8 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(C(F)(F)F)cc2)cc(OC)c1		CHEMBL4160898	=	Activity	%	46.73	CHEMBL1844	Homo sapiens	Activity	%	46.73
	18380208	CHEMBL4145926	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.23 x 10'-8 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2/N=C/c2cc(OC)cc(OC)c2)cc1		CHEMBL4165412	=	Activity	%	36.43	CHEMBL1844	Homo sapiens	Activity	%	36.43
	18380209	CHEMBL4145926	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.23 x 10'-8 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(F)cc2)cc(OC)c1		CHEMBL4161971	=	Activity	%	52.01	CHEMBL1844	Homo sapiens	Activity	%	52.01
	18380210	CHEMBL4145927	Inhibition of FMS (unknown origin) assessed as remaining activity at 4.12 x 10'-9 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2cccc(OC)c2)cc(OC)c1		CHEMBL4172190	=	Activity	%	60.01	CHEMBL1844	Homo sapiens	Activity	%	60.01
	18380211	CHEMBL4145927	Inhibition of FMS (unknown origin) assessed as remaining activity at 4.12 x 10'-9 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(C(F)(F)F)cc2)cc(OC)c1		CHEMBL4160898	=	Activity	%	68.98	CHEMBL1844	Homo sapiens	Activity	%	68.98
	18380212	CHEMBL4145927	Inhibition of FMS (unknown origin) assessed as remaining activity at 4.12 x 10'-9 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2/N=C/c2cc(OC)cc(OC)c2)cc1		CHEMBL4165412	=	Activity	%	49.44	CHEMBL1844	Homo sapiens	Activity	%	49.44
	18380213	CHEMBL4145927	Inhibition of FMS (unknown origin) assessed as remaining activity at 4.12 x 10'-9 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(F)cc2)cc(OC)c1		CHEMBL4161971	=	Activity	%	73.04	CHEMBL1844	Homo sapiens	Activity	%	73.04
	18380214	CHEMBL4145928	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.37 x 10'-9 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2cccc(OC)c2)cc(OC)c1		CHEMBL4172190	=	Activity	%	74.77	CHEMBL1844	Homo sapiens	Activity	%	74.77
	18380215	CHEMBL4145928	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.37 x 10'-9 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(C(F)(F)F)cc2)cc(OC)c1		CHEMBL4160898	=	Activity	%	78.17	CHEMBL1844	Homo sapiens	Activity	%	78.17
	18380216	CHEMBL4145928	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.37 x 10'-9 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2/N=C/c2cc(OC)cc(OC)c2)cc1		CHEMBL4165412	=	Activity	%	72.48	CHEMBL1844	Homo sapiens	Activity	%	72.48
	18380217	CHEMBL4145928	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.37 x 10'-9 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(F)cc2)cc(OC)c1		CHEMBL4161971	=	Activity	%	86.46	CHEMBL1844	Homo sapiens	Activity	%	86.46
	18380218	CHEMBL4145929	Inhibition of FMS (unknown origin) assessed as remaining activity at 4.57 x 10'-10 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2cccc(OC)c2)cc(OC)c1		CHEMBL4172190	=	Activity	%	89.26	CHEMBL1844	Homo sapiens	Activity	%	89.26
	18380219	CHEMBL4145929	Inhibition of FMS (unknown origin) assessed as remaining activity at 4.57 x 10'-10 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(C(F)(F)F)cc2)cc(OC)c1		CHEMBL4160898	=	Activity	%	95.01	CHEMBL1844	Homo sapiens	Activity	%	95.01
	18380220	CHEMBL4145929	Inhibition of FMS (unknown origin) assessed as remaining activity at 4.57 x 10'-10 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2/N=C/c2cc(OC)cc(OC)c2)cc1		CHEMBL4165412	=	Activity	%	87.95	CHEMBL1844	Homo sapiens	Activity	%	87.95
	18380221	CHEMBL4145929	Inhibition of FMS (unknown origin) assessed as remaining activity at 4.57 x 10'-10 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(F)cc2)cc(OC)c1		CHEMBL4161971	=	Activity	%	87.8	CHEMBL1844	Homo sapiens	Activity	%	87.8
	18380222	CHEMBL4145930	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.52 x 10'-10 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2cccc(OC)c2)cc(OC)c1		CHEMBL4172190	=	Activity	%	94.85	CHEMBL1844	Homo sapiens	Activity	%	94.85
	18380223	CHEMBL4145930	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.52 x 10'-10 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(C(F)(F)F)cc2)cc(OC)c1		CHEMBL4160898	=	Activity	%	95.64	CHEMBL1844	Homo sapiens	Activity	%	95.64
	18380224	CHEMBL4145930	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.52 x 10'-10 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2/N=C/c2cc(OC)cc(OC)c2)cc1		CHEMBL4165412	=	Activity	%	93.01	CHEMBL1844	Homo sapiens	Activity	%	93.01
	18380225	CHEMBL4145930	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.52 x 10'-10 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 105.74%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(F)cc2)cc(OC)c1		CHEMBL4161971	=	Activity	%	90.38	CHEMBL1844	Homo sapiens	Activity	%	90.38
	18380226	CHEMBL4145931	Inhibition of FMS (unknown origin) assessed as remaining activity at 5.08 x 10'-11 M after 120 mins in presence of 33P-ATP (Rvb = 103.65% to 105.74%)	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2/N=C/c2cc(OC)cc(OC)c2)cc1		CHEMBL4165412	=	Activity	%	93.16	CHEMBL1844	Homo sapiens	Activity	%	93.16
	18380227	CHEMBL4145932	Inhibition of FMS (unknown origin) assessed as remaining activity at 3 x 10'-6 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 101.08%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2cccc(OC)c2)cc(OC)c1		CHEMBL4172190	=	Activity	%	6.1	CHEMBL1844	Homo sapiens	Activity	%	6.1
	18380228	CHEMBL4145932	Inhibition of FMS (unknown origin) assessed as remaining activity at 3 x 10'-6 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 101.08%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(C(F)(F)F)cc2)cc(OC)c1		CHEMBL4160898	=	Activity	%	7.8	CHEMBL1844	Homo sapiens	Activity	%	7.8
	18380229	CHEMBL4145932	Inhibition of FMS (unknown origin) assessed as remaining activity at 3 x 10'-6 M after 120 mins in presence of 33P-ATP (Rvb = 94.28% to 101.08%)	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(F)cc2)cc(OC)c1		CHEMBL4161971	=	Activity	%	3.63	CHEMBL1844	Homo sapiens	Activity	%	3.63
	18380230	CHEMBL4145933	Inhibition of FMS (unknown origin) assessed as remaining activity at 2 x 10'-5 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Activity	%	1.54	CHEMBL1844	Homo sapiens	Activity	%	1.54
	18380231	CHEMBL4145934	Inhibition of FMS (unknown origin) assessed as remaining activity at 5 x 10'-6 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Activity	%	0.31	CHEMBL1844	Homo sapiens	Activity	%	0.31
	18380232	CHEMBL4145935	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.25 x 10'-6 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Activity	%	0.46	CHEMBL1844	Homo sapiens	Activity	%	0.46
	18380233	CHEMBL4145936	Inhibition of FMS (unknown origin) assessed as remaining activity at 3.13 x 10'-7 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Activity	%	1.11	CHEMBL1844	Homo sapiens	Activity	%	1.11
	18380234	CHEMBL4145937	Inhibition of FMS (unknown origin) assessed as remaining activity at 7.81 x 10'-8 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Activity	%	1.92	CHEMBL1844	Homo sapiens	Activity	%	1.92
	18380235	CHEMBL4145938	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.95 x 10'-8 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Activity	%	5.94	CHEMBL1844	Homo sapiens	Activity	%	5.94
	18380236	CHEMBL4145939	Inhibition of FMS (unknown origin) assessed as remaining activity at 4.88 x 10'-9 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Activity	%	18.03	CHEMBL1844	Homo sapiens	Activity	%	18.03
	18380237	CHEMBL4145940	Inhibition of FMS (unknown origin) assessed as remaining activity at 1.22 x 10'-9 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Activity	%	58.47	CHEMBL1844	Homo sapiens	Activity	%	58.47
	18380238	CHEMBL4145941	Inhibition of FMS (unknown origin) assessed as remaining activity at 3.05 x 10'-10 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Activity	%	89.91	CHEMBL1844	Homo sapiens	Activity	%	89.91
	18380239	CHEMBL4145942	Inhibition of FMS (unknown origin) assessed as remaining activity at 7.63 x 10'-11 M after 120 mins in presence of 33P-ATP (Rvb = 102.91%)	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Activity	%	93.41	CHEMBL1844	Homo sapiens	Activity	%	93.41
	18380240	CHEMBL4145907	Inhibition of FMS (unknown origin) after 120 mins in presence of 33P-ATP	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(C)cc2OC)cc(OC)c1		CHEMBL4161209	=	IC50	nM	883.0	CHEMBL1844	Homo sapiens	IC50	nM	883.0
	18380241	CHEMBL4145907	Inhibition of FMS (unknown origin) after 120 mins in presence of 33P-ATP	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2cccc(OC)c2)cc(OC)c1		CHEMBL4172190	=	IC50	nM	8.6	CHEMBL1844	Homo sapiens	IC50	nM	8.6
	18380242	CHEMBL4145907	Inhibition of FMS (unknown origin) after 120 mins in presence of 33P-ATP	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(C(F)(F)F)cc2)cc(OC)c1		CHEMBL4160898	=	IC50	nM	14.0	CHEMBL1844	Homo sapiens	IC50	nM	14.0
	18380243	CHEMBL4145907	Inhibition of FMS (unknown origin) after 120 mins in presence of 33P-ATP	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2/N=C/c2cc(OC)cc(OC)c2)cc1		CHEMBL4165412	=	IC50	nM	4.6	CHEMBL1844	Homo sapiens	IC50	nM	4.6
	18380244	CHEMBL4145907	Inhibition of FMS (unknown origin) after 120 mins in presence of 33P-ATP	B	COc1cc(/C=N/c2cnc(Nc3ccc(N4CCOCC4)cc3)nc2Oc2ccc(F)cc2)cc(OC)c1		CHEMBL4161971	=	IC50	nM	21.0	CHEMBL1844	Homo sapiens	IC50	nM	21.0
	18431052	CHEMBL4155733	Inhibition of recombinant His-tagged human CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system at 1 uM by Z'-Lyte assay relative to control	B	O=C1Nc2ccc(C(=O)N[C@H](CO)c3ccccc3)cc2/C1=C(\c1ccccc1)c1ncc[nH]1		CHEMBL4160587	=	Inhibition	%	78.0	CHEMBL1844	Homo sapiens	INH	%	78.0
	18431332	CHEMBL4155784	Inhibition of CSF1R (unknown origin) at 1 uM relative to control	B	Cn1ncc2c(Oc3ccc4c(c3)nc(Nc3ccc(OC(F)(F)F)cc3)n4C)ncnc21		CHEMBL4170025	=	Inhibition	%	40.5	CHEMBL1844	Homo sapiens	INH	%	40.5
	18434108	CHEMBL4156091	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	OC[C@@H](Nc1ncnc2sc(-c3ccc(O)cc3)cc12)c1ccccc1		CHEMBL4177361	=	Inhibition	%	31.0	CHEMBL1844	Homo sapiens	INH	%	31.0
	18434236	CHEMBL4156091	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	CCC(=O)Nc1ccc(-c2c[nH]c3ncnc(N[C@H](C)c4ccccc4)c23)cc1		CHEMBL4167749	=	Inhibition	%	21.0	CHEMBL1844	Homo sapiens	INH	%	21.0
	18434296	CHEMBL4156091	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	CN(C)CCn1cc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL4159505	=	Inhibition	%	39.0	CHEMBL1844	Homo sapiens	INH	%	39.0
	18434368	CHEMBL4156091	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system at 500 nM by Z-LYTE assay relative to control	B	OCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1		CHEMBL4175024	=	Inhibition	%	96.0	CHEMBL1844	Homo sapiens	INH	%	96.0
	18440137	CHEMBL4156961	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	97.0	CHEMBL1844	Homo sapiens	Activity	%	97.0
	18440138	CHEMBL4156962	Binding affinity to wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in mammalian expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	100.0	CHEMBL1844	Homo sapiens	Activity	%	100.0
	18463752	CHEMBL4181168	Inhibition of recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus Sf21 insect cells at 10 uM by filter binding radioactive ATP transferase assay relative to control	B	C=C(C)n1c(=O)n(C(C)=O)c2cc(Br)cnc21		CHEMBL4212680	=	Inhibition	%	-9.0	CHEMBL1844	Homo sapiens	INH	%	-9.0
	18477353	CHEMBL4183779	Inhibition of human N-terminal GST-tagged FMS expressed in baculovirus expression system at 10 nM relative to control	B	N[C@H]1CC[C@H](Nc2nc(Nc3ccc(CN4CCOCC4)cc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL4204373	>	Inhibition	%	90.0	CHEMBL1844	Homo sapiens	INH	%	90.0
	18484577	CHEMBL4185740	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	87.0	CHEMBL1844	Homo sapiens	Activity	%	87.0
	18484578	CHEMBL4185741	Binding affinity to wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	65.0	CHEMBL1844	Homo sapiens	Activity	%	65.0
	18485043	CHEMBL4185741	Binding affinity to wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	100.0	CHEMBL1844	Homo sapiens	Activity	%	100.0
	18485044	CHEMBL4185740	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	100.0	CHEMBL1844	Homo sapiens	Activity	%	100.0
	18489501	CHEMBL4187242	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	Fc1cc(F)cc(-n2cnc3c(NCc4nc5c(F)c(F)ccc5[nH]4)nc(N4CCOCC4)nc32)c1		CHEMBL4207079	=	Activity	%	98.0	CHEMBL1844	Homo sapiens	Activity	%	98.0
	18502865	CHEMBL4189702	Inhibition of recombinant human CSF1R using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	18502866	CHEMBL4189702	Inhibition of recombinant human CSF1R using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA	B	C=CC(=O)N[C@@H]1Cn2c(c(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1=C		CHEMBL4211949	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	18507780	CHEMBL4190982	Inhibition of recombinant human Fms Y969C mutant (538 to end residues) at 1 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	69.0	CHEMBL1844	Homo sapiens	INH	%	69.0
	18507781	CHEMBL4190981	Inhibition of recombinant human Fms (538 to end residues) at 1 uM using KKKSPGEYVNIEFG as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	76.0	CHEMBL1844	Homo sapiens	INH	%	76.0
	18531090	CHEMBL4195394	Inhibition of C-fms (unknown origin) after 40 mins by kinase-Glo assay	B	Cc1c2ccc(N(C)c3ccnc(Nc4ccc(C(=O)NCCCCCCC(=O)NO)cc4)n3)cc2nn1C		CHEMBL4212117	=	IC50	nM	581.0	CHEMBL1844	Homo sapiens	IC50	uM	0.581
	18531091	CHEMBL4195394	Inhibition of C-fms (unknown origin) after 40 mins by kinase-Glo assay	B	Cc1c2ccc(N(C)c3ccnc(Nc4ccc(C(=O)Nc5ccccc5N)cc4)n3)cc2nn1C		CHEMBL4213341	=	IC50	nM	351.0	CHEMBL1844	Homo sapiens	IC50	uM	0.351
	18531092	CHEMBL4195394	Inhibition of C-fms (unknown origin) after 40 mins by kinase-Glo assay	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	=	IC50	nM	274.0	CHEMBL1844	Homo sapiens	IC50	uM	0.274
	18556330	CHEMBL4200479	Inhibition of CSF1R (unknown origin) at 1 uM relative to control	B	C[C@H](Nc1c(C(N)=O)nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc12)C1CCOCC1		CHEMBL4217549	=	Inhibition	%	56.0	CHEMBL1844	Homo sapiens	INH	%	56.0
	18558654	CHEMBL4201064	Inhibition of human FMS at 1 uM relative to control	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1N1Cc2cnc(N)nc2N(C)C1=O		CHEMBL459850	=	Inhibition	%	99.1	CHEMBL1844	Homo sapiens	INH	%	99.1
	18568752	CHEMBL4220258	Inhibition of CSF1R (unknown origin)	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	nM	3.0
	18569119	CHEMBL4220344	Inhibition of CSF1R (unknown origin)	B	CC1(C)CC=C(c2nc(C3CC(C)(C)OC(C)(C)C3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3674570	=	IC50	nM	3.2	CHEMBL1844	Homo sapiens	IC50	nM	3.2
	18569120	CHEMBL4220344	Inhibition of CSF1R (unknown origin)	B	C1=C/COc2ccc(o2)-c2ccnc(n2)Nc2ccc(OCCN3CCCC3)c(c2)COC/1		CHEMBL4228766	=	IC50	nM	69.0	CHEMBL1844	Homo sapiens	IC50	nM	69.0
	18569121	CHEMBL4220344	Inhibition of CSF1R (unknown origin)	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	nM	60.0
	18569122	CHEMBL4220344	Inhibition of CSF1R (unknown origin)	B	CNC(=O)c1cc(Oc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)ccn1		CHEMBL4227505	=	IC50	nM	1.2	CHEMBL1844	Homo sapiens	IC50	nM	1.2
	18569123	CHEMBL4220344	Inhibition of CSF1R (unknown origin)	B	CNC(=O)c1cc(Oc2ccc3nc(N[C@@H]4CCCC[C@@H]4O)sc3c2)ccn1		CHEMBL4225509	=	IC50	nM	5.5	CHEMBL1844	Homo sapiens	IC50	nM	5.5
	18569124	CHEMBL4220344	Inhibition of CSF1R (unknown origin)	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	nM	13.0
	18569128	CHEMBL4220348	Inhibition of CSF-stimulated CSF1R phosphorylation in human MV4-11 cells by immunoblotting method	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	=	IC50	nM	600.0	CHEMBL1844	Homo sapiens	IC50	nM	600.0
	18569132	CHEMBL4220352	Inhibition of CSF1R signaling in human PBMC assessed as reduction in M-CSF-induced differentiation after 7 days by immunostaining analysis	B	C1=C/COc2ccc(o2)-c2ccnc(n2)Nc2ccc(OCCN3CCCC3)c(c2)COC/1		CHEMBL4228766	=	IC50	nM	277.0	CHEMBL1844	Homo sapiens	IC50	nM	277.0
	18569137	CHEMBL4220355	Inhibition of CSF1R (unknown origin) using biotinylated peptide substrate	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1		CHEMBL4224714	=	IC50	nM	28.0	CHEMBL1844	Homo sapiens	IC50	nM	28.0
	18569138	CHEMBL4220355	Inhibition of CSF1R (unknown origin) using biotinylated peptide substrate	B	COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)cc4)nc3)c2c1		CHEMBL4226338	=	IC50	nM	62.0	CHEMBL1844	Homo sapiens	IC50	nM	62.0
	18569146	CHEMBL4220362	Inhibition of CSF1-stimulated CSF1R (unknown origin) phosphorylation by cell based assay	B	CCOC(=O)[C@@H]1CCC(=O)N1		CHEMBL4229168	=	IC50	nM	26.0	CHEMBL1844	Homo sapiens	IC50	nM	26.0
	18569147	CHEMBL4220363	Inhibition of IL34-stimulated CSF1R (unknown origin) phosphorylation by cell based assay	B	CCOC(=O)[C@@H]1CCC(=O)N1		CHEMBL4229168	=	IC50	nM	33.0	CHEMBL1844	Homo sapiens	IC50	nM	33.0
	18569148	CHEMBL4220364	Inhibition of CSF1R (unknown origin) assessed as inhibition of CSF1-stimulated cell growth by cell based assay	B	CCOC(=O)[C@@H]1CCC(=O)N1		CHEMBL4229168	=	IC50	nM	38.0	CHEMBL1844	Homo sapiens	IC50	nM	38.0
	18569149	CHEMBL4220365	Inhibition of CSF1R (unknown origin) assessed as inhibition of IL34-stimulated cell growth by cell based assay	B	CCOC(=O)[C@@H]1CCC(=O)N1		CHEMBL4229168	=	IC50	nM	40.0	CHEMBL1844	Homo sapiens	IC50	nM	40.0
	18569152	CHEMBL4220368	Inhibition of CSF1R in human monocytes assessed as inhibition of CSF1-stimulated MCP release	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	IC50	nM	148.0	CHEMBL1844	Homo sapiens	IC50	nM	148.0
	18569153	CHEMBL4220368	Inhibition of CSF1R in human monocytes assessed as inhibition of CSF1-stimulated MCP release	B	CCOC(=O)[C@@H]1CCC(=O)N1		CHEMBL4229168	=	IC50	nM	93.0	CHEMBL1844	Homo sapiens	IC50	nM	93.0
	18569154	CHEMBL4220369	Inhibition of CSF1R in human monocytes assessed as inhibition of IL34-stimulated MCP release	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	IC50	nM	140.0	CHEMBL1844	Homo sapiens	IC50	nM	140.0
	18569155	CHEMBL4220369	Inhibition of CSF1R in human monocytes assessed as inhibition of IL34-stimulated MCP release	B	CCOC(=O)[C@@H]1CCC(=O)N1		CHEMBL4229168	=	IC50	nM	88.0	CHEMBL1844	Homo sapiens	IC50	nM	88.0
	18571117	CHEMBL4221039	Inhibition of human FMS using myelin basic protein as substrate after 40 mins in presence of [gamma-33P]-ATP by liquid scintillation counting method	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(C4=Nc5cscc5NC(=O)C4)cc3)cc2C(F)(F)F)CC1		CHEMBL4228601	=	IC50	nM	3.73	CHEMBL1844	Homo sapiens	IC50	nM	3.73
Active	18571121	CHEMBL4221037	Inhibition of human FMS using poly[Glu:Tyr] as substrate at 10 uM after 40 mins in presence of [gamma-33P]-ATP by liquid scintillation counting method	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(C4=Nc5cscc5NC(=O)C4)cc3)cc2C(F)(F)F)CC1		CHEMBL4228601		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
	18653621	CHEMBL4230093	Inhibition of FMS (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	99.0	CHEMBL1844	Homo sapiens	INH	%	99.0
	18653622	CHEMBL4230093	Inhibition of FMS (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	87.0	CHEMBL1844	Homo sapiens	INH	%	87.0
	18655594	CHEMBL4230641	Binding affinity to wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	100.0	CHEMBL1844	Homo sapiens	Activity	%	100.0
	18655595	CHEMBL4230640	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	10.0	CHEMBL1844	Homo sapiens	Activity	%	10.0
	18663777	CHEMBL4232881	Inhibition of human CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual activity at 5 uM by KINOMEscan assay relative to control	B	CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12		CHEMBL4247704	=	Activity	%	100.0	CHEMBL1844	Homo sapiens	Activity	%	100.0
	18663994	CHEMBL4232978	Binding affinity to human CSF1R (I564 to S939 residues) expressed in bacterial expression system by KINOMEscan assay	B	CC(C)CN(C(=O)c1cccnc1)c1c2ccccc2c(=O)n2c1[nH]c1ccccc12		CHEMBL4247704	>=	Kd	nM	5000.0	CHEMBL1844	Homo sapiens	Kd	uM	5.0
	18665419	CHEMBL4233328	Inhibition of FMS (unknown origin)	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	18674685	CHEMBL4235362	Inhibition of FMS (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4249925	>	Ki	nM	2000.0	CHEMBL1844	Homo sapiens	Ki	nM	2000.0
	18674686	CHEMBL4235362	Inhibition of FMS (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4245242	>	Ki	nM	2000.0	CHEMBL1844	Homo sapiens	Ki	nM	2000.0
	18697623	CHEMBL4254296	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCNc1cc(-c2ccc(NC(=O)Nc3cccc(Cl)c3)cc2C(F)(F)F)ccn1		CHEMBL4281348	=	Activity	%	85.0	CHEMBL1844	Homo sapiens	Activity	%	85.0
	18710952	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	N#Cc1c[nH]c(C(=O)Nc2ccc(CCN3CCOCC3)cc2C2=CCCCC2)n1.O=C(O)C(F)(F)F		CHEMBL4286176	=	IC50	nM	1.43	CHEMBL1844	Homo sapiens	IC50	uM	0.00143
	18710953	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCN(CCO)CC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085833	=	IC50	nM	0.88	CHEMBL1844	Homo sapiens	IC50	uM	0.00088
	18710954	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(CN3CCN(CCO)CC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1.O=C(O)C(F)(F)F		CHEMBL4295208	=	IC50	nM	0.75	CHEMBL1844	Homo sapiens	IC50	uM	0.00075
	18710956	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC(C)(NS(C)(=O)=O)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCCCC2)c1		CHEMBL3660753	=	IC50	nM	4.7	CHEMBL1844	Homo sapiens	IC50	uM	0.0047
	18710957	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	C=C(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCCCC2)c1		CHEMBL3660803	=	IC50	nM	32.9	CHEMBL1844	Homo sapiens	IC50	uM	0.0329
	18710958	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC(=O)NC(C)(C)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCCCC2)c1		CHEMBL3660754	=	IC50	nM	6.1	CHEMBL1844	Homo sapiens	IC50	uM	0.0061
	18710959	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC(C)(NC(N)=O)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCCCC2)c1		CHEMBL3660755	=	IC50	nM	12.4	CHEMBL1844	Homo sapiens	IC50	uM	0.0124
	18710962	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC(C)(NC(=O)NCCO)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCCCC2)c1		CHEMBL3660756	=	IC50	nM	31.7	CHEMBL1844	Homo sapiens	IC50	uM	0.0317
	18710963	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC(C)(NC(=O)C(N)=O)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCCCC2)c1		CHEMBL3660757	=	IC50	nM	8.6	CHEMBL1844	Homo sapiens	IC50	uM	0.0086
	18710964	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	N#Cc1c[nH]c(C(=O)Nc2ccc(CCC(N)=O)cc2C2=CCCCC2)n1		CHEMBL3085980	=	IC50	nM	2.7	CHEMBL1844	Homo sapiens	IC50	uM	0.0027
	18710965	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	N#Cc1c[nH]c(C(=O)Nc2ccc(CCC(=O)O)cc2C2=CCCCC2)n1		CHEMBL3085979	=	IC50	nM	5.9	CHEMBL1844	Homo sapiens	IC50	uM	0.0059
	18710966	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	NC(=O)c1c[nH]c(C(=O)Nc2ccc(CCC(=O)O)cc2C2=CCCCC2)n1		CHEMBL3660804	=	IC50	nM	79.0	CHEMBL1844	Homo sapiens	IC50	uM	0.079
	18710967	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(CCC(N)=O)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3085981	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	uM	0.0017
	18710968	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	N#Cc1cnc(C(=O)Nc2ccc(C(CO)CO)cc2C2=CCCCC2)[nH]1		CHEMBL3660758	>	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	uM	0.06
	18710969	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC(=O)OCC(COC(C)=O)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCCCC2)c1.O=C(O)C(F)(F)F		CHEMBL4289455	=	IC50	nM	4.4	CHEMBL1844	Homo sapiens	IC50	uM	0.0044
	18710970	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC(C)(C(=O)O)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCCCC2)c1		CHEMBL3660760	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	uM	0.008
	18710971	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCSCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3660761	=	IC50	nM	9.3	CHEMBL1844	Homo sapiens	IC50	uM	0.0093
	18710972	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)N3CC[S+]([O-])CC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3660762	=	IC50	nM	1.1	CHEMBL1844	Homo sapiens	IC50	uM	0.0011
	18710973	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCS(=O)(=O)CC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3085829	=	IC50	nM	3.3	CHEMBL1844	Homo sapiens	IC50	uM	0.0033
	18710974	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CSCCNC(C)(C)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3660763	=	IC50	nM	1.4	CHEMBL1844	Homo sapiens	IC50	uM	0.0014
	18710975	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)NCCS(C)(=O)=O)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086322	=	IC50	nM	1.8	CHEMBL1844	Homo sapiens	IC50	uM	0.0018
	18710976	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CN(CCS(C)(=O)=O)C(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3086323	=	IC50	nM	7.2	CHEMBL1844	Homo sapiens	IC50	uM	0.0072
	18710977	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	COCCNC(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3086320	=	IC50	nM	0.44	CHEMBL1844	Homo sapiens	IC50	uM	0.00044
	18710978	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	COCCN(C)C(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3086321	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	uM	0.0017
	18710979	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCOCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085828	=	IC50	nM	0.94	CHEMBL1844	Homo sapiens	IC50	uM	0.00094
	18710980	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CN1CCN(C(C)(C)c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3085830	=	IC50	nM	2.9	CHEMBL1844	Homo sapiens	IC50	uM	0.0029
	18710981	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)NCCN3CCOCC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3085976	=	IC50	nM	1.2	CHEMBL1844	Homo sapiens	IC50	uM	0.0012
	18710982	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	C[C@H]1CN(S(=O)(=O)Cc2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)C[C@@H](C)N1		CHEMBL3660764	=	IC50	nM	7.74	CHEMBL1844	Homo sapiens	IC50	uM	0.00774
	18710983	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	N#Cc1c[nH]c(C(=O)Nc2ccc(CCS(=O)(=O)N3CCOCC3)cc2C2=CCCCC2)n1		CHEMBL3086179	=	IC50	nM	3.2	CHEMBL1844	Homo sapiens	IC50	uM	0.0032
	18710984	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(CCS(=O)(=O)N3CCOCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3086314	=	IC50	nM	4.5	CHEMBL1844	Homo sapiens	IC50	uM	0.0045
	18710985	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CN(C)S(=O)(=O)CCc1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCCCC2)c1		CHEMBL3660765	=	IC50	nM	9.4	CHEMBL1844	Homo sapiens	IC50	uM	0.0094
	18710986	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CN(C)S(=O)(=O)CCc1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3660766	=	IC50	nM	2.9	CHEMBL1844	Homo sapiens	IC50	uM	0.0029
	18710987	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CNS(=O)(=O)CCc1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCCCC2)c1		CHEMBL3660767	=	IC50	nM	5.6	CHEMBL1844	Homo sapiens	IC50	uM	0.0056
	18710988	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CNS(=O)(=O)CCc1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3660768	=	IC50	nM	2.6	CHEMBL1844	Homo sapiens	IC50	uM	0.0026
	18710989	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	N#Cc1cnc(C(=O)Nc2ccc(CS(=O)(=O)N3CCOCC3)cc2C2=CCCCC2)[nH]1		CHEMBL3085985	=	IC50	nM	12.8	CHEMBL1844	Homo sapiens	IC50	uM	0.0128
	18710990	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	Cc1nc(C(=O)Nc2ccc(CCN3CCOCC3)cc2C2=CCCCC2)[nH]c1C#N		CHEMBL3660769	>	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	uM	0.06
	18710991	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CSc1ncc(C(=O)Nc2ccc(CCN3CCOCC3)cc2C2=CCCCC2)[nH]1		CHEMBL3660770	=	IC50	nM	373.0	CHEMBL1844	Homo sapiens	IC50	uM	0.373
	18710992	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	C[S+]([O-])c1ncc(C(=O)Nc2ccc(CCN3CCOCC3)cc2C2=CCCCC2)[nH]1		CHEMBL3660771	>	IC50	nM	500.0	CHEMBL1844	Homo sapiens	IC50	uM	0.5
	18710993	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CS(=O)(=O)c1ncc(C(=O)Nc2ccc(CCN3CCOCC3)cc2C2=CCCCC2)[nH]1.Cl		CHEMBL4280649	>	IC50	nM	500.0	CHEMBL1844	Homo sapiens	IC50	uM	0.5
	18710994	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	Cc1c[nH]c(C(=O)Nc2ccc(CCN3CCOCC3)cc2C2=CCCCC2)n1.O=C(O)C(F)(F)F		CHEMBL4294186	=	IC50	nM	300.0	CHEMBL1844	Homo sapiens	IC50	uM	0.3
	18710995	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	O=C(Nc1ccc(CCN2CCOCC2)cc1C1=CCCCC1)c1nc(Cl)c(Cl)[nH]1.O=C(O)C(F)(F)F		CHEMBL4293143	>	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	uM	0.06
	18710996	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	O=C(Nc1ccc(CCN2CCOCC2)cc1C1=CCCCC1)c1nc2ccccc2[nH]1.O=C(O)C(F)(F)F		CHEMBL4280472	>	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	uM	0.06
	18710997	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	Cl.O=C(Nc1ccc(CCN2CCOCC2)cc1C1=CCCCC1)c1ncc(Br)[nH]1		CHEMBL4287150	=	IC50	nM	27.9	CHEMBL1844	Homo sapiens	IC50	uM	0.0279
	18710998	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	Cl.O=C(Nc1ccc(CCN2CCOCC2)cc1C1=CCCCC1)c1ncc(Cl)[nH]1		CHEMBL4284579	=	IC50	nM	8.2	CHEMBL1844	Homo sapiens	IC50	uM	0.0082
	18710999	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	Cl.N#Cc1cnc(C(=O)Nc2ccc(CN3CCOCC3)cc2C2=CCCCC2)[nH]1		CHEMBL4293513	=	IC50	nM	4.6	CHEMBL1844	Homo sapiens	IC50	uM	0.0046
	18711000	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1.O=C(O)C(F)(F)F		CHEMBL4294553	=	IC50	nM	0.6	CHEMBL1844	Homo sapiens	IC50	uM	0.0006
	18711001	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(O)C(=O)O)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3660781	=	IC50	nM	2.5	CHEMBL1844	Homo sapiens	IC50	uM	0.0025
	18711002	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	COC[C@H](O)Cc1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3967115	=	IC50	nM	1.5	CHEMBL1844	Homo sapiens	IC50	uM	0.0015
	18711003	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	N#Cc1cnc(C(=O)Nc2ccc(/C=C/C(=O)O)cc2C2=CCCCC2)[nH]1		CHEMBL3889904	=	IC50	nM	3.9	CHEMBL1844	Homo sapiens	IC50	uM	0.0039
	18711004	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2nc(CC(=O)O)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3660784	=	IC50	nM	26.0	CHEMBL1844	Homo sapiens	IC50	uM	0.026
	18711005	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2nc(CC(=O)O)ccc2NC(=O)c2ccc(C#N)[nH]2)CC1		CHEMBL4288046	=	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	uM	0.06
	18711006	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2nc(CC(=O)O)ccc2NC(=O)c2cc(C#N)c[nH]2)CC1.O=C(O)C(F)(F)F		CHEMBL4286993	=	IC50	nM	36.2	CHEMBL1844	Homo sapiens	IC50	uM	0.0362
	18711007	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CN(C)CCOC(C)(C)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1.O=C(O)C(F)(F)F		CHEMBL4292129	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	uM	0.0008
	18711008	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CN(C)CCNC(=O)Cc1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1.O=C(O)C(F)(F)F		CHEMBL4288418	=	IC50	nM	2.9	CHEMBL1844	Homo sapiens	IC50	uM	0.0029
	18711009	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2nc(CC(=O)NCCCO)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL4293523	=	IC50	nM	2.4	CHEMBL1844	Homo sapiens	IC50	uM	0.0024
	18711010	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(CCN3CCOCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1.Cl		CHEMBL4294739	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	uM	0.0008
	18711011	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)OCCN3CCOCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3086318	=	IC50	nM	1.9	CHEMBL1844	Homo sapiens	IC50	uM	0.0019
	18711012	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCN(CCO)CC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1.Cl		CHEMBL3086324	=	IC50	nM	0.69	CHEMBL1844	Homo sapiens	IC50	uM	0.00069
	18711013	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCN(C(=O)[O-])CC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1.[Na+]		CHEMBL4286584	=	IC50	nM	0.93	CHEMBL1844	Homo sapiens	IC50	uM	0.00093
	18711014	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	C=C(CN1CCOCC1)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCCCC2)c1.O=C(O)C(F)(F)F		CHEMBL4285243	=	IC50	nM	3.9	CHEMBL1844	Homo sapiens	IC50	uM	0.0039
	18711015	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	C=C(CNCCOC)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCCCC2)c1.O=C(O)C(F)(F)F		CHEMBL4286210	=	IC50	nM	1.3	CHEMBL1844	Homo sapiens	IC50	uM	0.0013
	18711016	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	C=C(CNC)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCCCC2)c1.O=C(O)C(F)(F)F		CHEMBL4281126	=	IC50	nM	1.6	CHEMBL1844	Homo sapiens	IC50	uM	0.0016
	18711017	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	COCCNC(C)(C)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1.Cl		CHEMBL4282165	=	IC50	nM	0.51	CHEMBL1844	Homo sapiens	IC50	uM	0.00051
	18711018	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	COc1ccc(CSC(C)(C)c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCC(C)(C)CC3)c2)cc1		CHEMBL3660793	=	IC50	nM	140.0	CHEMBL1844	Homo sapiens	IC50	uM	0.14
	18711019	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC(=O)SC(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3660794	=	IC50	nM	33.0	CHEMBL1844	Homo sapiens	IC50	uM	0.033
	18711020	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)Nc3ccccn3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085827	=	IC50	nM	19.0	CHEMBL1844	Homo sapiens	IC50	uM	0.019
	18711021	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	Cc1cccc(NC(C)(C)c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCC(C)(C)CC3)c2)n1		CHEMBL3660795	=	IC50	nM	8.8	CHEMBL1844	Homo sapiens	IC50	uM	0.0088
	18711022	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CCN1CCN(C(C)(C)c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3085831	=	IC50	nM	1.5	CHEMBL1844	Homo sapiens	IC50	uM	0.0015
	18711023	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC(=O)N1CCN(C(C)(C)c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3085832	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	uM	0.0017
	18711024	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC(=O)NCCNC(C)(C)c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3085977	=	IC50	nM	0.68	CHEMBL1844	Homo sapiens	IC50	uM	0.00068
	18711025	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	COCCN1CCN(C(C)(C)c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3085834	=	IC50	nM	1.3	CHEMBL1844	Homo sapiens	IC50	uM	0.0013
	18711026	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CCOC(=O)CN1CCN(C(C)(C)c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3660796	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	uM	0.002
	18711027	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)OCCN3CCCC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3086317	=	IC50	nM	1.2	CHEMBL1844	Homo sapiens	IC50	uM	0.0012
	18711028	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CSCCNCC(C)(C)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3639596	=	IC50	nM	1.3	CHEMBL1844	Homo sapiens	IC50	uM	0.0013
	18711029	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)CNCCS(C)(=O)=O)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085974	=	IC50	nM	1.6	CHEMBL1844	Homo sapiens	IC50	uM	0.0016
	18711030	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)CN3C[C@@H]4OC(C)(C)O[C@@H]4C3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3660797	>	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	uM	0.1
	18711031	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)CN3C[C@H](O)[C@H](O)C3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1.Cl		CHEMBL4286533	=	IC50	nM	18.0	CHEMBL1844	Homo sapiens	IC50	uM	0.018
	18711032	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)CN3CCOCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085970	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	uM	0.008
	18711033	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC(=O)N1CCN(CC(C)(C)c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCC(C)(C)CC3)c2)CC1		CHEMBL3085971	=	IC50	nM	5.7	CHEMBL1844	Homo sapiens	IC50	uM	0.0057
	18711034	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)CN3CCSCC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3660799	=	IC50	nM	36.0	CHEMBL1844	Homo sapiens	IC50	uM	0.036
	18711035	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)CN3CCS(=O)(=O)CC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3085972	=	IC50	nM	3.5	CHEMBL1844	Homo sapiens	IC50	uM	0.0035
	18711036	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)CN3CCN(CCO)CC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3085975	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	uM	0.002
	18711037	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	COCCNCC(C)(C)c1ccc(NC(=O)c2nc(C#N)c[nH]2)c(C2=CCC(C)(C)CC2)c1		CHEMBL3085973	=	IC50	nM	0.64	CHEMBL1844	Homo sapiens	IC50	uM	0.00064
	18711038	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC(c1ccc(NC(=O)c2ncc(C#N)[nH]2)c(C2=CCC(C)(C)CC2)c1)N1C[C@H](C)N[C@H](C)C1		CHEMBL3660800	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	uM	0.0017
	18711039	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(C(C)(C)N3CCCCC3)ccc2NC(=O)c2ncc(C#N)[nH]2)CC1		CHEMBL3660801	=	IC50	nM	1.5	CHEMBL1844	Homo sapiens	IC50	uM	0.0015
	18711040	CHEMBL4256960	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R phosphorylation of tyrosine on synthetic CSF-1R (555 to 568) peptide using 1 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CC1(C)CC=C(c2cc(CN3CCNCC3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1.O=C(O)C(F)(F)F		CHEMBL4280188	=	IC50	nM	0.82	CHEMBL1844	Homo sapiens	IC50	uM	0.00082
	18711112	CHEMBL4256962	Inhibition of c-fms (unknown origin) assessed as inhibition of CSF-1R auto phosphorylation using 10 nM enzyme incubated for 80 mins by fluorescence polarization competition immunoassay	B	CCN(C)CCCc1ccc(NC(=O)c2ccc(C#N)o2)c(N2CCC(C)CC2)c1		CHEMBL3660788	=	IC50	nM	50.0	CHEMBL1844	Homo sapiens	IC50	uM	0.05
	18711114	CHEMBL4256963	Inhibition of c-FMS auto-phosphorylation (unknown origin) preincubated with enzyme followed by ATP addition measured after 45 mins by PTK green tracer based fluorescence polarization assay	B	CC1(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)OCCCO1		CHEMBL3643701	=	IC50	nM	3.9	CHEMBL1844	Homo sapiens	IC50	uM	0.0039
	18711115	CHEMBL4256963	Inhibition of c-FMS auto-phosphorylation (unknown origin) preincubated with enzyme followed by ATP addition measured after 45 mins by PTK green tracer based fluorescence polarization assay	B	CC1(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)OCCO1		CHEMBL3643700	=	IC50	nM	3.4	CHEMBL1844	Homo sapiens	IC50	uM	0.0034
	18751103	CHEMBL4263811	Inhibition of FMS (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	10.0	CHEMBL1844	Homo sapiens	INH	%	10.0
	18751673	CHEMBL4264230	Binding affinity to wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in mammalian expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	90.0	CHEMBL1844	Homo sapiens	Activity	%	90.0
	18751674	CHEMBL4264229	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	87.0	CHEMBL1844	Homo sapiens	Activity	%	87.0
	18761516	CHEMBL4266569	Inhibition of recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CN(C)[C@H]1CC[C@H](Nc2ncnc3[nH]cc([C@H]4CC[C@H](C(N)=O)CC4)c23)CC1		CHEMBL4279192	=	Inhibition	%	7.0	CHEMBL1844	Homo sapiens	INH	%	7.0
	18761787	CHEMBL4266569	Inhibition of recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C(C)C)c34)CC2)CC1	Outside typical range	CHEMBL4278882	=	Inhibition	%	-25.0	CHEMBL1844	Homo sapiens	INH	%	-25.0
	18761950	CHEMBL4266569	Inhibition of recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM relative to control	B	CC(=O)N1CCN([C@H]2CC[C@H](Nc3ncnn4ccc(C5CCOCC5)c34)CC2)CC1	Outside typical range	CHEMBL4290222	=	Inhibition	%	-17.0	CHEMBL1844	Homo sapiens	INH	%	-17.0
Not Active	18847330	CHEMBL4304890	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system at 1 uM by Kinomescan method	B	O=C(Nc1ccc2[nH]nc(-c3ccc4[nH]ccc4c3)c2c1)c1c(Cl)cccc1Cl		CHEMBL4517719		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
	18848116	CHEMBL4305112	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as enzyme remaining activity at 1 uM by Kinomescan assay relative to control	B	O=C(CC(=O)Nc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1)Nc1cccc(F)c1		CHEMBL4446361	=	Activity	%	0.0	CHEMBL1844	Homo sapiens	Activity	%	0.0
	18848124	CHEMBL4305120	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system after 1 hr by Z-LYTE assay	B	O=C(CC(=O)Nc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1)Nc1cccc(F)c1		CHEMBL4446361	=	IC50	nM	14.2	CHEMBL1844	Homo sapiens	IC50	nM	14.2
	18849484	CHEMBL4305550	Inhibition of recombinant N-terminal GST-fusion protein tagged human FMS cytoplasmic domain (538 to 972 residues) expressed in baculovirus expression system assessed as decrease in fluorescence labelled Srctide phosphorylation at 200 nM by off-chip mobility shift assay relative to control	B	Cc1cccc(Nc2nc(N[C@@H]3CCCC[C@@H]3N)c(C#N)c3cn[nH]c(=O)c23)c1		CHEMBL4461851	>	Inhibition	%	90.0	CHEMBL1844	Homo sapiens	INH	%	90.0
	18857898	CHEMBL4307744	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	97.0	CHEMBL1844	Homo sapiens	Activity	%	97.0
	18857899	CHEMBL4307745	Binding affinity to wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	87.0	CHEMBL1844	Homo sapiens	Activity	%	87.0
	18864267	CHEMBL4309590	Inhibition of human FMS at 10 uM using poly[Glu:Tyr] (4:1) as substrate after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	COc1cc(Cl)cc(-c2nn(-c3cccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)c3)cc2-c2ccncc2)c1		CHEMBL4436746	=	Inhibition	%	-0.94	CHEMBL1844	Homo sapiens	INH	%	-0.94
	18873994	CHEMBL4310499	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4ccc(OCCO)cn4)C3)cc2OC)cc1		CHEMBL4522333	=	IC50	nM	25.0	CHEMBL1844	Homo sapiens	IC50	nM	25.0
	18873995	CHEMBL4310499	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4cc(OCCO)ccn4)C3)cc2OC)cc1		CHEMBL4437645	=	IC50	nM	9.1	CHEMBL1844	Homo sapiens	IC50	nM	9.1
	18873996	CHEMBL4310499	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4cccc(C)n4)C3)cc2OC)cc1		CHEMBL4590640	=	IC50	nM	145.0	CHEMBL1844	Homo sapiens	IC50	nM	145.0
	18873997	CHEMBL4310499	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4ccc(C)cn4)C3)cc2OC)cc1		CHEMBL4551350	=	IC50	nM	86.0	CHEMBL1844	Homo sapiens	IC50	nM	86.0
	18873998	CHEMBL4310499	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4cc(C)ccn4)C3)cc2OC)cc1		CHEMBL4532484	=	IC50	nM	41.0	CHEMBL1844	Homo sapiens	IC50	nM	41.0
	18873999	CHEMBL4310499	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4ncccc4C)C3)cc2OC)cc1		CHEMBL4591823	=	IC50	nM	2216.0	CHEMBL1844	Homo sapiens	IC50	nM	2216.0
	18874000	CHEMBL4310499	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(c4cccnc4)C3)cc2OC)cc1		CHEMBL4542178	=	IC50	nM	1400.0	CHEMBL1844	Homo sapiens	IC50	nM	1400.0
	18874001	CHEMBL4310499	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(c4ccccn4)C3)cc2OC)cc1		CHEMBL4591955	>	IC50	nM	3000.0	CHEMBL1844	Homo sapiens	IC50	nM	3000.0
	18874002	CHEMBL4310499	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(Cc4cccnc4)C3)cc2OC)cc1		CHEMBL4577186	>	IC50	nM	3000.0	CHEMBL1844	Homo sapiens	IC50	nM	3000.0
	18874003	CHEMBL4310499	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(Cc4ccccn4)C3)cc2OC)cc1		CHEMBL4546499	>	IC50	nM	3000.0	CHEMBL1844	Homo sapiens	IC50	nM	3000.0
	18874004	CHEMBL4310499	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4ccccc4)C3)cc2OC)cc1		CHEMBL4470906	=	IC50	nM	430.0	CHEMBL1844	Homo sapiens	IC50	nM	430.0
	18874005	CHEMBL4310499	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4ccncc4)C3)cc2OC)cc1		CHEMBL4581622	=	IC50	nM	1100.0	CHEMBL1844	Homo sapiens	IC50	nM	1100.0
	18874006	CHEMBL4310499	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4cccnc4)C3)cc2OC)cc1		CHEMBL4533124	=	IC50	nM	510.0	CHEMBL1844	Homo sapiens	IC50	nM	510.0
	18874007	CHEMBL4310499	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4ccccn4)C3)cc2OC)cc1		CHEMBL4467529	=	IC50	nM	62.0	CHEMBL1844	Homo sapiens	IC50	nM	62.0
	18881248	CHEMBL4312058	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system by TR-FRET assay	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	10.0	CHEMBL1844	Homo sapiens	Ki	nM	10.0
	18886129	CHEMBL4313422	Inhibition of human FMS at 10 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	B	COc1ccc(-c2nn(-c3cccc(NC(=O)c4cccc(C(F)(F)F)c4)c3)cc2-c2ccncc2)cc1Cl		CHEMBL4553144	=	Inhibition	%	18.96	CHEMBL1844	Homo sapiens	INH	%	18.96
	18886214	CHEMBL4313422	Inhibition of human FMS at 10 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	B	COc1ccc(-c2nn(-c3cccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)c3)cc2-c2ccncc2)cc1Cl		CHEMBL4559825	=	Inhibition	%	5.95	CHEMBL1844	Homo sapiens	INH	%	5.95
	18890193	CHEMBL4314032	Inhibition of recombinant His-tagged human CSF1R cytoplasmic domain expressed in baculovirus expression system at 0.5 uM using tyr 01 as substrate in presence of ATP at Km concentration after 1 hr by Z'-LYTE assay relative to control	B	COc1cc(C(=O)NC2CCNCC2)ccc1Nc1nc(Nc2ccccc2P(C)(C)=O)c2cc[nH]c2n1		CHEMBL4448754	=	Inhibition	%	12.0	CHEMBL1844	Homo sapiens	INH	%	12.0
	18892871	CHEMBL4314837	Inhibition of recombinant human FMS (538 to end residues) assessed as residual activity at 10 uM using KKKSPGEYVNIEFG as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	102.0	CHEMBL1844	Homo sapiens	Activity	%	102.0
	18892872	CHEMBL4314838	Inhibition of recombinant human FMS Y969C mutant (538 to end residues) assessed as residual activity at 10 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	94.5	CHEMBL1844	Homo sapiens	Activity	%	94.5
	18893331	CHEMBL4315061	Inhibition of recombinant human His-tagged FMS expressed in baculovirus expression system	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	18893334	CHEMBL4315092	Inhibition of recombinant FMS (unknown origin)	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	nM	13.0
	18910092	CHEMBL4320886	Binding affinity to CSF1R (unknown origin)	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Kd	nM	10.0	CHEMBL1844	Homo sapiens	pKd		8.0
	18919460	CHEMBL4322816	Binding affinity to recombinant N-terminal His-FLAG-GST-tagged CSF1R (unknown origin) (538 to 972 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4465866	=	Kd	nM	279.0	CHEMBL1844	Homo sapiens	Kd	nM	279.0
	18919648	CHEMBL4322816	Binding affinity to recombinant N-terminal His-FLAG-GST-tagged CSF1R (unknown origin) (538 to 972 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4576489	=	Kd	nM	324.0	CHEMBL1844	Homo sapiens	Kd	nM	324.0
	18930893	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COC(=O)c1cnc(N)c(C#Cc2cc(C(=O)Nc3cc(OC)cc(OC)c3)ccc2C)c1		CHEMBL4573871	=	IC50	nM	5.5	CHEMBL1844	Homo sapiens	IC50	nM	5.5
	18930894	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	CNC(=O)c1cnc(N)c(C#Cc2cc(C(=O)Nc3cc(OC)cc(OC)c3)ccc2C)c1		CHEMBL4583617	=	IC50	nM	8.1	CHEMBL1844	Homo sapiens	IC50	nM	8.1
	18930895	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COc1cc(NC(=O)c2ccc(C)c(C#Cc3cc(C(N)=O)cnc3N)c2)cc(OC)c1		CHEMBL4459031	=	IC50	nM	3.5	CHEMBL1844	Homo sapiens	IC50	nM	3.5
	18930896	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COc1cc(NC(=O)c2ccc(C)c(C#Cc3cc(Cl)cnc3N)c2)cc(OC)c1		CHEMBL4453122	=	IC50	nM	16.6	CHEMBL1844	Homo sapiens	IC50	nM	16.6
	18930897	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COc1cc(NC(=O)c2ccc(C)c(C#Cc3cccnc3N)c2)cc(OC)c1		CHEMBL4436816	=	IC50	nM	28.5	CHEMBL1844	Homo sapiens	IC50	nM	28.5
	18930898	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COc1cc(NC(=O)c2ccc(C)c(C#Cc3cccnc3)c2)cc(OC)c1		CHEMBL4556986	=	IC50	nM	218.9	CHEMBL1844	Homo sapiens	IC50	nM	218.9
	18930899	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COc1cc(NC(=O)c2ccc(C)c(C#Cc3cnc4cccnn34)c2)cc(OC)c1		CHEMBL4463623	=	IC50	nM	25.1	CHEMBL1844	Homo sapiens	IC50	nM	25.1
	18930900	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COc1cc(NC(=O)c2ccc(C)c(C#Cc3cncc4ccccc34)c2)cc(OC)c1		CHEMBL4475726	=	IC50	nM	23.4	CHEMBL1844	Homo sapiens	IC50	nM	23.4
	18930901	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COc1cc(NC(=O)c2ccc(C)c(C#Cc3cc(-c4cnn(C)c4)cnc3N)c2)cc(OC)c1		CHEMBL4553298	=	IC50	nM	2.6	CHEMBL1844	Homo sapiens	IC50	nM	2.6
	18930902	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	=	IC50	nM	12.0	CHEMBL1844	Homo sapiens	IC50	nM	12.0
	18930903	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COc1cc(NC(=O)c2cccc(C#Cc3cc(-c4cnn(C)c4)cnc3N)c2)cc(OC)c1		CHEMBL4473841	=	IC50	nM	16.1	CHEMBL1844	Homo sapiens	IC50	nM	16.1
	18930904	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COc1cc(NC(=O)c2ccc(C(C)C)c(C#Cc3cc(-c4cnn(C)c4)cnc3N)c2)cc(OC)c1		CHEMBL4476740	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	18930905	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COc1cc(NC(=O)c2ccc(OC)c(C#Cc3cc(-c4cnn(C)c4)cnc3N)c2)cc(OC)c1		CHEMBL4462048	=	IC50	nM	263.0	CHEMBL1844	Homo sapiens	IC50	nM	263.0
	18930906	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COc1cc(NC(=O)c2ccc(F)c(C#Cc3cc(-c4cnn(C)c4)cnc3N)c2)cc(OC)c1		CHEMBL4476646	=	IC50	nM	160.3	CHEMBL1844	Homo sapiens	IC50	nM	160.3
	18930907	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COc1cc(NC(=O)c2ccc(Cl)c(C#Cc3cc(-c4cnn(C)c4)cnc3N)c2)cc(OC)c1		CHEMBL4565816	=	IC50	nM	6.5	CHEMBL1844	Homo sapiens	IC50	nM	6.5
	18930908	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COc1cc(NC(=O)c2ccc(C(F)(F)F)c(C#Cc3cc(-c4cnn(C)c4)cnc3N)c2)cc(OC)c1		CHEMBL4460712	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	18930909	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	Cc1ccc(C(=O)Nc2ccccc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4460375	=	IC50	nM	6.5	CHEMBL1844	Homo sapiens	IC50	nM	6.5
	18930910	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COc1ccccc1NC(=O)c1ccc(C)c(C#Cc2cc(-c3cnn(C)c3)cnc2N)c1		CHEMBL4441153	=	IC50	nM	20.2	CHEMBL1844	Homo sapiens	IC50	nM	20.2
	18930911	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COc1cccc(NC(=O)c2ccc(C)c(C#Cc3cc(-c4cnn(C)c4)cnc3N)c2)c1		CHEMBL4534671	=	IC50	nM	1.4	CHEMBL1844	Homo sapiens	IC50	nM	1.4
	18930912	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	COc1ccc(NC(=O)c2ccc(C)c(C#Cc3cc(-c4cnn(C)c4)cnc3N)c2)cc1		CHEMBL4452866	=	IC50	nM	1.4	CHEMBL1844	Homo sapiens	IC50	nM	1.4
	18930913	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	Cc1ccc(C(=O)Nc2ccccc2Cl)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4515738	=	IC50	nM	318.0	CHEMBL1844	Homo sapiens	IC50	nM	318.0
	18930914	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	Cc1ccc(C(=O)Nc2cccc(Cl)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4438121	=	IC50	nM	1.3	CHEMBL1844	Homo sapiens	IC50	nM	1.3
	18930915	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4576115	=	IC50	nM	0.7	CHEMBL1844	Homo sapiens	IC50	nM	0.7
	18930916	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4517659	=	IC50	nM	2.4	CHEMBL1844	Homo sapiens	IC50	nM	2.4
	18930917	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	Cc1ccc(C(=O)Nc2ccc(C(F)(F)F)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4589346	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	nM	3.0
	18930918	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2Cl)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4467948	=	IC50	nM	5.9	CHEMBL1844	Homo sapiens	IC50	nM	5.9
	18930919	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	Cc1ccc(C(=O)Nc2ccc(Cl)c(Cl)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4449868	=	IC50	nM	10.8	CHEMBL1844	Homo sapiens	IC50	nM	10.8
	18930920	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cncc2ccccc12		CHEMBL4105491	=	IC50	nM	46.0	CHEMBL1844	Homo sapiens	IC50	nM	46.0
	18931009	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	Cc1cc(C(=O)Nc2ccc(Cl)cc2)ccc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4439073	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	18931010	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	Cc1ccc(NC(=O)c2ccc(Cl)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4449943	=	IC50	nM	7.2	CHEMBL1844	Homo sapiens	IC50	nM	7.2
	18931011	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	Cc1ccc(C(=O)N(C)c2ccc(Cl)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4584624	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	18931012	CHEMBL4325582	Inhibition of recombinant CSF1R (unknown origin) using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA	B	Cc1ccc(CNc2ccc(Cl)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4482956	>	IC50	nM	1000.0	CHEMBL1844	Homo sapiens	IC50	nM	1000.0
	18937945	CHEMBL4327508	Inhibition of human FMS assessed as residual activity at 1 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	99.06	CHEMBL1844	Homo sapiens	Activity	%	99.06
	18937946	CHEMBL4327508	Inhibition of human FMS assessed as residual activity at 1 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	101.65	CHEMBL1844	Homo sapiens	Activity	%	101.65
	18938543	CHEMBL4328063	Inhibition of human FMS assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL1844	Homo sapiens	Activity	%	65.0
	18938921	CHEMBL4328427	Inhibition of human FMS using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	10'-9M	2.0
	18946668	CHEMBL4330215	Inhibition of human CSF1R catalytic domain by ATP-based kinase assay	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	IC50	nM	60.0	CHEMBL1844	Homo sapiens	IC50	uM	0.06
	18950231	CHEMBL4331083	Inhibition of human FMS assessed as residual activity at 10 uM using poly[Glu:Tyr] (4:1) as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by Hotspot assay relative to control	B	CN1CCC(Nc2ccc(C(=O)Nc3cc(-c4cc(C#N)cs4)n[nH]3)cc2)CC1		CHEMBL4473820	=	Activity	%	4.66	CHEMBL1844	Homo sapiens	Activity	%	4.66
	18950258	CHEMBL4331110	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system after 60 mins by Kinomescan method	B	CN1CCC(Nc2ccc(C(=O)Nc3cc(-c4cc(C#N)cs4)n[nH]3)cc2)CC1		CHEMBL4473820	=	Kd	nM	47.0	CHEMBL1844	Homo sapiens	Kd	nM	47.0
	18950259	CHEMBL4331111	Binding affinity to wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in mammalian expression system after 60 mins by Kinomescan method	B	CN1CCC(Nc2ccc(C(=O)Nc3cc(-c4cc(C#N)cs4)n[nH]3)cc2)CC1		CHEMBL4473820	=	Kd	nM	84.0	CHEMBL1844	Homo sapiens	Kd	nM	84.0
	18950270	CHEMBL4331117	Inhibition of human FMS using poly[Glu:Tyr] (4:1) as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by Hotspot assay	B	CN1CCC(Nc2ccc(C(=O)Nc3cc(-c4cc(C#N)cs4)n[nH]3)cc2)CC1		CHEMBL4473820	=	IC50	nM	52.94	CHEMBL1844	Homo sapiens	IC50	nM	52.94
	18950341	CHEMBL4331117	Inhibition of human FMS using poly[Glu:Tyr] (4:1) as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by Hotspot assay	B	CN1CCC(Nc2ccc(C(=O)Nc3cc(-c4cc(C#N)cs4)n[nH]3)cc2)CC1		CHEMBL4473820	=	IC50	nM	50.12	CHEMBL1844	Homo sapiens	pIC50		7.3
	18951026	CHEMBL4331424	Inhibition of human FMS using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	B	Cc1ccc(C(=O)Nc2ccc(Cl)c(C(F)(F)F)c2)cc1NC(=O)C1(c2ncnc3[nH]cnc23)CC1		CHEMBL4466555	=	IC50	nM	3.9	CHEMBL1844	Homo sapiens	IC50	nM	3.9
	18958816	CHEMBL4333335	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	97.0	CHEMBL1844	Homo sapiens	Activity	%	97.0
	18964311	CHEMBL4335093	Inhibition of recombinant human FMS (538 to end residues) assessed as residual activity at 1 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate at 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	106.0	CHEMBL1844	Homo sapiens	Activity	%	106.0
	18964312	CHEMBL4335093	Inhibition of recombinant human FMS (538 to end residues) assessed as residual activity at 1 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate at 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	117.0	CHEMBL1844	Homo sapiens	Activity	%	117.0
	18964313	CHEMBL4335094	Inhibition of recombinant human FMS Y969C mutant (538 to end residues) assessed as residual activity at 1 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate at 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	106.0	CHEMBL1844	Homo sapiens	Activity	%	106.0
	18964314	CHEMBL4335094	Inhibition of recombinant human FMS Y969C mutant (538 to end residues) assessed as residual activity at 1 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate at 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	95.0	CHEMBL1844	Homo sapiens	Activity	%	95.0
	18971910	CHEMBL4336920	Inhibition of recombinant human FMS (538 to end residues) assessed as residual activity at 10 uM using KKKSPGEYVNIEF as substrate at 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	21.0	CHEMBL1844	Homo sapiens	Activity	%	21.0
	18971911	CHEMBL4336921	Inhibition of recombinant human FMS Y969C mutant (538 to end residues) assessed as residual activity at 10 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate at 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	52.0	CHEMBL1844	Homo sapiens	Activity	%	52.0
	19021492	CHEMBL4347594	Inhibition of recombinant human CSFR at 20 nM using Ulight-TK peptide as substrate measured after 15 mins by LANCE method relative to control	B	O=C(CCCCCn1cc(Nc2ncc(Cl)c(Nc3ccc(Cl)cc3)n2)cn1)NO		CHEMBL4526274	=	Inhibition	%	2.0	CHEMBL1844	Homo sapiens	INH	%	2.0
	19021493	CHEMBL4347714	Inhibition of recombinant human CSFR at 200 nM using Ulight-TK peptide as substrate measured after 15 mins by LANCE method relative to control	B	O=C(CCCCCn1cc(Nc2ncc(Cl)c(Nc3ccc(Cl)cc3)n2)cn1)NO		CHEMBL4526274	=	Inhibition	%	37.0	CHEMBL1844	Homo sapiens	INH	%	37.0
Not Active	19039770	CHEMBL4351872	Inhibition of recombinant human FMS Y969C mutant (538 to end residues) at 10 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
Not Active	19039771	CHEMBL4351871	Inhibition of recombinant human FMS (538 to end residues) at 10 uM using KKKSPGEYVNIEFG as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
Active	19041119	CHEMBL4352380	Inhibition of human FMS at 10 uM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
	19043649	CHEMBL4353143	Inhibition of human FMS using poly(Glu,Tyr) 4:1 as substrate in presence of 33P-gamma ATP by hotspot kinase assay	B	CN1CCC(Nc2ccc(C(=O)Nc3cc(-c4ccc5c(c4)OCO5)n[nH]3)cc2)CC1		CHEMBL4456471	=	IC50	nM	247.0	CHEMBL1844	Homo sapiens	IC50	nM	247.0
	19043762	CHEMBL4353228	Inhibition of human FMS using poly (Glu,Tyr) 4:1 as substrate at 0.1 uM in presence of 33P-gamma ATP by hotspot kinase assay relative to control	B	CN1CCC(Nc2ccc(C(=O)Nc3cc(-c4ccc5c(c4)OCO5)n[nH]3)cc2)CC1		CHEMBL4456471	=	Inhibition	%	22.96	CHEMBL1844	Homo sapiens	INH	%	22.96
	19059517	CHEMBL4357818	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	7.3	CHEMBL1844	Homo sapiens	Activity	%	7.3
	19059518	CHEMBL4357819	Binding affinity to wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	79.0	CHEMBL1844	Homo sapiens	Activity	%	79.0
	19063669	CHEMBL4359456	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system at 100 nM by Kinomescan method relative to control	B	CC(C)(C)c1cc(NC(=O)Cc2ccc(-n3cnc4cc(-c5ccc(S(C)(=O)=O)cc5)ccc43)cc2)no1		CHEMBL4473213	>	Activity	%	90.0	CHEMBL1844	Homo sapiens	Activity	%	90.0
	19063677	CHEMBL4359464	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system using peptide substrate preincubated for 60 mins followed by substrate addition by microfluidic assay	B	CC(C)(C)c1cc(NC(=O)Cc2ccc(-n3cnc4cc(-c5ccc(S(C)(=O)=O)cc5)ccc43)cc2)no1		CHEMBL4473213	=	IC50	nM	46.0	CHEMBL1844	Homo sapiens	IC50	nM	46.0
	19069468	CHEMBL4361172	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	COc1cc2nccc(Oc3ccc(NC(=O)Cc4ccc(Cl)c(C(F)(F)F)c4)cc3)c2cc1OC		CHEMBL4577779	<	Activity	%	1.0	CHEMBL1844	Homo sapiens	Activity	%	1.0
	19069472	CHEMBL4361181	Inhibition of recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system by Z-lyte assay	B	COc1cc2nccc(Oc3ccc(NC(=O)Cc4ccc(Cl)c(C(F)(F)F)c4)cc3)c2cc1OC		CHEMBL4577779	=	IC50	nM	18.0	CHEMBL1844	Homo sapiens	IC50	nM	18.0
	19090088	CHEMBL4365662	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	20.0	CHEMBL1844	Homo sapiens	Activity	%	20.0
	19090089	CHEMBL4365663	Inhibition of wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	82.0	CHEMBL1844	Homo sapiens	Activity	%	82.0
	19091936	CHEMBL4366410	Inhibition of human FMS at 100 nM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1	Outside typical range	CHEMBL4528675	=	Inhibition	%	-14.17	CHEMBL1844	Homo sapiens	INH	%	-14.17
	19092274	CHEMBL4366694	Inhibition of FMS (unknown origin) at 1 uM relative to control	B	Nc1nccc(Oc2ccc(Nc3nccc4ccn(-c5ccc(F)cc5)c(=O)c34)cc2F)c1Cl		CHEMBL4474232	=	Inhibition	%	88.0	CHEMBL1844	Homo sapiens	INH	%	88.0
	19098121	CHEMBL4367951	Inhibition of FMS (unknown origin) at 1 uM relative to control	B	CCn1nc(C#Cc2c(C)ccc3c(Nc4ccc(Cl)cc4)nccc23)c2c(N)ncnc21		CHEMBL4593051	>	Inhibition	%	85.0	CHEMBL1844	Homo sapiens	INH	%	85.0
Active	19114763	CHEMBL4371398	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual binding level at 5 umol/L by Kinomescan method	B	COc1cc2c(Oc3ccc(NS(=O)(=O)c4ccccc4C(F)(F)F)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL4536115		Activity			CHEMBL1844	Homo sapiens	Activity		
Active	19114788	CHEMBL4371398	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual binding level at 5 umol/L by Kinomescan method	B	COc1cc2c(Oc3ccc(NS(=O)(=O)c4ccccc4C(F)(F)F)cc3F)ccnc2cc1OCCCN1CCC(C)CC1		CHEMBL4447225		Activity			CHEMBL1844	Homo sapiens	Activity		
	19118425	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3ccccc3)csc12		CHEMBL4532017	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	nM	13.0
	19118426	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3ccccc3)csc12		CHEMBL4532017	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118428	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	COc1ccc(Cn2nc(Br)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)cc1		CHEMBL4580020	=	IC50	nM	37.0	CHEMBL1844	Homo sapiens	IC50	nM	37.0
	19118429	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	COc1ccc(Cn2nc(Br)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)cc1		CHEMBL4580020	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118431	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3ccccn3)csc12		CHEMBL4448250	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	nM	9.0
	19118432	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3ccccn3)csc12		CHEMBL4448250	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118434	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3cccnc3)csc12		CHEMBL4455896	=	IC50	nM	6.0	CHEMBL1844	Homo sapiens	IC50	nM	6.0
	19118435	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3cccnc3)csc12		CHEMBL4455896	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118442	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3ccncc3)csc12		CHEMBL4462286	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	nM	7.0
	19118443	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3ccncc3)csc12		CHEMBL4462286	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118445	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3cccc(F)n3)csc12		CHEMBL4438472	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	nM	13.0
	19118446	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3cccc(F)n3)csc12		CHEMBL4438472	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118448	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3cccc(Br)n3)csc12		CHEMBL4446254	=	IC50	nM	12.0	CHEMBL1844	Homo sapiens	IC50	nM	12.0
	19118449	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3cccc(Br)n3)csc12		CHEMBL4446254	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118451	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	Cc1cccc(Cn2nc(Br)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)n1		CHEMBL4454323	=	IC50	nM	23.0	CHEMBL1844	Homo sapiens	IC50	nM	23.0
	19118452	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	Cc1cccc(Cn2nc(Br)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)n1		CHEMBL4454323	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118464	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	COc1cccc(Cn2nc(Br)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)n1		CHEMBL4519682	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19118465	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	COc1cccc(Cn2nc(Br)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)n1		CHEMBL4519682	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118467	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4CC3CCCCC3)csc12		CHEMBL4447898	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	nM	30.0
	19118468	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4CC3CCCCC3)csc12		CHEMBL4447898	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118470	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	CCn1nc(Cn2nc(Br)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)cc1C(C)C		CHEMBL4439265	=	IC50	nM	19.0	CHEMBL1844	Homo sapiens	IC50	nM	19.0
	19118471	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	CCn1nc(Cn2nc(Br)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)cc1C(C)C		CHEMBL4439265	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118473	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	C#CCn1nc(Br)c2c(NC(=O)c3csc4c(N)ncnc34)cccc21		CHEMBL4455645	=	IC50	nM	26.0	CHEMBL1844	Homo sapiens	IC50	nM	26.0
	19118474	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	C#CCn1nc(Br)c2c(NC(=O)c3csc4c(N)ncnc34)cccc21		CHEMBL4455645	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118476	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	Cc1cccc(Cn2nc(Cl)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)n1		CHEMBL4520105	=	IC50	nM	20.0	CHEMBL1844	Homo sapiens	IC50	nM	20.0
	19118477	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	Cc1cccc(Cn2nc(Cl)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)n1		CHEMBL4520105	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118480	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	Cc1cccc(Cn2nc(I)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)n1		CHEMBL4552261	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	nM	9.0
	19118481	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	Cc1cccc(Cn2nc(I)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)n1		CHEMBL4552261	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118483	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	Cc1cccc(Cn2nc(C)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)n1		CHEMBL4483816	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
	19118484	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	Cc1cccc(Cn2nc(C)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)n1		CHEMBL4483816	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118542	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3csc4c(N)ncnc34)c12		CHEMBL4436822	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	nM	9.0
	19118543	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	CCc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3csc4c(N)ncnc34)c12		CHEMBL4436822	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118545	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	C=Cc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3csc4c(N)ncnc34)c12		CHEMBL4446242	=	IC50	nM	12.0	CHEMBL1844	Homo sapiens	IC50	nM	12.0
	19118546	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	C=Cc1nn(Cc2cccc(C)n2)c2cccc(NC(=O)c3csc4c(N)ncnc34)c12		CHEMBL4446242	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19118548	CHEMBL4372327	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	nM	3.0
	19118549	CHEMBL4372328	Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 1 uM using IGF-R1tide as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP relative to control	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Inhibition	%	60.0	CHEMBL1844	Homo sapiens	INH	%	60.0
	19140810	CHEMBL4376574	Inhibition of recombinant full length human His-tagged CSF1R expressed in baculovirus expression system at 1 uM using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay relative to control	B	Cn1cc(-c2ccc(F)cc2)c(=O)c2c(Nc3ccc(Oc4ccnc(NC(=O)C5CC5)c4)c(F)c3)nccc21		CHEMBL4584949	<	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	19144851	CHEMBL4377867	Inhibition of recombinant human Fms (538 to end residues) at 1 uM using KKKSPGEYVNIEFG as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	68.0	CHEMBL1844	Homo sapiens	INH	%	68.0
	19144852	CHEMBL4377868	Inhibition of recombinant human Fms (538 to end residues) Y969C mutant at 1 uM using EEEEYEEEEEEYYIIEEEEEEYEEEEEEYYEEEEEEKKKK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	40.0	CHEMBL1844	Homo sapiens	INH	%	40.0
	19146941	CHEMBL4378851	Inhibition of recombinant human FMS (538 to end residues) at 10 uM using KKKSPGEYVNIEFG as substrate after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CS(=O)(=O)Nc1ccc(Cc2ccc3ccccc3c2)cc1		CHEMBL4459587	=	Inhibition	%	3.0	CHEMBL1844	Homo sapiens	INH	%	3.0
	19147861	CHEMBL4379335	Inhibition of recombinant human FMS (538 to end residues) using KKKSPGEYVNIEF as substrate after 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	19147862	CHEMBL4379336	Inhibition of recombinant human FMS Y969C mutant (538 to end residues) using EEEEYEEEEEEYY as substrate after 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	uM	10.0
	19159345	CHEMBL4382449	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	26.0	CHEMBL1844	Homo sapiens	Activity	%	26.0
	19159346	CHEMBL4382450	Binding affinity to wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	92.0	CHEMBL1844	Homo sapiens	Activity	%	92.0
	19161568	CHEMBL4383414	Inhibition of wild type C-terminal FLAG-tagged human TEL fused CSF1R (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	B	CN1CCN(Cc2ccc(NC(=O)CCSc3ccc4c(/C=C/c5ccccn5)n[nH]c4c3)cc2C(F)(F)F)CC1		CHEMBL4439424	<	GI50	nM	1.0	CHEMBL1844	Homo sapiens	GI50	uM	0.001
	19163564	CHEMBL4383829	Inhibition of human CSF1R at 10 uM using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method relative to control	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2NC(N)=O)cc1		CHEMBL4585766	=	Inhibition	%	65.02	CHEMBL1844	Homo sapiens	INH	%	65.02
	19163565	CHEMBL4383829	Inhibition of human CSF1R at 10 uM using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method relative to control	B	NC(=O)Nc1cnc(Nc2ccc(N3CCOCC3)cc2)nc1Oc1ccc(C(F)(F)F)cc1		CHEMBL4459764	=	Inhibition	%	59.61	CHEMBL1844	Homo sapiens	INH	%	59.61
	19163566	CHEMBL4383829	Inhibition of human CSF1R at 10 uM using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method relative to control	B	COc1cccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2NC(N)=O)c1		CHEMBL4522113	=	Inhibition	%	77.58	CHEMBL1844	Homo sapiens	INH	%	77.58
	19163567	CHEMBL4383829	Inhibition of human CSF1R at 10 uM using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method relative to control	B	COc1ccc(Oc2nc(Nc3ccc(F)cc3)ncc2NC(N)=O)cc1		CHEMBL4434760	=	Inhibition	%	20.99	CHEMBL1844	Homo sapiens	INH	%	20.99
	19163568	CHEMBL4383829	Inhibition of human CSF1R at 10 uM using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method relative to control	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)nc3)ncc2NC(N)=O)cc1		CHEMBL4443393	=	Inhibition	%	35.43	CHEMBL1844	Homo sapiens	INH	%	35.43
	19163569	CHEMBL4383829	Inhibition of human CSF1R at 10 uM using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method relative to control	B	COc1ccc(Oc2nc(Nc3ccc(N4CCCCC4)nc3)ncc2NC(N)=O)cc1		CHEMBL4587860	=	Inhibition	%	28.44	CHEMBL1844	Homo sapiens	INH	%	28.44
	19163570	CHEMBL4383829	Inhibition of human CSF1R at 10 uM using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method relative to control	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2NC(=O)c2cccc(C(F)(F)F)c2)cc1		CHEMBL4467582	=	Inhibition	%	74.7	CHEMBL1844	Homo sapiens	INH	%	74.7
	19163571	CHEMBL4383829	Inhibition of human CSF1R at 10 uM using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method relative to control	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2NC(=O)c2cc(OC)cc(OC)c2)cc1		CHEMBL4464585	=	Inhibition	%	95.34	CHEMBL1844	Homo sapiens	INH	%	95.34
	19163572	CHEMBL4383829	Inhibition of human CSF1R at 10 uM using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method relative to control	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2NC(=O)c2cccc(OC)c2)cc1		CHEMBL4568513	=	Inhibition	%	91.85	CHEMBL1844	Homo sapiens	INH	%	91.85
	19163573	CHEMBL4383829	Inhibition of human CSF1R at 10 uM using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method relative to control	B	COc1ccc(Oc2nc(Nc3ccc(N4CCCCC4)nc3)ncc2NC(=O)c2cc(OC)cc(OC)c2)cc1		CHEMBL4461940	=	Inhibition	%	75.99	CHEMBL1844	Homo sapiens	INH	%	75.99
	19163574	CHEMBL4383829	Inhibition of human CSF1R at 10 uM using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method relative to control	B	COc1ccc(Oc2nc(Nc3ccc(F)cc3)ncc2NC(=O)c2cc(OC)cc(OC)c2)cc1		CHEMBL4521651	=	Inhibition	%	35.2	CHEMBL1844	Homo sapiens	INH	%	35.2
	19163575	CHEMBL4383829	Inhibition of human CSF1R at 10 uM using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method relative to control	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)nc3)ncc2NC(=O)c2cc(OC)cc(OC)c2)cc1		CHEMBL4461911	=	Inhibition	%	77.94	CHEMBL1844	Homo sapiens	INH	%	77.94
	19163576	CHEMBL4383830	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2NC(N)=O)cc1		CHEMBL4585766	=	IC50	nM	4420.0	CHEMBL1844	Homo sapiens	IC50	uM	4.42
Not Determined	19163577	CHEMBL4383830	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method	B	NC(=O)Nc1cnc(Nc2ccc(N3CCOCC3)cc2)nc1Oc1ccc(C(F)(F)F)cc1		CHEMBL4459764		IC50			CHEMBL1844	Homo sapiens	IC50		
	19163578	CHEMBL4383830	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method	B	COc1cccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2NC(N)=O)c1		CHEMBL4522113	=	IC50	nM	1290.0	CHEMBL1844	Homo sapiens	IC50	uM	1.29
Not Determined	19163579	CHEMBL4383830	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method	B	COc1ccc(Oc2nc(Nc3ccc(F)cc3)ncc2NC(N)=O)cc1		CHEMBL4434760		IC50			CHEMBL1844	Homo sapiens	IC50		
Not Determined	19163580	CHEMBL4383830	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)nc3)ncc2NC(N)=O)cc1		CHEMBL4443393		IC50			CHEMBL1844	Homo sapiens	IC50		
Not Determined	19163581	CHEMBL4383830	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method	B	COc1ccc(Oc2nc(Nc3ccc(N4CCCCC4)nc3)ncc2NC(N)=O)cc1		CHEMBL4587860		IC50			CHEMBL1844	Homo sapiens	IC50		
	19163582	CHEMBL4383830	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2NC(=O)c2cccc(C(F)(F)F)c2)cc1		CHEMBL4467582	=	IC50	nM	4890.0	CHEMBL1844	Homo sapiens	IC50	uM	4.89
	19163583	CHEMBL4383830	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2NC(=O)c2cc(OC)cc(OC)c2)cc1		CHEMBL4464585	=	IC50	nM	120.0	CHEMBL1844	Homo sapiens	IC50	uM	0.12
	19163584	CHEMBL4383830	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2NC(=O)c2cccc(OC)c2)cc1		CHEMBL4568513	=	IC50	nM	780.0	CHEMBL1844	Homo sapiens	IC50	uM	0.78
	19163585	CHEMBL4383830	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method	B	COc1ccc(Oc2nc(Nc3ccc(N4CCCCC4)nc3)ncc2NC(=O)c2cc(OC)cc(OC)c2)cc1		CHEMBL4461940	=	IC50	nM	1720.0	CHEMBL1844	Homo sapiens	IC50	uM	1.72
Not Determined	19163586	CHEMBL4383830	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method	B	COc1ccc(Oc2nc(Nc3ccc(F)cc3)ncc2NC(=O)c2cc(OC)cc(OC)c2)cc1		CHEMBL4521651		IC50			CHEMBL1844	Homo sapiens	IC50		
	19163587	CHEMBL4383830	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 10 uM [gamma-33P]-ATP by filtration method	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)nc3)ncc2NC(=O)c2cc(OC)cc(OC)c2)cc1		CHEMBL4461911	=	IC50	nM	150.0	CHEMBL1844	Homo sapiens	IC50	uM	0.15
	19163615	CHEMBL4383837	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 1 uM [gamma-33P]-ATP by filtration method	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)nc3)ncc2NC(=O)c2cc(OC)cc(OC)c2)cc1		CHEMBL4461911	=	IC50	nM	69.0	CHEMBL1844	Homo sapiens	IC50	uM	0.069
	19163616	CHEMBL4383838	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of 100 uM [gamma-33P]-ATP by filtration method	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)nc3)ncc2NC(=O)c2cc(OC)cc(OC)c2)cc1		CHEMBL4461911	=	IC50	nM	273.0	CHEMBL1844	Homo sapiens	IC50	uM	0.273
	19163617	CHEMBL4383839	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate after 120 mins in presence of [gamma-33P]-ATP by filtration method	B	COc1ccc(Oc2nc(Nc3ccc(N4CCOCC4)nc3)ncc2NC(=O)c2cc(OC)cc(OC)c2)cc1		CHEMBL4461911	=	Ki	nM	129.0	CHEMBL1844	Homo sapiens	Ki	uM	0.129
	19181002	CHEMBL4387213	Inhibition of recombinant human His-tagged CSF1R catalytic domain (538 to 910 residues) expressed in Baculovirus expression system at 0.1 uM using tyrosine-1 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Inhibition	%	41.4	CHEMBL1844	Homo sapiens	INH	%	41.4
	19181228	CHEMBL4387213	Inhibition of recombinant human His-tagged CSF1R catalytic domain (538 to 910 residues) expressed in Baculovirus expression system at 0.1 uM using tyrosine-1 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2		CHEMBL4545456	=	Inhibition	%	88.0	CHEMBL1844	Homo sapiens	INH	%	88.0
	19191661	CHEMBL4389169	Inhibition of wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in mammalian expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	64.0	CHEMBL1844	Homo sapiens	INH	%	64.0
	19191662	CHEMBL4389168	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	20.0	CHEMBL1844	Homo sapiens	INH	%	20.0
	19191831	CHEMBL4389645	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	67.0	CHEMBL1844	Homo sapiens	INH	%	67.0
	19191832	CHEMBL4389646	Inhibition of wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	83.0	CHEMBL1844	Homo sapiens	INH	%	83.0
	19199950	CHEMBL4391272	Binding affinity to wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	0.54	CHEMBL1844	Homo sapiens	Activity	%	0.54
	19199951	CHEMBL4391271	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	0.2	CHEMBL1844	Homo sapiens	Activity	%	0.2
	19236759	CHEMBL4398832	Inhibition of CSF1R (unknown origin) at 100 nM relative to control	B	COc1cc2c(Nc3ccc(NC(=O)C(c4cc(F)ccc4F)N4Cc5ccccc5C4=O)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL4443483	<	Inhibition	%	25.0	CHEMBL1844	Homo sapiens	INH	%	25.0
	19260400	CHEMBL4403935	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system measured after 60 mins by LanthaScreen assay	B	COc1ccc(Nc2ncc3c(n2)n(C2CCCC2)c(=O)n3C)c(C)c1		CHEMBL4483014	=	IC50	nM	25.12	CHEMBL1844	Homo sapiens	pIC50		7.6
	19260401	CHEMBL4403935	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system measured after 60 mins by LanthaScreen assay	B	COc1ccc(Nc2ncc3c(n2)n([C@H]2CC[C@H](O)CC2)c(=O)n3C)c(C)c1		CHEMBL4555040	=	IC50	nM	12.59	CHEMBL1844	Homo sapiens	pIC50		7.9
	19260402	CHEMBL4403935	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus expression system measured after 60 mins by LanthaScreen assay	B	Cc1cc2ncnn2cc1Nc1ncc2c(n1)n(C1CCOCC1)c(=O)n2C		CHEMBL4439259	=	IC50	nM	3162.28	CHEMBL1844	Homo sapiens	pIC50		5.5
	19266432	CHEMBL4405382	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	19275997	CHEMBL4408000	Inhibition of recombinant human FMS (538 to end residues) at 1 uM using KKKSPGEYVNIEF as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	64.0	CHEMBL1844	Homo sapiens	INH	%	64.0
	19275998	CHEMBL4408001	Inhibition of recombinant human FMS Y969C mutant (538 to end residues) at 1 uM using EEEEYEEEEEEYY as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	73.0	CHEMBL1844	Homo sapiens	INH	%	73.0
	19292316	CHEMBL4411567	Inhibition of N-terminal GST tagged human FMS (538 to 972 end residues) cytoplasmic domain expressed in baculovirus expression system at 1 uM in presence of ATP at its Km level relative to control	B	Cn1cc(Nc2nccc(N3C[C@H]4CC[C@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1		CHEMBL4458435	=	Inhibition	%	59.0	CHEMBL1844	Homo sapiens	INH	%	59.0
	19295861	CHEMBL4412338	Inhibition of CSF-1R (unknown origin) at 1000 nM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2c(-c3cnn(C4CC4)c3)n[nH]c2c1		CHEMBL4534119	=	Inhibition	%	94.2	CHEMBL1844	Homo sapiens	INH	%	94.2
	19295891	CHEMBL4412368	Inhibition of CSF-1R (unknown origin) at 100 nM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2c(-c3cnn(C4CC4)c3)n[nH]c2c1		CHEMBL4534119	=	Inhibition	%	83.4	CHEMBL1844	Homo sapiens	INH	%	83.4
	19295921	CHEMBL4412398	Inhibition of CSF-1R (unknown origin) at 10 nM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2c(-c3cnn(C4CC4)c3)n[nH]c2c1		CHEMBL4534119	=	Inhibition	%	65.3	CHEMBL1844	Homo sapiens	INH	%	65.3
	19312952	CHEMBL4416507	Inhibition of recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells at 10 uM using IGFR1tide as substrate relative to control	B	N#CC[C@H]1CC[C@H](n2c(=O)[nH]c3cnc(Nc4ccc[nH]c4=O)nc32)CC1		CHEMBL4463007	=	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	19326118	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cc(C(F)(F)F)ccc5F)cc4)c12)CCC3		CHEMBL4436123	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326119	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccccc5)cc4)c12)CCC3		CHEMBL4519514	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326120	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccccc1CC(=O)Nc1ccc(-n2c3c(c4ncnc(N)c42)CCC3)cc1		CHEMBL4454237	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326121	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)c1		CHEMBL4450212	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326122	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)cc1		CHEMBL4524493	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326123	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)CCc5ccccc5)cc4)c12)CCC3		CHEMBL4579310	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326124	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)cc(OC)c1		CHEMBL4452478	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326125	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccncc5)cc4)c12)CCC3		CHEMBL4565074	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326126	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cccnc5)cc4)c12)CCC3		CHEMBL4483818	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326127	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)C(F)c5ccccc5)cc4)c12)CCC3		CHEMBL4435514	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326128	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	CN1CCN(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)CC1		CHEMBL4452626	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326129	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cn5ccnc5)cc4)c12)CCC3		CHEMBL4577830	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326130	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)CN5CCOCC5)cc4)c12)CCC3		CHEMBL4573454	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326131	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)CN5CCCC5)cc4)c12)CCC3		CHEMBL4565843	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326132	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc(Cl)c(Cl)c5)cc4)c12)CCC3		CHEMBL4532195	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326133	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc(F)cc5)cc4)c12)CCC3		CHEMBL4443568	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326134	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cccc(Cl)c5)cc4)c12)CCC3		CHEMBL4564670	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326135	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cccc(OC(F)(F)F)c5)cc4)c12)CCC3		CHEMBL4447027	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326136	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)cc1F		CHEMBL4525625	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326137	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)ccc1F		CHEMBL4446602	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326138	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc(F)cc5Br)cc4)c12)CCC3		CHEMBL4564502	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326139	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)c(F)c1		CHEMBL4527118	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326140	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc(O)cc5)cc4)c12)CCC3		CHEMBL4457866	=	IC50	nM	29.0	CHEMBL1844	Homo sapiens	IC50	nM	29.0
	19326141	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	N#Cc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)cc1		CHEMBL4474990	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326142	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cc(C(F)(F)F)ccc5Cl)cc4)c12)CCC3		CHEMBL4449893	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326143	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc(Cl)c(C(F)(F)F)c5)cc4)c12)CCC3		CHEMBL4447857	=	IC50	nM	14.0	CHEMBL1844	Homo sapiens	IC50	nM	14.0
	19326144	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cccc(OC(F)F)c5)cc4)c12)CCC3		CHEMBL4469441	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326145	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc6c(c5)OCO6)cc4)c12)CCC3		CHEMBL4541577	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326146	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1cc(C(F)(F)F)ccc1F		CHEMBL4515395	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326147	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)cn1		CHEMBL4525575	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326148	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccc(Cl)c(C(F)(F)F)c1		CHEMBL4451431	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326149	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccccn1		CHEMBL4459041	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326150	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccnc(C(F)(F)F)c5)cc4)c12)CCC3		CHEMBL4439124	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326151	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccccc1		CHEMBL4518456	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326152	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cc(C(F)(F)F)ccn5)cc4)c12)CCC3		CHEMBL4470561	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326153	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2OC)n1		CHEMBL4465745	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326154	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)n1		CHEMBL4588762	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326155	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(F)c(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)c(F)c1		CHEMBL4522385	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326156	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cc(Cl)ccc5F)cc4)c12)CCC3		CHEMBL4455256	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326157	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc(Cl)cc5F)cc4)c12)CCC3		CHEMBL4438291	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326158	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cccc(Cl)c5F)cc4)c12)CCC3		CHEMBL4451039	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326159	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccc(C(F)(F)F)nc1		CHEMBL4441203	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326160	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc(C(F)(F)F)nc5)cc4)c12)CCC3		CHEMBL4518957	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326161	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc(Cl)cc5)cc4)c12)CCC3		CHEMBL4452680	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326162	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2OC)c(F)c1		CHEMBL4439449	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326163	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc(F)cc5C(F)(F)F)cc4)c12)CCC3		CHEMBL4461293	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326164	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)cc1Br		CHEMBL4585993	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326165	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5c(F)cc(Cl)cc5F)cc4)c12)CCC3		CHEMBL4473957	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326166	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)nc1		CHEMBL4534772	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326167	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2OC)nc1		CHEMBL4441717	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326168	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1cc(C)ccc1F		CHEMBL4483480	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326169	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cc1ccc(F)c(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)c1		CHEMBL4516589	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326170	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cc1cc(F)cc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)c1		CHEMBL4553840	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326171	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccccc5)cc4)c12)COC3		CHEMBL4557891	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326172	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1ccccc1		CHEMBL4451588	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326173	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2)c(F)c1		CHEMBL4447322	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326174	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)c12)COC3		CHEMBL4516654	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326175	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cc1ccc(F)c(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2)c1		CHEMBL4557765	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326176	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)c(OC)c1		CHEMBL4448225	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326177	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cc(C(F)(F)F)ccc5F)c(F)c4)c12)CCC3		CHEMBL4592386	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326178	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)c5c[nH]c6ccccc56)cc4)c12)CCC3		CHEMBL4570803	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326179	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)CCCN5CCOCC5)cc4)c12)CCC3		CHEMBL4466557	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326180	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cn1cc(C(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)c2ccccc21		CHEMBL4593820	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326181	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cn1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)n1		CHEMBL4527042	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326182	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1cc(C(F)(F)F)ccc1F		CHEMBL4471379	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326183	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ncc(C)cc1F		CHEMBL4562675	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326184	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccccc5)c(F)c4)c12)CCC3		CHEMBL4515870	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326185	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2F)c(F)c1		CHEMBL4578311	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326186	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccccc5)cc4F)c12)CCC3		CHEMBL4582455	=	IC50	nM	47.0	CHEMBL1844	Homo sapiens	IC50	nM	47.0
	19326187	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cn1cc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)cn1		CHEMBL4586865	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326188	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)CC5CCN(C(=O)OCc6ccccc6)CC5)cc4)c12)CCC3		CHEMBL4475374	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326189	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)CC5CCNCC5)cc4)c12)CCC3		CHEMBL4456877	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326190	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	CC(=O)N1CCC(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)CC1		CHEMBL4572524	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326191	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cn1ccc2cc(CC(=O)Nc3ccc(-n4c5c(c6ncnc(N)c64)CCC5)cc3)ccc21		CHEMBL4445355	=	IC50	nM	4.0	CHEMBL1844	Homo sapiens	IC50	nM	4.0
	19326192	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1cc(C)ccc1F		CHEMBL4445685	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326193	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cn1ccc2cc(CC(=O)Nc3ccc(-n4c5c(c6ncnc(N)c64)COC5)cc3)ccc21		CHEMBL4444042	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326194	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2F)c(F)c1		CHEMBL4456744	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326195	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccccc5)c(F)c4)c12)COC3		CHEMBL4548772	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326196	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cc(C(F)(F)F)ccc5F)c(F)c4)c12)COC3		CHEMBL4576910	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326197	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cc1ccc(F)c(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2F)c1		CHEMBL4437240	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326198	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1ccc(OC(F)(F)F)cc1		CHEMBL4441235	=	IC50	nM	6.0	CHEMBL1844	Homo sapiens	IC50	nM	6.0
	19326199	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)CCc5c[nH]c6ccccc56)cc4)c12)CCC3		CHEMBL4569022	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326200	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2OC)cc1F		CHEMBL4564167	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326201	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1ccc(Cl)c(C(F)(F)F)c1		CHEMBL4560876	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326202	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccc(OC(F)(F)F)cc1		CHEMBL4474890	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326203	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2OC)cc1F		CHEMBL4580604	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326204	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccc(C)c(F)c1		CHEMBL4557099	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326205	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2OC)cc1C		CHEMBL4556624	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326206	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccc(C)cc1F		CHEMBL4541561	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326207	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)c(F)c1		CHEMBL4459013	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326208	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cn1cc(CCC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)c2ccccc21		CHEMBL4460094	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326209	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccc2c(ccn2C)c1		CHEMBL4525523	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326210	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)cc1F		CHEMBL4460428	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326211	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)cc1C		CHEMBL4458010	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326212	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc6c(c5)CCN6CC(F)(F)F)cc4)c12)CCC3		CHEMBL4444903	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326213	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccc2c(c1)CCN2CC(F)(F)F		CHEMBL4442955	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326214	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cn1ccc2cc(CC(=O)Nc3ccc(-n4c5c(c6ncnc(N)c64)CCC5)cc3)cnc21		CHEMBL4461567	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326215	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1cnc2c(ccn2C)c1		CHEMBL4559280	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326216	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1cnc2c(ccn2C)c1		CHEMBL4454252	=	IC50	nM	32.0	CHEMBL1844	Homo sapiens	IC50	nM	32.0
	19326217	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccnc(C(F)(F)F)c1		CHEMBL4457719	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326218	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1ccnc(C(F)(F)F)c1		CHEMBL4520988	=	IC50	nM	50.0	CHEMBL1844	Homo sapiens	IC50	nM	50.0
	19326219	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc(Cl)c(C(F)(F)F)c5)cc4)c12)COC3		CHEMBL4464449	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326220	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc6c(c5)CCC6)cc4)c12)CCC3		CHEMBL4552304	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326221	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cnn(-c6ccccc6)c5)cc4)c12)CCC3		CHEMBL4435086	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326222	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)ccc1C		CHEMBL4440348	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326223	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2OC)ccc1C		CHEMBL4449803	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326224	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2)ccc1C		CHEMBL4549424	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326225	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	CC(C)c1cn(C)c2ccc(CC(=O)Nc3ccc(-n4c5c(c6ncnc(N)c64)CCC5)cc3)cc12		CHEMBL4437786	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326226	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2OC)cn1		CHEMBL4543360	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326227	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(C3C4=C(COC4)c4ncnc(N)c43)cc2OC)cn1		CHEMBL4561331	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326228	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc(C(F)(F)F)nc5)cc4)c12)COC3		CHEMBL4456746	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326229	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc(OC(F)(F)F)cc5)cc4)c12)COC3		CHEMBL4452335	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326230	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2)cc1F		CHEMBL4550365	=	IC50	nM	14.0	CHEMBL1844	Homo sapiens	IC50	nM	14.0
	19326231	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2)cc1F		CHEMBL4456750	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326232	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2)cc1C		CHEMBL4582226	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326233	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2)c(F)c1		CHEMBL4457616	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326234	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1ccc(C(F)(F)F)nc1		CHEMBL4448055	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326235	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	CC(C(=O)Nc1ccc(-n2c3c(c4ncnc(N)c42)CCC3)cc1)c1ccccc1		CHEMBL4450607	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326236	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5coc(-c6ccccc6)n5)cc4)c12)CCC3		CHEMBL4448740	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326237	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccc(C(F)(F)F)nn1		CHEMBL4483817	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	nM	9.0
	19326238	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1coc(-c2ccccc2)n1		CHEMBL4572419	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326239	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5nc6ccccc6s5)cc4)c12)CCC3		CHEMBL4462298	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326240	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc(Cl)nn5)cc4)c12)CCC3		CHEMBL4443184	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326241	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	CN(C)c1cc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)ccc1C(F)(F)F		CHEMBL4466242	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326242	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc(Cl)nn5)cc4)c12)COC3		CHEMBL4580095	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326243	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc(C(F)(F)F)nn5)cc4)c12)COC3		CHEMBL4567369	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326244	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1cnccn1		CHEMBL4459673	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326245	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cc1cc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)on1		CHEMBL4449378	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326246	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)cc1N(C)C		CHEMBL4466231	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326247	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)cc1C(F)(F)F		CHEMBL4464095	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326248	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2)cc1C(F)(F)F		CHEMBL4458944	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326249	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccc(OC)c(C(F)(F)F)c1		CHEMBL4554125	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326250	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1ccc(OC)c(C(F)(F)F)c1		CHEMBL4583333	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326251	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)[C@@H](N)c5ccccc5)cc4)c12)CCC3		CHEMBL4587979	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326252	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)[C@@H](N)Cc5ccccc5)cc4)c12)CCC3		CHEMBL4530658	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326253	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccc(C(F)(F)F)nn5)cc4)c12)CCC3		CHEMBL4468161	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326254	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1ccc(C(F)(F)F)nn1		CHEMBL4583679	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326255	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccnc(C(F)(F)F)c5)cc4)c12)COC3		CHEMBL4445211	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326256	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1cc(C)no1		CHEMBL4553132	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326257	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccccc5)nc4)c12)CCC3		CHEMBL4454127	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326258	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	NC(=O)c1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)cc1C(F)(F)F		CHEMBL4462928	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326259	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5ccccc5)cc4)c12)CCC3		CHEMBL4453474	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326260	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)c12)CCC3		CHEMBL4536156	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326261	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5cccnc5)cc4)c12)CCC3		CHEMBL4456412	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326262	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccccc1		CHEMBL4454314	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326263	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cn1ccc2cc(NC(=O)Cc3ccc(-n4c5c(c6ncnc(N)c64)CCC5)cc3)ccc21		CHEMBL4571884	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326264	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cc1ccc(F)c(NC(=O)Cc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)c1		CHEMBL4572765	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326265	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5ccc(Cl)c(C(F)(F)F)c5)cc4)c12)CCC3		CHEMBL4442369	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	nM	9.0
	19326266	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)NCc5ccccc5)cc4)c12)CCC3		CHEMBL4452284	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326267	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(NC(=O)Cc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)c(F)c1		CHEMBL4436151	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326268	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(NC(=O)Cc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)cn1		CHEMBL4438966	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326269	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5ccc(C(F)(F)F)cn5)cc4)c12)CCC3		CHEMBL4476834	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326270	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5ccc(C(F)(F)F)nc5)cc4)c12)CCC3		CHEMBL4459240	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326271	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(NC(=O)Cc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)nn1		CHEMBL4461129	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326272	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(NC(=O)Cc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)cc1C(F)(F)F		CHEMBL4585626	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326273	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5ccnc(C(F)(F)F)c5)cc4)c12)CCC3		CHEMBL4581670	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326274	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5ccc(OC(F)(F)F)cc5)cc4)c12)CCC3		CHEMBL4471003	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326275	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5ccc(C(F)(F)F)c(Cl)c5)cc4)c12)CCC3		CHEMBL4471374	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326276	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5ccc(Cl)c(Cl)c5)cc4)c12)CCC3		CHEMBL4463293	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326277	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5ccc6c(c5)CCC6)cc4)c12)CCC3		CHEMBL4447901	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326278	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5ccc(Cl)c(C(F)(F)F)c5)cc4)c12)COC3		CHEMBL4436759	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326279	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cc1ccc(F)c(NC(=O)Cc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2)c1		CHEMBL4435623	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326280	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5ccc(OC(F)(F)F)cc5)cc4)c12)COC3		CHEMBL4591501	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326281	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(NC(=O)Cc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2)cc1C(F)(F)F		CHEMBL4476415	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326282	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)NC5CCCCC5)cc4)c12)CCC3		CHEMBL4542151	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326283	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)NC5CCOCC5)cc4)c12)CCC3		CHEMBL4573413	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326284	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5cnc(C(F)(F)F)nc5)cc4)c12)CCC3		CHEMBL4447676	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326285	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5ccc(C(F)(F)F)nn5)cc4)c12)CCC3		CHEMBL4463533	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326286	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(NC(=O)Cc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)cc1F		CHEMBL4469070	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326287	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)N5CCOc6ccccc65)cc4)c12)CCC3		CHEMBL4469851	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326288	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	CC(C)(C)c1cc(NC(=O)Cc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)n(-c2ccccc2)n1		CHEMBL4436435	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326289	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5ccc(C(F)(F)F)cn5)cc4)c12)COC3		CHEMBL4544668	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326290	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5nc(C(F)(F)F)cs5)cc4)c12)CCC3		CHEMBL4450149	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326291	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccc(OC(F)(F)F)cc1		CHEMBL4573032	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326292	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(NC(=O)Cc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2OC)cc1F		CHEMBL4562976	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326293	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)N1CCOc2ccccc21		CHEMBL4441451	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326294	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(NC(=O)Cc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2OC)c(F)c1		CHEMBL4471324	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326295	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccc(OC)c(C(F)(F)F)c1		CHEMBL4578994	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326296	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccc(Cl)c(Cl)c1		CHEMBL4454038	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326297	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccc(C(F)(F)F)cn1		CHEMBL4468982	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326298	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccnc(C(F)(F)F)c1		CHEMBL4453339	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326299	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1cc(C(F)(F)F)ccc1F		CHEMBL4589275	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326300	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1cc(C)ccc1F		CHEMBL4462246	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326301	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccc(Cl)c(C(F)(F)F)c1		CHEMBL4577723	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326302	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(CC(=O)Nc5nc(C(F)(F)F)co5)cc4)c12)CCC3		CHEMBL4530812	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326303	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccc(C(F)(F)F)nc1		CHEMBL4524659	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326304	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)CN1C(=O)COc2ccccc21		CHEMBL4458421	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326305	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)CN1C(=O)COc2ccccc21		CHEMBL4445496	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326306	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1nccc(C(F)(F)F)n1		CHEMBL4445048	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326307	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1nccc(C(F)(F)F)n1		CHEMBL4443800	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326308	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccnc(C(F)(F)F)n1		CHEMBL4445313	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326309	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1ccnc(C(F)(F)F)n1		CHEMBL4473617	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326310	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)CN1CCOc2ccccc21		CHEMBL4467103	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326311	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccccc5)c(Cl)c4)c12)CCC3		CHEMBL4587248	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326312	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)CN1CCOc2ccccc21		CHEMBL4580555	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326313	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)CN1CCCc2cc(F)ccc21		CHEMBL4465949	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326314	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccccc5)c(OC(F)(F)F)c4)c12)CCC3		CHEMBL4586857	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326315	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1nnccc1C(F)(F)F		CHEMBL4450119	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326316	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccn(C)n1		CHEMBL4566733	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326317	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1cnn(C)c1		CHEMBL4530993	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326318	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccc2c(c1)CN(C)C2=O		CHEMBL4589644	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326319	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1cc(C(F)(F)F)nn1C		CHEMBL4516978	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326320	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	CNC(=O)c1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2OC)cc1		CHEMBL4438015	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326321	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccc(C(=O)N(C)C)cc1		CHEMBL4449884	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326322	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2OC)cc(OC)c1		CHEMBL4451427	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326323	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2OC)cc(OC)c1		CHEMBL4576257	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326324	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2OC)c(F)c1		CHEMBL4467060	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326325	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1c(C)noc1C		CHEMBL4456721	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326326	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1cccc(OC)c1C		CHEMBL4473980	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326327	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1ccc(C)cc1F		CHEMBL4462436	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326328	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cn1ccc(C(F)(F)F)n1		CHEMBL4564176	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326329	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cn1ccc(C(F)(F)F)n1		CHEMBL4578013	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326330	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cn1cc(C(F)(F)F)cn1		CHEMBL4439844	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326331	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cn1cc(C(F)(F)F)cn1		CHEMBL4440574	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326332	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cn1nc(C)cc1C(F)(F)F		CHEMBL4551122	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326333	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cn1nc(C)cc1C(F)(F)F		CHEMBL4450461	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326334	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cn1nc(C)cc1C		CHEMBL4459408	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326335	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1cnn(C(F)F)c1		CHEMBL4556619	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326336	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1cc(C(F)(F)F)on1		CHEMBL4454143	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326337	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccccc5)c(C(F)(F)F)c4)c12)CCC3		CHEMBL4466988	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326338	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cn1cc(C)cn1		CHEMBL4592264	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326339	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cn1cnc(C(F)(F)F)c1		CHEMBL4435175	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326340	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cn1cnc(C(F)(F)F)c1		CHEMBL4452419	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326341	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cn5ccc(C(F)(F)F)n5)cc4)c12)CCC3		CHEMBL4446976	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326342	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cn5cc(C(F)(F)F)cn5)cc4)c12)COC3		CHEMBL4565826	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326343	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cn5cc(C(F)(F)F)cn5)cc4)c12)CCC3		CHEMBL4472357	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326344	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cc(C(F)(F)F)on5)cc4)c12)CCC3		CHEMBL4583616	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326345	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cn1nc(C(F)(F)F)cc1CC(=O)Nc1ccc(-n2c3c(c4ncnc(N)c42)CCC3)cc1		CHEMBL4561553	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326346	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1cnn(C)c1C(F)(F)F		CHEMBL4462486	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326347	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Cn1ncc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)c1C(F)(F)F		CHEMBL4459558	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326348	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cn1cc(C(F)(F)F)nc1C		CHEMBL4537823	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326349	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1cc(C(F)(F)F)on1		CHEMBL4584460	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326350	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1cc(C(F)(F)F)no1		CHEMBL4458606	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326351	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cn5cnc(C(F)(F)F)c5)cc4)c12)COC3		CHEMBL4462183	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326352	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cn5cnc(C(F)(F)F)c5)cc4)c12)CCC3		CHEMBL4514080	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326353	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cn1ncc2ccccc21		CHEMBL4472926	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326354	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cn5ccc(C(F)(F)F)n5)cc4)c12)COC3		CHEMBL4446954	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326355	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cc(C(F)(F)F)no5)cc4)c12)CCC3		CHEMBL4438422	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326356	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1cc(C(F)F)on1		CHEMBL4435999	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326357	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cc(C(F)F)on5)cc4)c12)CCC3		CHEMBL4543002	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326358	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	CC(C)c1noc(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)n1		CHEMBL4571829	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326359	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1nc(C(C)C)no1		CHEMBL4436945	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326360	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cn1ccc(C(C)(C)C)n1		CHEMBL4568852	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326361	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5nnc(C(F)(F)F)o5)cc4)c12)CCC3		CHEMBL4531832	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326362	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1csc(C(C)(C)C)n1		CHEMBL4593289	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326363	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1csc(C(C)C)n1		CHEMBL4543116	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326364	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1csc(C(C)C)n1		CHEMBL4550627	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326365	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cn1ccc(C(C)(C)C)n1		CHEMBL4459715	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326366	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	CC(C)c1ccn(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)n1		CHEMBL4465640	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326367	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cn5ccc(C6CC6)n5)cc4)c12)CCC3		CHEMBL4540196	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326368	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	CC(C)(C)c1cnn(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)c1		CHEMBL4576936	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326369	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cn1ccc(C2CC2)n1		CHEMBL4542220	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326370	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1cnn(C)c1C(F)(F)F		CHEMBL4524242	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326371	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1coc(C(C)C)n1		CHEMBL4450186	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326372	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1nnn(C(C)(C)C)n1		CHEMBL4544361	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326373	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	CC(C)(C)c1cnn(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2)c1		CHEMBL4529227	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326374	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cn1cc(C(C)(C)C)cn1		CHEMBL4439551	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326375	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	CC(C)(C)c1ccn(CC(=O)Nc2ccc(-n3c4c(c5ncnc(N)c53)COC4)cc2)n1		CHEMBL4444196	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326376	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccc(C(C)(C)C)cc1		CHEMBL4464818	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326377	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cn1ccc(C(C)C)n1		CHEMBL4462573	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326378	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1NC(=O)Cc1ccc(C)c(F)c1		CHEMBL4436981	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326379	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1cc(C(F)(F)F)cnn1		CHEMBL4461323	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326380	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cnn(C(F)F)c5)cc4)c12)CCC3		CHEMBL4445152	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326381	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccn(C(F)F)n1		CHEMBL4582921	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326382	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccn(C(F)F)n5)cc4)c12)CCC3		CHEMBL4447125	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326383	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5ccn(C(F)F)n5)cc4)c12)COC3		CHEMBL4462937	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326384	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1cnc(C(F)(F)F)nc1		CHEMBL4451533	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326385	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccc(C2(O)COC2)cc1		CHEMBL4443213	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326386	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccc(C(C)(C)O)cn1		CHEMBL4450389	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326387	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1CC(=O)Nc1ccccc1		CHEMBL4474365	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326388	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1nc(C(F)(F)F)cs1		CHEMBL4458830	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326389	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccc2c(c1)COC2(C)C		CHEMBL4444952	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326390	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccc(C(C)(C)O)nc1		CHEMBL4440869	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326391	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)COC3)ccc1CC(=O)Nc1ccc(C(F)(F)F)nc1		CHEMBL4465442	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326392	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1cc(C(F)(F)F)cnn1		CHEMBL4465761	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326393	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	CNC(=O)c1cccc(NC(=O)Cc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2OC)c1		CHEMBL4592632	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326394	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccc(C(C)(C)OC)nc1		CHEMBL4566177	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326395	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(NC(=O)Cc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2OC)cc(C(F)(F)F)c1		CHEMBL4472389	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326396	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1cnc(OC)c(F)c1		CHEMBL4545531	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326397	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ncc(NC(=O)Cc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2)cc1F		CHEMBL4441476	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326398	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccc2nonc2c1		CHEMBL4524994	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326399	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccc(C(C)(C)C)cc1		CHEMBL4580091	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326400	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1cnn(C)c1		CHEMBL4442367	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326401	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccn(C)n1		CHEMBL4471716	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326402	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1ccnn1C		CHEMBL4537456	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19326403	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1ccc(NC(=O)Cc2ccc(-n3c4c(c5ncnc(N)c53)CCC4)cc2OC)nn1		CHEMBL4565199	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326404	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1CC(=O)Nc1cnn(C(F)F)c1		CHEMBL4539031	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326405	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	COc1cc(-n2c3c(c4ncnc(N)c42)CCC3)ccc1NC(=O)Cc1ccc(C2(O)COC2)cc1		CHEMBL4467310	<	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19326406	CHEMBL4418433	Displacement of kinase tracer 236 from recombinant human His-tagged CSF1R cytoplasmic domain (538 to 910 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay	B	Nc1ncnc2c3c(n(-c4ccc(NC(=O)Cc5cc(C(F)(F)F)ccc5F)c(C(F)(F)F)c4)c12)CCC3		CHEMBL4437792	>	IC50	nM	200.0	CHEMBL1844	Homo sapiens	IC50	nM	200.0
	19370907	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4cc(COCC(CO)(CO)CO)ccn4)C3)cc2OC)cc1		CHEMBL4526802	=	IC50	nM	17.0	CHEMBL1844	Homo sapiens	IC50	nM	17.0
	19370908	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	COc1cc(C2CN(C(=O)c3cc(COC[C@H](O)CO)ccn3)C2)ccc1OCc1ccc(C2CC2)cc1		CHEMBL4555993	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	nM	13.0
	19370909	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	COc1cc(C2CN(C(=O)c3cc(COC[C@@H](O)CO)ccn3)C2)ccc1OCc1ccc(C2CC2)cc1		CHEMBL4474690	=	IC50	nM	14.0	CHEMBL1844	Homo sapiens	IC50	nM	14.0
	19370910	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4cc(COC[C@@H](O)CO)ccn4)C3)cc2OC)cc1		CHEMBL4455662	=	IC50	nM	18.0	CHEMBL1844	Homo sapiens	IC50	nM	18.0
	19370911	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	COc1cc(C2CN(C(=O)c3cc(OC[C@@H](O)CO)ccn3)C2)ccc1OCc1ccc(C2CC2)cc1		CHEMBL4467199	=	IC50	nM	15.0	CHEMBL1844	Homo sapiens	IC50	nM	15.0
	19370912	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	COc1cc(C2CN(C(=O)c3cc(OC[C@H](O)CO)ccn3)C2)ccc1OCc1ccc(C2CC2)cc1		CHEMBL4526056	=	IC50	nM	15.0	CHEMBL1844	Homo sapiens	IC50	nM	15.0
	19370913	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	COc1ccc(COc2ccc(C3CN(C(=O)c4cc(OCCO)ccn4)C3)cc2OC)cc1		CHEMBL4543929	=	IC50	nM	12.0	CHEMBL1844	Homo sapiens	IC50	nM	12.0
	19370914	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	COc1cc(C2CN(C(=O)c3cc(OCCO)ccn3)C2)ccc1OCc1ccc(C2CC2)cc1		CHEMBL4575001	=	IC50	nM	12.0	CHEMBL1844	Homo sapiens	IC50	nM	12.0
	19370915	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4cc(OCCO)ccn4)C3)cc2OC)cc1		CHEMBL4437645	=	IC50	nM	9.1	CHEMBL1844	Homo sapiens	IC50	nM	9.1
	19370916	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4cc(OCCN5CCNC(=O)C5)ccn4)C3)cc2OC)cc1		CHEMBL4574414	=	IC50	nM	15.0	CHEMBL1844	Homo sapiens	IC50	nM	15.0
	19370917	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4cc(OCCN5C[C@H](O)[C@H](O)C5)ccn4)C3)cc2OC)cc1		CHEMBL4460662	=	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	19370918	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4cc(OCCN5C[C@@H](O)[C@H](O)C5)ccn4)C3)cc2OC)cc1		CHEMBL4539279	=	IC50	nM	8.9	CHEMBL1844	Homo sapiens	IC50	nM	8.9
	19370919	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	COc1cc(C2CN(C(=O)c3cc(OCCN4CCOCC4)ccn3)C2)ccc1OCc1ccc(C2CC2)cc1		CHEMBL4473704	=	IC50	nM	12.0	CHEMBL1844	Homo sapiens	IC50	nM	12.0
	19370920	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4cc(OCCN5CCOCC5)ccn4)C3)cc2OC)cc1		CHEMBL4570496	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	nM	13.0
	19370921	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	COc1ccc(COc2ccc(C3CN(C(=O)c4cc(OCCN5CCN(C)CC5)ccn4)C3)cc2OC)cc1		CHEMBL4547269	=	IC50	nM	17.0	CHEMBL1844	Homo sapiens	IC50	nM	17.0
	19370922	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	COc1cc(C2CN(C(=O)c3cc(OCCN4CCN(C)CC4)ccn3)C2)ccc1OCc1ccc(C2CC2)cc1		CHEMBL4452717	=	IC50	nM	4.4	CHEMBL1844	Homo sapiens	IC50	nM	4.4
	19370923	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	CCc1ccc(COc2ccc(C3CN(C(=O)c4cc(OCCN5CCN(C)CC5)ccn4)C3)cc2OC)cc1		CHEMBL4586087	=	IC50	nM	53.0	CHEMBL1844	Homo sapiens	IC50	nM	53.0
	19370924	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	COc1cc(C2CN(C(=O)c3cc(OCCCC(C)(C)C(=O)O)ccn3)C2)ccc1OCc1ccc(C2CC2)cc1		CHEMBL4472513	=	IC50	nM	64.0	CHEMBL1844	Homo sapiens	IC50	nM	64.0
	19370925	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	COc1cc(C2CN(C(=O)c3cc(OCCCC(=O)O)ccn3)C2)ccc1OCc1ccc(C2CC2)cc1		CHEMBL4543802	=	IC50	nM	29.0	CHEMBL1844	Homo sapiens	IC50	nM	29.0
	19370926	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	COc1cc(C2CN(C(=O)c3cc(COCC(CO)(CO)CO)ccn3)C2)ccc1OCc1ccc(C2CC2)cc1		CHEMBL4451717	=	IC50	nM	20.0	CHEMBL1844	Homo sapiens	IC50	nM	20.0
	19370927	CHEMBL4424848	Inhibition of human CSF1R tyrosine kinase domain (538 to 972 residues) using Poly(Glu, Tyr)-biotinylated peptide as substrate preincubated for 5 mins followed by substrate addition and measured after 10 mins by HTRF assay	B	COc1cc(C2CN(C(=O)c3cc(COCC(CO)CO)ccn3)C2)ccc1OCc1ccc(C2CC2)cc1		CHEMBL4522278	=	IC50	nM	11.0	CHEMBL1844	Homo sapiens	IC50	nM	11.0
	19433048	CHEMBL4429591	Inhibition of partial length human CSF1R expressed in bacterial expression system assessed as activity remaining at 1 uM by kinome scan assay	B	CCC(=O)NCC1CCN(c2ccc(NC(=O)Nc3cccc(Oc4ccnc5cc(OC)c(OC)cc45)c3)cc2C(F)(F)F)CC1		CHEMBL4445808	=	Activity	%	0.05	CHEMBL1844	Homo sapiens	Activity	%	0.05
	19433055	CHEMBL4429573	Inhibition of TEL-fused partial length human CSF1R expressed in mouse BA/F3 cells after 72 hrs by cell titer-glo assay	B	CCC(=O)NCC1CCN(c2ccc(NC(=O)Nc3cccc(Oc4ccnc5cc(OC)c(OC)cc45)c3)cc2C(F)(F)F)CC1		CHEMBL4445808	=	GI50	nM	110.0	CHEMBL1844	Homo sapiens	GI50	uM	0.11
	19469417	CHEMBL4478339	Inhibition of human CSF1R expressed in bacterial system assessed as remaining enzyme activity at 1 uM relative to untreated control	B	Cc1cc(Nc2ncc3ncc(=O)n(-c4ccc(N)cc4)c3n2)ccc1N1CCN(C)CC1		CHEMBL4550647	<=	Activity	%	1.0	CHEMBL1844	Homo sapiens	Activity	%	1.0
	19476562	CHEMBL4479710	Inhibition of recombinant human His-tagged cytoplasmic CSF1R expressed in baculovirus expression system by Z'-LYTE assay	B	O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1		CHEMBL4569508	=	IC50	nM	41.0	CHEMBL1844	Homo sapiens	IC50	nM	41.0
	19476662	CHEMBL4479710	Inhibition of recombinant human His-tagged cytoplasmic CSF1R expressed in baculovirus expression system by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)NCC(F)(F)F)c4)cnn3c2)cn1		CHEMBL4550702	=	IC50	nM	100.0	CHEMBL1844	Homo sapiens	IC50	nM	100.0
	19476762	CHEMBL4479710	Inhibition of recombinant human His-tagged cytoplasmic CSF1R expressed in baculovirus expression system by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)N[C@@H]5CCCC[C@@H]5N)c4)cnn3c2)cn1		CHEMBL4568087	=	IC50	nM	3.3	CHEMBL1844	Homo sapiens	IC50	nM	3.3
	19476862	CHEMBL4479710	Inhibition of recombinant human His-tagged cytoplasmic CSF1R expressed in baculovirus expression system by Z'-LYTE assay	B	Cc1sc(C(=O)N[C@@H]2[C@H](N)CCCC2(F)F)cc1-c1cnn2cc(Cl)cnc12		CHEMBL4552628	=	IC50	nM	22000.0	CHEMBL1844	Homo sapiens	IC50	nM	22000.0
	20600492	CHEMBL4603444	Inhibition of recombinant human His-tagged CSF1R catalytic domain (538 to 910 residues) expressed in baculovirus expression system using tyrosine-1 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL1844	Homo sapiens	IC50	uM	100.0
	20609552	CHEMBL4605803	Inhibition of FMS (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay	B	COc1ccc(-c2cnn3c(N)c(-c4ccccc4)c(OC4CCN(C)CC4)nc23)cc1OC		CHEMBL4640601	=	IC50	nM	400.0	CHEMBL1844	Homo sapiens	IC50	uM	0.4
	20609553	CHEMBL4605803	Inhibition of FMS (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay	B	COC(=O)Nc1ccc(-c2c(OC3CCN(C)CC3)nc3c(-c4ccc(OC)c(OC)c4)cnn3c2N)cc1		CHEMBL4634073	=	IC50	nM	82.0	CHEMBL1844	Homo sapiens	IC50	uM	0.082
	20609554	CHEMBL4605803	Inhibition of FMS (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay	B	COc1ccc(-c2cnn3c(N)c(-c4nccs4)c(OC4CCN(C)CC4)nc23)cc1OC		CHEMBL4636995	=	IC50	nM	4300.0	CHEMBL1844	Homo sapiens	IC50	uM	4.3
	20679561	CHEMBL4622432	Binding affinity to recombinant human CSF1R (564 to 939 residues) expressed in bacterial expression system by Kinomescan method	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn(-c4ccc(OCCN5CCOCC5)cc4Cl)nn3)cc2)no1		CHEMBL4645320	=	Kd	nM	100.0	CHEMBL1844	Homo sapiens	Kd	nM	100.0
	20679562	CHEMBL4622432	Binding affinity to recombinant human CSF1R (564 to 939 residues) expressed in bacterial expression system by Kinomescan method	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	=	Kd	nM	15.0	CHEMBL1844	Homo sapiens	Kd	nM	15.0
	20683655	CHEMBL4623634	Inhibition of CSF1R (unknown origin) at 10 nM relative to control	B	C[C@@H](Oc1cncc(-c2cnn(C3CCNCC3)c2)c1)c1c(Cl)ccc(F)c1Cl.Cl		CHEMBL4644985	=	Inhibition	%	15.0	CHEMBL1844	Homo sapiens	INH	%	15.0
	20683656	CHEMBL4623635	Inhibition of CSF1R (unknown origin) at 100 nM relative to control	B	C[C@@H](Oc1cncc(-c2cnn(C3CCNCC3)c2)c1)c1c(Cl)ccc(F)c1Cl.Cl		CHEMBL4644985	=	Inhibition	%	67.0	CHEMBL1844	Homo sapiens	INH	%	67.0
	20714352	CHEMBL4629871	Binding affinity to wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	NC(=O)c1cnc(N2CCC[C@H](N)C2)nc1Nc1cccc(C(F)(F)F)c1		CHEMBL1835063	=	Activity	%	8.6	CHEMBL1844	Homo sapiens	Activity	%	8.6
	20714377	CHEMBL4629882	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by hotspot kinase assay	B	NC(=O)c1cnc(N2CCC[C@H](N)C2)nc1Nc1cccc(C(F)(F)F)c1		CHEMBL1835063	=	IC50	nM	168.0	CHEMBL1844	Homo sapiens	IC50	uM	0.168
	22388101	CHEMBL4666413	Inhibition of CSF1R (unknown origin) at 500 nM relative to control	B	Cc1cc(Nc2cc(N3CCN(CCCN(C)C)CC3)ncn2)c(=O)n2c1C(=O)NC21CCCCC1		CHEMBL4757546	=	Inhibition	%	6.0	CHEMBL1844	Homo sapiens	INH	%	6.0
	22391710	CHEMBL4666976	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system using Tyr 01 as substrate at 0.1 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	O=C(Nc1c[nH]nc1-c1cc(Cl)ccc1OC(F)F)c1cnn2cccnc12		CHEMBL4744172	=	Inhibition	%	6.0	CHEMBL1844	Homo sapiens	INH	%	6.0
	22391711	CHEMBL4666976	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system using Tyr 01 as substrate at 0.1 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	Cn1cc(NC(=O)c2cnn3cccnc23)c(-c2cc(Cl)ccc2OC(F)F)n1		CHEMBL4777342	=	Inhibition	%	29.0	CHEMBL1844	Homo sapiens	INH	%	29.0
	22391712	CHEMBL4666976	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system using Tyr 01 as substrate at 0.1 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	O=C(Nc1c[nH]nc1-c1cc2ccccc2cc1OC(F)F)c1cnn2cccnc12		CHEMBL4745474	=	Inhibition	%	-3.0	CHEMBL1844	Homo sapiens	INH	%	-3.0
	22392029	CHEMBL4667124	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system using Tyr 01 as substrate at 10 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	CN1C(=O)[C@@H](NC(=O)c2n[nH]c3ncc(C(F)(F)C(F)(F)F)cc23)COc2ccccc21		CHEMBL4785812	=	Inhibition	%	15.0	CHEMBL1844	Homo sapiens	INH	%	15.0
	22423597	CHEMBL4674374	Inhibition of human FMS using poly[Glu:Tyr] (4:1) as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	67.23	CHEMBL1844	Homo sapiens	Activity	%	67.23
	22423598	CHEMBL4674374	Inhibition of human FMS using poly[Glu:Tyr] (4:1) as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	72.81	CHEMBL1844	Homo sapiens	Activity	%	72.81
	22425206	CHEMBL4674901	Inhibition of human FMS at 10 uM using myelin basic protein as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CCCCCCCC(=O)Nc1nc2[nH]c(CN3CCN(Cc4cccc(F)c4)CC3)c(CN3CCN(Cc4cccc(F)c4)CC3)c2c(=O)[nH]1		CHEMBL4786524	=	Inhibition	%	70.3	CHEMBL1844	Homo sapiens	INH	%	70.3
	22782810	CHEMBL4707751	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system at 1 uM by Z-lyte assay relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-n3c(SC)nnc3-c3ccc(F)cc3)ccn2)c(OC)cc1N(C)CCN(C)C		CHEMBL4798177	=	Inhibition	%	12.0	CHEMBL1844	Homo sapiens	INH	%	12.0
	22795682	CHEMBL4710585	Inhibition of CSF1R (unknown origin)	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	=	IC50	nM	20.0	CHEMBL1844	Homo sapiens	IC50	nM	20.0
	22798251	CHEMBL4710994	Inhibition of human FMS at 10 uM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]ATP by scintillation counting method relative to control	B	CCN1CCN(c2cc(C(=O)Nc3cccc(Nc4ccc5c(OC)cccc5n4)c3)cc(C(F)(F)F)c2)CC1		CHEMBL4795732	=	Inhibition	%	60.68	CHEMBL1844	Homo sapiens	INH	%	60.68
	22820480	CHEMBL4716242	Inhibition of recombinant N-terminal His6-tagged human FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	=	Activity	%	84.0	CHEMBL1844	Homo sapiens	Activity	%	84.0
	22820481	CHEMBL4716242	Inhibition of recombinant N-terminal His6-tagged human FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control	B	COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCNC2		CHEMBL4782674	=	Activity	%	13.0	CHEMBL1844	Homo sapiens	Activity	%	13.0
	22826330	CHEMBL4717515	Inhibition of recombinant N-terminal His6-tagged human FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 10 uM relative to control	B	CN1CCN(CCCOc2cccc3nc(Nc4ccc(Cl)c(C(F)(F)F)c4)ccc23)CC1		CHEMBL4797203	<	Activity	%	60.0	CHEMBL1844	Homo sapiens	Activity	%	60.0
	22836162	CHEMBL4718849	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system at 500 nM using Tyr 01 peptide as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	=	Inhibition	%	38.0	CHEMBL1844	Homo sapiens	INH	%	38.0
	22836163	CHEMBL4718849	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system at 500 nM using Tyr 01 peptide as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	OCC[C@@H](Nc1ncnc2[nH]c(-c3ccccc3)cc12)c1ccccc1		CHEMBL4786776	=	Inhibition	%	74.0	CHEMBL1844	Homo sapiens	INH	%	74.0
	22836164	CHEMBL4718849	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system at 500 nM using Tyr 01 peptide as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	CN(C)CCNCc1ccc(-c2cc3c(N[C@H](CO)c4ccccc4)ncnc3[nH]2)cc1F		CHEMBL4748367	=	Inhibition	%	86.0	CHEMBL1844	Homo sapiens	INH	%	86.0
	22836165	CHEMBL4718849	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system at 500 nM using Tyr 01 peptide as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	CCOc1ccccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1		CHEMBL4776396	=	Inhibition	%	82.0	CHEMBL1844	Homo sapiens	INH	%	82.0
	22836166	CHEMBL4718849	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system at 500 nM using Tyr 01 peptide as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	COc1ccccc1-c1cc2c(N[C@H](CO)c3ccccc3)ncnc2[nH]1		CHEMBL4783569	=	Inhibition	%	79.0	CHEMBL1844	Homo sapiens	INH	%	79.0
	22836167	CHEMBL4718849	Inhibition of recombinant human His-tagged CSF1R (538 to 910 residues) expressed in baculovirus expression system at 500 nM using Tyr 01 peptide as substrate incubated for 1 hr in presence of ATP at its Km concentration by Z'-LYTE assay relative to control	B	OC[C@@H](Nc1ncnc2[nH]c(-c3ccccc3)cc12)c1ccccc1		CHEMBL4780286	=	Inhibition	%	88.0	CHEMBL1844	Homo sapiens	INH	%	88.0
	22843228	CHEMBL4720250	Inhibition of recombinant human FMS using Ulight-TK peptide as substrate incubate for 15 mins by LANCE assay	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4755698	>	IC50	nM	10000.0	CHEMBL1844	Homo sapiens	IC50	nM	10000.0
	22843229	CHEMBL4720250	Inhibition of recombinant human FMS using Ulight-TK peptide as substrate incubate for 15 mins by LANCE assay	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	=	IC50	nM	5545.0	CHEMBL1844	Homo sapiens	IC50	nM	5545.0
	22843736	CHEMBL4720722	Inhibition of human FMS using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	1.3	CHEMBL1844	Homo sapiens	IC50	10^-9M	1.3
	22844089	CHEMBL4721075	Inhibition of human FMS assessed as residual activity using poly[Glu:Tyr] (4:1) as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	92.33	CHEMBL1844	Homo sapiens	Activity	%	92.33
	22844717	CHEMBL4721392	Inhibition of FMS (unknown origin) assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	106.16	CHEMBL1844	Homo sapiens	Activity	%	106.16
	22874831	CHEMBL4725522	Inhibition of human FMS assessed as remaining enzyme activity at 1 uM	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	=	Activity	%	10.0	CHEMBL1844	Homo sapiens	Activity	%	10.0
	22874865	CHEMBL4725556	Inhibition of human FMS assessed as remaining enzyme activity at 0.1 uM	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	=	Activity	%	36.0	CHEMBL1844	Homo sapiens	Activity	%	36.0
	22874891	CHEMBL4725582	Inhibition of human FMS assessed as remaining enzyme activity at 0.01 uM	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	=	Activity	%	73.0	CHEMBL1844	Homo sapiens	Activity	%	73.0
	22889056	CHEMBL4728926	Inhibition of CSF1R (unknown origin)	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	nM	30.0
	22889057	CHEMBL4728926	Inhibition of CSF1R (unknown origin)	B	CNC(=O)c1cc(Oc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)ccn1		CHEMBL4227505	=	IC50	nM	1.0	CHEMBL1844	Homo sapiens	IC50	nM	1.0
	22889058	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	COc1cc(OCc2ccnc(NC(C)=O)c2)cc2sc(N[C@@H]3CCCC[C@H]3O)nc12		CHEMBL4754431	=	IC50	nM	4.0	CHEMBL1844	Homo sapiens	IC50	nM	4.0
	22889059	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	Nc1nccc(COc2ccc3nc(N[C@H]4CCCC[C@H]4O)sc3c2)c1Cl		CHEMBL4798876	=	IC50	nM	1.1	CHEMBL1844	Homo sapiens	IC50	nM	1.1
	22889060	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	COc1cc(OCc2ccnc(N)c2)cc2sc(N[C@@H]3CCCC[C@H]3O)nc12		CHEMBL4751359	=	IC50	nM	76.0	CHEMBL1844	Homo sapiens	IC50	nM	76.0
	22889061	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	Nc1nccc(COc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)c1Cl		CHEMBL4759047	=	IC50	nM	1.4	CHEMBL1844	Homo sapiens	IC50	nM	1.4
	22889062	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	COc1cc(OCc2ccnc(N)n2)c(Cl)c2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4779878	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
	22889063	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	Nc1nccc(COc2ccc3nc(N[C@H]4CCCC[C@@H]4O)sc3c2)c1Cl		CHEMBL4741283	=	IC50	nM	2.0	CHEMBL1844	Homo sapiens	IC50	nM	2.0
	22889064	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	COc1cc(OCc2ccnc(Nc3cnn(C)c3)n2)c(Cl)c2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4740157	=	IC50	nM	1.2	CHEMBL1844	Homo sapiens	IC50	nM	1.2
	22889065	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	COc1cc(OCc2ccnc(N)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4762843	=	IC50	nM	7.0	CHEMBL1844	Homo sapiens	IC50	nM	7.0
	22889066	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	Nc1nccc(COc2ccc3nc(NC4CCCCC4)sc3c2)c1Cl		CHEMBL4788945	=	IC50	nM	4.0	CHEMBL1844	Homo sapiens	IC50	nM	4.0
	22889067	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	COc1cc(OCc2ccnc(Nc3cccnc3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4783368	=	IC50	nM	626.0	CHEMBL1844	Homo sapiens	IC50	nM	626.0
	22889068	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	COc1cc(OCc2ccnc(N)n2)cc2sc(N[C@@H]3CCCC[C@H]3O)nc12		CHEMBL4788832	=	IC50	nM	21.0	CHEMBL1844	Homo sapiens	IC50	nM	21.0
	22889069	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	Clc1cnccc1COc1ccc2nc(NC3CCCCC3)sc2c1		CHEMBL4764974	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	nM	30.0
	22889070	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	COc1cc(OCc2ccnc(Nc3cn(C)nn3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4763289	=	IC50	nM	5.7	CHEMBL1844	Homo sapiens	IC50	nM	5.7
	22889071	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	Nc1nccc(COc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2F)c1Cl		CHEMBL4795462	=	IC50	nM	1.1	CHEMBL1844	Homo sapiens	IC50	nM	1.1
	22889072	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	Nc1cc(COc2ccc3nc(NC4CCCCC4)sc3c2)ccn1		CHEMBL4777344	=	IC50	nM	52.0	CHEMBL1844	Homo sapiens	IC50	nM	52.0
	22889073	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	COc1cc(OCc2ccnc(Nc3cnoc3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4779197	=	IC50	nM	2.6	CHEMBL1844	Homo sapiens	IC50	nM	2.6
	22889074	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	Nc1nccc(COc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2Cl)c1Cl		CHEMBL4798601	=	IC50	nM	1.2	CHEMBL1844	Homo sapiens	IC50	nM	1.2
	22889075	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	c1cc(NCc2ccc3nc(NC4CCCCC4)sc3c2)ccn1		CHEMBL4791937	=	IC50	nM	27712.0	CHEMBL1844	Homo sapiens	IC50	nM	27712.0
	22889076	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	COc1cc(OCc2ccnc(Nc3cc[nH]n3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4743008	=	IC50	nM	48.0	CHEMBL1844	Homo sapiens	IC50	nM	48.0
	22889077	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	Nc1nccc(COc2cc(F)c3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)c1Cl		CHEMBL4763875	=	IC50	nM	1.0	CHEMBL1844	Homo sapiens	IC50	nM	1.0
	22889078	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	c1cncc(NCc2ccc3nc(NC4CCCCC4)sc3c2)c1		CHEMBL4742978	=	IC50	nM	655.0	CHEMBL1844	Homo sapiens	IC50	nM	655.0
	22889079	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	COc1cc(OCc2ccnc(Nc3cn[nH]c3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4758092	=	IC50	nM	0.8	CHEMBL1844	Homo sapiens	IC50	nM	0.8
	22889080	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	Nc1nccc(COc2cc(Cl)c3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)c1Cl		CHEMBL4751287	=	IC50	nM	1.0	CHEMBL1844	Homo sapiens	IC50	nM	1.0
	22889081	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	c1cc(OCc2ccc3nc(NC4CCCCC4)sc3c2)ccn1		CHEMBL4742128	=	IC50	nM	4413.0	CHEMBL1844	Homo sapiens	IC50	nM	4413.0
	22889082	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	COc1cc(OCc2ccnc(Nc3ccn(C)n3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4787609	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	nM	9.0
	22889083	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	Nc1nccc(COc2cc(OC(F)(F)F)c3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)c1Cl		CHEMBL4798920	=	IC50	nM	17.0	CHEMBL1844	Homo sapiens	IC50	nM	17.0
	22889084	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	c1cncc(OCc2ccc3nc(NC4CCCCC4)sc3c2)c1		CHEMBL4797083	=	IC50	nM	450.0	CHEMBL1844	Homo sapiens	IC50	nM	450.0
	22889085	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	COc1cc(OCc2ccnc(Nc3cnn(C)c3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4748740	=	IC50	nM	1.7	CHEMBL1844	Homo sapiens	IC50	nM	1.7
	22889086	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	COc1cc(OCc2ccnc(N)c2Cl)cc2sc(N[C@@H]3CCCC[C@H]3O)nc12		CHEMBL4746711	=	IC50	nM	4.0	CHEMBL1844	Homo sapiens	IC50	nM	4.0
	22889087	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	c1cc(COc2ccc3nc(NC4CCCCC4)sc3c2)ccn1		CHEMBL4781950	=	IC50	nM	303.0	CHEMBL1844	Homo sapiens	IC50	nM	303.0
	22889088	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	CNC(=O)Nc1nccc(COc2cc(OC)c3nc(N[C@H]4CCCC[C@@H]4O)sc3c2)n1		CHEMBL4790139	=	IC50	nM	11.0	CHEMBL1844	Homo sapiens	IC50	nM	11.0
	22889089	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	Nc1nccc(COc2ccc3nc(N[C@@H]4CCCC[C@@H]4O)sc3c2)c1Cl		CHEMBL4756510	=	IC50	nM	2.4	CHEMBL1844	Homo sapiens	IC50	nM	2.4
	22889090	CHEMBL4728927	Inhibition of AlexaFluor-labeled tracer 236 binding to recombinant human His-tagged CSF1R (538 to 910 residues) preincubated for 20 mins followed by Eu-labeled anti-His antibody addition and measured after 90 mins by FRET based LanthaScreen assay	B	c1cncc(COc2ccc3nc(NC4CCCCC4)sc3c2)c1		CHEMBL4745859	=	IC50	nM	781.0	CHEMBL1844	Homo sapiens	IC50	nM	781.0
	22889091	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	COc1cc(OCc2ccnc(N)n2)c(Cl)c2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4779878	=	Kd	nM	2.6	CHEMBL1844	Homo sapiens	Kd	nM	2.6
	22889092	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	Nc1nccc(COc2ccc3nc(N[C@H]4CCCC[C@@H]4O)sc3c2)c1Cl		CHEMBL4741283	=	Kd	nM	1.1	CHEMBL1844	Homo sapiens	Kd	nM	1.1
	22889093	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	Nc1nccc(COc2ccc3nc(NC4CCCCC4)sc3c2)c1Cl		CHEMBL4788945	=	Kd	nM	2.5	CHEMBL1844	Homo sapiens	Kd	nM	2.5
	22889094	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	COc1cc(OCc2ccnc(N)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4762843	=	Kd	nM	4.1	CHEMBL1844	Homo sapiens	Kd	nM	4.1
Not Determined	22889095	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	Clc1cnccc1COc1ccc2nc(NC3CCCCC3)sc2c1		CHEMBL4764974		Kd			CHEMBL1844	Homo sapiens	Kd		
	22889096	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	COc1cc(OCc2ccnc(N)n2)cc2sc(N[C@@H]3CCCC[C@H]3O)nc12		CHEMBL4788832	=	Kd	nM	6.7	CHEMBL1844	Homo sapiens	Kd	nM	6.7
Not Determined	22889097	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	Nc1cc(COc2ccc3nc(NC4CCCCC4)sc3c2)ccn1		CHEMBL4777344		Kd			CHEMBL1844	Homo sapiens	Kd		
	22889098	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	Nc1nccc(COc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2F)c1Cl		CHEMBL4795462	=	Kd	nM	1.3	CHEMBL1844	Homo sapiens	Kd	nM	1.3
	22889099	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	Nc1nccc(COc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2Cl)c1Cl		CHEMBL4798601	=	Kd	nM	3.4	CHEMBL1844	Homo sapiens	Kd	nM	3.4
	22889100	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	Nc1nccc(COc2cc(F)c3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)c1Cl		CHEMBL4763875	=	Kd	nM	2.5	CHEMBL1844	Homo sapiens	Kd	nM	2.5
	22889101	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	Nc1nccc(COc2cc(Cl)c3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)c1Cl		CHEMBL4751287	=	Kd	nM	8.1	CHEMBL1844	Homo sapiens	Kd	nM	8.1
Not Determined	22889102	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	Nc1nccc(COc2cc(OC(F)(F)F)c3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)c1Cl		CHEMBL4798920		Kd			CHEMBL1844	Homo sapiens	Kd		
	22889103	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	COc1cc(OCc2ccnc(N)c2Cl)cc2sc(N[C@@H]3CCCC[C@H]3O)nc12		CHEMBL4746711	=	Kd	nM	0.6	CHEMBL1844	Homo sapiens	Kd	nM	0.6
	22889104	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	Nc1nccc(COc2ccc3nc(N[C@@H]4CCCC[C@@H]4O)sc3c2)c1Cl		CHEMBL4756510	=	Kd	nM	1.9	CHEMBL1844	Homo sapiens	Kd	nM	1.9
	22889105	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	CNC(=O)c1cc(Oc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)ccn1		CHEMBL4227505	=	Kd	nM	3.4	CHEMBL1844	Homo sapiens	Kd	nM	3.4
	22889106	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	Nc1nccc(COc2ccc3nc(N[C@H]4CCCC[C@H]4O)sc3c2)c1Cl		CHEMBL4798876	=	Kd	nM	1.2	CHEMBL1844	Homo sapiens	Kd	nM	1.2
	22889107	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	Nc1nccc(COc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)c1Cl		CHEMBL4759047	=	Kd	nM	0.6	CHEMBL1844	Homo sapiens	Kd	nM	0.6
	22889108	CHEMBL4728928	Binding affinity to human wild type CSF1R (I564 to S939 residues) expressed in bacterial expression system by kinome scan assay	B	COc1cc(OCc2ccnc(Nc3cnn(C)c3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4748740	=	Kd	nM	1.0	CHEMBL1844	Homo sapiens	Kd	nM	1.0
Not Determined	22889199	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	Nc1cc(COc2ccc3nc(NC4CCCCC4)sc3c2)ccn1		CHEMBL4777344		IC50			CHEMBL1844	Homo sapiens	IC50		
Not Determined	22889200	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	Clc1cnccc1COc1ccc2nc(NC3CCCCC3)sc2c1		CHEMBL4764974		IC50			CHEMBL1844	Homo sapiens	IC50		
Not Determined	22889201	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	Nc1nccc(COc2ccc3nc(NC4CCCCC4)sc3c2)c1Cl		CHEMBL4788945		IC50			CHEMBL1844	Homo sapiens	IC50		
Not Determined	22889202	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	Nc1nccc(COc2ccc3nc(N[C@H]4CCCC[C@@H]4O)sc3c2)c1Cl		CHEMBL4741283		IC50			CHEMBL1844	Homo sapiens	IC50		
	22889203	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	Nc1nccc(COc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)c1Cl		CHEMBL4759047	=	IC50	nM	183.0	CHEMBL1844	Homo sapiens	IC50	nM	183.0
Not Determined	22889204	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	Nc1nccc(COc2ccc3nc(N[C@H]4CCCC[C@H]4O)sc3c2)c1Cl		CHEMBL4798876		IC50			CHEMBL1844	Homo sapiens	IC50		
Not Determined	22889205	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	Nc1nccc(COc2ccc3nc(N[C@@H]4CCCC[C@@H]4O)sc3c2)c1Cl		CHEMBL4756510		IC50			CHEMBL1844	Homo sapiens	IC50		
	22889206	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	COc1cc(OCc2ccnc(N)c2Cl)cc2sc(N[C@@H]3CCCC[C@H]3O)nc12		CHEMBL4746711	=	IC50	nM	243.0	CHEMBL1844	Homo sapiens	IC50	nM	243.0
Not Determined	22889207	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	Nc1nccc(COc2cc(OC(F)(F)F)c3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)c1Cl		CHEMBL4798920		IC50			CHEMBL1844	Homo sapiens	IC50		
	22889208	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	Nc1nccc(COc2cc(Cl)c3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)c1Cl		CHEMBL4751287	=	IC50	nM	191.0	CHEMBL1844	Homo sapiens	IC50	nM	191.0
	22889209	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	Nc1nccc(COc2cc(F)c3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)c1Cl		CHEMBL4763875	=	IC50	nM	127.0	CHEMBL1844	Homo sapiens	IC50	nM	127.0
	22889210	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	Nc1nccc(COc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2Cl)c1Cl		CHEMBL4798601	=	IC50	nM	176.0	CHEMBL1844	Homo sapiens	IC50	nM	176.0
Not Determined	22889211	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	Nc1nccc(COc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2F)c1Cl		CHEMBL4795462		IC50			CHEMBL1844	Homo sapiens	IC50		
	22889212	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	COc1cc(OCc2ccnc(N)n2)cc2sc(N[C@@H]3CCCC[C@H]3O)nc12		CHEMBL4788832	=	IC50	nM	486.0	CHEMBL1844	Homo sapiens	IC50	nM	486.0
	22889213	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	COc1cc(OCc2ccnc(N)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4762843	=	IC50	nM	215.0	CHEMBL1844	Homo sapiens	IC50	nM	215.0
	22889214	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	COc1cc(OCc2ccnc(N)n2)c(Cl)c2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4779878	=	IC50	nM	63.0	CHEMBL1844	Homo sapiens	IC50	nM	63.0
	22889215	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	COc1cc(OCc2ccnc(Nc3cnn(C)c3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4748740	=	IC50	nM	17.0	CHEMBL1844	Homo sapiens	IC50	nM	17.0
	22889216	CHEMBL4728934	Inhibition of CSF1R phosphorylation in M-CSF induced human THP1 cells incubated for 30 mins by ELISA assay	B	CNC(=O)c1cc(Oc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)ccn1		CHEMBL4227505	=	IC50	nM	155.0	CHEMBL1844	Homo sapiens	IC50	nM	155.0
Active	22889498	CHEMBL4729017	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system at 1 uM by Kinomescan method	B	COc1cc(OCc2ccnc(Nc3cnn(C)c3)n2)cc2sc(N[C@H]3CCCC[C@@H]3O)nc12		CHEMBL4748740		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
	22952846	CHEMBL4766783	Inhibition of recombinant human FMS (538 to end residues) assessed as residual activity at 10 uM using KKKSPGEYVNIEFG as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	-1.0	CHEMBL1844	Homo sapiens	Activity	%	-1.0
	22953092	CHEMBL4767029	Inhibition of recombinant human FMS (538 to end residues) using KKKSPGEYVNIEFG as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	IC50	nM	9.0	CHEMBL1844	Homo sapiens	IC50	uM	0.009000000000000001
	22960874	CHEMBL4768789	Inhibition of human FMS at 100 nM in presence of ATP relative to control	B	Cl.O=C1Nc2ccc(F)cc2/C1=C1/Nc2ccccc2/C1=N\OCCN1CCNCC1		CHEMBL4791998	=	Inhibition	%	92.0	CHEMBL1844	Homo sapiens	INH	%	92.0
	22960875	CHEMBL4768790	Inhibition of human FMS in presence of ATP	B	Cl.O=C1Nc2ccc(F)cc2/C1=C1/Nc2ccccc2/C1=N\OCCN1CCNCC1		CHEMBL4791998	=	IC50	nM	4.2	CHEMBL1844	Homo sapiens	IC50	nM	4.2
	22964392	CHEMBL4769123	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system at 100 nM by Kinomescan method relative to control	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Inhibition	%	99.2	CHEMBL1844	Homo sapiens	INH	%	99.2
	22964393	CHEMBL4769123	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system at 100 nM by Kinomescan method relative to control	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CCO)cc32)c1C		CHEMBL4800500	=	Inhibition	%	24.0	CHEMBL1844	Homo sapiens	INH	%	24.0
	22964394	CHEMBL4769123	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system at 100 nM by Kinomescan method relative to control	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CCC(N)=O)cc32)c1C		CHEMBL4781578	=	Inhibition	%	18.0	CHEMBL1844	Homo sapiens	INH	%	18.0
	22964395	CHEMBL4769124	Inhibition of wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in mammalian expression system at 100 nM by Kinomescan method relative to control	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Inhibition	%	99.8	CHEMBL1844	Homo sapiens	INH	%	99.8
	22964396	CHEMBL4769124	Inhibition of wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in mammalian expression system at 100 nM by Kinomescan method relative to control	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CCO)cc32)c1C		CHEMBL4800500	=	Inhibition	%	0.0	CHEMBL1844	Homo sapiens	INH	%	0.0
	22964397	CHEMBL4769124	Inhibition of wild-type human partial length autoinhibited CSF1R (Y538 to S939 residues) expressed in mammalian expression system at 100 nM by Kinomescan method relative to control	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(CCC(N)=O)cc32)c1C		CHEMBL4781578	=	Inhibition	%	14.0	CHEMBL1844	Homo sapiens	INH	%	14.0
	22969934	CHEMBL4770451	Binding affinity to human CSF1R	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Kd	nM	0.58	CHEMBL1844	Homo sapiens	Kd	nM	0.58
	22969935	CHEMBL4770451	Binding affinity to human CSF1R	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	=	Kd	nM	28.0	CHEMBL1844	Homo sapiens	Kd	nM	28.0
	22986120	CHEMBL4774187	Inhibition of CSF1R (unknown origin)	B	CC(C)(C)c1cc(NC(=O)Cc2ccc(Nc3ncnc4[nH]c(-c5ccc(S(C)(=O)=O)cc5)cc34)cc2)no1		CHEMBL4791960	=	IC50	nM	1650.0	CHEMBL1844	Homo sapiens	IC50	uM	1.65
	22988691	CHEMBL4774720	Inhibition of wild type TEL fused CSF1R (unknown origin) transfected in mouse BAF3 cells assessed as growth inhibition after 72 hrs by CCK8 assay	B	Cc1nc(NC(=O)CN2CCN(C)CC2)sc1-c1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL4794404	=	GI50	nM	4.0	CHEMBL1844	Homo sapiens	GI50	nM	4.0
	22988716	CHEMBL4774733	Inhibition of human CSF1R assessed as remaining enzyme activity at 1 uM by Kinomescan method relative to control	B	Cc1nc(NC(=O)CN2CCN(C)CC2)sc1-c1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL4794404	=	Activity	%	0.1	CHEMBL1844	Homo sapiens	Activity	%	0.1
	22988726	CHEMBL4774743	Inhibition of human CSF1R by Z-LYTE or ADP-Glo assay	B	Cc1nc(NC(=O)CN2CCN(C)CC2)sc1-c1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL4794404	=	IC50	nM	1.2	CHEMBL1844	Homo sapiens	IC50	nM	1.2
	22989352	CHEMBL4774932	Inhibition of FMS (unknown origin) at 1 uM relative to control	B	Nc1n[nH]c2cccc(C#Cc3cccc(NC(=O)c4ccc(N5CCOCC5)c(C(F)(F)F)c4)c3)c12		CHEMBL4793906	=	Inhibition	%	87.75	CHEMBL1844	Homo sapiens	INH	%	87.75
	22989375	CHEMBL4774952	Inhibition of FMS (unknown origin) in presence of ATP	B	Nc1n[nH]c2cccc(C#Cc3cccc(NC(=O)c4ccc(N5CCOCC5)c(C(F)(F)F)c4)c3)c12		CHEMBL4793906	=	IC50	nM	16.2	CHEMBL1844	Homo sapiens	IC50	uM	0.0162
	22989376	CHEMBL4774952	Inhibition of FMS (unknown origin) in presence of ATP	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	1.24	CHEMBL1844	Homo sapiens	IC50	uM	0.00124
	22990677	CHEMBL4775119	Inhibition of human CSF1R expressed in baculovirus expression system at 1 uM relative to control	B	CC(C)n1c(=O)n(C)c2cnc3cc(F)c(-c4ccc(OCCCN5CCCCC5)nc4)cc3c21		CHEMBL4594429	>=	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	23122503	CHEMBL4804854	Inhibition of human CSF1R assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	85.0	CHEMBL1844	Homo sapiens	Activity	%	85.0
	23122504	CHEMBL4804855	Inhibition of human autoinhibited CSF1R assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	91.0	CHEMBL1844	Homo sapiens	Activity	%	91.0
	23123198	CHEMBL4805442	Inhibition of human CSF1R assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	91.0	CHEMBL1844	Homo sapiens	Activity	%	91.0
	23123199	CHEMBL4805443	Inhibition of human autoinhibited CSF1R assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	54.0	CHEMBL1844	Homo sapiens	Activity	%	54.0
	23123693	CHEMBL4805937	Inhibition of DNA-tagged human CSF1R assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	98.0	CHEMBL1844	Homo sapiens	Activity	%	98.0
	23124486	CHEMBL4806459	Inhibition of human CSF1R assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	98.0	CHEMBL1844	Homo sapiens	Activity	%	98.0
	23124487	CHEMBL4806459	Inhibition of human CSF1R assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	95.0	CHEMBL1844	Homo sapiens	Activity	%	95.0
	23124488	CHEMBL4806460	Inhibition of human autoinhibited CSF1R assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	88.0	CHEMBL1844	Homo sapiens	Activity	%	88.0
	23124489	CHEMBL4806460	Inhibition of human autoinhibited CSF1R assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	83.0	CHEMBL1844	Homo sapiens	Activity	%	83.0
	23127990	CHEMBL4807805	Inhibition of CSF1-R (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	<	Activity	%	25.0	CHEMBL1844	Homo sapiens	Activity	%	25.0
	23127991	CHEMBL4807805	Inhibition of CSF1-R (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	<	Activity	%	25.0	CHEMBL1844	Homo sapiens	Activity	%	25.0
	23127992	CHEMBL4807805	Inhibition of CSF1-R (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Activity	%	25.0	CHEMBL1844	Homo sapiens	Activity	%	25.0
	23128903	CHEMBL4808087	Inhibition of FMS (unknown origin) at 0.5 uM relative to control	B	CNC(=O)c1cc(Oc2ccc(NC(=O)c3nc(S(C)(=O)=O)sc3-c3ccc(F)cc3)cc2)ccn1		CHEMBL4850066	=	Inhibition	%	39.0	CHEMBL1844	Homo sapiens	INH	%	39.0
	23128904	CHEMBL4808087	Inhibition of FMS (unknown origin) at 0.5 uM relative to control	B	CNC(=O)c1cc(Oc2ccc(NC(=O)c3n[nH]nc3-c3ccc(F)cc3)cc2)ccn1		CHEMBL4853006	=	Inhibition	%	47.0	CHEMBL1844	Homo sapiens	INH	%	47.0
	23128905	CHEMBL4808087	Inhibition of FMS (unknown origin) at 0.5 uM relative to control	B	CNC(=O)c1cc(Oc2ccc(NC(=O)c3nc(C(F)(F)F)sc3-c3ccc(F)cc3)cc2)ccn1		CHEMBL4870763	=	Inhibition	%	43.0	CHEMBL1844	Homo sapiens	INH	%	43.0
	23128906	CHEMBL4808087	Inhibition of FMS (unknown origin) at 0.5 uM relative to control	B	CNC(=O)c1cc(Oc2ccc(NC(=O)c3nc(SC)n(CCN(C)C)c3-c3ccc(F)cc3)cc2)ccn1		CHEMBL4847460	=	Inhibition	%	65.0	CHEMBL1844	Homo sapiens	INH	%	65.0
	23161152	CHEMBL4812446	Inhibition of human CSF1R at 1 uM using KKKSPGEYVNIEFG as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	Nc1ncc(-c2cc3ccccc3o2)c(N2CCC3(CCNC3=O)CC2)c1Cl		CHEMBL4878007	>	Inhibition	%	50.0	CHEMBL1844	Homo sapiens	INH	%	50.0
	23161155	CHEMBL4812449	Inhibition of human FMS using KKKSPGEYVNIEFG as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay	B	Nc1ncc(-c2cc3ccccc3o2)c(N2CCC3(CCNC3=O)CC2)c1Cl		CHEMBL4878007	=	Ki	nM	166.0	CHEMBL1844	Homo sapiens	Ki	uM	0.166
	23178057	CHEMBL4815839	Inhibition of CSF1R (unknown origin)	B	Cn1cc(-c2cc3ncnc(Nc4ccc(CC(=O)Nc5cc(C(C)(C)C)nn5C)cc4)c3s2)cn1		CHEMBL4868797	=	IC50	nM	13600.0	CHEMBL1844	Homo sapiens	IC50	uM	13.6
	23180178	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NCc4cnc5cccnn45)c3)cc2C(F)(F)F)CC1		CHEMBL4855169	=	Inhibition	%	32.0	CHEMBL1844	Homo sapiens	INH	%	32.0
	23180179	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NCc4cnc5ccc(OC)nn45)c3)cc2C(F)(F)F)CC1		CHEMBL4876020	=	Inhibition	%	49.0	CHEMBL1844	Homo sapiens	INH	%	49.0
	23180180	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(NC(=O)c4cnc5cccnn45)c3)cc2C(F)(F)F)CC1		CHEMBL4864961	=	Inhibition	%	94.0	CHEMBL1844	Homo sapiens	INH	%	94.0
	23180181	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4cnc5cccnn45)c3)cc2C(F)(F)F)CC1		CHEMBL4865467	=	Inhibition	%	81.0	CHEMBL1844	Homo sapiens	INH	%	81.0
	23180182	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4cnnc5ccccc45)c3)cc2C(F)(F)F)CC1		CHEMBL4857997	=	Inhibition	%	30.0	CHEMBL1844	Homo sapiens	INH	%	30.0
	23180183	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4cnc5ccccn45)c3)cc2C(F)(F)F)CC1		CHEMBL4851173	=	Inhibition	%	54.0	CHEMBL1844	Homo sapiens	INH	%	54.0
	23180184	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4cnn5ccccc45)c3)cc2C(F)(F)F)CC1		CHEMBL4861416	=	Inhibition	%	62.0	CHEMBL1844	Homo sapiens	INH	%	62.0
	23180185	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4cnc5ncccn45)c3)cc2C(F)(F)F)CC1		CHEMBL4852093	=	Inhibition	%	32.0	CHEMBL1844	Homo sapiens	INH	%	32.0
	23180186	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4n[nH]c5ccccc45)c3)cc2C(F)(F)F)CC1		CHEMBL4871582	=	Inhibition	%	23.0	CHEMBL1844	Homo sapiens	INH	%	23.0
	23180187	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4n[nH]c5ncccc45)c3)cc2C(F)(F)F)CC1		CHEMBL4859074	=	Inhibition	%	93.0	CHEMBL1844	Homo sapiens	INH	%	93.0
	23180188	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4cc[nH]n4)c3)cc2C(F)(F)F)CC1		CHEMBL4849874	=	Inhibition	%	18.0	CHEMBL1844	Homo sapiens	INH	%	18.0
	23180189	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4ccn(C)n4)c3)cc2C(F)(F)F)CC1		CHEMBL4857910	=	Inhibition	%	15.0	CHEMBL1844	Homo sapiens	INH	%	15.0
	23180190	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4c[nH]cn4)c3)cc2C(F)(F)F)CC1		CHEMBL4859467	=	Inhibition	%	31.0	CHEMBL1844	Homo sapiens	INH	%	31.0
	23180191	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4ncc[nH]4)c3)cc2C(F)(F)F)CC1		CHEMBL4868017	=	Inhibition	%	26.0	CHEMBL1844	Homo sapiens	INH	%	26.0
	23180192	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1ccc(NC(=O)c2ccc(C(F)(F)F)nc2)cc1NC(=O)c1cnc2cccnn12		CHEMBL4849641	=	Inhibition	%	5.0	CHEMBL1844	Homo sapiens	INH	%	5.0
	23180193	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1ccc(NC(=O)c2ccc(C(F)(F)F)nc2)cc1NC(=O)c1cnc2ccccn12		CHEMBL4846916	=	Inhibition	%	87.0	CHEMBL1844	Homo sapiens	INH	%	87.0
	23180194	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1ccc(NC(=O)c2ccc(C(F)(F)F)nc2)cc1NC(=O)c1cnn2ccccc12		CHEMBL4874374	=	Inhibition	%	82.0	CHEMBL1844	Homo sapiens	INH	%	82.0
	23180195	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1ccc(NCc2ccc(C(F)(F)F)nc2)cc1NC(=O)c1cnc2cccnn12		CHEMBL4862769	=	Inhibition	%	0.0	CHEMBL1844	Homo sapiens	INH	%	0.0
	23180196	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1ccc(NCc2ccc(C(F)(F)F)nc2)cc1NC(=O)c1cnc2ccccn12		CHEMBL4867269	=	Inhibition	%	14.0	CHEMBL1844	Homo sapiens	INH	%	14.0
	23180197	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1ccc(NCc2ccc(C(F)(F)F)nc2)cc1NC(=O)c1cnn2ccccc12		CHEMBL4879275	=	Inhibition	%	10.0	CHEMBL1844	Homo sapiens	INH	%	10.0
	23180198	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(NC(=O)c4cnc5cccnn45)c3)cc(C(F)(F)F)c2)cn1		CHEMBL4864873	=	Inhibition	%	32.0	CHEMBL1844	Homo sapiens	INH	%	32.0
	23180199	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(NC(=O)c4cnc5ccccn45)c3)cc(C(F)(F)F)c2)cn1		CHEMBL4853664	=	Inhibition	%	20.0	CHEMBL1844	Homo sapiens	INH	%	20.0
	23180200	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	46.0	CHEMBL1844	Homo sapiens	INH	%	46.0
	23180201	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CNC(=O)c1cc(Oc2ccc3nc(N[C@H]4CCCC[C@H]4O)sc3c2)ccn1		CHEMBL4868857	=	Inhibition	%	76.0	CHEMBL1844	Homo sapiens	INH	%	76.0
	23180202	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	=	Inhibition	%	67.0	CHEMBL1844	Homo sapiens	INH	%	67.0
	23180203	CHEMBL4816256	Inhibition of human CSF1R at 10 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	=	Inhibition	%	14.0	CHEMBL1844	Homo sapiens	INH	%	14.0
	23180204	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NCc4cnc5cccnn45)c3)cc2C(F)(F)F)CC1		CHEMBL4855169	=	Inhibition	%	94.0	CHEMBL1844	Homo sapiens	INH	%	94.0
	23180205	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NCc4cnc5ccc(OC)nn45)c3)cc2C(F)(F)F)CC1		CHEMBL4876020	=	Inhibition	%	98.0	CHEMBL1844	Homo sapiens	INH	%	98.0
	23180206	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(NC(=O)c4cnc5cccnn45)c3)cc2C(F)(F)F)CC1		CHEMBL4864961	=	Inhibition	%	98.0	CHEMBL1844	Homo sapiens	INH	%	98.0
	23180207	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4cnc5cccnn45)c3)cc2C(F)(F)F)CC1		CHEMBL4865467	=	Inhibition	%	99.0	CHEMBL1844	Homo sapiens	INH	%	99.0
	23180208	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4cnnc5ccccc45)c3)cc2C(F)(F)F)CC1		CHEMBL4857997	=	Inhibition	%	89.0	CHEMBL1844	Homo sapiens	INH	%	89.0
	23180209	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4cnc5ccccn45)c3)cc2C(F)(F)F)CC1		CHEMBL4851173	=	Inhibition	%	98.0	CHEMBL1844	Homo sapiens	INH	%	98.0
	23180210	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4cnn5ccccc45)c3)cc2C(F)(F)F)CC1		CHEMBL4861416	=	Inhibition	%	100.0	CHEMBL1844	Homo sapiens	INH	%	100.0
	23180211	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4cnc5ncccn45)c3)cc2C(F)(F)F)CC1		CHEMBL4852093	=	Inhibition	%	89.0	CHEMBL1844	Homo sapiens	INH	%	89.0
	23180212	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4n[nH]c5ccccc45)c3)cc2C(F)(F)F)CC1		CHEMBL4871582	=	Inhibition	%	83.0	CHEMBL1844	Homo sapiens	INH	%	83.0
	23180213	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4n[nH]c5ncccc45)c3)cc2C(F)(F)F)CC1		CHEMBL4859074	=	Inhibition	%	97.0	CHEMBL1844	Homo sapiens	INH	%	97.0
	23180214	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4cc[nH]n4)c3)cc2C(F)(F)F)CC1		CHEMBL4849874	=	Inhibition	%	59.0	CHEMBL1844	Homo sapiens	INH	%	59.0
	23180215	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4ccn(C)n4)c3)cc2C(F)(F)F)CC1		CHEMBL4857910	=	Inhibition	%	56.0	CHEMBL1844	Homo sapiens	INH	%	56.0
	23180216	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4c[nH]cn4)c3)cc2C(F)(F)F)CC1		CHEMBL4859467	=	Inhibition	%	87.0	CHEMBL1844	Homo sapiens	INH	%	87.0
	23180217	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CCN1CCN(Cc2ccc(C(=O)Nc3ccc(C)c(NC(=O)c4ncc[nH]4)c3)cc2C(F)(F)F)CC1		CHEMBL4868017	=	Inhibition	%	80.0	CHEMBL1844	Homo sapiens	INH	%	80.0
	23180218	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1ccc(NC(=O)c2ccc(C(F)(F)F)nc2)cc1NC(=O)c1cnc2cccnn12		CHEMBL4849641	=	Inhibition	%	29.0	CHEMBL1844	Homo sapiens	INH	%	29.0
	23180219	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1ccc(NC(=O)c2ccc(C(F)(F)F)nc2)cc1NC(=O)c1cnc2ccccn12		CHEMBL4846916	=	Inhibition	%	97.0	CHEMBL1844	Homo sapiens	INH	%	97.0
	23180220	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1ccc(NC(=O)c2ccc(C(F)(F)F)nc2)cc1NC(=O)c1cnn2ccccc12		CHEMBL4874374	=	Inhibition	%	95.0	CHEMBL1844	Homo sapiens	INH	%	95.0
	23180221	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1ccc(NCc2ccc(C(F)(F)F)nc2)cc1NC(=O)c1cnc2cccnn12		CHEMBL4862769	=	Inhibition	%	4.0	CHEMBL1844	Homo sapiens	INH	%	4.0
	23180222	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1ccc(NCc2ccc(C(F)(F)F)nc2)cc1NC(=O)c1cnc2ccccn12		CHEMBL4867269	=	Inhibition	%	47.0	CHEMBL1844	Homo sapiens	INH	%	47.0
	23180223	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1ccc(NCc2ccc(C(F)(F)F)nc2)cc1NC(=O)c1cnn2ccccc12		CHEMBL4879275	=	Inhibition	%	37.0	CHEMBL1844	Homo sapiens	INH	%	37.0
	23180224	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(NC(=O)c4cnc5cccnn45)c3)cc(C(F)(F)F)c2)cn1		CHEMBL4864873	=	Inhibition	%	74.0	CHEMBL1844	Homo sapiens	INH	%	74.0
	23180225	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(NC(=O)c4cnc5ccccn45)c3)cc(C(F)(F)F)c2)cn1		CHEMBL4853664	=	Inhibition	%	65.0	CHEMBL1844	Homo sapiens	INH	%	65.0
	23180226	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	85.0	CHEMBL1844	Homo sapiens	INH	%	85.0
	23180227	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	CNC(=O)c1cc(Oc2ccc3nc(N[C@H]4CCCC[C@H]4O)sc3c2)ccn1		CHEMBL4868857	=	Inhibition	%	94.0	CHEMBL1844	Homo sapiens	INH	%	94.0
	23180228	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	=	Inhibition	%	97.0	CHEMBL1844	Homo sapiens	INH	%	97.0
	23180229	CHEMBL4816257	Inhibition of human CSF1R at 100 nM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by radiometric assay relative to control	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	=	Inhibition	%	47.0	CHEMBL1844	Homo sapiens	INH	%	47.0
	23180270	CHEMBL4816272	Inhibition of CSF1R (unknown origin)	B	CNC(=O)c1cc(Oc2ccc3nc(N[C@H]4CCCC[C@H]4O)sc3c2)ccn1		CHEMBL4868857	=	IC50	nM	1.2	CHEMBL1844	Homo sapiens	IC50	nM	1.2
	23180271	CHEMBL4816273	Inhibition of CSF1R (unknown origin) (538 to 972 residues) expressed in baculovirus expression system using SYEGNSYTFIDPTQ as substrate incubated for 80 mins in presence of ATP by fluorescence polarization assay	B	CC1(C)CC=C(c2nc(C3CC(C)(C)OC(C)(C)C3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1		CHEMBL3674570	=	IC50	nM	3.2	CHEMBL1844	Homo sapiens	IC50	nM	3.2
	23180272	CHEMBL4816274	Inhibition of CSF1R (unknown origin) expressed in baculovirus infected Sf9 cells using biotinylated peptide substrate incubated for 30 mins in presence of ATP by Alphascreen assay	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	nM	13.0
	23180273	CHEMBL4816275	Inhibition of human CSF1R using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1		CHEMBL2035185	=	IC50	nM	69.0	CHEMBL1844	Homo sapiens	IC50	nM	69.0
	23180274	CHEMBL4816276	Inhibition of N-terminal GST-tagged CSF1R (unknown origin) (547 to 980 residues) expressed in baculovirus infected Sf9 cells using biotin-EAIYAPFAKKK-NH2 as substrate incubated for 40 mins in presence of ATP by scintillation counting method	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	nM	30.0
	23208879	CHEMBL4822241	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	CCc1cc(NC(=O)[C@H](O)c2cc(F)cc(F)c2)ccc1-c1cnc(N)c(C(=O)NC(C)C)c1		CHEMBL4857782	=	Activity	%	74.0	CHEMBL1844	Homo sapiens	Activity	%	74.0
	23208880	CHEMBL4822241	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1		CHEMBL2441340	=	Activity	%	1.8	CHEMBL1844	Homo sapiens	Activity	%	1.8
	23212967	CHEMBL4822887	Inhibition of CSF1R (unknown origin) at 500 nM	B	N[C@H]1CCCN(C(=O)c2ccc(-c3ccc4ncc(-c5ccc6cnccc6c5)n4n3)cc2)C1		CHEMBL4878199	=	Inhibition	%	11.64	CHEMBL1844	Homo sapiens	INH	%	11.64
	23216535	CHEMBL4823737	Inhibition of CSF1R (unknown origin) incubated for 30 mins in presence of ATP by mobility shift assay	B	Cc1c(NC(=O)CCN2CCCC2)c[nH]c1/C=C1\C(=O)Nc2ccc(F)cc21		CHEMBL4869059	=	IC50	nM	715.6	CHEMBL1844	Homo sapiens	IC50	nM	715.6
	23216536	CHEMBL4823737	Inhibition of CSF1R (unknown origin) incubated for 30 mins in presence of ATP by mobility shift assay	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	IC50	nM	82.5	CHEMBL1844	Homo sapiens	IC50	nM	82.5
	23250204	CHEMBL4831025	Inhibition of CSF-1R (unknown origin) using 5' FAM-KKKKEEIYFFF-CONH2 peptide as a substrate in the presence of ATP incubated for 60 mins by microfluidics assay	B	Cn1cc(-c2ccn3c(-c4ccc(-c5cccc(Cl)c5)s4)cnc3c2)cn1		CHEMBL4847680	=	IC50	nM	8560.0	CHEMBL1844	Homo sapiens	IC50	uM	8.56
	23250205	CHEMBL4831025	Inhibition of CSF-1R (unknown origin) using 5' FAM-KKKKEEIYFFF-CONH2 peptide as a substrate in the presence of ATP incubated for 60 mins by microfluidics assay	B	COc1cccc(OC)c1-c1ccc(-c2cnc3cc(-c4cnn(C)c4)ccn23)s1		CHEMBL4852822	=	IC50	nM	2840.0	CHEMBL1844	Homo sapiens	IC50	uM	2.84
Not Active	23257270	CHEMBL4832367	Inhibition of CSF1R (unknown origin)	A	FC(F)(F)c1cccc(CN2CCN(c3nnc(Nc4ccc(N5CCOCC5)cc4)c4ccccc34)CC2)c1		CHEMBL4873715		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
Not Active	23257271	CHEMBL4832367	Inhibition of CSF1R (unknown origin)	A	CN1CCN(c2ccc(Nc3nnc(N4CCN(Cc5cccc(C(F)(F)F)c5)CC4)c4ccccc34)cc2)CC1		CHEMBL4860840		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
Not Active	23257272	CHEMBL4832367	Inhibition of CSF1R (unknown origin)	A	CC1COCCN1c1ccc(Nc2nnc(N3CCN(Cc4cccc(C(F)(F)F)c4)CC3)c3ccccc23)cc1		CHEMBL4874645		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
	23265623	CHEMBL4834272	Inhibition of FMS (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2[C@H]1C[C@@H](CO)C1		CHEMBL4858720	=	IC50	nM	960.0	CHEMBL1844	Homo sapiens	IC50	uM	0.96
	23265624	CHEMBL4834272	Inhibition of FMS (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCCC1		CHEMBL169390	=	IC50	nM	480.0	CHEMBL1844	Homo sapiens	IC50	uM	0.48
	23265625	CHEMBL4834272	Inhibition of FMS (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay	B	CC(=O)N1CCN([C@H]2C[C@@H](n3cc(-c4cc(O)ccc4F)c4c(N)ncnc43)C2)CC1		CHEMBL4854822	>	IC50	nM	11000.0	CHEMBL1844	Homo sapiens	IC50	uM	11.0
	23284728	CHEMBL4838038	Inhibition of recombinant human FMS (538 to end residues) at 10 uM using KKKSPGEYVNIEF as substrate at 40 mins in presence of [gamma33P]ATP by radiometric scintillation counting analysis relative to control	B	COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)c(=O)n3c2)c1		CHEMBL4862576	>	Inhibition	%	90.0	CHEMBL1844	Homo sapiens	INH	%	90.0
	23291080	CHEMBL4839494	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide incubated for 15 mins	B	COc1cc(NC(=O)c2ccc(C)c(C#Cc3cc(-c4cnn(C)c4)cnc3N)c2)cc(OC)c1		CHEMBL4553298	=	IC50	nM	2.6	CHEMBL1844	Homo sapiens	IC50	nM	2.6
	23291081	CHEMBL4839494	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide incubated for 15 mins	B	Cc1ccc(C(=O)Nc2cccc(Cl)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4438121	=	IC50	nM	1.3	CHEMBL1844	Homo sapiens	IC50	nM	1.3
	23291082	CHEMBL4839494	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide incubated for 15 mins	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4576115	=	IC50	nM	0.7	CHEMBL1844	Homo sapiens	IC50	nM	0.7
	23291083	CHEMBL4839494	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide incubated for 15 mins	B	Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4517659	=	IC50	nM	2.4	CHEMBL1844	Homo sapiens	IC50	nM	2.4
	23291084	CHEMBL4839494	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide incubated for 15 mins	B	Cc1ccc(C(=O)Nc2ccc(C(F)(F)F)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4589346	=	IC50	nM	3.0	CHEMBL1844	Homo sapiens	IC50	nM	3.0
	23291085	CHEMBL4839494	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide incubated for 15 mins	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2Cl)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4467948	=	IC50	nM	5.9	CHEMBL1844	Homo sapiens	IC50	nM	5.9
	23291086	CHEMBL4839494	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide incubated for 15 mins	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	=	IC50	nM	13.0	CHEMBL1844	Homo sapiens	IC50	nM	13.0
	23291087	CHEMBL4839494	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide incubated for 15 mins	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	=	IC50	nM	8.6	CHEMBL1844	Homo sapiens	IC50	nM	8.6
	23291088	CHEMBL4839494	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide incubated for 15 mins	B	Cc1ccc(C(=O)Nc2cccc(OC(F)(F)F)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4854116	=	IC50	nM	24.0	CHEMBL1844	Homo sapiens	IC50	nM	24.0
	23291089	CHEMBL4839494	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide incubated for 15 mins	B	Cc1ccc(C(=O)Nc2ccc(OC(F)(F)F)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4850154	=	IC50	nM	22.0	CHEMBL1844	Homo sapiens	IC50	nM	22.0
	23291090	CHEMBL4839494	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide incubated for 15 mins	B	COc1cc(NC(=O)c2ccc(C)c(C#Cc3cc(-c4cnn(C)c4)cnc3N)c2)cc(OC)c1OC		CHEMBL4854948	=	IC50	nM	8.0	CHEMBL1844	Homo sapiens	IC50	nM	8.0
	23291091	CHEMBL4839494	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide incubated for 15 mins	B	Cc1ccc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4862806	=	IC50	nM	48.0	CHEMBL1844	Homo sapiens	IC50	nM	48.0
	23291092	CHEMBL4839494	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide incubated for 15 mins	B	Cc1ccc(C(=O)Nc2ccc(Cl)c(C(F)(F)F)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4869362	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	nM	30.0
	23291252	CHEMBL4839533	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide at 5 nM incubated for 15 mins relative to control	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2Cl)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4467948	=	Inhibition	%	34.0	CHEMBL1844	Homo sapiens	INH	%	34.0
	23291253	CHEMBL4839533	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide at 5 nM incubated for 15 mins relative to control	B	Cc1ccc(C(=O)Nc2ccc(OC(F)(F)F)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4850154	=	Inhibition	%	39.0	CHEMBL1844	Homo sapiens	INH	%	39.0
	23291254	CHEMBL4839533	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide at 5 nM incubated for 15 mins relative to control	B	Cc1ccc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4862806	=	Inhibition	%	25.0	CHEMBL1844	Homo sapiens	INH	%	25.0
	23291324	CHEMBL4839557	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide at 50 nM incubated for 15 mins relative to control	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2Cl)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4467948	=	Inhibition	%	94.0	CHEMBL1844	Homo sapiens	INH	%	94.0
	23291325	CHEMBL4839557	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide at 50 nM incubated for 15 mins relative to control	B	Cc1ccc(C(=O)Nc2ccc(OC(F)(F)F)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4850154	=	Inhibition	%	69.0	CHEMBL1844	Homo sapiens	INH	%	69.0
	23291326	CHEMBL4839557	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide at 50 nM incubated for 15 mins relative to control	B	Cc1ccc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4862806	=	Inhibition	%	83.0	CHEMBL1844	Homo sapiens	INH	%	83.0
	23291396	CHEMBL4839581	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide at 500 nM incubated for 15 mins relative to control	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2Cl)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4467948	=	Inhibition	%	98.0	CHEMBL1844	Homo sapiens	INH	%	98.0
	23291397	CHEMBL4839581	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide at 500 nM incubated for 15 mins relative to control	B	Cc1ccc(C(=O)Nc2ccc(OC(F)(F)F)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4850154	=	Inhibition	%	90.0	CHEMBL1844	Homo sapiens	INH	%	90.0
	23291398	CHEMBL4839581	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide at 500 nM incubated for 15 mins relative to control	B	Cc1ccc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4862806	=	Inhibition	%	96.0	CHEMBL1844	Homo sapiens	INH	%	96.0
	23291462	CHEMBL4839606	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide at 50 nM incubated for 15 mins	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2Cl)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4467948	=	IC50	nM	11.0	CHEMBL1844	Homo sapiens	IC50	nM	11.0
	23291463	CHEMBL4839606	Inhibition of human recombinant CSF1R using ATP/Ulight-TK peptide at 50 nM incubated for 15 mins	B	Cc1ccc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4862806	=	IC50	nM	48.0	CHEMBL1844	Homo sapiens	IC50	nM	48.0
	23314851	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ncnc2c1		CHEMBL4877247	=	IC50	nM	21.0	CHEMBL1844	Homo sapiens	IC50	nM	21.0
	23314852	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)NCc4ccc(F)cc4)cc3)ncnc2c1		CHEMBL4851635	=	IC50	nM	8.3	CHEMBL1844	Homo sapiens	IC50	nM	8.3
	23314853	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCNc2ncnc3cc(F)ccc23)s1		CHEMBL4867079	>	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	23314854	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	COc1ccc2c(NCCc3cnc(NC(=O)Nc4cccc(Cl)c4)s3)ncnc2c1		CHEMBL4861838	=	IC50	nM	112.0	CHEMBL1844	Homo sapiens	IC50	nM	112.0
	23314855	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	COc1ccc2c(Nc3ccc(NC(=O)Nc4ccccc4)cc3)ncnc2c1		CHEMBL4877038	=	IC50	nM	124.0	CHEMBL1844	Homo sapiens	IC50	nM	124.0
	23314856	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	COc1ccc2c(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ncnc2c1		CHEMBL4872597	=	IC50	nM	76.0	CHEMBL1844	Homo sapiens	IC50	nM	76.0
	23314857	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	O=C(Nc1ccccc1)Nc1ccc(Oc2ncnc3cc(F)ccc23)cc1		CHEMBL4871510	=	IC50	nM	753.0	CHEMBL1844	Homo sapiens	IC50	nM	753.0
	23314858	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	Nc1ccc2c(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ncnc2c1		CHEMBL4851294	=	IC50	nM	58.0	CHEMBL1844	Homo sapiens	IC50	nM	58.0
	23314859	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CNc1ccc2c(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ncnc2c1		CHEMBL4877828	=	IC50	nM	44.0	CHEMBL1844	Homo sapiens	IC50	nM	44.0
	23314860	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Nc3ccc(NC(=O)Nc4ccccc4)cc3)ncnc2c1		CHEMBL4871756	=	IC50	nM	243.0	CHEMBL1844	Homo sapiens	IC50	nM	243.0
	23314861	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	O=C(Nc1ccccc1)Nc1ccc(Oc2ncnc3cc(N4CCCC4)ccc23)cc1		CHEMBL4871989	=	IC50	nM	63.0	CHEMBL1844	Homo sapiens	IC50	nM	63.0
	23314862	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	COc1cc2ncnc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)c2cc1OC		CHEMBL1277162	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	nM	30.0
	23314863	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2ncnc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)c2c1		CHEMBL4876562	=	IC50	nM	41.0	CHEMBL1844	Homo sapiens	IC50	nM	41.0
	23314864	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	O=C(Nc1ccccc1)Nc1ccc(Oc2ncnc3ccc(N4CCCC4)cc23)cc1		CHEMBL4850463	>	IC50	nM	10.0	CHEMBL1844	Homo sapiens	IC50	nM	10.0
	23314865	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)Nc4ccccc4Cl)cc3)ncnc2c1		CHEMBL4864248	=	IC50	nM	15.4	CHEMBL1844	Homo sapiens	IC50	nM	15.4
	23314866	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)ncnc2c1		CHEMBL4860468	=	IC50	nM	10.5	CHEMBL1844	Homo sapiens	IC50	nM	10.5
	23314867	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)Nc4ccc(Cl)cc4)cc3)ncnc2c1		CHEMBL4846414	=	IC50	nM	164.0	CHEMBL1844	Homo sapiens	IC50	nM	164.0
	23314868	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	COc1ccccc1NC(=O)Nc1ccc(Oc2ncnc3cc(N(C)C)ccc23)cc1		CHEMBL4857617	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	nM	30.0
	23314869	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	COc1cccc(NC(=O)Nc2ccc(Oc3ncnc4cc(N(C)C)ccc34)cc2)c1		CHEMBL4857271	=	IC50	nM	11.6	CHEMBL1844	Homo sapiens	IC50	nM	11.6
	23314870	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	COc1ccc(NC(=O)Nc2ccc(Oc3ncnc4cc(N(C)C)ccc34)cc2)cc1		CHEMBL4877440	=	IC50	nM	14.1	CHEMBL1844	Homo sapiens	IC50	nM	14.1
	23314871	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)ncnc2c1		CHEMBL4878431	=	IC50	nM	64.0	CHEMBL1844	Homo sapiens	IC50	nM	64.0
	23314872	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)Nc4ccc(C(F)(F)F)cc4)cc3)ncnc2c1		CHEMBL4874053	=	IC50	nM	64.0	CHEMBL1844	Homo sapiens	IC50	nM	64.0
	23314873	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	COc1ccc(NC(=O)Nc2ccc(Oc3ncnc4cc(N(C)C)ccc34)cc2)cc1Cl		CHEMBL4877148	=	IC50	nM	11.1	CHEMBL1844	Homo sapiens	IC50	nM	11.1
	23314874	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	COc1ccc(Cl)cc1NC(=O)Nc1ccc(Oc2ncnc3cc(N(C)C)ccc23)cc1		CHEMBL4859405	=	IC50	nM	36.0	CHEMBL1844	Homo sapiens	IC50	nM	36.0
	23314875	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)NCc4ccccc4)cc3)ncnc2c1		CHEMBL4873828	=	IC50	nM	16.3	CHEMBL1844	Homo sapiens	IC50	nM	16.3
	23314876	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)NCCc4ccccc4)cc3)ncnc2c1		CHEMBL4849425	=	IC50	nM	15.4	CHEMBL1844	Homo sapiens	IC50	nM	15.4
	23314877	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)NCc4ccc(S(N)(=O)=O)cc4)cc3)ncnc2c1		CHEMBL4857690	=	IC50	nM	16.3	CHEMBL1844	Homo sapiens	IC50	nM	16.3
	23314878	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)NCc4ccc(C#N)cc4)cc3)ncnc2c1		CHEMBL4846051	=	IC50	nM	50.0	CHEMBL1844	Homo sapiens	IC50	nM	50.0
	23314879	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)NCc4ccc(C(F)(F)F)cc4)cc3)ncnc2c1		CHEMBL4854210	=	IC50	nM	91.0	CHEMBL1844	Homo sapiens	IC50	nM	91.0
	23314880	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	COc1ccc(CNC(=O)Nc2ccc(Oc3ncnc4cc(N(C)C)ccc34)cc2)cc1		CHEMBL4870448	=	IC50	nM	12.9	CHEMBL1844	Homo sapiens	IC50	nM	12.9
	23314881	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	COc1ccc(CNC(=O)Nc2ccc(Oc3ncnc4cc(N(C)C)ccc34)cc2)cc1OC		CHEMBL4876396	=	IC50	nM	83.0	CHEMBL1844	Homo sapiens	IC50	nM	83.0
	23314882	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)NCc4c(F)c(F)c(F)c(F)c4F)cc3)ncnc2c1		CHEMBL4866196	=	IC50	nM	18.6	CHEMBL1844	Homo sapiens	IC50	nM	18.6
	23314883	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)NCc4cccnc4)cc3)ncnc2c1		CHEMBL4878471	=	IC50	nM	79.0	CHEMBL1844	Homo sapiens	IC50	nM	79.0
	23314884	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	Cc1ccc(CNC(=O)Nc2ccc(Oc3ncnc4cc(N(C)C)ccc34)cc2)cn1		CHEMBL4846384	=	IC50	nM	11.0	CHEMBL1844	Homo sapiens	IC50	nM	11.0
	23314885	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	COc1ccc(CNC(=O)Nc2ccc(Oc3ncnc4cc(N(C)C)ccc34)cc2)cn1		CHEMBL4870360	=	IC50	nM	12.7	CHEMBL1844	Homo sapiens	IC50	nM	12.7
	23314886	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CC(NC(=O)Nc1ccc(Oc2ncnc3cc(N(C)C)ccc23)cc1)c1nccs1		CHEMBL4851545	=	IC50	nM	1.41	CHEMBL1844	Homo sapiens	IC50	nM	1.41
	23314887	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)NCc4nccs4)cc3)ncnc2c1		CHEMBL4863584	=	IC50	nM	24.0	CHEMBL1844	Homo sapiens	IC50	nM	24.0
	23314888	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)NCc4ccn(C)n4)cc3)ncnc2c1		CHEMBL4878293	=	IC50	nM	204.0	CHEMBL1844	Homo sapiens	IC50	nM	204.0
	23314889	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)NCc4ccc(C(F)(F)F)nc4)cc3)ncnc2c1		CHEMBL4847875	=	IC50	nM	14.4	CHEMBL1844	Homo sapiens	IC50	nM	14.4
	23314890	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	=	IC50	nM	30.0	CHEMBL1844	Homo sapiens	IC50	nM	30.0
	23314891	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	CN(C)CCCOc1ccc2c(NCCc3cnc(NC(=O)Nc4cccc(Cl)c4)s3)ncnc2c1		CHEMBL4864729	=	IC50	nM	19.0	CHEMBL1844	Homo sapiens	IC50	nM	19.0
	23314892	CHEMBL4845008	Inhibition of human recombinant GST-CSF1R (residues L534 to C972) expressed in Sf9 insect cells using poly(Glu,Tyr) as substrate incubated for 20 mins by ATP Kinase Glo assay	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	=	IC50	nM	35.0	CHEMBL1844	Homo sapiens	IC50	nM	35.0
	23315111	CHEMBL4845024	Inhibition of wild-type human partial length CSF1R (I564 to S939 residues) expressed in bacterial expression system by Kinomescan method	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)NCc4ccc(C(F)(F)F)nc4)cc3)ncnc2c1		CHEMBL4847875	=	IC50	nM	0.53	CHEMBL1844	Homo sapiens	IC50	nM	0.53
Dose-Dependent Effect	23315129	CHEMBL4845042	Inhibition of CSF1R phosphorylation in human THP-1 cells by Western blotting analysis	B	CN(C)c1ccc2c(Oc3ccc(NC(=O)NCc4ccc(C(F)(F)F)nc4)cc3)ncnc2c1		CHEMBL4847875		Inhibition	%		CHEMBL1844	Homo sapiens	INH		
Not Active	23317338	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	91.0	CHEMBL1844	Homo sapiens	% Control	%	91.0
Not Active	23317339	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23317806	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	90.0	CHEMBL1844	Homo sapiens	% Control	%	90.0
Not Active	23317807	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	98.0	CHEMBL1844	Homo sapiens	% Control	%	98.0
Not Active	23318476	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	94.0	CHEMBL1844	Homo sapiens	% Control	%	94.0
Not Active	23318477	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	93.0	CHEMBL1844	Homo sapiens	% Control	%	93.0
Not Active	23318956	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	85.0	CHEMBL1844	Homo sapiens	% Control	%	85.0
Not Active	23318957	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23319595	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Slightly Active	23319596	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	43.0	CHEMBL1844	Homo sapiens	% Control	%	43.0
Not Active	23320068	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	86.7	CHEMBL1844	Homo sapiens	% Control	%	86.7
Not Active	23320069	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23320746	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	98.0	CHEMBL1844	Homo sapiens	% Control	%	98.0
Not Active	23320747	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23321214	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23321215	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	73.0	CHEMBL1844	Homo sapiens	% Control	%	73.0
Not Active	23321844	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	90.0	CHEMBL1844	Homo sapiens	% Control	%	90.0
Not Active	23321845	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	61.0	CHEMBL1844	Homo sapiens	% Control	%	61.0
Not Active	23322312	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23322313	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	90.0	CHEMBL1844	Homo sapiens	% Control	%	90.0
Not Active	23323001	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23323002	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	82.0	CHEMBL1844	Homo sapiens	% Control	%	82.0
Not Active	23323469	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23323470	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23324017	CHEMBL4880636	Fms (h) Millipore kinase activity assay	B	CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1	Outside typical range	CHEMBL4593677		Inhibition	%	-20.0	CHEMBL1844	Homo sapiens	% inhibition	%	-20.0
Not Active	23324323	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23324324	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23324958	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	81.0	CHEMBL1844	Homo sapiens	% Control	%	81.0
Not Active	23324959	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23325426	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23325427	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	94.0	CHEMBL1844	Homo sapiens	% Control	%	94.0
Not Active	23326073	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	87.0	CHEMBL1844	Homo sapiens	% Control	%	87.0
Not Active	23326074	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	51.0	CHEMBL1844	Homo sapiens	% Control	%	51.0
Not Active	23326541	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	85.0	CHEMBL1844	Homo sapiens	% Control	%	85.0
Not Active	23326542	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23327241	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23327242	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23327709	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	87.0	CHEMBL1844	Homo sapiens	% Control	%	87.0
Not Active	23327710	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	74.0	CHEMBL1844	Homo sapiens	% Control	%	74.0
Not Active	23328296	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	83.0	CHEMBL1844	Homo sapiens	% Control	%	83.0
Not Active	23328297	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23328764	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23328765	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23329351	CHEMBL4881058	Fms(h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	118.0	CHEMBL1844	Homo sapiens	% residual kinase activity	%	118.0
Not Active	23329710	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23329711	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	92.0	CHEMBL1844	Homo sapiens	% Control	%	92.0
Not Active	23330178	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	99.0	CHEMBL1844	Homo sapiens	% Control	%	99.0
Not Active	23330179	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	94.0	CHEMBL1844	Homo sapiens	% Control	%	94.0
Not Active	23330934	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23330935	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23331402	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23331403	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23331989	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	85.5	CHEMBL1844	Homo sapiens	% Control	%	85.5
Not Active	23331990	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	92.9	CHEMBL1844	Homo sapiens	% Control	%	92.9
Not Active	23332457	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23332458	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	89.0	CHEMBL1844	Homo sapiens	% Control	%	89.0
Not Active	23333173	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	99.4	CHEMBL1844	Homo sapiens	% Control	%	99.4
Not Active	23333174	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23333812	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	91.0	CHEMBL1844	Homo sapiens	% Control	%	91.0
Not Active	23333813	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23334280	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	91.0	CHEMBL1844	Homo sapiens	% Control	%	91.0
Not Active	23334281	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23334898	CHEMBL4881521	Fms (h) Upstate kinase activity assay	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		Inhibition	%	64.0	CHEMBL1844	Homo sapiens	% inhibition	%	64.0
Not Active	23335259	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23335260	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23335727	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	93.0	CHEMBL1844	Homo sapiens	% Control	%	93.0
Not Active	23335728	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	89.0	CHEMBL1844	Homo sapiens	% Control	%	89.0
Not Active	23336354	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	99.0	CHEMBL1844	Homo sapiens	% Control	%	99.0
Not Active	23336355	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	95.0	CHEMBL1844	Homo sapiens	% Control	%	95.0
Not Active	23336822	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	88.0	CHEMBL1844	Homo sapiens	% Control	%	88.0
Not Active	23336823	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23337552	CHEMBL4881923	CSF1R Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	73.0	CHEMBL1844	Homo sapiens	% Ctrl	%	73.0
Not Active	23337903	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	92.0	CHEMBL1844	Homo sapiens	% Control	%	92.0
Not Active	23337904	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	96.0	CHEMBL1844	Homo sapiens	% Control	%	96.0
Not Active	23338371	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23338372	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	84.0	CHEMBL1844	Homo sapiens	% Control	%	84.0
Not Active	23338983	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23338984	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23339451	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23339452	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	94.0	CHEMBL1844	Homo sapiens	% Control	%	94.0
Not Active	23340088	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	79.0	CHEMBL1844	Homo sapiens	% Control	%	79.0
Not Active	23340089	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23340556	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23340557	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23341213	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23341214	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	85.0	CHEMBL1844	Homo sapiens	% Control	%	85.0
Not Active	23341681	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23341682	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	94.0	CHEMBL1844	Homo sapiens	% Control	%	94.0
Not Active	23342297	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	93.0	CHEMBL1844	Homo sapiens	% Control	%	93.0
Not Active	23342298	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	56.0	CHEMBL1844	Homo sapiens	% Control	%	56.0
Not Active	23342765	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	88.0	CHEMBL1844	Homo sapiens	% Control	%	88.0
Not Active	23342766	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23343395	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23343396	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	94.0	CHEMBL1844	Homo sapiens	% Control	%	94.0
Not Active	23343863	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23343864	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	98.0	CHEMBL1844	Homo sapiens	% Control	%	98.0
Not Active	23344501	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23344502	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23345074	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	71.0	CHEMBL1844	Homo sapiens	% Control	%	71.0
Not Active	23345075	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	89.0	CHEMBL1844	Homo sapiens	% Control	%	89.0
Not Active	23345542	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	95.0	CHEMBL1844	Homo sapiens	% Control	%	95.0
Not Active	23345543	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	92.0	CHEMBL1844	Homo sapiens	% Control	%	92.0
Not Active	23346119	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23346120	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	85.6	CHEMBL1844	Homo sapiens	% Control	%	85.6
Not Active	23346588	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23346589	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	84.0	CHEMBL1844	Homo sapiens	% Control	%	84.0
Not Active	23347196	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	89.3	CHEMBL1844	Homo sapiens	% Control	%	89.3
Not Active	23347197	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	87.3	CHEMBL1844	Homo sapiens	% Control	%	87.3
Not Active	23347679	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23347680	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	94.8	CHEMBL1844	Homo sapiens	% Control	%	94.8
Not Active	23348258	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23348259	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23348726	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23348727	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23349313	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23349314	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23349931	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	86.0	CHEMBL1844	Homo sapiens	% Control	%	86.0
Not Active	23349932	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23350399	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	92.0	CHEMBL1844	Homo sapiens	% Control	%	92.0
Not Active	23350400	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	93.0	CHEMBL1844	Homo sapiens	% Control	%	93.0
Not Active	23351004	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23351005	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23351472	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23351473	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	93.0	CHEMBL1844	Homo sapiens	% Control	%	93.0
Not Active	23352003	CHEMBL4882694	CSF1R (FMS) Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	6.905	CHEMBL1844	Homo sapiens	% Inhibition	%	6.9054
Not Active	23352496	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	91.0	CHEMBL1844	Homo sapiens	% Control	%	91.0
Not Active	23352497	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	84.0	CHEMBL1844	Homo sapiens	% Control	%	84.0
Not Active	23352964	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23352965	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	55.0	CHEMBL1844	Homo sapiens	% Control	%	55.0
Not Active	23353846	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23353847	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	85.0	CHEMBL1844	Homo sapiens	% Control	%	85.0
Not Active	23354314	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23354315	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	96.0	CHEMBL1844	Homo sapiens	% Control	%	96.0
Not Active	23355046	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23355047	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23355514	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23355515	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23356150	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	99.0	CHEMBL1844	Homo sapiens	% Control	%	99.0
Not Active	23356151	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23356618	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23356619	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	89.0	CHEMBL1844	Homo sapiens	% Control	%	89.0
Not Active	23357227	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23357228	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	65.0	CHEMBL1844	Homo sapiens	% Control	%	65.0
Not Active	23357874	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	95.0	CHEMBL1844	Homo sapiens	% Control	%	95.0
Not Active	23357875	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23358342	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23358343	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	87.0	CHEMBL1844	Homo sapiens	% Control	%	87.0
Not Active	23358928	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23358929	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23359526	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23359527	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23359994	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23359995	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	96.0	CHEMBL1844	Homo sapiens	% Control	%	96.0
Not Active	23360579	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	82.0	CHEMBL1844	Homo sapiens	% Control	%	82.0
Not Active	23360580	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	91.0	CHEMBL1844	Homo sapiens	% Control	%	91.0
Not Active	23361047	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23361048	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23361620	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	89.0	CHEMBL1844	Homo sapiens	% Control	%	89.0
Not Active	23361621	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	82.0	CHEMBL1844	Homo sapiens	% Control	%	82.0
Not Active	23362156	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23362157	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23362624	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	85.0	CHEMBL1844	Homo sapiens	% Control	%	85.0
Not Active	23362625	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23364266	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	86.0	CHEMBL1844	Homo sapiens	% Control	%	86.0
Not Active	23364267	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	88.0	CHEMBL1844	Homo sapiens	% Control	%	88.0
Not Active	23364734	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23364735	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	85.0	CHEMBL1844	Homo sapiens	% Control	%	85.0
Not Active	23365473	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23365474	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	87.0	CHEMBL1844	Homo sapiens	% Control	%	87.0
Not Active	23366016	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23366017	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23366606	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	91.0	CHEMBL1844	Homo sapiens	% Control	%	91.0
Not Active	23366607	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23367074	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23367075	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23367525	CHEMBL4883878	CSF1-R ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	106.0	CHEMBL1844	Homo sapiens	% Residual activity with Skepinone-L	%	106.0
Not Active	23367952	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	78.0	CHEMBL1844	Homo sapiens	% Control	%	78.0
Not Active	23367953	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	93.0	CHEMBL1844	Homo sapiens	% Control	%	93.0
Not Active	23368420	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	90.0	CHEMBL1844	Homo sapiens	% Control	%	90.0
Not Active	23368421	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	95.0	CHEMBL1844	Homo sapiens	% Control	%	95.0
Not Active	23369019	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23369020	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	90.0	CHEMBL1844	Homo sapiens	% Control	%	90.0
Not Active	23369487	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23369488	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	50.0	CHEMBL1844	Homo sapiens	% Control	%	50.0
Not Active	23370073	CHEMBL4884317	Fms(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	99.0	CHEMBL1844	Homo sapiens	% residual kinase activity	%	99.0
Not Active	23370455	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23370456	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23370923	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	99.0	CHEMBL1844	Homo sapiens	% Control	%	99.0
Not Active	23370924	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23371732	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	65.0	CHEMBL1844	Homo sapiens	% Control	%	65.0
Not Active	23371733	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23372200	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23372201	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
	23372705	CHEMBL4884670	FmS [CSFR(CSF1LGC1)] Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL1844	Homo sapiens	pIC50		6.0
	23373114	CHEMBL4884961	FmS [CSFR(CSF1LGC1)] Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL1844	Homo sapiens	pIC50		6.0
	23373475	CHEMBL4885252	FmS [CSFR(CSF1LGC1)] Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL1844	Homo sapiens	pIC50		6.0
Not Active	23374948	CHEMBL4885942	CSF1R Kinase panel	B	CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O		CHEMBL4475494		Inhibition	%	25.3	CHEMBL1844	Homo sapiens	% Inhibition	%	25.3
Not Active	23375216	CHEMBL4886198	colony stimulating factor 1 receptor Millipore kinase panel	B	COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1		CHEMBL2180408		Inhibition	%	4.0	CHEMBL1844	Homo sapiens	% inhibition	%	4.0
Not Active	23375627	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	96.0	CHEMBL1844	Homo sapiens	% Control	%	96.0
Not Active	23375628	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	95.0	CHEMBL1844	Homo sapiens	% Control	%	95.0
Not Active	23376095	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	97.0	CHEMBL1844	Homo sapiens	% Control	%	97.0
Not Active	23376096	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23376672	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	85.0	CHEMBL1844	Homo sapiens	% Control	%	85.0
Not Active	23376673	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	95.0	CHEMBL1844	Homo sapiens	% Control	%	95.0
Not Active	23377142	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	85.0	CHEMBL1844	Homo sapiens	% Control	%	85.0
Not Active	23377143	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	91.0	CHEMBL1844	Homo sapiens	% Control	%	91.0
Not Active	23378000	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	99.0	CHEMBL1844	Homo sapiens	% Control	%	99.0
Not Active	23378001	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	90.0	CHEMBL1844	Homo sapiens	% Control	%	90.0
Not Active	23378468	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	98.0	CHEMBL1844	Homo sapiens	% Control	%	98.0
Not Active	23378469	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23379635	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	95.0	CHEMBL1844	Homo sapiens	% Control	%	95.0
Not Active	23379636	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23380103	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	94.0	CHEMBL1844	Homo sapiens	% Control	%	94.0
Not Active	23380104	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	86.0	CHEMBL1844	Homo sapiens	% Control	%	86.0
Not Active	23380797	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23380798	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	75.0	CHEMBL1844	Homo sapiens	% Control	%	75.0
Not Active	23381445	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23381446	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23381913	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23381914	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23382537	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23382538	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	76.0	CHEMBL1844	Homo sapiens	% Control	%	76.0
Not Active	23383005	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23383006	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	100.0	CHEMBL1844	Homo sapiens	% Control	%	100.0
Not Active	23383743	CHEMBL4887389	CSF1R Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	58.0	CHEMBL1844	Homo sapiens	% Ctrl	%	58.0
Active	23383744	CHEMBL4887389	CSF1R Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	14.0	CHEMBL1844	Homo sapiens	% Ctrl	%	14.0
Not Active	23384282	CHEMBL4887877	Fms(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	-5.04	CHEMBL1844	Homo sapiens	% inhibition	%	-5.04
Not Active	23384920	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	77.0	CHEMBL1844	Homo sapiens	% Control	%	77.0
Not Active	23384921	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	95.0	CHEMBL1844	Homo sapiens	% Control	%	95.0
Not Active	23385387	CHEMBL4879644	KinomeScan assay: inhibition of CSF1R	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	72.0	CHEMBL1844	Homo sapiens	% Control	%	72.0
Not Active	23385388	CHEMBL4879645	KinomeScan assay: inhibition of CSF1R-autoinhibited	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	88.0	CHEMBL1844	Homo sapiens	% Control	%	88.0
